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A G4C2 hexanucleotide repeat expansion in the gene C9ORF72 is the most common 
cause of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal dementia (FTD). 
Although intronic, the G4C2 repeat is translated in the absence of an ATG start codon 
through a mechanism known as repeat-associated non-ATG translation resulting in 
the production of five different dipeptide-repeat proteins (DPRs). These DPRs form 
inclusions in brains of C9+ ALS and FTD sufferers. Further, C9+ patients are also 
characterised by cytoplasmic inclusions of the protein TDP-43, whose dysfunction is 
causally related to ALS and FTD. However, the pathogenic mechanisms underlying 
C9ALS/FTD and its relation to TDP-43 remain elusive. I have characterised 
numerous transgenic Drosophila to study G4C2 and DPR toxicity, and its relation to 
TDP-43 dysfunction. These Drosophila models of C9ALS/FTD are characterised by 
behavioural deficits that varied in age of onset and severity. The characteristics of 
motor impairment and subsequent neurodegeneration were dependent on the levels 
and identity of DPRs produced rather than G4C2 RNA. Severe, early onset 
phenotypes correlated with the presence of poly-GR whereas high levels of poly-GP 
and poly-GA correlated with late onset phenotypes. Non-G4C2 derived poly-GR 
caused a cytoplasmic accumulation of Drosophila TDP-43 (TBPH) whilst non-G4C2 
derived poly-GA sequestered TBPH into inclusions. No change in TBPH localisation 
was seen following G4C2 RNA expression only. These alterations were accompanied 
with changes in the localisation of importins α2 and α3, the Drosophila homologues 
of karyopherins KPNA2 and KPNA4, respectively. However, expression and 
localisation of nucleocytoplasmic transport components such as RanGAP and 
nuclear pore complex proteins previously implicated in C9ALS/FTD appeared 
unperturbed. Further, cytoplasmic mislocalisation of TBPH enhanced DPR levels 
and cytotoxicity. Similar phenotypes were observed for patient frontal cortex in 
sporadic FTD and C9FTD; with KPNA4 being depleted from the nucleus and 
overlapping with TDP-43 inclusions. Taken together, these findings establish DPR 
accumulation as a cause of TDP-43 proteinopathy.  
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Chapter 1: Introduction 
1.1 Motor neuron disease 
The motor neuron diseases (MND) are a collection of neurodegenerative disorders 
characterised by dysfunction of the upper motor neurons (UMNs) of the primary 
motor cortex and/or dysfunction of the lower motor neurons (LMNs) of the brainstem 
and spinal cord (figure 1.1). The specific type of motor neurons affected determines 
the clinical presentation of the disease. Degeneration of the cortical upper motor 
neurons leads to symptoms such as spasticity, muscle weakness, hyperreflexia and 
hypertonia. Examples of lower motor neuron dysfunction include atrophy of muscles, 
fasciculation, muscle weakness, hypotonia, hyporeflexia and cramps. The MNDs can 
be classified into 6 main subtypes according to the whether the UMNs or LMNs are 
involved. The UMN diseases include primary lateral sclerosis (PLS) and hereditary 
spastic paraplegia (HSP). MNDs affecting primarily the LMNs include progressive 
muscular atrophy (PMA), progressive bulbar palsy (PBP) and spinal muscular 
atrophy (SMA). And finally the most common form of MND is amyotrophic lateral 









Figure 1.1 | Upper and lower motor neurons in the brain and spinal cord. 
Upper motor neurons (UMNs) originate from the motor cortex of the brain and 
synapse with lower motor neurons (LMNs) either in the brain stem (corticobulbar 
tract; green) or spinal cord (anterior and lateral corticospinal tracts; blue & red). 
LMNs originating from the brainstem synapse with the muscles of the face, head 
and neck. LMNs of the spinal cord synapse innervate muscles of the digits, limbs 







1.1.1 Primary Lateral Sclerosis 
 
PLS is a rare form of MND in which patients present with upper motor neuron 
symptoms only (Swinnen and Robberecht, 2014). PLS accounts for around 5% of 
MND cases (D’amico et al., 2013). Disease progression is slow compared to other 
forms of MND with sufferers retaining core LMN features and living longer than 
patients with ALS (Pringle et al., 1992; Tartaglia et al., 2007). PLS is usually 
associated with focal cortical atrophy in precentral regions (Kuipers-Upmeijer et al., 
2001). Despite being a UMN disease, LMN dysfunction has been shown to develop 
over time (Le Forestier et al., 2001). Further, many of the pathogenic hallmarks of 
ALS are seen in PLS, such as ubiquitinated inclusions and bubina bodies (Tartaglia 
et al., 2007). This had led to the suggestion that PLS may be a rare slowly 
progressive form of ALS. 
1.1.2 Hereditary Spastic Paraplegia 
 
The HSPs are a clinically and genetically diverse group of diseases typified by a 
progressive weakness and spasticity of the lower limbs (Lo Giudice et al., 2014). 
Neuronal death is typically rare in HSP; rather HSP is a distal axonopathy that 
causes degeneration of the long corticospinal tract axons (Blackstone et al., 2011). 
HSP can be divided into pure and complicated forms. Pure forms of the disease 
present only with spasticity of the lower extremities whereas complicated forms of 
the disease have additional clinical features including cognitive dysfunction, epilepsy, 
optic atrophy and skeletal abnormalities (Lo Giudice et al., 2014; Blackstone et al., 
2011). HSP has a prevalence of around 18 per 100,000 (Blackstone et al., 2011) 
with pure forms of the disease being more common in Northern Europe, North 
America and Japan and complicated forms seen more frequently in Mediterranean 
populations (Lo Giudice et al., 2014). 
1.1.3  Progressive Muscular Atrophy 
 
Patients with PMA present with lower motor neuron symptoms exclusively (Kim et 
al., 2009). 2.5-11% of patients with MND are classified as having PMA (Kim et al., 
2009). PMA patients often show at autopsy corticospinal tract degeneration with 
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surviving motor neurons presenting with ubiquitinated inclusions as seen in ALS 
(Ince et al., 2003). However, around 20% of PMA patients show UMN symptoms 
(Kim et al., 2009); additionally in a transcranial magnetic stimulation (TMS) study, 
around 35% PMA patients were found to have UMN dysfunction (Floyd et al., 2009). 
Even though PMA patients live longer than classic ALS sufferers; risk factors 
associated with reduced life-span in PMA are the same for ALS (Kim et al., 2009). 
Taking these observations together has led some to conclude that PMA may 
represent a rare form of ALS rather than being a separate disease (Kim et al., 2009). 
1.1.4  Progressive bulbar palsy 
 
PBP involves the selective degeneration of motor neurons of the lower brain stem 
and can present with or without corticobulbar tract complications (Karam et al., 
2009). Difficulties in speech and swallowing occur early in the disease and are 
rapidly followed by dysfunction of the limbs, respiratory system and muscles (Talbot, 
2009). PBP is more common in women than men with age of onset typically being 
over 65 years of age (Talbot, 2009). Some PBP patients present with UMN 
symptoms, however, independently of this, nearly all PBP patients will go on to 
develop ALS (Karam et al., 2009). Hence some consider PBP to represent bulbar 
onset ALS instead of a distinct disease (Swinnen and Robberecht, 2014). 
1.1.5  Spinal muscular atrophy 
 
SMA is the term for a collective group of diseases that affect the motor neurons in 
the brainstem and spinal cord (Faravelli et al., 2015). The different types of SMA are 
associated with different genetic mutations and clinical presentations (Arnold et al., 
2015). The most common form of SMA is autosomal recessive proximal SMA or 5q-
SMA that accounts for 95% of cases (Arnold et al., 2015). 5q-SMA is caused either 
by a homozygous deletion or mutation in the gene Survival Motor Neuron 1 (SMN1) 
(Faravelli et al., 2015; Arnold et al., 2015). 5q-SMA is the most common cause of 
infant death and affects around 1:10,000 births (Prior et al 2010). The 5q-SMA 
disease spectrum is divided into 5 different types (type 0 – 4) depending on age of 
onset, disease severity and age of death (Faravelli et al., 2015). The most common 
form, type 1, usually occurs at around 6 months of age (Arnold et al., 2015), but 5q-
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SMA can present as early as in utero (type 0) or as late as the third decade of life 
(type 4) (Faravelli et al., 2015). Typically, all types of 5q-SMA present with muscle 
atrophy and weakness at different severities usually starting in the lower limbs 
(Faravelli et al., 2015).  
1.1.6  Amyotrophic lateral sclerosis  
 
ALS is the most common form of MND (Lattante et al., 2015). ALS has a European 
incidence rate of around 2.16 per 100,000, with the disease being slightly more 
prevalent in men than women (3 per 100,000 and 2.4 per 100,000 respectively) 
(Logroscino et al., 2010). ALS is characterised by the degeneration of cortical UMNs 
together with degeneration of bulbar and spinal LMNs (figure 1.2) (Swinnen and 
Robberecht, 2014). Disease onset is typically after the age of 40, usually in fifth or 
sixth decade of life, although there are rare juvenile forms of ALS beginning before 
the age of 25 (Robberecht and Phillips, 2013; Swinnen and Robberecht, 2014). 
Around 10% if patients have a family history of the disease where the cause of most, 
if not all, is through the inheritance of ALS causing genetic mutations (Swinnen and 
Robberecht, 2014). Such patients are categorised as having familial ALS (FALS). In 
the remaining 90% of patients no familial history of the disease is present hence are 
recorded as having sporadic ALS (SALS). The causes of SALS are unknown but it is 
likely to have both a genetic and environmental component (Swinnen and 
Robberecht, 2014).   
ALS is a heterogeneous disease both genetically and phenotypically (Swinnen and 
Robberecht, 2014). Patients show significant variability in the precise area of 
symptom onset (Kiernan et al., 2011). The most common presentation is spinal-
onset ALS which accounts for around 70% of cases (Kiernan et al., 2011). Spinal-
onset ALS begins with an asymmetric limb weakness (Swinnen and Robberecht, 
2014). Patients show classic signs of UMN dysfunction such as hypertonia and 
hyperreflexia and LMN dysfunction including muscle weakness and atrophy (figure 
1.2) (Swinnen and Robberecht, 2014). 25% of patients have a bulbar-onset form of 
ALS (Kiernan et al., 2011) which typically commences with a weakness in the bulbar 
muscles accompanied by difficulties in speech and swallowing in addition to wasting 
of the tongue (Swinnen and Robberecht, 2014). 5% of ALS patients have a 







Figure 1.2 | Neurons affected in ALS. ALS involves both the upper motor 
neurons (UMNs) in the primary motor cortex (blue) and bulbospinal lower motor 
neurons (LMNs) (red). UMN loss leads to symptoms such as hyperreflexia and 
spasticity whilst LMN loss leads to muscle atrophy and weakness. ALS also 
frequently involves neurons in the frontotemporal cortex (orange). The ocular 
(green) and vesicorectal (yellow) motor neurons are rarely involved. From 
Swinnen and Robberecht, (2014).  
 
difficulties that requires rapid respiratory intervention (Gautier et al., 2009). Most 
patients die within 3-5 years of diagnosis although there is significant variability in 
disease duration with some patients living for decades (Robberecht and Phillips, 
2013). Patients with bulbar-onset ALS have a much shorter survival (2 years mean 
survival with a 10 year survival rate of 3.4%) compared to those with spinal-onset 
(2.6 years mean survival with 10 year survival rate of 13%) (Chiò et al., 2011). The 
prognosis for those with respiratory-onset ALS is bleak, with a mean survival of only 
1.4 years and no one surviving up to 10 years (Chiò et al., 2011). Interestingly a 




1.2 Frontotemporal Dementia  
 
Frontotemporal dementia (FTD) is a group of clinically and pathologically distinct 
neurodegenerative diseases characterised by the selective loss of neurons in the 
frontal and temporal cortices (figure 1.3) (Warren et al., 2013). The prevalence of 
FTD varies, ranging from 2.7 per 100,000 to 15.1 per 100,000 in different 
epidemiological studies (Rabinovici and Miller, 2010). A higher number of FTD cases 
are recorded as familial compared to ALS (Turner et al., 2017); up to 30% of FTD 
cases are thought to be familial with a known genetic cause (FFTD) whilst the 
remaining 70% are sporadic (SFTD) (Turner et al., 2017). FTD typically occurs in the 
sixth decade of life, although can present as early as the third (Rabinovici and Miller, 
2010). Clinically FTD patients undergo a progressive decline in behavioural and/or 
language faculties. Based on the exact clinical presentation of the disease, FTD can 
be subdivided into three syndromes; behavioural variant frontotemporal dementia 
(bvFTD), semantic dementia (SD) and progressive non-fluent aphasia (PNFA) 
(Warren et al., 2013).  
The bvFTD subtype of FTD is the most common of the FTD clinical syndromes 
(Rohrer et al., 2015). Patients with bvFTD show a loss of interpersonal and executive 
skills that is accompanied by emotional blunting and the appearance of unusual 
behaviours such as social withdrawal, confrontation seeking, personality changes, 
overeating, a loss of personal hygiene, obsessions, rituals and even sociopathic 
behaviours (Rohrer et al., 2015, Warren et al., 2013, Rabinovici and Miller, 2010). 
The cognitive decline in bvFTD is more subtle, with patients most commonly showing 
deficits in executive dysfunctions including attentiveness, judgement, planning and 
organisation (Rabinovici and Miller, 2010). This subtype of FTD is associated with 
pronounced frontal, insular and anterior cingulate atrophy (figure 1.3) (Meeter et al., 
2017). 
The SD form of FTD involves the continuous deterioration of semantic memory 
required for general knowledge about the world accumulated from life experiences 
(Warren et al., 2013). It accounts for around 20 – 25% of diagnosed FTD cases 
(Gosh and Lippa, 2015). SD predominantly involves language problems, in particular 
a difficulty understanding the meaning of words, objects and concepts (Warren et al., 
2013, Rabinovici and Miller, 2010). Speech is fluent but patients are unable to 
30 
 
retrieve words, show an impaired knowledge of familiar objects and are commonly 
unaware of their lack of comprehension (Gosh and Lippa, 2015). Structural magnetic 
resonance imaging (MRI) of SD shows a typical anteroinferior temporal lobe cortical 
atrophy which is asymmetric and frequently worst in the left hemisphere (figure 1.3) 
(Gosh and Lippa, 2015, Warren et al., 2013; Meeter et al., 2017). 
The final subtype of FTD is PNFA, presenting in around 25% of FTD patients (Gosh 
and Lippa, 2015). Both the PFNA and SD forms of FTD can be grouped together into 
a broader language syndrome known as primary progressive aphasia (PPA) (Gosh 
and Lippa, 2015).  PPA is classified into 3 clinical variants dependent on the precise 
speech and language deficits observed (Gosh and Lippa., 2015). The first variant is 
PNFA, also known as non-fluent variant PPA (nfvPPA) (Rohrer et al., 2015). PNFA 
sufferers show severe language deficits characterised by deterioration in language 
output and slow, non-fluent speech (Warren et al., 2013). Patients present with 
agrammatism, speech apraxia and a difficulty in understanding complicated 
sentences (Gosh and Lippa., 2015, Warren et al., 2013). The second variant is SD, 
which can also be referred to as svPPA (Rohrer et al., 2015); SD involves loss of 
semantic memory as described previously (Gosh and Lippa, 2015, Warren et al., 
2013). The final form of PPA is termed logopenic variant PPA (lvPPA) or logopenic 
aphasia (Rohrer et al., 2015); those diagnosed with lvPPA have grammatically 
correct speech, but this speech is hesitant and marked by constant word-finding 
pauses and difficulties in repetition (Gosh and Lippa., 2015, Warren et al., 2013). 
Brain atrophy varies between PFNA patients (Warren et al., 2013) but left-sided 
frontal and insular atrophy is often reported (figure 1.3) (Meeter et al., 2017)  
FTD is a progressive disease; however, survival is variable across the FTD spectrum 
(Warren et al., 2013). Mean survival is around 6-12 years after diagnosis (Kansal et 
al., 2016). A recent meta-analysis of 27 FTD survival studies revealed all 3 subtypes 
of FTD (bvFTD, SD and PNFA) had similar survival rates with mean survival being 
longest in bvFTD and PNFA (8 years) and median survival being greatest for SD (12 
years) (Kansal et al., 2016). Heritability varies between the different FTD syndromes; 
bvFTD has a stronger familial basis compared to both SD and PNFA, with the 








Figure 1.3 | Grey matter atrophy in FTD variants. The behavioural variant 
subtype of FTD (bvFTD) is associated with a pronounced atrophy of the frontal, 
insular and anterior cingulate cortices. Semantic dementia (SD) typically involves 
asymmetrical left-sided temporal atrophy. Progressive non-fluent aphasia (PFNA) 











Figure 1.4 | Phenotypic variability across the ALS-FTD spectrum. ALS and 
FTD lie on a disease spectrum with ALS on one end and FTD the other. This 
includes patients with pure ALS, those who have ALS with cognitive or 
behavioural impairment (ALSci or ALSbi) and those ALS patients who meet the 
diagnosis for FTD (ALS-FTD). Some FTD patients do not have sufficient motor 
neuron involvement for an ALS diagnosis so are diagnosed as FTD-MND. 
Adapted from Swinnen & Robberecht, (2014). 
 
1.3 The ALS-FTD disease spectrum 
Over the past several decades based on clinical, pathological and genetic 
observations there has been recognition of a significant overlap between ALS and 
other neurodegenerative diseases (Taylor et al., 2016). Cognitive impairment in seen 
a significant proportion of ALS patients and motor symptoms resembling ALS are 
reported in numerous cases of FTD (Taylor et al., 2016). Indeed, the two diseases 
have been brought together at the clinical, pathological and genetic level (Swinnen 
and Robberecht, 2014; Ling et al., 2013). ALS and FTD are now thought to lie on a 
clinical continuum with pure ALS and FTD at the polar ends of this spectrum and a 
combined syndrome, ALS-FTD, in the centre (figure 1.4) (Swinnen and Robberecht, 







1.3.1 Converging clinical features of ALS and FTD 
 
Around 20% of ALS patients meet the clinical criteria for an accompanying FTD 
diagnosis, with cognitive dysfunction being reported in almost half of all ALS cases 
(Taylor et al., 2016). The most common cognitive symptoms experienced in ALS are 
deficits in verbal fluency, visual memory, attention and working memory (Strong and 
Yang, 2011; Phukan et al., 2007). In addition to these cognitive deficits, behavioural 
impairments are also prevalent in patients; typical abnormalities include apathy, 
disinhibition and the development of delusions and stereotypical behaviours 
(Swinnen and Robberecht, 2014; Strong and Yang, 2011). ALS patients suffering 
from mild abnormalities in behaviour are diagnosed as ALS with behavioural 
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impairment (ALSbi) and those with mild cognitive and language impairment are 
categorized as having ALS with cognitive impairment (ALSci) (Swinnen and 
Robberecht, 2014). MRI and computerized tomography (CT) scans reveal ALS 
patients with these frontotemporal syndromes have degeneration of neurons in the 
frontotemporal cortex (Strong and Yang, 2011). Both single positron emission 
computerized tomography (SPECT) and positron emission tomography (PET) 
imaging techniques have shown deficits in verbal fluency correlate with reduced 
cerebral blood flow to the anterior cingulate gyrus and regions of both the frontal and 
temporal cortices (Strong and Yang, 2011).  
Motor symptoms are estimated to be found in anywhere between 5-10% of FTD 
cases (Seelar et al., 2007) to as high as 50% of cases (Swinnen and Robberecht, 
2014). Patients who do not have severe enough motor neuron involvement for ALS 
are categorized as having FTD-MND (Swinnen and Robberecht, 2014). All subtypes 
of FTD can come concomitant with MND; however, it most commonly occurs with the 
bvFTD form and more rarely with the language variants of the disease (Seelar at al., 
2011). Depending on the patient, MND may occur early or late during FTD 
progression; with weakness and atrophy of the muscles being the most common 
symptoms reported, particularly in the arms and tongue (Seelar et al., 2011). Those 
suffering from ALS-FTD tend to have a uniquely rapid onset of dementia that usually 
comes before the motor symptoms (Lillo and Hodges, 2009). ALS-FTD patients 
present with a mixture of language and behavioural deficits (Lillio and Hodges, 2009) 
with these cognitive deficits usually appearing before signs of obvious motor 
impairment (Swinnen and Robberecht, 2014). Patients with ALS-FTD have on 
average worse survival than those with pure ALS or FTD, with a survival average of 
2.4 years after diagnosis (Olney et al., 2005, Kansal et al., 2016). In addition to the 
strong clinical overlap between ALS and FTD, the strongest evidence that these two 
diseases are two clinical manifestations of the same pathological process comes 
from research into the pathology and genetics underlying these two disorders (Ling 









Figure 1.5 | The major neuropathological subtypes in the ALS and FTD 
disease spectrum. FTD and ALS patients can be classified according to the 
protein aggregates found in neurons at post-mortem. Some protein deposits are 
only associated with FTD such as Tau (FTLD-tau); whilst others are only found in 
ALS such as SOD1 (ALS-SOD1). Other proteins form inclusions in both diseases, 
such as TDP-43 (FTLD-TDP and ALS-TDP,) and FUS (ALS-FUS and FTLD-




1.3.2 Shared pathological features of ALS and FTD 
 
Both ALS and FTD can be categorised into different subtypes in accordance with the 
histopathology shown in the brain at post-mortem analysis; with both diseases 
characterised by the presence of proteinaceous inclusions (figure 1.5). Some of the 
misaccumulated proteins are found only in ALS but not FTD and vice versa. For 
example, inclusions of superoxide dismutase 1 (SOD1) are found in 2% of ALS 
cases but not in any FTD patients (Ling et al., 2013). SOD1 is a cytoplasmic and 
mitochondrial antioxidant enzyme that converts superoxide into molecular oxygen 
and hydrogen peroxide (Bunton-Stasyshyn et al., 2015). For FTD, 45% of patients 
harbour pathological protein deposits of microtubule-associated protein tau (MAPT), 
such inclusions are not found in ALS post-mortem brains (Ling et al., 2013). Tau 
promotes microtubule assembly and stability; in FTD an abnormal intracellular 











However, several proteins have been found to form protein aggregates in both 
diseases (figure 1.5). Deposits of the RNA binding protein Fused in Sarcoma (FUS) 
are found in <1% of ALS and 9% of FTD cases respectively (Ling et al., 2013) (figure 
1.6). The major pathological breakthrough linking these two diseases was the 
discovery that Transactive DNA response (TAR) DNA-binding protein with a 
molecular weight of 43kDa (TDP-43) is main component of the ubiquitated inclusions 
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found in both sporadic ALS and the most common pathological form of FTD 
(Neumann et al., 2006). TDP-43 proteinaceous inclusions are found in 97% of all 
ALS cases and 45% of FTD brains (Ling et al., 2013) (figure 1.6). TDP-43 is an RNA 
binding protein with large number of roles in RNA processing (Ling et al., 2013). 
TDP-43 shuttles between the nucleus and cytoplasm but is predominantly found to 
be nuclear in its steady state (Ling et al., 2013). In ALS and FTD TDP-43 is cleared 
from the nucleus forming ubiquitinated and hyperphosphorylated inclusions that 
aggregate in the cytoplasm (Neumann et al., 2006; Arai et al., 2006). Pathological 
TDP-43 aggregates consist of full length TDP-43 in addition to N-terminal and C-
terminal fragments of the protein (Scotter et al., 2015; Xiao et al., 2015b). The loss of 
TDP-43 from the nucleus suggests a loss of nuclear TDP-43 function as a central 
pathogenic mechanism; whilst the presence of cytoplasmic TDP-43 aggregates 
indicates a toxic gain of function as a potential disease mechanism; indeed, 
functional studies in animal models support both of these possibilities (Lee et al., 
2011; Ling et al., 2013). It is likely both a toxic loss of TDP-43 function and a 
cytoplasmic gain of TDP-43 function play a role in TDP-43 mediated 
neurodegeneration (Ling et al., 2013). Neurodegenerative diseases with major TDP-
43 deposition are termed TDP-43 proteinopathies (Scotter et al., 2015); in such 
diseases the TDP-43 pathology correlates with neuronal loss and in ALS the regional 
spread of TDP-43 proteinopathy from the spinal cord and motor neurons to cortical 
areas can used to stage the progression of the disease (Scotter et al., 2015). Hence 
understanding TDP-43 dysfunction, and risk factors underpinning the development of 
TDP-43 proteinopathy - is key to understanding neurodegeneration in these 







Figure 1.6 | Pathological inclusions in ALS and FTD. Pathological protein 
inclusions seen in ALS and FTD. The major misaccumlated protein in ALS is 
TDP-43, being observed in 97% of ALS cases. TDP-43 pathology is also 
observed in a significant proportion of FTD cases (45%). FUS inclusions are also 
observed in both ALS (<1%) and FTD (9%). Hence aggregates of TDP-43 and 
FUS demonstrate the pathological overlap between ALS and FTD. SOD1 and Tau 
inclusions are seen only in ALS (2%) and FTD (45%) respectively. Adapted from 











Figure 1.7 | The major genes associated with the ALS and FTD disease 
spectrum. Both FTD-ALS and ALS have similar genetic mutations, in particular 
the G4C2 repeat expansion in C9ORF72. Some genes when mutated cause FTD 
alone; such as Tau. Other genes when mutated cause pure ALS e.g. SOD1. 




1.3.3 Genetics of ALS and FTD 
 
A direct molecular link between ALS and FTD has come from the identification of 
genes which when mutated cause both diseases (Ling et al., 2013) (figure 1.7). The 
most prominent example of this is the GGGGCC (G4C2) hexanucleotide repeat 
expansion in the non-coding region of Chromosome 9 open reading frame 72 
(C9ORF72) - the most common single genetic abnormality for both FALS and FFTD 
(Haeusler et al., 2016). The number of genes known to be associated with both 
diseases has greatly expanded over recent years with the development of exome 
sequencing - which enables only the protein coding regions of the human genome, 










Mutations in genes such as SOD1 cause pure ALS (figure 1.7) whereas mutations in 
other genes are associated only with FTD including MAPT (figure 1.7) (Hardy and 
Rogaeva, 2014). These mutations give rise to distinct disorders (ALS and FTD 
respectively) and lead to disease through pathways not involved in other forms of 
ALS, FTD and ALS/FTD (Hardy and Rogaeva, 2014). A closer look at the functions 
of the genes which cause ALS alone demonstrates such genes are typically involved 
in RNA/DNA metabolism; such as TAR DNA binding protein (TARDBP) and Fused in 
Sarcoma (FUS) (Hardy and Rogaeva., 2014). This indicates motor neurons have 
specific requirements for RNA processing and a disruption in this biological function 
is particularly detrimental to their function (Hardy and Rogaeva, 2014). Genes which 
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cause ALS-FTD or FTD alone seem to have functions in the same biological 
pathways (figure 1.7). These genes are typically associated with protein degradation 
and a damaged autophagy/lysosomal pathway; examples include mutations in 
C9ORF72, valosin containing protein (VCP), sequestosome 1 (SQSTM1), optineurin 
(OPTN), ubiquilin-2 (UBQLN2), charged multivesicular body protein 2B (CHMP2B) 
and progranulin (PGRN). This suggests FTD and the ALS/FTD disease continuum is 
associated with inhibited protein degradation and defective autophagy (Hardy and 
Rogaeva, 2014). Hardy and Rogaeva, (2014) argue the function of the genes 
associated with ALS and FTD points to common disease mechanisms detrimental to 
susceptible neuronal populations; i.e. perturbed RNA metabolism in motor neurons 
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Figure 1.8 | Genetics of ALS and FTD*. Genes which lead to ALS alone are strongly associated with RNA/DNA metabolism, such as TARDBP and FUS. Genes which cause FTD alone or 
both ALS and FTD are associated with autophagic processing. Adapted from Guerreiro et al., (2015). *Table does not include the recent identification of mutations in TUB4A in ALS 
(cytoskeleton) (Smith et al., 2014); TBK1 in ALS and FTD (autophagy) (Cirulli et al., 2015; Freischmidt et al., 2015); NEK1 in ALS and FTD (cell cycle regulation) (Cirulli et al., 2015); CCNF 
(E3 ubiquitin-protein ligase complex and cell cycle regulation) (Williams et al., 2016); ANXA11 in ALS (Vesicular protein trafficking) (Smith et al., 2017); and TIA1 in ALS and FTD (RNA 







1.4 Chromosome 9 open reading frame 72 (C9ORF72) 
 
A linkage of a 9.8 megabase (Mb) region located between chromosome 9p13.3-
p21.3 was observed within European ALS and FTD families (Morita et al., 2006; 
Vance et al., 2006). Linkage analysis managed to narrow the linkage region to 3.7 
Mbs but did not identify any disease causing mutations (Boxer et al., 2011; Pearson 
et al., 2011). Complimentary genome-wide association studies (GWAS) also 
identified the same region in a Dutch FALS cohort (van Es et al., 2009) and in 47.3% 
of FALS patients and nearly 25% of ALS patients in a Finnish cohort (Laaksovirta et 
al., 2010). A larger GWAS study in SALS patients from seven different countries 
again reported an association with the same region of the chromosome (Shatunov et 
al., 2010). GWAS studies also identified SFTD with TDP-43 pathology associated 
with this locus (Van Deerlin et al., 2010). These GWAS studies identified the same 
single nucleotide polymorphism (SNP), rs3849942, on the chromosome 9p locus 
(Laaksovirta et al., 2010; Shatunov et al., 2010). The disease associated SNPs 
narrowed the associated signal on chromosome 9p to a block of linkage 
disequilibrium ~106.5Kb in size which included three genes; MOBKL2B, INFK and 
C9ORF72 (Shatunov et al., 2010). 
The disease causing mutation on chromosome 9p-linked FTD-ALS locus was 
discovered in 2011 by DeJesus-Hernandez et al. (2011) and Renton et al. (2011). 
The mutation was discovered to be a massive hexanucleotide repeat expansion of 
the sequence G4C2 within intron 1 of C9ORF72. The G4C2 repeat number in healthy 
individuals ranged from 2-23 repeats whereas repeat number in affected individuals 
was expanded into the hundreds to thousands (DeJesus-Hernandez et al., 2011; 
Renton et al., 2011). The difficulty in identifying the mutation previously owed to the 
GC rich nature of the repeats making standard PCR sequencing techniques 
inadequate. The DeJesus-Hernandez et al. (2011) and Renton et al. (2011) studies 
got around this problem by utilizing repeat-primed PCR and next-generation 
sequencing to identify to the presence of the G4C2 repeats. This repeat expansion in 
C9ORF72 is the most common single genetic abnormality in FALS and FFTD 
(Haeusler et al., 2016). Across different studies conducted in several populations the 
expansion is has been shown to account for concomitant FALS-FTD (10-87.5%), 
SALS-FTD (6.3%-22.2%), FALS (3-46%), SALS (0.4%-21%), FFTD (3-48%) and 
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SFTD (2-23%) (Cruts et al., 2013). The repeat expansion is particularly prevalent in 
European and North American populations (Cruts et al., 2013). Majounie et al. 
(2012b) found in a large cohort of 4448 patients diagnosed with ALS and 1425 
patients diagnosed with FTD that the most frequent cause of sporadic ALS and 
sporadic FTD identified thus far was the expansion, accounting in total for around 
5·0–7·0% of cases in white Europeans, Americans and Australians. Particularly high 
frequencies of the expansion are seen in the Scandinavian countries Finland, 
Sweden and Denmark with the expansion being rarer in Asian populations; 
suggesting a northern European founder (Cruts et al., 2013).  
The C9ORF72 gene consists of 12 exons - 10 coding exons (exons 2 – 11) and 2 
non- coding exons (exons 1a and 1b) (figure 1.9). (Stepto et al., 2014; Haeusler et 
al., 2016). Based on intron-exon structure and differential transcriptional start and 
termination sites the C9ORF72 gene is alternatively spliced to produce 3 mRNA 
transcripts in which the non-coding exons 1a and 1b are differentially incorporated 
into the pre-mRNA. The three transcripts are V1 (NM_145005.5), V2 
(NM_0183525.3) and V3 (NM_001256054.1) (Stepto et al., 2014); transcripts V1 
and V3 utilise exon 1a whilst V2 utilises 1b.  Together they code for 2 different 
C9ORF72 protein isoforms – the short 24 kDa isoform (C9S) derived from V1 (exons 
2-5) and the long 54kDa isoform derived from both V2 and V3 (exons 2-11) (Stepto 
et al., 2014; Haeusler et al., 2016). The G4C2 repeat expansion is in-between exons 
1a and 1b, hence is located either within intron 1 or in the promoter depending on 
the transcript variant (Stepto et al., 2014; Haeusler et al., 2016). As transcripts V1 
and V3 utilise exon 1a they contain the G4C2 sequence within intron 1 leading to the 
production of pre-mRNA harbouring the expansion (Stepto et al., 2014; Haeusler et 
al., 2016). V2 incorporates exon 1b hence the repeats are located within the 
predicted promotor region of V2 (Stepto et al., 2014; Haeusler et al., 2016). The 
discovery of the G4C2 expansion located in intron 1 of C9ORF72 (figure 1.9) 
provided the strongest molecular link between ALS and FTD. As the expansion is so 
common in familial forms of both ALS and FTD and the combined ALS-FTD 
syndrome, in addition to its occurrence in sporadic forms of both diseases; 
understanding the underlying pathogenic mechanisms is essential for the future 








Figure 1.9 | C9ORF72 transcript variants and protein isoforms. The C9ORF72 
gene consists of 12 exons, 10 coding exons (exons 2 – 11) and 2 non- coding 
exons (exons 1a and 1b). C9ORF72 is alternatively spliced to produce 3 mRNA 
transcripts, V1, V2 and V3 in which the non-coding exons 1a and 1b are 
differentially incorporated into the pre-RNA. The G4C2 repeat expansion is located 
in-between exons 1a and 1b, hence is located either within intron 1 or in the 
promoter depending on the transcript variant. Together they code for 2 different 
C9ORF72 protein isoforms – the short 24 kDa isoform (C9S) derived from V1 
(exons 2-5) and the long 54kDa isoform derived from both V2 and V3 (exons 2-
11). * The mRNA is depicted without presence of the G4C2 repeats. Adapted from 






1.4.1 Origin of the C9ORF72 repeat expansion 
 
An important question remains as to whether the G4C2 repeat expansion in 
C9ORF72 has a single founder that has spread throughout the population or if the 
C9ORF72 locus is prone to expansion and occurred on multiple occasions 
throughout human history (Pliner et al., 2014). A closer analysis of the original 
Finnish GWAS that identified the C9ORF72 locus revealed all patients had a 232-kb 
haplotype which increased ALS incidence (Laaksovirta et al., 2010). Furthermore, 
the majority of non-Finnish patients also carry this 20-single nucleotide 
polymorphism (SNP) risk haplotype (Majounie et al., 2012b). The link between the 
repeat expansion in C9ORF72 and this risk haplotype not only holds for European 
populations (Ratti et al., 2012, Smith et al., 2013; van der Zee et al., 2013) but also 
Japanese (Ishiura et al., 2012; Ogaki et al., 2012) and Chinese (Jiao et al., 2014) 
populations.  
Genome-wide genotype data from Finland shows the G4C2 repeat expansion 
appeared in the Finnish population 100 generations ago (Majounie et al., 2012b; 
Pliner et al., 2014); which suggests the mutation occurred around 500 A.D., the time 
the Vikings invaded Europe (Pliner et al., 2014). A “Viking horde” theory has been 
proposed which suggests the expansion spread through Europe during the Viking 
conquests (Mok et al., 2012; Pliner et al., 2014). Pliner et al. (2014) describe how the 
geographic distribution of the C9ORF72 repeat expansion and the conquests of the 
Vikings are strikingly similar. Increased globalisation will have spread the C9ORF72 
expansion to other populations, explaining the Finnish haplotype occurring in Asian 
expansion carriers (Pliner et al., 2014). Pliner et al. (2014) argue the geographic 
distribution of the C9ORF72 expansion within Europe supports the single founder 
theory, as if the expansion occurred numerous times throughout human history then 
several areas with high numbers of C9ORF72 disease frequency would be predicted 
across the globe.  
Rohrer et al. (2015) note however that the high prevalence of the C9ORF72 
expansion in certain southern European populations and its occurrence in large 
populations in East Asia such as China do not support this “Viking horde” theory. 
Rohrer et al. (2015) further argue the common 20-SNP haplotype is more likely to 
have an out-of-Africa origin as it is observed in European, African, and Asian 
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populations. Rather than a single common founder the alternative hypothesis is that 
of a predisposing haplotype prone to mutations leading to the occurrence of multiple 
expansions and hence multiple origins worldwide (Rohrer et al., 2015).  Several 
studies looking at generational changes in repeat length within families and somatic 
instability of the repeats support a multiple origin hypothesis for the C9ORF72 
expansion (Rohrer et al., 2015). Fratta et al. (2015) found within a UK ALS cohort a 
patient with a 90 repeat unit expansion in ectodermally derived cauda equine and 
other tissues such as fibroblasts, blood and dura mater that arise from the 
mesoderm and/or ectoderm. A much larger expansion of between 900 – 3500 
repeats was only present in CNS tissue. The authors argue the large number of 
small expanded alleles similar in size across multiple non-CNS tissues makes the 
retraction of the large expansion improbable as this would have to involve multiple 
retraction events that lead to a similar final repeat length. Rather, Fratta et al. (2015) 
suggest this indicates the expansion has occurred multiple times on a permissive 
haplotype; indeed the patient with the 90 repeat unit expansion in non-CNS tissue 
did have the Finnish founder haplotype. Xi et al. (2015a) described a British-
Canadian family with a paternal 70 repeat unit expansion allele which expanded to 
around ~1750 repeats in the blood of 4 of the 5 children; two of which have ALS. 
Similarly, Dols-Icardo et al. (2014) report a family of 3 brothers with expansions 
ranging between 116 – 148 in blood; with the children of two of these brothers 
having repeat lengths of 120 and 1401 respectively. Gijselinck et al. (2016) also 
observed a large increase of around ~1000 repeats from a father to his children. 
Hence there is strong evidence for both unfaithful inheritance (Beck et al., 2013; 
Dols-Icardo et al., 2014; Xi et al., 2015a) and somatic instability (van Blitterswijk et 
al., 2013; Fratta et al., 2015; Nordin et al., 2015) for intermediate (20-30) and small 
(30-150) repeat G4C2 expansions. Such generational increases indicate it is 
improbable that the repeat expansion only happened once during the history of 
humanity since expansion events are still occurring today. 
1.4.2 Pathogenic threshold of the C9ORF72 repeat expansion 
 
With the discovery of G4C2 repeats in C9ORF72, an important question is what the 
minimum repeat length required for disease is (figure 1.10). The normal repeat size 
in healthy controls varies but is between 2 – 10 repeats in 90% of the European 
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population (Renton et al., 2011). Most controls however possess 2, 5 or 8 repeats on 
each allele (Woollacott and Mead, 2014) although intermediate repeat lengths of 30 
repeats and above are seen uncommonly in healthy populations (Rohrer et al., 
2015). An expansion of 400 repeats has been reported in controls and has been 
attributed to reduced penetrance of the C9ORF72 expansion and variations in age of 
onset (Beck et al., 2013; Mossevelde et al., 2017). Repeat expansions in patients 
are much larger than what is observed in healthy controls, ranging from the 
hundreds to the thousands (Rohrer et al., 2015; Mossevelde et al., 2017) (figure 
1.10). Accurately sizing the repeat expansion is difficult due to the high GC content 
of the expansion (Stepto et al., 2014). Repeat prime PCR used in the discovery of 
the expansion cannot accurately distinguish repeat sizes larger than 30 – 50 repeats 
(Renton et al., 2011); although new protocols have been developed that sequence 
more than ~100 repeats (Cleary et al., 2016). Southern blotting is generally 
considered the gold standard for detecting and sizing large repeat expansions 
(Cleary et al., 2016); however somatic mosaicism for the repeat length in blood 
samples makes accurate interpretation difficult; additionally, the resolution of 
agarose gel electrophoresis used in southern blotting is lower than PCR and is more 
affected by secondary structure as the gel is non-denaturing (Cleary et al., 2016).  It 
is recommended that the use of both PCR and southern blotting should be used for 

















Figure 1.10 | Repeat lengths in C9orf72 associated with disease risk. The 
G4C2 repeat expansion in C9ORF72 is in intron 1 of the gene. Repeat lengths in 
the healthy range are between 2-20 repeats; repeat lengths between 20 – a few 
hundred repeats are rare in both patients and healthy controls hence present an 
unknown risk for disease. Over 400 hundred repeats are pathogenic. Adapted 

















There appears to be an intermediate range between 20 – a few hundred repeats that 
are rarely seen in healthy controls or patients that confer an unknown risk for the 
disease (Rohrer et al., 2015) (figure 1.10). G4C2 expansions ranging between 24 – 
28 repeats have previously been reported in ALS patients (Milliecamps et al., 2012; 
Ratti et al., 2012; García-Redondo et al., 2013) and repeat lengths of 20 – 22 units 
have been seen in FTD patients (Gómez-Tortosa et al., 2013). Gijselinck et al. 
(2016) found short expansions between 47 – 78 repeat units in blood co-segregate 
with ALS and FTD. Some of these patients with short expansions presented with 
C9ORF72 repeat expansion associated ALS/FTD pathology in the brain that was 
indistinguishable from the pathology seen patients with much longer expansions 
(Gijselinck et al., 2016). However, in non-expansion carriers there is at present no 
clear association between repeat lengths within the normal range and the risk of 
developing ALS, FTD or ALS-FTD (Mossevelde et al., 2017). Healthy individuals 
harbouring repeat expansions between 20 – a few hundred repeats have been 
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reported by a number of groups (Simón-Sánchez et al., 2012; Cooper-Knock et al., 
2012; Majounie et al., 2012a; Beck et al., 2013; Smith et al., 2013; Gami et al., 
2015). Gami et al. (2015) reported the case of an 84-year-old woman who had a 30-
unit repeat expansion but did not develop ALS or FTD or experience any sort of 
significant cognitive decline. One study has observed an increased chance of 
developing sporadic ALS is associated with intermediate 24 – 30 repeats expansions 
(Chen et al., 2015). Hence whether intermediate repeat lengths are pathogenic or 
confer increased risk to develop clinical disease is at present unclear. 
There is currently no clear evidence for a strong correlation between repeat length 
and disease severity and survival (Rutherford et al., 2012). No association has been 
found between repeat length and the clinical and pathological diagnosis of either 
FTD or ALS (van Blitterswijk et al., 2013; Nordin et al., 2015). Furthermore, in ALS 
patients repeat length did not influence bulbar or spinal presentations of the disease 
(Dols-Icardo et al., 2014; Chen et al., 2015).  On the other hand, some have reported 
links between repeat length and patient survival. Suh et al. (2015) found large G4C2 
repeat expansions correlate with reduced disease duration in FTD. Post mortem 
analysis of the brains of FTD and ALS patients by van Blitterswijk et al. (2013) 
showed a correlation between repeat length in the cerebellum and disease duration; 
with repeats over 1467 in length conferring reduced survival after onset in FTD. 
Similarly, Nordin et al. (2015) found large expansions in the parietal lobe associated 
with quicker disease progression in a cohort of 13 ALS patients and 5 ALS/FTD 
patients; this was significant for both the total cohort and the ALS patient group when 
analysed in isolation. However, the authors saw no correlation between length of 
repeat in the spinal cord and disease duration after onset (Nordin et al., 2015). Other 
studies have found no correlation between the size of the repeat expansion and 
disease duration of either ALS or FTD (Rutherford et al., 2012; Dols-Icardo et al., 
(2014).  Some indirect data suggests an inverse correlation may exist between 
repeat size and disease duration; hypermethylation of the CpG island located 5’ of 
the G4C2 repeats correlates with both larger repeat size (Gijselinck et al., 2016) and 
increased duration of the disease in FTD (Russ et al., 2015). Hypermethylation of the 
5’ CpG island has been proposed to be protective due to epigenetic silencing which 
causes a reduction in mutant C9ORF72 mRNA, and as a consequence potentially 
attenuating the toxic effects of the gain of function species derived from the G4C2 
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expansion (Russ et al., 2015). Indeed, reduced pathology is seen in post-mortem 
patient brains with CpG hypermethylation (Liu et al., 2014). However, a conflicting 
study by Xi et al. (2013) found increased methylation of the 5’ CpG island correlated 
with reduced disease duration in ALS. Hence a firm association between repeat size 
and disease severity and duration is unclear at present.  
Repeat length may be an age of onset modifier; an earlier age of onset is seen in the 
younger generations of C9ORF72 families indicating genetic anticipation (Chiò et al., 
2012a; Boeve et al., 2012; Gijselinck et al., (2016). Gijselinck et al. (2016) found the 
offspring of families showing intergenerational decreases in age of onset have a 
higher methylation state of the flanking CpG island compared to the parent. 
Hypermethylation is associated with increased repeat sizes; suggesting an increase 
in expansion size between generations has occurred and may explain the earlier 
disease onset. Indeed, in one of the families studied Gijselinck et al. (2016), elevated 
methylation and an increase of around 1000 repeats units was seen from parent to 
child. Genetic anticipation has not been universally observed in all C9ORF72 families 
(Renton et al., 2011; DeJesus-Hernandez et al., 2011; Boeve et al., 2012; Chiò et 
al., 2012a). Indeed, Gijselinck et al. (2016) found when comparing  the age of onset 
of 6 patients harbouring a short expansion with 51 patients with a long expansion, 
that 47-80 repeat units in blood was significantly associated with a later age of onset 
compared to 80 or more repeats. Gijselinck et al. (2016) propose this difference in 
age of onset maybe attributable to reduced methylation of the CpG island 5’ of the 
repeats in both the blood and brain of patients with short repeat expansions. 
Conversely, Beck et al. (2013), Waite et al. (2014) and Hübers et al. (2014). all found 
a positive correlation between length of the expansion and age of onset, with those 
patients with smaller expansions having an earlier age of onset. Additionally, van 
Blitterswijk et al. (2013) found larger repeat lengths in the frontal cortex are 
significantly associated with increased age of onset. This finding was not replicated 
by Nordin et al. (2015) but the authors did observe a positive correlation between 
repeat length in parietal lobe and cerebellum and age of onset. However, 
Mossevelde et al. (2017) note such results must be interpreted with caution as these 
studies used different measures to assess repeat size which may impact the results. 
In addition Hübers et al. (2014) found this positive correlation is no longer significant 
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when an outlier with an extremely early age of onset (27 years of age) and a repeat 
length of 250 units was removed from the analysis. 
1.4.2 Clinical presentation of patients harbouring the 
C9ORF72 repeat expansion 
 
Patients harbouring the hexanucleotide G4C2 in C9ORF72 typically have a rapid 
disease progression like the majority of ALS and ALS-FTD patients (Rohrer et al., 
2015). Life expectancy does however depend on the clinical diagnosis. ALS 
associated C9ORF72 repeat expansions usually has a disease duration between 3 
to 96 months (Cruts et al., 2015) whereas for C9ORF72 associated FTD disease 
duration can range from 1 to 22 years (Cruts et al., 2015). Atypical slowly 
progressive forms of C9ORF72 associated ALS and FTD have been reported with 
patients living 20 years without a significant worsening of symptoms after diagnosis 
(Khan et al., 2012; Suhoen et al., 2014; Gómez-Tortosa et al., 2014). Age of onset is 
highly variable, between 30 – 70 years (range: 27 – 85 years), irrespective of how 
the disease initially manifests itself (Cruts et al., 2013; Cruts et al., 2015) with mean 
age of onset being around 58.0 (± 8 years) (Majounie et al., 2012a; van der Zee et 
al., 2013; Murphy et al., 2017). The expansion is typically not penetrant in those 
younger than 35 years of age although a 25-year-old ALS patient with the expansion 
has been reported (Murphy et al., 2017). Penetrance of the expansion is around 50% 
at around 60 years with penetrance being 99.5% by 83 years of age (Murphy et al., 
2017). Penetrance by age is slightly increased in C9ORF72 patients with pure ALS 
(median range: 56 – 58) compared to those presenting with pure FTD (median 
range: 57.0–60.0) (Murphy et al., 2017). Increased penetrance by age is also seen 
in patients initially presenting with a spinal-onset form (median range: 56 – 58) of 
ALS compared to bulbar onset (median range: 57.0–60.0) (Murphy et al., 2017). 
Interestingly there appears to be increased penetrance in men compared to 
woman (Williams et al., 2013; Murphy et al., 2017); with males who carry the 
repeat expansion in C9ORF72 having an increased chance of developing disease 
at earlier ages (median range: 56 – 58) compared to females (median range: 86 – 
68). This gender difference is seen across the entire range of age of onset 
(Murphy et al., 2017), although the effect on survival is relatively small (2-year 
difference in median survival) (Murphy et al., 2017). 
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C9ORF72 repeat expansion carriers typically present with bvFTD, ALS, or a 
combination of both (Rohrer et al., 2015). The language variants of FTD are rarely 
associated with the C9ORF72 expansion (Rohrer et al., 2015). Interestingly features 
of psychosis (including delusions and hallucinations) are commonly observed in 
bvFTD patients with the expansion in C9ORF72 compared to those without the 
expansion (Rohrer et al., 2015). In certain patients these symptoms are particularly 
prevalent during the early stages of the disease, so much so that schizophrenia 
(Galimberti et al., 2014), bipolar disorder (Meisler et al., 2013), obsessive-
compulsive disorder (Calvo et al., 2013) or depressive pseudodementia (Bieniek et 
al., 2014) are misdiagnosed closer to onset. C9ORF72 expansion carriers can also 
present with amnesic phenotypes such as impairments in episodic memory (Rohrer 
et al., 2015).  
These neuropsychiatric and amnesic features combined complicate the assigning of 
a bvFTD diagnosis as patients are less likely to fit in with the typical diagnostic 
criteria seen in non-expansion carriers (Rohrer et al., 2015), potentially leading to 
patients incorrectly being classified as having Alzheimer’s disease (Rohrer et al., 
2015). C9ORF72 repeat expansion carriers presenting with ALS demonstrate 
symptoms identical to classic ALS phenotypes (Rohrer et al., 2015); although 
cognitive and behavioural impairments are more frequently observed in ALS patients 
with the C9ORF72 expansion compared to those without (Montuschi et al., 2015). 
Repeat expansions in C9ORF72 have also been reported in Parkinson disease 
(Lesage et al., 2013), dementia with Lewy bodies (Robinson et al., 2014), multiple 
system atrophy (Goldman et al., 2014), Huntington disease phenocopies (Hensman 
et al., 2014), pure cerebellar ataxia (Corcia et al., 2016) and corticobasal syndrome 
(Lindquist et al., 2013). Further some FTD patients with the C9ORF72 repeat 







1.4.3 Pathological hallmarks of C9orf72 ALS/FTD 
 
Like nearly all ALS cases, the majority of C9ORF72 cases have TDP-43 pathology 
irrespective of the clinical phenotype (Murray et al., 2011; Cooper-knock et al., 2012; 
Snowden et al., 2012; Mackenzie et al., 2014; Rohrer et al., 2015). Although, rare, 
but notable cases have been reported that lack TDP-43 aggregation or the pathology 
is too sparse to classify (Gijselinck et al., 2012; Proudfoot et al., 2014; Baborie et al., 
2015; Vatsavayai et al., 2016). Consistent with other TDP-43 proteinopathies, TDP-
43 aggregate formation in the C9ORF72 associated ALS/FTD brain is associated 
with reduction in the normal diffuse nuclear TDP-43 stain (Mackenzie et al., 2014). 
Pathological TDP-43 is hyperphosphorylated, ubiquitinated and N-terminally 
truncated (Mackenzie et al., 2014). In C9ORF72 cases the TDP-43 pathology 
presents as compact or granular neuronal cytoplasmic inclusions (NCI), diffuse 
neuronal cytoplasmic staining, dystrophic neurites (DN), (oligodendro)glial 
cytoplasmic inclusions (GCI) and neuronal intranuclear inclusions (NII) (Mackenzie 
et al., 2014). The length of the repeat expansion does not appear to influence the 
presentation of TDP-43 pathology (Mann et al., 2013). TDP-43 pathology is seen in a 
wide range of brain areas including the frontal cortex, temporal cortex, motor cortex, 
hippocampus, amygdala, basal ganglia regions and the thalamus (Murray et al., 
2011; Hsiung et al., 2012; Mackenzie et al., 2014). Similar brain areas show TDP-43 
pathology across the C9ORF72 clinical spectrum of ALS, ALS/FTD and FTD, the 
severity of TDP-43 pathology in specific brain regions does differ with the different 
clinical phenotypes (Mackenzie et al., 2014). However, the extent of TDP-43 
pathology shows a high degree of association with neurodegeneration irrespective of 
the anatomical region (Hsiung et al., 2012; Mackenzie et al., 2013; Mackenzie et al., 
2014). The pathology of C9ORF72 associated ALS (C9ALS) is identical to classic 
ALS pathology - marked neurodegeneration, TDP-43 NCI and pre-inclusions seen 
mainly in the upper motor neurons, spinal motor neurons and brain stem (Mackenzie 
et al., 2014). C9ORF72 carriers with FTD (C9FTD) show less neurodegeneration 
and TDP-43 pathology in the motor system compared to ALS cases (Mackenzie et 
al., 2014). In C9FTD lower motor neuron TDP-43 pathology and cell loss is 
attenuated compared to pure ALS and ALS/FTD cases; although TDP-43 inclusions 
are still present (Mackenzie et al., 2014). In the combined C9ORF72 ALS/FTD 
(C9ALS/FTD) syndrome neurodegeneration and TDP-43 pathology in the frontal and 
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temporal cortices is more severe compared to patients with a pure ALS phenotype 
(Murray et al., 2011; Hsiung et al., 2012; Mackenzie et al., 2014). The TDP-43 
pathology in the neocortex of C9ORF72 brains is reminiscent of FTD-TDP type B 
pathology with most of TDP-43 inclusions being compact NCI present in all cortical 
layers (Mackenzie et al., 2014). Although there is heterogeneity with cases showing 
FTD-TDP type A, particularly those with pure FTD, and also a rare FTD-TDP type C 
pathology also being reported in the literature (Mackenzie et al., 2014) 
A unique pathology to patients harbouring the C9ORF72 repeat expansion is the 
presence of ubiquitin and p62 positive; but TDP-43 negative NCI, NII and DNs; 
particularly in the cerebellar granular layer, neocortex, hippocampus, thalamus and 
amygdala (Al-Sarraj et al., 2011; Troakes et al., 2012; Cooper-Knock et al., 2012; 
Brettschneider et al., 2012; Hsiung et al., 2012; Mahoney et al., 2012; Mori et al., 
2013a; Ash et al., 2013; Zu et al., 2013; Mackenzie et al., 2014; Schludi et al., 2015). 
These TDP-43 negative inclusions are the dipeptide repeat proteins translated from 
the G4C2 repeat expansion via an unconventional mechanism known as repeat-
associated non-ATG initiated (RAN) translation (Mori et al., 2013a; Ash et al., 2013; 
Mackenzie et al., 2014; Schludi et al., 2015). The repeats are translated from both 
the sense G4C2 strand (Mori et al., 2013a; Ash et al., 2013) and the antisense C4G2 
strand (Gendron et al., 2013; Mori et al., 2013b; Zu et al., 2013).  
Translation occurs in all reading frames, the 3 sense frames and the 3 anti-sense 
frames - generating 5 different poly-dipeptide species each of which consists of two 
amino acids in a repetitive sequence (Mackenzie et al., 2014). The 5 DPRs are – 
poly glycine-proline (poly-GP), poly glycine-alanine (poly-GA), poly-glycine-arginine 
(poly-GR), poly proline-alanine (poly-PA) and poly proline-arginine (poly-PR) (Mori et 
al., 2013a; Ash et al., 2013; Gendron et al., 2013; Mori et al., 2013b; Mackenzie et 
al., 2014; Schludi et al., 2015). Poly-GP is transcribed from both the sense and anti-
sense strands (Gendron et al., 2013; Mori et al., 2013b; Zu et al., 2013), poly-GA 
and poly-GR are produced from the sense G4C2 mRNA (Mori et al., 2013a; Ash et 
al., 2013) whereas poly-PA and poly-PR result from translation of the anti-sense 
C4G2 mRNA. (Gendron et al., 2013; Mori et al., 2013b). Additionally, presumed ATG 
start codons exist within the poly-PR and poly-GP anti-sense reading frames (Zu et 
al., 2013). RAN proteins from 5 of the 6 reading frames are predicted to have a 
unique C-terminal region assuming translation terminates at the first STOP codon 
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after the repeat sequence; this is not the case for the anti-sense poly-GP frame as a 
STOP codon is present directly after the repeats (Zu et al., 2013). Indeed Zu et al., 
(2013) developed unique C-terminal polyclonal antibodies for the RAN peptides in 
addition to generating antibodies to the repeat motifs; the authors were able to show 
sense and antisense RAN proteins accumulate in the C9ORF72 post mortem brain 
using both the repeat motif and C-terminal DPR antibodies (Zu et al., 2013).  
Investigation of DPR pathology in human tissue has shown sense derived DPRs are 
more abundant than their anti-sense counterparts; with poly-GA being the most 
abundant DPR followed by poly-GP and then poly-GR (Mori et al., 2013a; Mann et 
al., 2013; Schludi et al., 2015); with poly-PA and poly-PR pathology being rare 
(Gendron et al., 2013; Mori et al., 2013b; Zu et al 2013; Schludi et al., 2015). 
Although this appears not the be the case for poly-GP, by performing double 
immunofluorescence using a pure repeat motif antibody which detects both the 
sense and anti-sense protein and an antibody that detects the C-terminal of the 
sense poly-GP peptide the authors demonstrated that most of the poly-GP inclusions 
are produced from the anti-sense C4G2 mRNA strand. Double-labelling revealed two 
different inclusion types, sense inclusions labelled by both antibodies and anti-sense 
inclusions labelled only with the pure repeat motif antibody. Approximately 18% of 
inclusions were sense (detected by both pure repeat motif and C-terminal 
antibodies) whereas 82% of inclusions were antisense (detected only by the pure 
repeat motif antibody) (Zu et al., 2013). However more recently Jiang et al. (2016) 
using anti-sense oligonucleotides (ASOs) against human C9ORF72 in a transgenic 
mouse model reduced poly-GP to almost undetectable levels suggesting at least in 
this murine model poly-GP is primarily translated from the sense strand. 
DPR inclusions are primarily found in neuronal populations (figure 1.11) and are 
virtually always p62 positive with double labelling revealing DPR inclusions can 
consist of co-aggregates of more than one DPR species (Mori et al., 2013a). Cortical 
DPR NCIs can appear as granular dot-like aggregates in small non-pyramidal 
neurons to larger star shaped aggregates in pyramidal neurons (Mackenzie et al., 
2014). Diffuse cytoplasmic DPR staining has also been reported; suggestive of pre-
inclusions (Mackenzie et al., 2014). The majority of DPR inclusions are NCIs 
however NIIs and DNs, although less abundant, are observed (Mackenzie et al., 
2014; Schludi et al., 2015). The majority of NIIs are p62-positive and aggregate in a 
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para-nucleolar compartment but do not aggregate within the nucleolus itself (Schludi 
et al., 2015). DPRs have also been reported in glia (Schludi et al., 2015). DPR NIIs 
have been observed in the ependymal cells of the spinal cord central canal and 
ependymal and subependymal cells that line the lateral ventricle in C9ALS cases 
using antibodies for poly-GA, poly-GP and poly-GR (Schludi et al., 2015). Very few 
of the DPR glial inclusions were cytoplasmic unlike what is seen for neuronal DPR 
pathology (Schludi et al., 2015). Furthermore, unlike DPR NIIs found in neurons, 
these glial inclusions were not para-nucleolar (Schludi et al., 2015). There is no clear 
association between DPR and TDP-43 pathology; indeed, DPR and TDP-43 
inclusions are seldom seen in the same cell and their pathologies appear distinct 
(Mackenzie et al., 2014) However poly-GA has been found to surround TDP-43 
aggregates (Mori et al., 2013a; Mackenzie et al 2013) suggesting that DPR 
aggregation may precede TDP-43 pathology.  
Schludi et al., (2015) performed an extensive analysis of DPR inclusions in 36 CNS 
regions to analyse the extent of DPR NCI, NII and DN pathology. As was previously 
reported, Schludi et al., (2015) observed NCI, NII and DN pathology was most 
severe for poly-GA, followed by poly-GP and poly-GR. The most extensive DPR 
pathology was seen in the neocortex, followed by the hippocampus and cerebellum, 
with a high DPR burden being seen also in the amygdala and hippocampus. DPR 
pathology was sparse in the basal ganglia, brain stem and spinal cord. The majority 
of DPR inclusions are NCI; although a large amount of DNs are seen in the 
molecular layer of the cerebellum for poly-GA and poly-GP. Poly-GR shows less 
DNs as compared to the other sense DPRs; indeed, the authors note there is almost 
a complete lack of poly-GR DNs in the CNS. Poly-GR NIIs were also less frequent 
than poly-GA and poly-GP NIIs; although were more prevalent in the thalamus 
compared to poly-GR NCIs. No pathological analysis was performed for anti-sense 
DPRs as the number of inclusions were too low for accurate analysis; although the 
authors note the pathological distribution of poly-PR resembled what was reported 
for the sense DPRs (Schludi et al., 2015). Although Poly-PR inclusions were rare 
they were reported with highest frequency in the hippocampus (Schludi et al., 2015). 
Poly-PR was not found in the spinal cord contradicting previous reports of poly-PR 
inclusions in spinal motor neurons (Wen et al., 2014). Intriguingly poly-PR, but not 
poly-GR inclusions show a different distribution in FTD cases compared to ALS 
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(Schludi et al., 2015). Schludi et al. (2015) counted inclusions in three neocortical 
regions (medial frontal gyrus, motor cortex and the occipital cortex), two 
hippocampal regions (granular cell layer of the dentate gyrus, pyramidal cell layer of 
cornu ammonis regions 3 and 4) and the granular and molecular layers of the 
cerebellum. Poly-GR pathology was similar in C9FTD, C9ALS and C9ALS/FTD 
patient subgroups, however poly-PR was observed significantly more frequently in 
the CA3/4 region of C9FTD cases compared to C9ALS and C9ALS/FTD cases. As 
noted previously there is an apparent lack of DPR pathology in spinal motor neurons 
leading some to question the pathogenic contribution of the DPRs in C9ALS and 
C9ALS/FTD cases (Gomez-Deza et al., 2015; Mackenzie et al., 2015). Indeed, the 
pathological distribution of DPR proteins that can be visualised with current 
antibodies does not correlate with areas of the brain that undergo the most 
significant loss of neurons in C9ALS/FTD (Mackenzie et al., 2015). A summary of the 



















Figure 1.11 | DPR pathology in C9orf72 ALS/FTD. (A) Poly-GR pathology in the 
dentate nucleus of a C9ALS/FTD patient. (B) Poly-GA pathology in the dentate 












Figure 1.12 | Distribution of sense DPR pathology in different regions of the 
brain. (a, b & c) Poly-GA is the most abundant DPR species seen in the human 
C9 brain followed by poly-GP and poly-GR. Poly-GA, poly-GP and poly-GR 
neuronal cytoplasmic inclusions (NCI), neuronal intranuclear inclusions (NII) and 
dystrophic neurites (DN) are primarily seen in cortical areas, the hippocampus, 
amygdaloid nuclei, thalamus and cerebellum. DPR inclusions are rare in the 




































Figure 1.13 | RNA foci in C9ORF72 expansion carriers. Neuronal sense G4C2 
RNA foci in the frontal cortex, labelled with a Cy3-labelled (G4C2)4 
oligonucleotide probe (red). Arrows denote nuclear foci; arrow heads denote 






The second unique feature of the C9ORF72 brain is the presence of G4C2 RNA foci 
in brain tissue (De-Jesus Hernandez et al., 2011; Gendron et al., 2013; Lagier-
Tourenne et al., 2013; Mizielinska et al., 2013; Mackenzie et al., 2014; De-Jesus 
Hernandez et al., 2017) (figure 1.13). The G4C2 DNA is transcribed from both the 
sense and anti-sense strand; hence both sense and anti-sense G4C2 RNA foci are 
detected in patient brains in addition to lymphoblasts, fibroblasts and patient derived 
induced pluripotent stem cells (IPSCs) (Almedia et al., 2013; Donnelly et al., 2013; 
Lagier-Tourenne et al., 2013).  RNA foci are most abundant in neurons but are 
observed to a lesser extent in astrocytes, oligodendrocytes and microglia (Lagier-
Tourenne et al., 2013; Mizielinska et al., 2013). The vast majority of RNA foci are 
nuclear although rare cytoplasmic RNA foci have been reported (Mackenzie et al., 
2014). RNA foci have been observed in several brain regions including the frontal 
cortex, temporal lobe, hippocampus, cerebellum, thalamus and lower motor neurons 
(De-Jesus Hernandez et al., 2011; Lagier-Tourenne et al., 2013; Mizielinska et al., 
2013; Lee et al., 2013; Cooper-Knock et al., 2015; Vatsavayai et al., 2016). Sense 
RNA foci are more abundant than anti-sense foci within regions of the brain 
(Mizielinska et al., 2013; Cooper-Knock et al., 2015; De-Jesus Hernandez et al., 
2017); although there are notable exceptions such as motor neurons (Cooper-Knock 













A recent study has conducted an extensive clinico-pathological study (n=63 brains) 
of sense and anti-sense RNA foci in frontal cortex and cerebellum (De-Jesus 
Hernandez et al., 2017). In frontal cortex sense RNA foci were present in 26% of 
cells, with 32% of sense foci bearing cells being neurons; as has previously been 
reported anti-sense foci were much less abundant – present in only 12% of frontal 
cortex cells with 16% of these being neurons. Within the cerebellum 23% of granule 
cells harboured sense RNA foci; sense foci were much more abundant in Purkinje 
cells; being found in 70% of these neurons. Anti-sense RNA foci were only found in 
1% of granule cells however again were markedly present in Purkinje cells – 74% of 
Purkinje cells were found to contain anti-sense foci. Usually 1, 2 or 3 foci were found 
per cell – although there were exceptions with some cells containing a larger number 
of foci (De-Jesus Hernandez et al., 2017). Interestingly when anti-sense foci were 
found, in both the frontal cortex and cerebellar Purkinje cells, they were more 
common than sense foci; this was not the case for cerebellar granular cells (De-
Jesus Hernandez et al., 2017). In the hippocampal neurons no difference was 
reported been sense and anti-sense foci burden (Cooper-Knock et al., 2015).  
Interestingly Cooper-Knock et al. (2015) reported anti-sense foci are more prevalent 
in motor neurons than their sense counterparts; further the authors also found anti-
sense foci correlated with TDP-43 mislocalisation in motor neurons. This data 
suggests the different foci patterns seen in distinct neuronal populations may 
potentially mean there are differences in the contribution of sense and anti-sense 
foci to pathogenesis (Cooper-Knock et al., (2015). Bacterial artificial chromosome 
(BAC) transgenic mice show an accumulation of anti-sense foci in vulnerable regions 
of the CNS including layers II/III and V of the cerebral cortex, DG and CA regions of 
the hippocampus and cerebellar Purkinje neurons; whereas sense foci were seen 
widespread throughout the mouse brain (Liu et al., 2016c). In contrast to Cooper-
Knock et al. (2015), only sense foci were found in motor neurons leading the authors 
to suggest potentially that motor neurons are more susceptible to sense foci toxicity 
(Liu et al., 2016c). Additionally, RNA foci and DPRs are seldom seen in the same 
cell (Gendron et al., 2013) although RNA foci are reported in p62 and TDP-43 







Figure 1.14 | The structure of C9ORF72 protein isoforms. The C9ORF72 
protein isoforms bare structural homology to DENN proteins. The long isoform, 
C9L, contains an N-terminal longin domain, a DENN domain and a C-terminal 
alpha domain. The short isoform (C9S) contains only the N-terminal longin 










1.5 C9ORF72 protein function 
 
The C9ORF72 transcripts code for 2 different C9ORF72 protein isoforms – a short 
24 kDa isoform (C9S) derived from transcript V1 and a longer 54kDa isoform which 
is derived from transcripts V2 and V3 (Stepto et al., 2014; Haeusler et al., 2016). 
Early bioinformatics analysis revealed C9ORF72 is a distant evolutionary relative of 
proteins of the Differentially Expressed in Normal and Neoplasia (DENN) family, 
GDP/GTP exchange factors (GEFs) that activate the Rab family GTPases (Zhang et 
al., 2012; Levine et al., 2013). The protein is highly conserved throughout evolution 
suggesting a common eukaryotic ancestor– with some notable exceptions including 
insects such as Drosophila Melanogaster (Stepto et al., 2014). C9ORF72 bares 
structural homology to DENN proteins which consist of an N-terminal longin domain, 
a DENN domain and a C-terminal alpha domain (figure 1.14) (Zhang et al., 2012; 










C9ORF72 does not contain similarity to other DENN domains at the primary amino 
acid level (Amick and Ferguson, 2017), its putative DENN domain was identified by 
the structural similarity it shares with FLCN interacting proteins 1 and 2 (FNIP1/2) 
and their interacting partner FLCN; both FLCN and FNIP1/2, despite not harbouring 
amino acid similarity with other DENN proteins, have been shown to contain DENN 
domains (Zhang et al., 2012; Levine et al., 2013; Amick and Ferguson 2017). DENN 
proteins function as GEFs for Rab GTPases, a family of small GTPases which are 
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master regulators cellular of membrane trafficking (Stenmark, 2009; Hutaglung and 
Novick, 2011). Rab GTPases exist in two conformation states – an “on” GTP bound 
state and an “off” GDP bound state (Stenmark, 2009). The transition between these 
states is controlled by Rab regulatory proteins – GEFs, GDP dissociation inhibitors 
(GDIs) and GTPase activating proteins (GAPs) (Stenmark, 2009; Hutaglung and 
Novick, 2013; Amick and Ferguson, 2017). GEFs bind to nucleotide-free GTPases 
causing a conformational switch leading to bound GDP being swapped for GTP 
(Amick and Ferguson, 2017). GEFs cause Rab GTPase proteins to be enriched at 
membranes where they recruit numerous molecules to regulate membrane 
trafficking (Amick and Ferguson, 2017). The predicted DENN domain of C9ORF72 
suggested the protein may function as a GEF and hence the recruitment Rabs and 
associated molecules to membranes. DENN proteins mainly activate endocytotic 
Rabs (Cherfils and Zeghouf, 2013) indicating C9ORF72 may play a role in 
endosomal trafficking events, including the regulation and degradation of proteins by 
autophagy (Farg et al., 2014).  
1.5.1 C9ORF72 and endosomal trafficking 
 
Indeed, initial studies by Farg et al. (2014) demonstrated a role for C9ORF72 in 
endosomal trafficking. Using a construct encoding a GFP-tagged human C9ORF72, 
Farg et al. (2014) observed C9ORF72 formed vesicles in the nucleus and cytoplasm 
that strongly co-localised with Rab1, Rab7, Rab5 and Rab11 in both neuronal cell 
lines and cultured cortical neurons from mice. Furthermore Rab5, Rab7 and Rab11 
were all found to co-localise with C9ORF72 in human spinal cord motor neurons. 
These Rabs are all associated with autophagy and endosomal transport (Farg et al., 
2014). Using a siRNA to C9ORF72 Farg et al. (2014) found cells in which human 
C9ORF72 had been silenced the transport of the endocytosis was impaired. Aoki et 
al. (2017) who found a novel interaction between C9ORF72 and RAB7L1 and the 
loss of the C9ORF72 interaction with RAB7L1 resulted in impaired trans-Golgi 
network trafficking and defective multivesicular endosome formation. 
C9ORF72 also regulates autophagy in neuronal cell lines (Farg et al., 2014); 
C9ORF72 punctate were found to co-localise with the autophagosome marker 
microtubule-associated protein 1 light chain 3 (LC3) and also lysosomes. Further 
autophagosome formation was also impaired using a C9ORF72 siRNA. 
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Furthermore, a dysfunctional trans-Golgi network, such as is observed when 
C9ORF72 is knocked down (Farg et al., 2014; Aoki et al., 2017) is known to cause 
disturbances in autophagy and lysosomal protein degradation pathways (Eskelinen 
and Saftig, 2009). This data suggest C9ORF72 participates in the macroautophagy 
pathway; an autophagic process in which substrates, such as misfolded proteins and 
damaged organelles are sequestered within a cytoplasmic double-membrane vesicle 
labelled autophagosomes, these autophagosomes then fuse with the lysosome 
where most of the degradation occurs (Feng et al., 2014). The degradation process 
can be divided into four steps; (i) translocation and initiation, (ii) elongation and cargo 
recruitment, (iii) completion and (iv) lysosome fusion and degradation (Rubinsztein et 
al., 2015).  
1.5.2 Functional role for C9ORF72 in macroautophagy and 
lysosomal biology 
 
The role of C9ORF72 in macroautophagy (herein referred to as autophagy) has 
been clarified by a series of studies by Webster et al. (2016a) and Sellier et al. 
(2016). Webster et al. (2016a) demonstrated C9ORF72 participates in the initiation 
step of the macroautophagy pathway, by acting as a Rab1a effector. Webster et al. 
(2016a) using two siRNAs that targeted both isoforms (C9S and C9L) found a 
reduction in autophagosome formation. Webster et al. (2016a) go on to show that 
overexpression of both C9S and C9L isoforms induced autophagy, and this induction 
was dependent on its interaction with the ULK1 autophagy initiation complex. This 
complex consists of Unc‐51‐like kinase 1 (ULK1), FAK family kinase-interacting 
protein of 200 kDa (FIP200), autophagy-related 13 (ATG13) and ATG101 (Webster 
et al., 2016b). Using a FIP200 siRNA to disrupt the ULK1 complex it was found 
overexpression of C9ORF72 no longer promoted the induction of autophagy. Both 
co-immunoprecipitation and proximity ligation assays demonstrated the C9S and 
C9L isoforms directly interact with ULK1, FIP200 and ATG13. C9ORF72 did not 
seem interact with the ULK1 complex at the level of mTOR; rather C9ORF72 was 
shown to regulate the translocation of the ULK1 complex to the phagophore by 
acting as a Rab1a effector.  
Further insight into how C9ORF72 regulates autophagy has come from a 
complimentary study published in conjunction with Webster et al. (2016a) by Sellier 
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et al. (2016). Sellier et al. (2016) demonstrated that C9ORF72 forms a complex with 
WDR41 and SMCR8; this C9ORF72, SMCR8, and WDR41 complex acts as a 
GDP/GTP exchange factor for RAB8a and RAB39b; with the GEF activity of the 
C9ORF72 protein complex with RAB39b being crucial for the modulatory role 
C9ORF72 plays in autophagy in neurons. This protein complex was found by Sellier 
et al. (2016) to only be active in the presence of SMCR8. Indeed, SMCR8 appears 
vital for the stability of C9ORF72 and vice versa; levels of both proteins are 
decreased markedly when either is knocked down (Amick et al., 2016; Ugolino et al., 
2016). Yang et al. (2016a) demonstrated C9ORF72 interacts with SMCR8 in a 
DENN-domain dependent manner; as deletion of the SMCR8 DENN domain 
completely removed its interaction with C9ORF72. Further investigation of this 
emerging C9ORF72, SMCR8, and WDR41 pathway by Sellier et al. (2016) revealed 
TANK-Binding Kinase 1 (TBK1) phosphorylates SMCR8, and this post-translational 
modification is significant for the regulation of autophagy. Sullivan et al. (2016) 
demonstrated the C9ORF72/SMCR8/WDR41 forms a ternary complex, with FIP200 
identified by Webster et al. (2016a) as a C9ORF72 binding partner; this suggests the 
formation of the C9ORF72/SMCR8/WDR41 complex enables their interaction with 
the FIP200/Ulk1/ATG13/ATG101 autophagy initiation complex (Sullivan et al., 2016). 
Related to autophagy; C9ORF72 and SMCR8 also appear to play a role in lysosomal 
biology (figure 1.13). Both proteins localise to the lysosome during cellular starvation 
(Amick et al., 2016) – although are not present at the lysosome under basal 
conditions (Webster et al., 2016a; Yang et al., 2016a). Following knockout of 
SMCR8 and C9ORF72 the lysosomal deficits have been reported -  including 
enlarged lysosomes, increased swollen perinuclear lysosomes, and build-up of 
lysosomes and lysosomal enzymes (O'Rourke et al., 2016; Amick et al., 2016; Sellier 
et al., 2016; Sullivan et al., 2016; Ugolino et al., 2016; Nassif et al., 2017). Nassif et 
al. (2017) note this suggests C9ORF72 might play a role in the Coordinated 
Lysosomal Expression and Regulation (CLEAR) network involved in transcription of 
genes involved in both lysosomal biogenesis and macroautophagy. The transcription 
factor EB (TFEB) plays a key role in CLEAR, and phosphorylation by mTORC1 is an 
important inhibitor of TFEB nuclear translocation (Nassif et al., 2017). C9ORF72 
knockout cells show mTORC1 inhibition under starvation conditions or amino acid 
deprivation (Amick et al., 2016; Ugolino et al., 2016). In C9ORF72 knockout cells, 
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mTORC1 inhibition leads to increased translocation of TFEB to the nucleus and an 
enhancement of autophagy flux (Ugolino et al., 2016).  
In summary a pathway is emerging in which C9ORF72 regulates the initiation of 
autophagy by playing a central role in the RAB cascade pathway (figure 1.15) 
(Webster et al., 2016b). C9ORF72 functions as a RAB1a effector; interacting with 
the ULK1 complex and active GTP-RAB1a thereby controlling the translocation of 
the ULK1 initiation complex to the site of phagophore formation (Webster et al., 
2016a; Nassif et al., 2017). Once at the site of phagophore formation C9ORF72 
forms a complex with SMCR8 and WDR41 where it acts as a GEF for RAB8a and 
RAB36b (Sellier et al., 2016). Active RAB8a and RAB36b are potentially involved in 
the delivery of additional membrane to the site of phagophore formation and further 
promoting ULK1 translocation (Webster et al., 2016b; Nassif et al., 2017). RAB8a 
and RAB36b are known to interact with the autophagy receptors p62 and optineurin 
(Sellier et al., 2016; Webster et al., 2016b); their activation via C9ORF72 may 
promote nucleation and the recruitment of autophagic substrates such as misfolded 
proteins to the phagophore (Webster et al., 2016b). TBK1 phosphorylation of 
SMCR8 enhances the GEF activity of C9ORF72 encouraging its interaction with 
RAB36b (Sellier et al., 2016). Following C9ORF72 mediated RAB dependent 
trafficking of the ULK1 complex, the inhibitory phosphorylation of ULK1 via mTORC1 
is lost allowing the ULK1 complex to interact with the FIP200 complex and initiate 
autophagy. Hence C9ORF72 plays a central role in a Rab dependent trafficking 
pathway involved in the initiation of autophagy. C9ORF72 may also influence 
autophagic influx via its modulation of mTORC1 signalling and TFEB when localised 














Figure 1.15 | Role of C9ORF72 in macroautophagy and lysosomal biology. 
(A) C9ORF72 functions as a Rab1a effector; interacting with the ULK1 complex 
and active GTP-Rab1a controlling ULK1 initiation complex translocation to the site 
of phagophore formation. C9ORF72 then forms a complex with SMCR8 and 
WDR41 where it acts as a GEF for RAB8a and RAB36b (Sellier et al., 2016). The 
phosphorylation of TBK1 via SMCR8 enhances the GEF activity of C9ORF72. 
Following C9ORF72 mediated delivery of the ULK1 complex inhibitory 
phosphorylation of ULK1 by mTORC1 is lost allowing the ULK1 complex to 
interact with the FIP200 complex to initiate autophagy. (B) RAB8a and RAB36b 
are known to interact with autophagy receptors such as p62; C9ORF72 may 
promote the recruitment of autophagic substrates to the phagophore (Sellier et al., 
2016). (C) C9ORF72 also interacts with RAB11 (Farg et al., 2014) RAB7 and 
RAB7L1 (Farg et al., 2014; Aoki et al., 2017) hence may also be involved in 
membrane trafficking to the phagophore and fusion of the autophagosome and 
lysosome. (D) Finally, both C9ORF72 and SMCR8 may modulate mTORC1 
nutrient sensing promoting TFEB nuclear translocation increasing lysosomal 
biogenesis and removing ULK1 mTORC1 inhibition of ULK1 thereby initiating 








1.5.3 Other functions of C9ORF72  
 
A role for C9ORF72 in actin dynamics has come from studies of the mouse 
homologue of C9ORF72. The mouse C9ORF72 homologue (Ms-C9orf72) is known 
as 3111004O21Rik (Atkinson et al., 2015). The mouse homologue has 3 transcript 
variants; V1 (exons 2-11) encoding isoform 1 (Ms-C9orf72-1); V2 (exons 3-11) 
encoding isoform 2 (Ms-C9orf72-2) and V3 (exons 2-10) encoding isoform 3 (Ms-
C9orf72-3) (Xiao et al., 2016). Ms-C9orf72-1 and Ms-C9orf72-3 have a highly similar 
domain structure to C9L, containing the longin, DENN and alpha domains; although 
Ms-C9orf72-3 misses 60 amino acids from the C-terminal of the peptide (Xiao et al., 
2016). Ms-C9orf72-2 contains both the DENN and alpha domains but not the longin 
domain, hence differing from human C9S which contains only the longin domain 
(Xiao et al, 2016).  
Atkinson et al. (2015) demonstrated in cultured cortical neurons the mouse 
homologue of C9ORF72 was found extensively within the microtubule cytoskeleton 
including the axon, soma and dendritic arbor and actin-rich structures including 
growth cones and filopodia (Atkinson et al., 2015). A role for C9ORF72 
mechanistically in actin dynamics was provided by Sivadasan et al. (2016). 
Sivadasan et al. (2016) either overexpressed or knocked down Ms-C9orf72 in 
primary mouse embryonic motor neurons. Axons were found to be longer in motor 
neurons overexpressing human C9ORF72; whilst knockdown of Ms-C9orf72 led to a 
shortening of the axon. This knockdown phenotype could be rescued by 
overexpressing human C9ORF72. Further mass spectrometry-based proteomics 
revealed C9ORF72 interacted with proteins that regulate actin dynamics such as 
cofilin, Arp2/3 and coronin (Flynn et al., 2012).  
Ms-C9orf72 knockout mice show autoimmunity and inflammation phenotypes 
(O’Rourke et al., 2016; Atanasio et al., 2016; Burberry et al., 2016; Sudria-Lopezet 
al., 2016; Ugolino et al., 2016; Sullivan et al., 2016). Ms-C9orf72 null mice develop 
progressive splenomegaly and lymphadenopathy in addition to defective lysosomal 
trafficking and altered immune responses in macrophages and microglia (O’Rourke 
et al., 2016). Atanasio et al. (2016) observed myeloid expansion, T cell activation, 
increased plasma cells and enhanced autoantibodies in null mice. Burberry et al. 
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(2016) observed similar phenotypes including increased expression of inflammatory 
cytokines and severe autoimmunity. Atanasio et al. (2016) suggest based on these 
findings that C9ORF72 regulates immune homeostasis.  
C9ORF72 appears to also play a role in stress granule (SG) formation. Maharjan et 
al. (2017) found C9ORF72 is predominantly nuclear and localised to P-Bodies in 
neuronal and non-neuronal cell lines. C9ORF72 was found to colocalise with SGs 
in response to stressors such as ER stress and heat shock. Furthermore, 
C9ORF72 was shown to be required for SG formation via knockdown of both 
C9ORF72 isoforms using the CRISPR/Cas9 system. C9ORF72 knockdown 
inhibited the formation of SGs and reduced the phosphorylation of EIF2alpha which 
is required for stress granule assembly. Likewise, reductions in the levels of 
proteins involved in SG assembly were also observed; including downregulation of 
TIA-1, HuR and G3BP1. This reduction was also seen at the transcript level for 
TIA-1 and HuR suggesting C9ORF72 regulates the transcription of SG proteins.  
1.5.4 C9ORF72 protein isoforms 
 
A contentious issue in the field related to the function of the C9ORF72 protein is 
distinguishing between the two isoforms, C9L and C9S, and whether they have 
differing or complimentary roles in the processes just described. This is not helped 
by the lack of commercially available quality antibodies for C9ORF72 that can 
accurately detect the protein and distinguish between the two isoforms (Webster et 
al., 2016a). Structurally the two isoforms are different; the short isoform does not 
contain the DENN or alpha domains, only the longin domain (Xiao et al., 2016). The 
lack of the DENN domain in the short isoform would suggest it is the long isoform 
which regulates autophagy, as SMCR8 and C9ORF72 have been shown to interact 
by their DENN domains. Yang et al. (2016a) found in their gel filtration assay that 
C9L, but not C9S, comigrated with SMCR8, WDR41, and ATG101. Interestingly 
Sullivan et al. (2016) observed only C9L, and not C9S binds SMCR8; Xiao et al. 
(2016) also found in preliminary mass spectrometry and co-immunoprecipitation that 
only C9L bound to SMCR8 and WDR41. Taken together this data does suggest C9L 
may play a more important role in regulating autophagy than C9S.  
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Xiao et al. (2015a) are currently the only group to have developed and published 
antibodies specific for either of the isoforms. The isoform specific antibodies were 
generated by taking advantage of a unique lysine residue in the C-terminus of C9S 
encoded by the partial retention of intron 5 (Xiao et al., 2015b). Antibodies were 
generated for the C-terminal of C9L and the last 12 amino acids of C9S which 
includes a unique lysine residue. Both isoforms show a similar staining pattern in 
HEK293T cells and N2a cells, where they are found to localise diffusely in the 
cytoplasm and the nuclear envelope (Xiao et al., 2016). In the post-mortem human 
brain however labelling of the isoforms is strikingly different in neurons (Xiao et al., 
2015a). In control tissue C9L was mainly diffuse in the cytoplasm of spinal motor 
neurons and cerebellar Purkinje neurons, however in these cerebellar Purkinje 
neurons speckle-like structures in the cytoplasm and dendrites were also observed. 
The identity of these speckles was not discovered, although they did not co-localise 
with endosomal, lysosomal, autophagosome or polysomal markers (Xiao et al., 
2015a). C9S on the other hand had a completely different localisation, C9S was 
observed to localise to the nuclear membrane of Purkinje and spinal motor neurons. 
The localisation of C9S to the nuclear membrane suggests a potential role in 
nucleocytoplasmic transport and indeed C9S was found to co-localise with Lamin B, 
Importin-β1 and RAN-GTPase in lumbar spinal cord tissue. Hence C9ORF72 may 
have role in shuttling proteins across the nuclear membrane (Xiao et al., 2016).  
Maharjan et al. (2017) found the interaction between SGs and C9ORF72 was 
specific for the long isoform of the protein. Cells were transfected with the C9-
CRISPR followed by a second transfection with either the long isoform or short 
isoform. Transfection with C9L isoform led to strong SG formation after 
dithiothreitol (DTT) exposure; rescuing the inhibition of SG formation following 
knockdown of all isoforms using the C9-CRISPR. This rescue was not seen for 
cells transfected with C9S – implying isoform specificity. more precisely that the 






1.5.5 Summary of C9ORF72 protein function 
 
Prior to the discovery of the repeat expansion located in intron 1 C9ORF72 in 2011 
as a cause of ALS/FTD nothing was known about the proteins function; no previous 
publications had investigated C9ORF72. Discovering the function of C9ORF72 was 
originally hampered by the poor quality of commercially available antibodies and 
difficulties in generating antibodies that could distinguish between the two protein 
isoforms of C9ORF72. Structural analysis revealed C9ORF72 has homology to the 
DENN family of proteins suggesting C9ORF72 may have a functional role in 
endosomal trafficking events, including autophagic and lysosomal pathways. 
C9ORF72 has been shown to have a functional role in the initiation of 
macroautophagy and may also regulate lysosomal biogenesis. Both biological 
pathways are strongly associated with ALS/FTD (Hardy and Rogaeva, 2014). 
Additionally, mouse studies have revealed the protein appears to regulate immune 
homeostasis, previously associated with neurodegenerative disease (Heneka et al., 
2014) and also SG dynamics (Maharjan et al., 2017); particularly relevant to the 




1.6 Mechanisms of C9ORF72 ALS/FTD toxicity  
 
Currently three non-mutually exclusive hypotheses have been proposed as to how 
expanded G4C2 repeats may cause pathogenesis (figure 1.16) (Gitler and Tsuiji, 
2016). Firstly, the presence of expanded G4C2 repeats within C9ORF72 leads to 
reduced transcription of the gene and hence a reduction in C9ORF72 protein levels. 
The second hypothesis is that the repeats cause disease via RNA-mediated toxicity; 
through the formation of RNA foci which sequester essential RNA binding proteins. 
The third proposed mechanism for toxicity is the translation of the expansion from 
both the sense and anti-sense strand leading to the production of the DPRs which 
aggregate in patient brain and spinal cord. Defining which of these mechanisms are 
the driving force behind the disease is crucial to the development of potential 
treatments; for example, anti-sense oligonucleotides (ASOs) directed against the 
G4C2 RNA would potentially protect against RNA and DPR toxicity but may enhance 
the effects of a loss of C9ORF72 protein function by lowering C9ORF72 expression 
(Gitler and Tsuiji, 2016). The evidence for and against these 3 mechanisms will now 















Figure 1.16 | Pathogenic mechanisms associated with the G4C2 repeat 
expansion in C9ORF72. (A) The repeat expansion is in intron 1 of C9ORF72 
between non-coding exons 1a and 1b. (B) The repeat expansion interferes with 
the transcription of the gene leading to a reduction in C9ORF72 gene expression 
resulting in decreased C9ORF72 protein expression and potentially a loss of 
function of the protein. (C) The sense and anti-sense repeat RNA transcripts form 
nuclear and cytoplasmic RNA foci which sequester RNA binding proteins involved 
in numerous RNA processing pathways including splicing leading to defective pre-
mRNA splicing. (D) The sense and anti-sense transcripts are translated via RAN 
translation leading to the formation of dipeptide repeat proteins which form 
inclusions in the brains of ALS/FTD patients which may confer toxicity. From 






















1.7 Mechanisms of toxicity: protein loss of function 
 
Analysis of post-mortem C9ALS/FTD brain samples has revealed both transcript 
(De-Jesus Hernandez et al., 2011; Gijselinck et al., 2012; Belzil et al., 2013; Ciura et 
al., 2013; Xi et al., 2013; Fratta et al., 2013; Waite et al., 2014; van Blitterswijk et al., 
2015) and protein (Xiao et al., 2015a; Sivadasan et al., 2016) levels are decreased. 
As the C9ORF72 plays a role in trafficking and autophagy then impairments in these 
cellular functions would be predicted to result from C9ORF72 loss of function. Aoki et 
al. (2017) reported markedly impaired intracellular and extracellular vesicle trafficking 
and a defective trans-Golgi network phenotype in C9ALS/FTD iPSC motor neurons; 
such phenotypes could be rescued by overexpression of C9ORF72 or ASOs 
designed to upregulate transcript V1. These phenotypes were associated with the 
interaction of C9ORF72 with RAB7L1. C9ORF72 repeat expansion associated 
pathology is associated with the accumulation of unique p62 positive inclusions (Al-
Sarraj et al., 2011). The p62 protein is an autophagy receptor known to have an 
important role in targeting specific cargoes for autophagic degradation (Rusten and 
Stenmark, 2010). Further a number of genes associated with ALS have roles in 
autophagy including SQSTM1 (encoding p62), OPTN, VCP, UBQLN2 and TBK1 
(Oakes et al., 2017).  
Webster et al. (2016a) tested whether this p62 pathology was related to a potential 
loss of C9ORF72 protein function. A loss of C9ORF72 resulted in the accumulation 
of p62 positive puncta in both HeLa cells and primary cortical neurons. Reintroducing 
C9ORF72 reduced the number of p62 puncta to control levels. Webster et al. 
(2016a) went on to measure basal levels of autophagy in C9ALS/FTD iNeurons. 
Compared to controls, cell lines from C9ALS/FTD patients displayed higher levels of 
LC3-I and following treatment with bafilomycin A1, LC3-II levels were also increased 
but this increase was significantly lower than what was seen in treated control cells. 
Hence although autophagy was not blocked, basal levels were attenuated in 
C9ALS/FTD iNeurons compared to controls. Sellier et al. (2016) demonstrated the 
C9ORF72, SMRC8 and WDR41 complex interacts weakly with p62 and also OPTN, 
another autophagy receptor. Sellier et al. (2016) also demonstrated lowering 
C9ORF72 levels alters autophagy, specifically acting upon the formation of 
autophagosomes. C9ORF72 knockdown led to the formation of p62 aggregates in 
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primary mouse cortical neurons and GT1-7 neuronal cells. Aggregates of p62 were 
also observed following SMRC8 and WDR41 knockdown in GT1-7 cells. Re-
expressing C9ORF72 mRNA fully rescued autophagy dysfunction caused by 
C9ORF72 knockdown; however only the C9L isoform and not the C9S isoform 
rescued autophagy defects. Importantly decreased C9ORF72 expression promoted 
the aggregation of TDP-43; shRNA mediated knockdown of Ms-C9orf72 in mouse 
embryonic cortical neurons led to the accumulation of a ~30kDA fragment of mouse 
TDP-43 (Tdp-43). Furthermore, using an antibody against phosphorylated serine 
409/410 of Tdp-43, cytoplasmic aggregates of Tdp-43 were observed in these 
neurons (Sellier et al., 2016). In addition, overexpression of C9ORF72 reduced the 
aggregation propensity of the D196G mutant of TDP-43. The short isoform of 
C9ORF72 has been implicated in nucleocytoplasmic transport deficits; C9S was 
found at the nuclear membrane in healthy control spinal motor neurons, however for 
both C9 and sporadic ALS cases the C9-S isoform was mislocalised to the plasma 
membrane (Xiao et al., 2015a). The loss of C9-S from the nuclear membrane 
correlated with a mislocalisation of KPNB1, RAN and TDP-43 in C9ALS spinal motor 
neurons (Xiao et al., 2015a). 
A single zebrafish knockdown model demonstrated loss of the zebrafish homologue 
of C9ORF72 leads to motor deficits in fish (Ciura et al., 2013). Ciura et al. (2013) 
used an antisense morpholino oligonucleotide (AMO) in order to block the translation 
of the 1 zebrafish homologue of C9ORF72 (z C9orf72). As with the human gene, the 
fish homologue also encodes for 3 separate transcript variants that leads to 2 protein 
isoforms. Two different AMOs were designed and injected into the fish in order to 
target 2 translation initiation sites contained within the 3 transcripts. Knockdown of z 
C9orf72 led to disrupted arborisation and shortening of motor neuron axons 
compared to controls; further co-injection of the human C9ORF72 long transcript 
with the 2 AMOs rescued this axonal phenotype. These axonal phenotypes are 
potentially explained by the role C9ORF72 plays in regulating cellular actin dynamics 
via its modulation of Arf6 GTPase activity and the phosphorylation of cofilin 
(Sivadasan et al., 2016). No changes in the levels of zTDP-43 were observed. C9 
AMO injection led to abnormalities in both spontaneous and evoked swimming, 
these motor deficits could be rescued upon co-expression of C9ORF72 mRNA. 
However, another unpublished zebrafish study did not observe any axonal deficits or 
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impaired motor function in fish following C9ORF72 knockdown (Schmid, Hruscha, 
Haass, unpublished; as referenced in Stepto et al., 2014). Deletion of the C. elegans 
C9orf72 homologue, F18A1.6, also called alfa-1, leads to age-dependent motor 
phenotypes eventually causing paralysis and also the specific degeneration of 
GABAergic motor neurons (Therrien et al., 2013). Furthermore alfa-1 mutants were 
highly sensitive to osmotic stress indicating alfa-1 plays a role in protecting worms 
from osmotic stress. Therrien et al. (2013) also found the motor impairment caused 
by alfa-1 loss was additive with mutant TDP-43, but not FUS, toxicity.  Ugolino et al. 
(2016) found homozygous Ms-C9orf72 knockout mice showed decreased survival 
compared to controls with 50% being dead by 600 days. A decrease was also 
observed for heterozygous mice with around 20% being dead after 600 days. The 
authors note both homozygous and heterozygous mice develop normally before 
demonstrating rapid progressive lethargy prior to death. As was reported previously 
splenomegaly was observed in homozygous Ms-C9orf72 null mice (O’Rourke et al., 
2016; Atanasio et al., 2016; Burberry et al., 2016; Sudria-Lopezet al., 2016). Loss of 
Ms-C9orf72 also impaired mTOR signalling in mouse embryonic fibroblasts 
generated from these mice. Sullivan et al. (2016) observed both autophagy and 
lysosomal deficits in Ms-C9orf72 deficient mice. Interestingly the mouse homologue 
of C9ORF72 is enriched in neurons known to be vulnerable and degenerate in ALS 
and FTD (Suzuki et al., 2013).  
1.7.1 Mechanisms of C9ORF72 protein loss of function 
 
Several studies have probed into the mechanisms behind a C9ORF72 protein loss of 
function. Early studies demonstrated downregulation of C9ORF72 in expansion 
carriers (DeJesus-Hernandez et al., 2011). In the fontal cortex reduced expression 
levels have been reported for all C9ORF72 transcripts (Gijselinck et al., 2012; Ciura 
et al., 2013; Belzil et al., 2013; Waite et al., 2014), the V1 transcript (Gijselinck et al., 
2012) and the V2 transcript (DeJesus-Hernandez et al., 2011; Fratta et al., 2013; 
Waite et al., 2014). In the cerebellum a decrease in total transcript levels has been 
reported (Belzil et al., 2013) and a specific reduction in V2 cerebellar transcript levels 
has also been observed (Waite et al., 2014). The most detailed study investigating 
C9ORF72 transcript expression levels has been performed by van Blitterswijk et al. 
(2015). Using quantitative and digital molecular barcoding techniques the authors 
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observed a decrease in expression levels in patients compared to controls for total 
C9ORF72 transcripts, V1 and V2 levels, with the strongest decrease being seen for 
V2 - no decreases were seen for transcript V3. Further increased V1 levels in the 
frontal cortex and cerebellum associated with increased survival. The repeats are 
located in an intron between two alternatively spliced exons for transcripts V1 and 
V3; whereas for V2 the expanded repeats are located within the promoter region 
(Stepto et al., 2014). It has been proposed that this reduced expression of V2 leads 
to haploinsufficiency if transcription from the wild-type allele is unable to compensate 
in producing enough C9ORF72 protein (Gitler and Tsuiji et al., 2016) (figure 1.17). 
Indeed Sareen et al. (2013) observed the presence of G4C2 repeats potentially 
causes transcription of exon 1a (from transcripts V1 and V3) to be favoured over 
exon 1a (from transcript V2). One mechanism for this downregulation is the 
methylation of C9ORF72 discussed previously; this epigenetic change has been 
intensively studied to determine whether such a change may play a role on 
C9ORF72 loss of function (Belzil et al., 2016). Hypermethlylation of the 5’ CpG 
island in the C9ORF72 promotor is found in 10-30% of C9ALS/FTD cases (Belzil et 
al., 2016). The length of the repeat has been found to influence this 
hypermethylation; with longer repeats being associated with increases in promoter 
methylation (Xi et al., 2015b). Xi et al. (2013) demonstrated increased methylation of 
the 5’ CpG island correlates with a shorter duration of disease in ALS. A second 
mechanism potentially underlying the decreased mRNA expression of C9ORF72 is 
abortive transcription due to the presence of the G4C2 repeats (Haeusler et al., 
2014). Haeusler et al. (2014) found the repeat expansion perturbs normal 
transcription generating abortive RNA transcripts; this process was facilitated by the 
formation of G-quadruplexs and RNA: DNA hybrids known as R-loops. These 
abortive RNA transcripts were bound by specific proteins such as nucleolin, which 
was mislocalised in patient cells. The binding nucleolin to the repeat RNA was 
































Figure 1.17 | G4C2 repeat associated epigenetic silencing associated 
resulting in reduced C9ORF72 expression and therefore haploinsufficiency. 
C9ORF72 is alternatively spliced to produce 3 mRNA transcripts. The G4C2 
repeat expansion is located in-between exons 1a and 1b and is proposed to 
cause an epigenetic silencing of the C9ORF72 gene through either 
hypermethylation or abortive transcription leading to reduced C9ORF72 protein 







1.7.2 Evidence against loss of protein function  
 
A central role for a loss of C9ORF72 in C9ALS/FTD neurodegeneration is unlikely 
(Edbauer and Haass, 2016). Despite C9ORF72 knockdown clearly leading to 
defective autophagy, no reduction in neuronal viability is observed following either 
siRNA or shRNA treatment of neuronal primary cultures (Sellier et al., 2016). 
Reduced C9ORF72 transcript expression because of hypermethylation may be 
neuroprotective (Belzil et al., 2013; Liu et al., 2014; McMillan et al., 2015; Russ et al., 
2015). (Belzil et al., 2016). For example, reduced RNA foci and DPR burden is seen 
in post-mortem patient brains with CpG hypermethylation (Liu et al., 2014). Bauer, 
(2016) demonstrated in vitro that methylation of the G4C2 reduces poly-GP levels 
and RNA foci formation. Hence reducing C9ORF72 mRNA appears to be 
neuroprotective as it reduces the toxic the gain of function species derived from the 
G4C2 expansion. Indeed, lowering levels of C9ORF72 in patient iPSC neurons and 
iPSC motor neurons improves, rather than worsens gene expression changes 
associated with the repeat expansion (Donnelly et al., 2013; Sareen et al., 2013). 
Genetic evidence also suggests a loss of C9ORF72 protein function is not sufficient 
for the development of clinical disease; no loss of function mutations identified 
including nonsense or frameshift mutations have been found in C9ORF72 (Harms et 
al., 2013). A splice site mutation in C9ORF72 was found in a Chinese ALS patient 
(Liu et al., 2016c); however, it is unclear if this mutation is disease causative (Moens 
et al., 2017). Further a rare homozygous expansion case showed no enhanced 
pathological or clinical phenotype (Fratta et al 2013). Despite evidence in worms 
(Therrien et al., 2013) and fish (Ciura et al., 2013) demonstrating a loss of C9ORF72 
homologues can cause motor dysfunction and neurodegeneration; this has not been 
replicated in murine models of C9ORF72 loss of function. ASO knockdown reducing 
levels of Ms-C9orf72 by up to 50% for several months does not result in any 
neuropathology or behavioural phenotypes (Lagier-Tourenne et al., 2013). Selective 
depletion of Ms-C9orf72 from neurons and glial cells also does not produce any 
motor dysfunction, motor neuron degeneration or reduced survival (Koppers et al., 
2015). Furthermore, no TDP-43 mislocalisation or changes ubiquitin staining were 
seen in these mice. Jiang et al. (2016) observed very mild social interaction defects 
and a mild reduction in rotarod performance without changes in grip strength, gait, 
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general activity or a loss of motor neurons in Ms-C9orf72 null mice. Taken together 
this data strongly suggests a loss of C9ORF72 is not sufficient to cause ALS/FTD 
phenotypes or neurodegeneration. This indicates a loss of function of the protein is 
not the primary disease mechanism in C9ALS/FTD. 
1.7.3 Summary of loss of protein function 
 
In summary findings from murine knockout models and genetic evidence from 
patients has shown a loss of C9ORF72 function is unlikely to be the main pathogenic 
cause of C9ALS/FTD (Edbauer and Haass, 2016). C9ORF72 loss of function does 
not lead to TDP-43 associated neurodegeneration or any motor neuron cell loss for 
that matter (Koppers et al., 2015). The role of C9ORF72 in autophagy and immune 
dysregulation is interesting considering both processes are associated with ALS and 
FTD (Heneka et al., 2014; Gao et al., 2017). Defective autophagy could enhance 
DPR accumulation and thereby DPR toxicity (Webster et al., 2016b). Indeed, the 
DPRs are mainly cleared via autophagy (Cristofani et al., 2017); hence a loss of 
C9ORF72 protein function may enhance DPR accumulation.  Furthermore, the link 
between C9ORF72 and SG formation (Maharjan et al., 2017) is interesting given the 
recent findings that the arginine DPRs perturb SG dynamics (Lee et al., 2016; 
Boeynaems et al., 2017). Hence a loss of C9ORF72 protein function likely plays a 











1.8 Mechanisms of toxicity: G4C2 RNA toxicity  
 
Analogues to what is seen in other neurodegenerative diseases caused by 
expanded nucleotide sequences in the non-coding regions, it is hypothesized that 
the formation of sense G4C2 and anti-sense C4G2 foci causes the sequestration of 
RNA binding proteins and splicing factors leading to their loss of function (DeJesus-
Hernandez et al., 2011). Indeed, the accumulation of these RNA foci in the 
C9ALS/FTD brain is similar to the RNA foci identified in myotonic dystrophy type 1 
(DM1), myotonic dystrophy type 2 (DM2) and fragile X-associated tremor (FXTAS); 
these diseases are caused by expanded nucleotide sequences in the non-coding 
regions of the genes DMPK, CNBP and FMR1 respectively (Taylor et al., 2016). In 
these diseases the RNA foci sequester RNA binding proteins and splicing factors 
leading to a loss of their normal function which underlies some of the pathogenesis 
of these diseases (Taylor et al., 2016). For example, in myotonic dystrophy type 1 
(DM1) caused by a CTG repeat expansion in the 3’UTR of the DMPK gene (Brook et 
al., 1992); the RNA binding protein muscleblind (MBNL) is sequestered into CUG 
RNA foci (Fardaei et al., 2001); upregulation of MBNL is sufficient to rescue toxicity 
in vivo (de Haro et al., 2006).  Indeed, restoration of MBNL function rescues DM1 
phenotypes (Pettersson et al., 2015). Based on this several labs sought to identify 
RNA binding proteins sequestered by the sense and/or anti-sense foci produced 
from the C9ORF72 expansion; and whether a loss of function of these RNA binding 
proteins contributes to neurodegeneration (Gitler and Tsuiji, 2016). 
1.8.1 Sequestration of RNA binding proteins by G4C2 RNA 
 
Numerous RNA binding proteins have been found to be sequestered by G4C2 or 
C4G2 RNA foci in patient tissue and model systems or bind to the repeat RNA in in 
vitro assays. Interacting proteins include ADARB2, ALYREF, hnRNP A1, hnRNP A3, 
hnRNP H, hnRNP H1, hnRNP H2, hnRNP F, hnRNP K, hnRNP Q, hnRNP U, 
Nucleolin, PABPc, Pur-alpha, SRSF1 (SF2) SRSF2 (SC35) and Zfp106 (Donnelly et 
al., 2013; Lee et al., 2013; Sareen et al., 2013, Almedia et al., 2013, Haeusler et al., 
2014; Cooper-Knock et al., 2014; Cooper-Knock et al., 2015; Mori et al., 2016; Rossi 
et al., 2015; Celona et al., 2017). The RNA binding partners for sense and anti-sense 
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foci are similar (Haeusler et al., 2014; Cooper-Knock et al., 2015). The RAN GTPase 
protein RanGAP1 involved in nucleocytoplasmic transport has also been identified 
as a component of G4C2 RNA foci (Zhang et al., 2015). Importantly TDP-43 has not 
been identified as interacting directly with G4C2 RNA foci (Donnelly et al., 2013; Lee 
et al., 2013; Sareen et al., 2013, Almedia et al., 2013; Lagier-Tourenne et al., 2013; 
Chew et al., 2015).  
The sequestration of RNA‐binding proteins into foci (figure 1.18) has been proposed 
to perturb several aspects of post‐transcriptional gene regulation; including 
alternative mRNA splicing, translational regulation and mRNA transport (Rossi et al., 
2015; Barker et al., 2017). Whilst a number of different RNA binding proteins have 
been found to interact with G4C2 or C4G2 RNA foci; if any of these are critical for 
pathogenesis remains an open question (Gitler and Tsuiji, 2016). The binding of 
proteins to the repeat RNA is structural dependent (Haeusler et al., 2014). The G-
rich DNA and RNA of the repeat expansion, due to the highly repetitive nature of the 
sequence, forms highly complex secondary structures including unimolecular and 
multimolecular G-quadruplexes (Fratta et al., 2012; Reddy et al., 2013; Haeusler et 
al., 2014; Zhou et al., 2015; Conlon et al., 2016). G-quadruplexes are stable four 
strand structures formed of planar guanine tetramers stacked on top of one another 
(Zhou et al., 2015). Further the G4C2 RNA and the anti-sense C4G2 RNA both form a 
stable hairpin secondary structure (Haeusler et al., 2014). Haeusler et al. (2014) 
demonstrated RNA binding proteins favour specific RNA topologies formed by the 
repeats; unique proteins bound the G4C2 G-quadruplex, the G4C2 hairpin and the 
C4G2 hairpin. For example, nucleolin preferentially bound the G4C2 G-quadruplex; 
hnRNP F bound both the G4C2 G-quadruplex and hairpin whereas hnRNP K showed 

















1.8.2 Splicing alterations associated with G4C2 RNA toxicity  
 
A number of the proteins that bind to the repeat RNA have important functions in 
RNA splicing; in particular several members of the hnRNP family of splicing factors 
(Barker et al., 2017). Lee et al. (2013) found in SH-SY5Y cells’ expressing 72 G4C2 
repeats that splicing efficiency was reduced. hnRNP H is required for the inclusion of 
exon 7 into the mature TARBP2 RNA. Lee et al. (2013) observed inclusion of exon 7 
into TARBP2 is dramatically reduced; a lesser reduction in exon 7 inclusion was also 
seen in cells transfected with the 72 G4C2 repeat construct. This data therefore 
shows the sequestration of RNA binding proteins into RNA foci perturbs splicing and 
indicates a loss of hnRNP H function may play a role in C9ORF72 ALS/FTD 
pathogenesis. Indeed Colon et al. (2016) found hnRNP H is the major protein 
associated with G4C2 RNA and 1.9x more insoluble in C9ALS motor cortex 
compared to controls due to the formation of insoluble hnRNP H aggregates with G-
quadruplex RNAs in the C9ALS brain. Colon et al. (2016) also found reduced exon 
inclusion for a number of known hnRNP H RNA targets from C9ALS cerebellum, 
most notably ataxin-2 – a disease modifier of C9ALS/FTD (van Blitterswijk et al., 
2014). Indeed Colon et al. (2016) note splicing dysregulation, in particular exon 
skipping, has previously been reported in RNA-seq data from the cerebellum and 
frontal cortex of C9ALS patients (Prudencio et al., 2015). It was suggested hnRNP H 
may potentially be driving these splicing changes as misregulated alternative splicing 





Figure 1.18 | G4C2 repeat RNA toxicity. G4C2 RNA is potentially neurotoxic by 
sequestering RNA binding proteins leading to perturbed RNA processing. 







in binding motifs for hnRNP H (Prudencio et al., 2015). Prudencio et al. (2015) found 
splicing abnormalities were 3-fold higher in the C9ALS brain compared to SALS.  In 
addition, both Cooper-Knock et al., (2015) and Colon et al. (2016) found a reduction 
in the duration of disease correlated with enhanced alterations in exon inclusion.  
1.8.3 Translational deficits associated with G4C2 RNA toxicity 
 
Rossi et al. (2015) identified translational repression as one consequence of the 
sequestration of RNA binding proteins into repeat foci. Rossi et al. (2015) generated 
a 31 repeat G4C2 construct (G4C2)31 which when transfected in mouse motor 
neuronal NSC34 cells formed RNA foci. Proteins that bound to the (G4C2)31 repeats 
were regulators of translation including initiation and elongation factors (EF1α, 
eIF2α, eIF2β and eIF2γ) and a number of other proteins that regulate translation 
including Pur‐alpha, Pur‐beta, ILF2, ILF3 and RAX. One of these targets Pur-alpha 
has previously been identified as a binding partner of repeat RNA in vitro and in an in 
vivo Drosophila model of repeat toxicity by Xu et al. (2013). Xu et al. (2013) found 
overexpression of Pur-alpha rescued retinal induced repeat toxicity and was found to 
form aggregates in post mortem human cerebellum and the Drosophila retina. Pur-
alpha, although rarely co-localising with RNA foci, was grossly mislocalised in cells 
expressing the repeats. In un-transfected cells Pur-alpha is diffusely localised in the 
cytoplasm, however in cells with RNA foci, Pur-alpha, and its binding partner FMRP, 
accumulated in cytoplasmic and nuclear granules. Rossi et al. (2015) observed 
increased SG formation (a marker for translational arrest) and a reduction in the rate 
of mRNA translation in cells transfected with the (G4C2)31 construct. Furthermore 
Rossi et al. (2015) demonstrated the repeats cause defective mRNA export from 
nucleus, causing poly(A) RNAs to accumulate. Rossi et al. (2015) observed the 
poly(A) binding protein PABPC1 which has a crucial role in cytoplasmic mRNA 
translation and stability, accumulated in the nucleus of (G4C2)31 cells. Furthermore, 
PABPC1 accumulated in RNA foci and bound repeat RNA. Barker et al. (2017) 
suggest nuclear sequestration of PAPBC1 is likely to be detrimental to global 
translational efficiency of cytoplasmic mRNAs due to its role in promoting the 
interaction between translation initiation factors and the 5’ cap of mRNA, causing an 
association of the ribosome with the nascent transcript (Barker et al., 2017). 
Interestingly PAPBC1 inclusions have been found previously in human post-mortem 
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ALS spinal cord, where intriguingly the colocalization between PAPBC1 and TDP-43 
in spinal cord motor neurons was twice as frequent in C9 ALS compared to sporadic 
ALS (McGurk et al., 2014).  
Burguette et al. (2015) demonstrated G4C2 repeat RNA perturbs local translation in 
neurites. The authors detected G4C2 RNA particles in neurites that are actively 
transported to distal neuronal processes, indicting the repeat RNA is assembling into 
mRNA transport granules. Branching defects were also reported in both spinal cord 
motor neurons cultured from rats and Drosophila sensory dendritic arborisation 
neurons (Burguette et al., 2015). These branching defects were due to altered 
transport granule function, when components of mRNA transport granules such as 
fly fragile x mental retardation protein (dFMRP) were up or downregulated the 
branching phenotypes were potentiated or rescued respectively. FMRP in rat spinal 
cord neurons was found to colocalise with (G4C2)31 in neuritic granules in neuronal 
processes which suggests FMRP function might be perturbed. FMRP controls the 
spatial and temporal expression of proteins involved in synaptic plasticity, it is found 
at postsynaptic dendritic spines where it binds dendritic mRNAs and 
represses/derepresses their translation (Santoro et al., 2012). Indeed, protein levels 
of the FMRP target dendritic mRNA postsynaptic density protein (PSD-95); total 
PSD-95 levels were increased in addition to increases in the number of PSD-95 foci 
per neuron (Burguette et al. 2015).  
These data suggest G4C2 RNA disrupts mRNA transport and the translational 
machinery, leading to transport granule dysfunction. Interestingly it has previously 
been shown that the G-quadruplex RNA structure is a signal for the targeting of 
mRNAs to neurites (Subramanian et al. 2011).  Taken together the aforementioned 
studies suggest translational arrest may play an important role in C9ORF72 repeat 
expansion mediated toxicity.   
1.8.4 Nucleocytoplasmic transport deficits associated with 
G4C2 RNA toxicity 
 
Defective nucleocytoplasmic transport is now established as a key pathogenic 
mechanism in C9ALS/FTD (Zhang et al., 2015; Freibaum et al., 2015; Boeynaems et 
al., 2016). Zhang et al. (2015) performed a genetic screen using the 30 G4C2 repeat 
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flies generated by Xu et al. (2013). One of the strongest suppressors of G4C2 toxicity 
was RanGAP, a key regulator of nucleocytoplasmic transport. Human RanGAP was 
found to bind to the sense G4C2 RNA G-quadruplex, additionally RanGAP puncta 
were also observed in C9ALS iPSCs with the protein also occasionally co-localising 
with G4C2 RNA foci. Cells expressing the 30 G4C2 repeat construct showed 
disturbances in the nuclear/cytoplasmic ratio of Ran, with higher levels of 
cytoplasmic RAN seen. RanGAP hydrolyses RAN inducing its GTPase activity; 
catalysing its conversion from RanGTP to RanGDP (Cautain et al., 2014); complex 
bound GDP RAN binds to cytosolic cargoes and translocates to the nucleus 
(Stewart, 2007). Hence this data indicates the repeat RNA induces a loss of 
RanGAP function. Further the nuclear/cytoplasmic ratio of RAN returned to levels of 
controls when RanGAP was overexpressed or when an ASO that removed RNA foci 
was used to target the sense G4C2 RNA. Nuclear import was also found to be 
defective in Drosophila salivary gland cells expressing 30 G4C2 repeats as evidenced 
by the cytosolic accumulation of a NLS-ΔNES-GFP construct and Drosophila TDP-
43, TBPH. These phenotypes were rescued by the ASO and the G-quadruplex 
inhibiter TMPyP4 - which would prevent RanGAP interacting with the G-quadruplex 
G4C2 RNA. Based on the above data the authors suggested the nucleocytoplasmic 
transport deficits were due to C9ORF72 sense strand RNA toxicity. DPRs were not 
detectable using dot blotting in the 30 G4C2 repeat flies, although the authors were 
not able to rule out undetectable levels of DPRs potentially having an effect.  Indeed, 
several other studies have shown the DPRs to cause deficits in nucleocytoplasmic 
transport (Jovičić et al., 2015; Boeynaems et al., 2016a) (see section 1.9.3.1). 
1.8.5 Evidence against G4C2 RNA toxicity 
 
Animal models provide a conflicting picture as to whether the G4C2 RNA plays a toxic 
role in disease. Xu et al. (2013) generated a 30 sense repeat fly model, the toxicity of 
which was attributed to the G4C2 RNA by Zhang et al. (2015) as DPRs were not 
detectable under most conditions. Several other Drosophila studies however argue 
against RNA toxicity as a driving factor behind pathogenesis (Mizielinska et al., 
2014; Tran et al., 2015). Mizielinska et al. (2014) generated RNA-only G4C2 repeat 
constructs by inserting one of three 6-base-pair interruptions, each of which 
contained a STOP codon in both the sense and antisense direction every 12 G4C2 
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repeats, which meant there was a stop codon present for all 6 reading frames. These 
RNA-only constructs developed were equivalent in length to 36, 107 and 288 pure 
G4C2 repeats. The RNA-only constructs were shown to still form the characteristic 
RNA G-quadruplex formed by pure G4C2 RNA repeats. The RNA-only constructs 
also formed RNA foci at the same propensity as pure repeat constructs of an 
equivalent length.  To compare RNA toxicity to DPR toxicity Mizielinska et al. (2014) 
generated transgenic flies harbouring these RNA-only constructs, flies with pure 
G4C2 repeats and DPR only flies. DPR only constructs were generated using 
alternative non-G4C2 codons that produce for the same peptide from an ATG. 
Alternative codon DPR only flies were generated for all DPRs except poly-GP. 
Expression of either 36 or 103 pure repeats in the Drosophila eye (in which RAN 
translation occurred) caused degeneration, however RNA-only constructs of an 
equivalent length caused no degeneration, and thus pure repeat toxicity is 
attributable to DPRs rather than G4C2 RNA. When DPR producing pure repeat 
constructs were expressed in adult fly neurons, a reduction in life-span was seen, 
whereas RNA only repeats had no effect. Additionally, treating flies with 
cycloheximide which reduces protein synthesis rescued the lifespan deficits seen in 
the pure repeat flies; demonstrating toxicity in the pure repeat flies is likely due to 
DPR expression. Furthermore poly-GR and poly-PR protein only constructs caused 
both severe neurodegeneration and markedly reduced in lifespan in flies. Tran et al. 
(2015) generated a Drosophila model in which the G4C2 repeats were in an intronic 
context. Flies were generated containing a minigene with exon 1, part of intron 1 with 
the G4C2 repeats and exon 3 of C9ORF72. This differs from the Mizielinska et al. 
(2014) flies and other Drosophila models (Xu et al., 2013; Zhang et al., 2015; 
Freibaum et al., 2015) in which the G4C2 repeats are transcribed as part of a poly(A) 
mRNA. Flies expressing 106 intronic G4C2 repeats develop normally and had no 
alterations in lifespan. Numerous sense RNA foci were seen, however, rRNA 
biogenesis and mRNA processing were both unperturbed. Only a small number of 
differentially expressed genes and exon skipping events were seen suggesting that if 
RNA foci are sequestering RNA binding proteins in these flies, it is having little effect 
on RNA processing. When the 106 intronic repeat flies were compared to the 36 
repeat pure G4C2 flies generated by Mizielinska et al. (2014) in which the repeats are 
part of the poly(A) mRNA (in which eye degeneration and life span abnormalities are 
seen), DPR levels were found to be >100 fold higher in the poly(A) 36 repeat flies. 
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Modest reductions in lifespan could be observed in the 106 intronic repeat flies when 
they were raised at 29°C; however, DPR production was 4x higher under these 
conditions compared to basal levels. Hence this study further supports the 
conclusions of Mizielinska et al. (2014) indicating toxicity is primarily driven through 
DPRs, rather than sense RNA foci.  
BAC transgenic mouse models also argue against RNA toxicity.  BAC models allow 
repeat sizes found in the human cases to be modelled in vivo. Peters et al. (2015) 
and O’Rourke et al. (2015) both generated BAC transgenic mice harbouring 
expansion sizes pathogenic in humans (500 and ~100-1000 repeats respectively). 
These mice displayed the typical pathological features seen in patient brains 
including widespread sense and anti-sense RNA foci in brain regions such as the 
frontal cortex, primary motor cortex, cerebellar neurons and spinal cord motor 
neurons. Despite wide-spread RNA foci formation no neurodegeneration, cognitive 
or motor phenotypes were seen, additionally these mice had a lifespan similar to 
controls. DPRs were also detected in these models although only poly-GP was 
probed for in both studies. Liu et al. (2016a) generated numerous BAC transgenic 
mice of different repeat lengths that displayed motor phenotypes, cognitive decline, 
muscle denervation, a loss of motor neurons and cortical degeneration. Sense and 
anti-sense foci were detected in numerous brain regions in addition to aggregates of 
all three sense DPRs, poly-GP, poly-GA and poly-GR in addition to Tdp-43 
pathology. The anti-sense foci in particular were found to accumulate in vulnerable 
brain regions in these mice. In one of the BAC lines harbouring a short expansion 
(36 and 29 repeats) DPRs were produced but no RNA foci were seen. These mice 
demonstrated motor phenotypes, cognitive impairment and end stage Tdp-43 
pathology arguing against RNA foci toxicity. Chew et al. (2015) presented evidence 
in favour of sense G4C2 RNA toxicity. Using the adeno-associated virus AAV2/9 to 
express 66 G4C2 repeats in the nervous system of mice Chew et al. (2015) 
demonstrated nuclear sense RNA foci, all 3 sense DPRs, Tdp-43 pathology, 
neurodegeneration, motor and cognitive impairment. Interestingly Tdp-43 pathology 
in this model correlated with the presence of nuclear RNA foci; suggesting repeat 
RNA may drive TDP-43 dysfunction. It has also been shown the expression of sense 
repeats from an intron causes toxicity in mouse primary cortical and motor neurons 
without detectable DPRs (Wen et al., 2014). 
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However, a recent in-depth clinico-pathological study of RNA foci in a large cohort of 
C9ORF72 expansion carries suggest RNA foci are not associated with clinico-
pathological variability seen in expansion carries nor does it follow the pattern of 
neurodegeneration (DeJesus-Hernandez et al., 2017). In fact, increased anti-sense 
RNA foci burden was associated with a delayed age of onset. Sense RNA foci were 
not associated with age of onset and neither sense nor anti-sense foci were 
associated with repeat length, C9ORF72 transcripts, DPR proteins, gender, disease 
subgroups or survival after onset. For example, increased foci burden was not seen 
in C9FTD frontal cortex compared to C9ALS frontal cortex, which would be predicted 
if foci are toxic. Most RNA foci were present in cerebellar Purkinje neurons; however, 
no loss of Purkinjie neurons has been reported in the cerebellum of C9ALS/FTD 
patients (DeJesus-Hernandez et al.., 2017; Tran et al., 2016). It has been suggested 
RNA foci may act as neutral intermediates and may even be neuroprotective by 
preventing the export of the repeat RNA into the cytoplasm where it is translated into 
DPRs (Tran et al., 2015).  
1.8.6 Summary of RNA toxicity 
 
There is clear evidence to demonstrate the formation of RNA foci disrupts numerous 
cellular processes including splicing, translation and nucleocytoplasmic transport. 
The findings from in vivo models and studies of foci burden in the human brain and 
their correlations with disease variables suggest the repeat RNA is at least not the 
sole contributor to C9ALS/FTD pathogenesis; with some going as far as proposing 
the repeat RNA may even be neuroprotective (Tran et al., 2015). One issue with the 
in vivo models is that although these animals express the repeat RNA they may not 
have the key RNA binding proteins whose sequestration could be important for RNA 
toxicity, especially in motor neurons (Liu et al., 2016c). Disentangling the contribution 
of sense and anti-sense transcripts will also be important for further understanding 
the contribution of RNA toxicity to disease. At present no study has investigated the 
potential toxicity of anti-sense C4G2 RNA in isolation; indirect evidence suggests the 
anti-sense foci may have bigger impact in disease associated cell loss (Cooper-




1.9 Mechanisms of toxicity: DPR toxicity  
 
In order to investigate DPR toxicity in isolation from the G4C2 RNA researchers have 
taken advantage of the degeneracy in the genetic code. By using alternative non 
G4C2 triplet codons that code for the same amino acids that constitute the 5 DPRs 
translated from the different G4C2 reading frames, constructs have been generated in 
which the induvial DPR proteins are produced from an ATG. (Mizielinska et al., 2014; 
Zhang et al., 2014; May et al., 2014; Tao et al., 2015; Yamakawa et al., 2015; Yang 
et al., 2015; Zhang et al., 2016; Callister et al., 2016; Boeynaems et al., 2016a; Lee 
et al., 2016; Lee et al., 2017; Schludi et al., 2017). This allows the potential toxicity of 
the different DPRs to be studied in isolation from the repeat RNA and also the other 
DPRs, as RAN translation will not occur. One issue with such models is that they 
lead to a massive overexpression of the DPRs due to the use of ATG, which may 
overestimate their contribution to pathogenesis, as RAN translation is less efficient 
than canonical translation (Kearse et al., 2016). Being able to potentially turn off and 
on RAN translation would be the most accurate way to study and differentiate 
between repeat RNA and DPR toxicity and also accurately assess the relative 
contribution of the DPRs to pathogenesis as the amount of DPR protein will be 
similar to physiological patient levels. Such work requires a better understanding 
about the mechanisms of RAN translation and how it initiates. 
1.9.1 Mechanisms of RAN translation 
 
Repeat associated non-ATG (RAN) translation is the production of peptides from an 
mRNA sequence lacking a traditional ATG start codon (Green et al., 2016). RAN 
translation was first discovered by Zu et al. (2011) in their study of spinocerebellar 
ataxia type 8 (SCA8). Zu et al. (2011) found when studying the poly-glutamine (poly-
Gln) produced from ATXN8 expansion transcripts, that mutation of the only ATG 
codon 5’ of the CAG expansion surprisingly did not prevent the translation of poly-
Gln. Further translation of the CAG repeat was found to initiate in multiple reading 
frames generating a total of 3 homopolymeric proteins, poly-glutamine (poly-Gln), 
poly-alanine (poly-Ala) and poly-serine (poly-Ser). The authors found RAN 
translation to be dependent on the secondary structure of the CAG RNA as reducing 
either the number of CAG repeats or the GC content inhibited RAN translation. Zu et 
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al. (2011) went on to generate antibodies against the poly-Ala peptide finding the 
protein is present in the cerebellum of SCA8 patients and mouse models of SCA8. 
Further in vitro evidence was presented for poly-Gln anti-sense translation from 
DMPK antisense transcripts with CAG expansion linked myotinic dystrophy type 1 
(DM1). Since this initial discovery, RAN translation was been found to occur in a 
number of neurological diseases associated with nucleotide repeat expansions 
including C9ALS/FTD (Mori et al., 2013a; Ash et al., 2013), fragile X tremor ataxia 
syndrome (FXTAS) (Todd et al., 2013), Huntington disease (HD) (Bañez-Coronel et 
al., 2015), spinocerebellar ataxia type 31 (SCA31) (Ishiguro et al., 2017) and most 
recently in myotonic dystrophy type 2 (DM2) (Zu et al., 2017). There is increasing 
evidence that these RAN translated proteins are not just pathological bystanders but 
rather, actively contribute to the pathogenesis of disease (Green et al., 2016).  
How RAN translation occurs and the mechanisms behind this non-canonical form of 
translation are not yet fully understood. Much of the current understanding into 
mechanisms of RAN translation has come from work studying the CGG repeat 
expansion in the 5’UTR of FMR1 associated with FXTAS (Todd et al., 2013; Kearse 
et al., 2016). Todd et al. (2013) found RAN translation of CGG repeats occurs in at 
least 2 reading frames; the GGC (+1) frame producing a polyglycine peptide 
(FMRpolyG), and the GCG (+2) frame leading to the production of a polyalanine 
peptide (FMRpolyA). Todd et al. (2013) found both the sequence 5’ of the repeats 
and repeat length are important factors in influencing the levels of RAN translation. 
For example, it was observed that the insertion of a STOP codon upstream of the 
CGG repeat sequence inhibited FMRpolyG production. Additionally, mutation 
analysis revealed FMRpolyG translation occurs at multiple near cognate AUG start 
codons in the 5’UTR. STOP codons however did not prevent translation of 
FMRpolyA indicating translation occurs within the repeats itself for this reading 
frame. Hence RAN translation appears to be mechanistically different in different 
reading frames (Green et al., 2016). Further research by the same group revealed 
RAN translation in FXTAS is cap-dependent in multiple reading frames, and does not 
utilize cap-intendent mechanisms such as an internal ribosomal entry sites (IRES) 
(Kearse et al., 2016). Canonical translation usually beings with recognition of the 5’ 
methyl-7-guanosine (m7G) cap on mRNA by the eIF4F complex (Green et al., 2016). 
Kearse et al. (2016) demonstrated when the m7G cap is substituted with an A-cap, 
89 
 
not recognized by eIF4, RAN translation from CGG repeats is inhibited. Further by 
sequestering eIF4E using excess free m7G cap, RAN translation of both FMRpolyG 
and FMRpolyA is inhibited. Neither of these modifications disrupted IRES translation, 
indicating CGG RAN translation in the FMR1 5’UTR is cap-dependent similar to the 
initiating stage of canonical translation (Kearse et al., 2016; Green et al., 2016). 
Following cap-dependent initiation the 43S pre-initiation complex (PIC) joins the 
eIF4F complex still bound to the m7G cap and scans through the 5’ UTR in search of 
an AUG codon (Green et al., 2016). Kearse et al. (2016) note that if this scanning 
model holds for CGG expansion in FXTAS, then the 43S PIC would have to scan 
through the CGG repeats in the 5’UTR until it reaches the AUG of FMR1. Indeed, the 
authors found by inhibiting 43S PIC scanning RAN translation from both CGG 
reading frames was attenuated – indicating RAN translation requires ribosomal 
scanning.  
Both Todd et al. (2013) and Kearse et al. (2016) have a proposed a model in which 
the secondary structure of the CGG repeats causes the scanning ribosome to stall 
increasing the chances of translation occurring at AUG-like codons in sequence 
optimal positions. Green et al. (2016) suggest a stalling scanning ribosome causes 
congestion of 43S PICs on the mRNA sequence upstream of the repeat and 
increases the time the 40S subunit spends on AUG-like codons. Furthermore, Green 
et al. (2016) propose stalling is likely to favour the dissociation of important eIFs 
required for AUG start codon recognition or cause changes in ribosomal confirmation 
similar to what occurs in IRES translation. Green et al. (2016) go on further to argue 
such occurrences will likely increase the speed of enzymatic catalysis and 48S 
complex formation at AUG-like codons upstream of the repeats. Green et al. (2016) 
propose a working model of CGG RAN translation in FMR1 in which both the eIF4F 
complex and 43S PIC bind to the m7G cap on FMR1 mRNA; this complex scans 
through the 5’UTR where it stalls upon encountering the secondary structure of the 
CGG repeats or the surrounding 5’UTR sequence. This ribosomal stalling leads to 
the initiation of translation at AUG-like codons either upstream or within the repeats 
leading to FMRpolyG and FMRpolyA production.  
This model has been supported by a recent study by Sellier et al. (2017). Sellier et 
al. (2017) using a novel CGG mouse model found RAN translation is dependent on a 
ACG near-cognate start codon found within a putative kozak sequence providing an 
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optimal context for the initiation of translation. Additionally the N terminus of 
FMRpolyG starts with a methionine, strongly indicating canonical translation is 
occurring. Furthermore, translation initiated at the ACG codon was independent of 
the CGG repeats, as small FMRpolyG peptides were detected when fused to GFP in 
controls and even without any CGG repeats. Sellier et al. (2017) note this indicates 
the existence of a short upstream open reading frame (uORF); such uORFs are 
normally translated into small undetectable peptides but are detectable when fused 
with large tags due to the formation of a stable protein. However, an expansion of 
over 70 CGG repeats was required to generate a large enough uORF to create a 
stable, detectable FMRpolyG protein. This data is consistent with ribosomal stalling 
at CGG hairpins promoting initiation of translation at near-cognate start codons 5’ of 
the repeats. Hence these results indicate FMRpolyG is not a product on RAN 
translation; rather it is translated via conventional ribosome scanning at an upstream 
ACG codon decoded by Met-tRNA; the ribosomal complex reads through 55-200 
CGG codons and before finally terminating at a TAA STOP codon within a differing 
reading frame to the FMR1 coding region.  Translation of the FMRpolyA peptide was 
not investigated, with previous work suggesting its translation is a result of RAN 
translation with initiation beginning in the repeats (Todd et al., 2013). 
Mechanisms of RAN translation of the G4C2 expansion is currently unknown and no 
studies have as of yet looked into this. Some insight has come from G4C2 constructs 
used to study repeat toxicity. For example, when the G4C2 repeats are placed in the 
5’UTR, RAN translation of DPRs is clearly repeat length dependent; with larger 
repeat sequences producing more DPR protein (Mori et al., 2013a; Zu et al., 2013; 
Su et al., 2014). For example, Jiang et al. (2016) developed BAC transgenic mice 
with either 110 repeats or 450 repeats; despite RNA levels being higher in the 110 
repeat mice, RAN translation was only seen in mice harbouring 450 repeats. Green 
et al. (2016) note however that this repeat length requirement appears to be different 
for different reading frames and in different sequence contexts. For example, all 
DPRs are detectable at repeat unit lengths ranging between 30 – 40 repeats placed 
downstream of a synthetic sequence (Zu et al., 2013). Mori et al. (2013a) found 
when the G4C2 repeats are placed 113 nucleotides downstream of intron 1; that the 
repeat length required for RAN translation within this sequence context differed for 
the different sense DPRs. For example, poly-GA was detected at 38 repeats, poly-
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GP at 66 repeats and poly-GR was not detectable up to 145 repeats. Gendron et al. 
(2013) also reported a length requirement for the anti-sense DPRs, with poly-GP and 
poly-PR detectable from 66 repeat length construct whilst poly-PA was not observed. 
Sellier et al. (2017) note that the G4C2 repeats which are 5’ to the C9ORF72 ORF 
are in frame with a near-cognate CTG codon within a correct kozak sequence 
(gctCTGg) encoding poly-GA; which incidentally is the most abundant DPR species 
(Schludi et al., 2015). Examination of the flanking sequences around the anti-sense 
C4G2 transcript shows the presence of an ATG codon in both the poly-PR and poly-
GP reading frames (Zu et al., 2013); hence a mixture of canonical translation and 
RAN translation may occur for these anti-sense DPRs (Cleary and Ranum., 2017). If 
true this would fit in with the previously discussed finding that poly-GP from the anti-
sense strand is more common than poly-GP from the sense strand (Zu et al., 2013). 
Unlike the CGG repeats in FXTAS which are found within the 5’UTR of FRM1, the 
G4C2 repeats are located in an intron so should be spliced out and not come in 
contact with the scanning ribosome; hence at present it is unclear what RNA species 
is responsible for RAN translation of the G4C2 repeats (Green et al., 2016). Green et 
al. (2016) note there are three potential RNA species that may act as the template 
for G4C2 RAN translation; a retained intron, a spliced intron in a lariat, or an aberrant 
disease-specific transcript formed from stalling during transcription. Indeed, how the 
repeat containing intron is processed remains an important question in the field 
(Barker et al., 2017). Experimental evidence supports the first of these potential 
templates; it has been demonstrated that intron 1 containing the G4C2 repeats are 
retained in a proportion of polyadenylated C9ORF72 mRNA transcripts and exported 
to the cytoplasm where they are thought to be subject to RAN translation (Niblock et 
al., 2016; Hautbergue et al., 2017). A larger number of transcripts containing intron 1 
have been detected in C9ORF72 patient brain tissue compared to controls (Mori et 
al., 2013b; Niblock et al., 2016) indicating a preferential usage of exon 1a due to the 
presence of the repeats, which would mean increases in RNA levels of transcript 
containing variants (Barker et al., 2017). Splicing of C9ORF72 intron 1 seems not to 
be altered by G4C2 repeats as the amount of unspliced C9ORF72 transcripts as 
measured by the exon1-intron 1 junction is unchanged between control and patient 
tissue (Tran et al., 2015). The mechanisms behind this intron 1 retention is unknown 
however intron 1 retention was seen in C9ORF72 polyadenylated RNA from both 
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wild-type and alleles containing the expansion suggesting intronic retention of intron 
1 is part of the normal processing of C9ORF72 transcripts (Niblock et al., 2016). The 
majority of intron 1 retaining C9ORF72 transcripts were found to accumulate within 
the nucleus with a small proportion detected in the cytoplasm (Niblock et al., 2016).  
Based on these findings it has been proposed by Niblock et al. (2016) that the 
nuclear intron 1 retaining C9ORF72 mRNA is not degraded due to the presence of 
the G4C2 repeats, hence aggregating forming nuclear RNA foci. Some of 
the C9ORF72 mRNA containing intron 1 is however exported to the cytoplasm 
where it is subject to RAN translation producing the DPRs. Indeed, indirect support 
of this hypothesis comes from Hautbergue et al. (2017) who found knockdown of the 
nuclear export adaptor SRSF1 rescues neurodegeneration in Drosophila and patient 
derived motor neurons. SRSF1 depletion prevents nuclear export of C9ORF72 
mRNA and reduces DPR levels. Interestingly the nuclear export 
of C9ORF72 transcripts without the expansion was not dependent on SRSF1. van 
Blitterswijk et al. (2015) found both intron 1 containing (1a and 1b) transcripts 
correlated positively with levels of poly-GP and poly-GA in the cerebellum of 
expansion carriers. No association was found between intron 1 containing transcripts 
and poly-GP levels in the frontal cortex. van Blitterswijk et al. (2015) also observed 
an increase in the expression levels of transcripts harbouring sequences 5’ of the 
repeats (intron 1a) but not for transcripts 3’ of the repeats (intron 1b) in the frontal 
cortex, but not cerebellum, providing evidence to suggest at least some of the intron 
1 containing transcripts are truncated. The authors suggest such truncated 
transcripts may not be suitable templates for RAN translation, and that the 
cerebellum may contain less truncated transcripts. Indeed, no increase in intron 1a 
containing transcripts was observed for this brain region and as just noted poly-GP 
and poly-GA levels in the cerebellum are associated with levels of both intron 1a and 
1b transcripts, with this correlation being most pronounced for intron 1b, indicating 
the entire first intron is the main template for RAN translation - at least in the 
cerebellum. Further, antibodies used to detect the DPRs directed against the 
sequences flanking the repeats efficiently detect the RAN peptides (Zu et al., 2013). 
Tran et al. (2015) observed RAN translation in Drosophila is markedly reduced when 
the G4C2 repeats are located within an efficiently spliced intron arguing against a 
spliced intron in a lariat being used as the major template for RAN translation (Green 
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et al., 2016). Green et al. (2016) note however that DPRs are still seen in this model 
when the flies are raised at higher temperatures; indicating an intron lariat is still 
potentially capable of being a template for RAN translation.  
Proteins sequestered by the G4C2 RNA foci may also influence RAN translation. It 
has recently been shown by Zu et al. (2017) that RAN translation of the 
CCTG⋅CAGG expansion in DM2 to produce poly-LPAC and poly-QAGR tetrapeptide 
RAN proteins is modulated by the sequestration and nuclear retention of the repeat 
RNA by muscleblind like splicing regulator 1 (MBNL1). RAN translation could be 
blocked by MBLN1 overexpression potentially via sequestration of the repeat RNA 
into the nucleoplasm; whereas reducing levels of MBLN1 had the opposite effect. 
Further in cells RNA foci were inversely correlated with RAN protein accumulation. 
Whether such a cross-talk between G4C2 RNA gain of function effects and RAN 
translation in C9ALS/FTD exists remains an interesting avenue to explore. 
Interestingly, wt-TDP-43, FUS and hnRNPA2B1 were shown to modulate RAN 
translation in SCA31 by potentially acting as chaperones for repeat RNA; thereby 
potentially preventing the export of the RNA into the cytoplasm (Ishiguro et al., 
2017). It will be important for future studies to perform genetic screens to look for 
proteins that specifically modulate RAN translation of the G4C2 transcript and RAN 
translation in general. 
1.9.2 Poly-GA toxicity 
 
Poly-GA is the most abundant of the 5 DPR species in the human brain (Schludi et 
al., 2015). Poly-GA has strong aggregation properties due to the biophysical 
properties of the peptide (Freibaum and Taylor, 2017), the peptide is composed of 
small hydrophobic residues which are uncharged; it is expected to collapse into 
poorly soluble globules with strong aggregation tendencies (Lee et al., 2016; 
Freibaum and Taylor, 2017). Indeed poly-GA forms amyloidogenic fibrils which are 
positively stained by Congo red and thioflavin T (Chang et al., 2016; Freibaum and 
Taylor., 2017) and is predominantly found in the urea soluble fraction when 
expressed in cells (Lee et al., 2016). The poly-GA amyloidogenic fibrils form a 
parallel β-sheet structure with similar structural properties to the amyloid-beta protein 
in Alzheimer’s disease (Chang et al., 2016; Freibaum and Taylor, 2017). Poly-GA 
has shown to be toxic in many in vitro and in vivo model systems (Zhang et al., 2014; 
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May et al., 2014; Mizielinska et al., 2014; Yamakawa et al., 2015; Zhang et al., 2016; 
Schludi et al., 2017; Khosravi et al., 2017; Lee et al., 2017). 
1.9.2.1 UPS dysfunction and ER stress associated with poly-GA 
 
Initial studies using poly-GA only alternative codon constructs by both Zhang et al. 
(2014) and May et al. (2014) showed poly-GA expression is cable of inducing cellular 
toxicity. In both papers poly-GA was highly aggregate prone in transfected HEK293T 
cells, forming both cytoplasmic and nuclear aggregates. Poly-GA inclusions co-
localised with ubiquitin and p62 and were dot-like and star-shaped and comprised of 
filamentous structures; features reminiscent of the poly-GA aggregates seen in 
FTLD/ALS C9+ patients. Interestingly both papers used HEK293T cells, yet only 
Zhang et al. (2014) saw toxicity. However, poly-GA expressed in cortical and 
hippocampal neurons was toxic and rapidly formed aggregates co-localising with 
both p62 and ubiquitin. Furthermore, neurons had reduced neurite outgrowth and 
increased caspase3 activation. May et al. (2014) saw no co-localization of poly-GA 
with TDP-43 – nor were TDP-43 protein levels altered; such observations fit with 
patient data with a lack of spatial correlation between DPR pathology and TDP-43 
pathology (Mackenzie et al., 2015). Interestingly May et al. (2014) found the poly-GA 
inclusions in their cell culture model were more numerous, but smaller and the GFP 
signal less intense when compared to poly-GA aggregates in C9+ patient neurons, 
leading them to suggest they may underestimate poly-GA toxicity.  The formation of 
ubiquitinated poly-GA aggregates suggests an impairment of the ubiquitin 
proteasome system (UPS); a notion converged on in both papers. May et al. (2014) 
performed mass spectrometry with most top hits being members of the UPS. The 
paper focuses on Unc119, a myristoyl-binding protein, which they go on to show co-
localises with GA inclusions in both rat primary neurons and post-mortem patient 
tissue. Zhang et al. (2014) note a consequence of UPS dysfunction would be 
endoplasmic reticulum (ER) stress. Indeed, levels of numerous ER stress markers in 
the PERK-CHOP pathway were enhanced in poly-GA transfected neurons and 
patient tissue. Furthermore, ER stress inhibitors salubrinal and TUDCA rescued 
poly-GA-induced toxicity. Schludi et al. (2015) found abundant Unc119 pathology in 
the C9ALS/FTD frontal cortex and cerebellum that resembled poly-GA DPR 
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pathology; in addition, poly-GA and Unc119 pathology was more severe in the 
C9FTD cerebellum compared to C9ALS or C9ALS/FTD cerebellar tissue. 
Poly-GA is also toxic in vivo; Zhang et al. (2016) generated a poly-GA only mouse 
model. These poly-GA mice developed brain atrophy with neurodegeneration seen in 
the cortex and hippocampus in addition to astrogliosis. Further poly-GA mice 
demonstrated anxiety-like behaviour as well as motor and cognitive deficits. The 
UPS-related proteins HR23A and HR23B both formed nuclear and cytosolic 
inclusions in the brains of poly-GA mice and were sequestered by poly-GA inclusions 
further indicting poly-GA exerts toxicity via UPS dysfunction (Zhang et al., 2014; May 
et al., 2014; Zhang et al., 2016). Zhang et al. (2016) also observed HR23 inclusions 
in the mice expressing 66 G4C2 repeats developed by Chew et al. (2015) and in 
post-mortem human hippocampus where the inclusions again co-localised with poly-
GA. Transfection of HEK293T cells with poly-GA led to HR23A and HR23B cytosolic 
accumulation with concomitant nuclear depletion. HR23 stabilises the DNA-binding 
protein xeroderma pigmentosum C (XPC). Poly-GA expression led to enhanced XPC 
degradation as evidenced by reduced XPC levels in poly-GA mice compared to 
controls in addition to the presence of XPC inclusions that co-localised with poly-GA 
in cortical and hippocampal neurons. Hence the co-aggregation of poly-GA and 
HR23 appears to lead to a loss of HR23 function. Furthermore, co-
immunoprecipitation revealed only poly-GA and not poly-GP or poly-GR interacted 
with HR23B; and analysis of the brains of 66 repeat G4C2 mice revealed 85% of 
HR32B inclusions were positive for poly-GA indicating poly-GA and not the other 
sense DPRs is the primary cause of H32 dysfunction. Zhang et al. (2016) also 
demonstrated poly-GA sequestered the nuclear pore proteins RanGAP1 and 
Pom121 indicating poly-GA also disrupts the nuclear pore complex; the authors note 
this finding may partially contribute to poly-GA induced HR23 protein mislocalisation.  
The toxicity of poly-GA in murine models has been replicated by Schludi et al. 
(2017). In their model mice developed poly-GA inclusions primarily in motor neurons, 
the interneurons of the spinal cord and brain stem and deep cerebellar nuclei. 
However, poly-GA did not lead to any overt neuronal loss in these mice; despite this 
the authors also observed poly-GA sequestered the UPS-related protein Rad23b; 
although no sequestration of Unc119 or RanGAP1 as has previously been reported 
was observed. The Hsp-70 associated protein, Mlf2, co-aggregated with poly-GA in 
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the spinal cord of mice; Mlf2 pathology was also seen in patient post-mortem brain 
tissue. Unlike Zhang et al. (2016) who observed astogliosis but not microgliosis, 
Schludi et al. (2017) saw no astroglisos in their mice but did see marked microglial 
activation. Indeed, markers for neuroinflammation were upregulated in the spinal 
cord of 6 month old poly-GA mice. Schludi et al. (2017) note microglial activation 
correlates with the progression of disease in ALS, and C9ORF72 patients 
demonstrate increased levels of microglial activation as compared to non C9ORF72 
ALS patients (Brettschneider et al., 2012). A progressive decline in motor 
performance was also observed in these mice. Zebrafish (Ohki et al., 2016) and 
Drosophila (Mizielinska et al., 2014) models of poly-GA also show the poly-GA 
peptide to be toxic. Poly-GA was highly toxic to fish although toxicity did not correlate 
with aggregation as poly-GA inclusions were exclusively found in the musculature 
fish; however overall muscle structure was not affected (Ohki et al., 2016). In flies 
poly-GA leads to a modest reduction in lifespan compared to controls (Mizielinska et 
al., 2014).   
1.9.2.2 Summary of poly-GA toxicity 
 
It has been argued that as poly-GA inclusions are by far the most abundant DPR 
species, that poly-GA has a critical role in pathogenesis (Schludi et al., 2015).  
However, although poly-GA seems to be toxic when expressed at high levels (Zhang 
et al., 2014; May et al., 2014; Yamakawa et al., 2015; Ohki et al., 2016; Zhang et al., 
2016; Lee et al., 2017) when compared head to head with the arginine DPRs in 
Drosophila, poly-GA is less toxic (Freibaum and Taylor, 2017; Mizielinska et al., 
2014; Wen et al., 2014; Yang et al., 2015; Freibaum et al., 2015; Lee et al., 2016). 
Freibaum and Taylor, (2017) suggest this may be due to the lower expression levels 
of poly-GA in these studies compared to those using viral-mediated expression 
systems; hence it remains to be seen whether poly-GA is toxic at physiologically 






1.9.3 Poly-GR and Poly-PR toxicity  
 
The arginine rich DPRs, poly-GR and poly-PR, are highly positively charged and 
polar due to the presence of arginine residues (Freibaum and Taylor, 2017). Both 
are predicted to have a flexible coil structure (Freibaum and Taylor, 2017). 
Biochemical characterisation of a (GR)3 peptide by Flores et al. (2016) revealed 
poly-GR forms spherical aggregates as visualised by transmission electron 
microscopy. Secondary structure predicted from circular dichroism spectra indicates 
55% of the protein has turn and/or random coil conformation and the other 41% of 
the protein is β-sheet (Flores et al., 2016). Initial studies in Drosophila using 
alternative codon ATG constructs revealed poly-GR and poly-PR to be highly toxic, 
causing severe eye degeneration and a dramatic reduction in lifespan (Mizielinska et 
al., 2014). Both DPRs are much more potent toxins in Drosophila when compared 
with the effects of the other DPRs; with poly-GA the only other DPR to show mild 
toxicity (Mizielinska et al., 2014).  The high toxicity of poly-GR and poly-PR has been 
replicated in numerous other Drosophila studies (Wen et al., 2014; Freibaum et al., 
2015; Yang et al., 2015; Lee et al., 2016) and also cellular models and human iPSCs 
(Kwon et al., 2014; Wen et al., 2014; Tao et al., 2015; Lee et al., 2016). Poly-PR is 
far more stable than poly-GR; with a half-life of ~72h compared to <30min for poly-
GR (Kwon et al., 2014). The mechanisms of poly-GR and poly-PR induced toxicity 
have been revealed over recent years; these will now be discussed. 
1.9.3.1 Poly-GR and poly-PR associated nucleocytoplasmic 
transport deficits  
 
As discussed in section 1.8.4, defective nucleocytoplasmic transport has been 
identified as a pathogenic mechanism in C9ALS/FTD (Zhang et al., 2015). Zhang et 
al. (2015) attributed defective nucleocytoplasmic transport to the G4C2 RNA rather 
than DPRs. However, under certain conditions the flies used in this study can 
produce poly-GR, hence it cannot be ruled out that undetectable levels of poly-GR 
contribute to the defective nucleocytoplasmic transport observed in this model. A 
second Drosophila study published in parallel by Freibaum et al. (2015) also 
reported nucleocytoplasmic transport deficits in transgenic flies harbouring the 
repeats. Freibaum et al. (2015) generated flies harbouring 58 G4C2 repeats in which 
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poly-GP and poly-GR (but not poly-GA, poly-PR or poly-PA) was detectable. These 
flies demonstrated both motor deficits and retinal degeneration. Using these 58 
repeat flies Freibaum et al. (2015) performed a chromosomal deficiency screen 
spanning the entire 2nd and 3rd chromosomes. The authors identified numerous 
proteins involved in nucleocytoplasmic transport as enhancers and suppressors of 
the 58 G4C2 repeat induced degenerative eye phenotype. One of the strongest 
enhancers was the nuclear pore protein Nup50, whilst the strongest suppressor was 
Ref1, the Drosophila homologue of ALYREF, an RNA binding protein which acts in a 
complex to deliver processed mRNAs to the nuclear pore (Freibaum et al., 2015). 
Indeed numerous other nucleocytoplasmic transport proteins were identified as 
suppressors and enhancers of 58 G4C2 repeat degeneration including Crm1, 
Nup153, Nup107, Nup106 Transportin, Gle1 and Ran. Further characterisation of 
Nup107 morphology in Drosophila salivary glands revealed the protein, which in 
controls labels the nuclear envelope, forming a distinct nuclear boundary, appeared 
wrinkled and jagged and also formed inclusions near the nuclear envelope in the 
presence of the repeats. Morphological deficits in the nuclear envelope were further 
visualised by Lamin C staining, in which an abnormal frayed nuclear envelope was 
seen in over 40% of cells expressing the 58 G4C2 repeats. Additionally 58 G4C2 
repeat cells showed a nuclear retention of RNA. The authors of this study were 
ambivalent as to whether it was the DPRs or G4C2 RNA that caused these nuclear 
pore deficits.  
Confirmation that the arginine DPRs are indeed sufficient to disrupt 
nucleocytoplasmic transport came from a yeast screen using poly-PR only 
alternative codon constructs by Jovičić et al. (2015). By combining the results from a 
gain and loss of function screen Jovičić et al. (2015) found an overrepresentation of 
genes involved in nucleocytoplasmic transport as modifiers of poly-PR toxicity. Some 
of the strongest suppressors of poly-PR toxicity were an upregulation of yeast 
karyopherin genes. Survival of rodent cortical neurons transfected with poly-PR was 
more than doubled when co-transfected with KPNA3. Other notable modifiers 
included the yeast homologue of human RCC1, which was depleted from the 
nucleus in 70-80% of C9ORF72 iPSCs. The link between the arginine DPRs and 
nucleocytoplasmic transport was further elucidated in a Drosophila screen by 
Boeynaems et al. (2016a).  
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The authors performed an RNAi screen to look for modifiers of poly-PR toxicity using 
Drosophila homologues of the genes identified from the Jovičić et al. (2015) yeast 
screen. Nuclear pore complex (NPC) proteins, importins, exportins, regulators of 
the Ran-GTP cycle and arginine methylases were all modifiers of poly-PR retinal 
degeneration. The strongest enhancer was the Drosophila homologue of the 
importin TNPO1, Trn. Boeynaems et al. (2016a) proposed that poly-PR may 
compete with Trn for Trn cargoes, and indeed the neuronal RNA binding protein 
Elav, a Trn cargo, was depleted from the nucleus and accumulated in the cytosol 
of Drosophila retinas expressing poly-PR. Furthermore, the TNPO1 cargo hnRNP 
A3 was aggregated in patient C9FTD brain. In addition, the arginine 
methyltransferase PRMT1 co-localised with both poly-GR and poly-PR in cells; 
and the arginine methyltransferase ASYM24 was able to detect asymmetric 
arginine dimethylation of poly-GR. Methylated inclusions using the ASYM24 
antibody were also detected in human post-mortem tissue.  It is worth noting that 
TNPO1 is involved in shuttling of FUS between the cytoplasm and nucleus 
(Dormann et al., 2012) and PRMT1 is associated with FUS (Dormann et al., 2012); 
however, FUS pathology is absent from the C9ORF72 ALS/FTD brain. TNPO1 
binds to PY-NLS motifs (Dormann et al., 2012) to initiate the nuclear import of 
proteins such hnRNPA1 (Mihevc et al., 2017). Khosravi et al. (2017) using an RFP-
NLSPY containing the PY-NLS of hnRNP A1 found that none of the arginine DPRs 
disrupts this import pathway as the nuclear localisation of the reporter was 
unchanged following co-expression with the reporter. It must be noted however that 
FUS has been shown to interact distinctly differently with TNPO1 as compared to 
other PY NLSs’ (Niu et al., 2012).  
Mechanistic insight into how poly-PR might disrupt nucleocytoplasmic transport 
has come from Shi et al. (2017). Shi et al. (2017) found poly-PR binds to the 
central channel of the nuclear pore, binding to polymeric forms of the 
phenylalanine:glycine (FG) repeat domain. By binding to the FG repeat domain poly-
PR shifts these FG repeats toward a polymerised state. By either mutating or melting 
the FG domain polymers using aliphatic alcohols, poly-PR was unable to bind to 
nuclear pore proteins. The authors suggest the FG repeats of nuclear pore proteins 
exist in equilibrium between the polymerized and unpolymerized state; poly-PR binds 
to the FG repeats thereby stabilizing them in the polymerized state, this change in 
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the equilibrium of FG repeat polymerization disrupts transport through the nuclear 
pore, potentially by making the barrier of central channel less permeable.  
1.9.3.2 Poly-GR and poly-PR associated nucleolar dysfunction 
 
Studies investigating poly-GR and poly-PR from alternative codon ATG constructs 
revealed the peptides have a nucleolar localisation in cells (Kwon et al., 2014; Wen 
et al., 2014; Zhang et al., 2014; May et al., 2014; Tao et al., 2015; Lee et al., 2016). 
The nucleolus is required for ribosomal RNA (rRNA) transcription, pre-rRNA 
processing and ribosome subunit assembly (Lam et al., 2005). Kwon et al. (2014) 
provided the first evidence showing the arginine DPRs disrupt nucleolar function; 
observing the ability of nucleoli to synthesize mature rRNA was dramatically reduced 
following poly-PR expression. Jovičić et al. (2015) found in addition to proteins 
involved in nuclear import and export, genes involved in rRNA processing were also 
potent modifiers of poly-PR toxicity in yeast. Indeed, the authors discovered by 
restoring the function of rRNA processing machinery poly-PR toxicity can be 
overcome, suggesting deficits in the rRNA processing pathway are involved in 
arginine DPR toxicity. Additionally, in the Boeynaems et al. (2016a) Drosophila 
screen investigating modifiers of poly-PR toxicity the authors identified numerous 
genes linked to rRNA processing. For example, the Drosophila homologue nucleolin, 
a nucleolar RNA binding protein also identified in the Jovičić et al. (2015) yeast 
screen, was one the strongest modifiers of poly-PR toxicity identified. Tao et al. 
(2015) found the both arginine DPRs, but not any of the other RAN peptides cause 
the translocation of the nucleolar stress sensor protein B23 to the nucleoplasm in 
addition to nucleolar swelling. The maturation of 18S and 28S rRNA was also 
perturbed by these arginine DPRs (Tao et al., 2015).  
Combined these studies suggest nucleolar stress resulting from actions of poly-GR 
and poly-PR may contribute to disease pathogenesis. The clinical relevance of 
nucleolar stress in C9ALS/FTD was recently investigated in the human brain. 
Mizielinska et al. (2017) found neuronal nucleoli in the C9FTD brain were 
significantly smaller compared to controls. However, in C9FTD brains, neurons 
which contained a poly-GR inclusion had a significantly increased nucleolar volume 
compared to cells without a poly-GR inclusion. Overexpression of poly-GR (and poly-
GA but to a much lesser extent) caused nucleolar enlarged in Drosophila neurons. 
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Mizielinska et al. (2017) suggest this nucleolar enlargement may represent a 
disruption in the normal physiological structure of the organelle. Nucleolar 
dysfunction has also been associated with repeat RNA toxicity. Haeusler et al. 
(2014) found nucleolin preferentially binds the sense G4C2 RNA G-quadruplex. 
Nucleolin was found to be sequestered into RNA foci in the motor cortex of 
expansion carriers. Mizielinska et al. (2017) also observed a significant increase in 
nucleolar volume in C9FTD frontal cortex neurons containing sense RNA foci. This 
data taken together suggests a synergism between RNA and arginine DPR toxicity 
with regards to nucleolar dysfunction. 
1.9.3.3 Poly-GR and poly-PR associated mis-splicing 
 
As discussed in section 1.8.2 mis-splicing associated with the C9ORF72 mutation 
have been attributed to the sequestration of splicing factors by the G4C2 RNA 
(Cooper-Knock et al., 2014; Haeusler et al., 2014; Cooper-Knock et al., 2015; 
Conlon et al., 2016). Mis-splicing events also occur as a result of arginine DPR 
expression. Kwon et al. (2014) cultured human astrocytes and exposed them to poly-
PR for 6 hours. RNA sequencing analysis revealed changes in splicing to a number 
of mRNAs. Splicing errors resulting from poly-PR included exon skipping, different 5’ 
UTRs and intronic retention. Skipping of exon 9 of the excitatory amino acid 
transporter 2 (EAAT2) and the inclusion of intronic sequence downstream from the 
splice donor site of exon 7 is observed in ALS patients (Lin et al., 1998). Cultured 
human astrocytes incubated with poly-PR showed the same disrupted EAAT2 
splicing alterations in a poly-PR concentration dependent manner. This alteration in 
EAAT2 splicing was specific to poly-PR as other toxins failed elicit changes in EAAT 
splicing in cultured human astrocyte cells (Kwon et al., 2014).  
The mechanisms of arginine DPR induced mis-splicing have been further elucidated 
by Yin et al. (2017). Yin et al. (2017) found when either poly-GR or poly-PR was 
added to nuclear extracts splicing was dramatically blocked. Splicing intermediates 
exon 1 and lariat-exon 2 were not detected suggesting that this inhibition of splicing 
occurs prior to the first catalytic step of splicing. Further poly-GR and poly-PR seem 
to specifically block splicing, as other stages of gene expression and RNA 
processing - such as primary mircoRNA processing, transcription, U6 snRNA 
processing, and tRNA processing were not affected.  
102 
 
Yin et al. (2017) found both poly-GR and poly-PR associate with the U2 small 
nuclear ribonucleoprotein particle complex (U2 snRNP). All known U2 snRNP 
snRNP components were found from proteomic analysis of poly-GR and poly-PR 
pulldowns. On the other hand only 3 of 8 components specific for U5 snRNP were 
found in the pulldowns. Hence poly-GR and poly-PR specifically associate with U2 
snRNP components. Ying et al. (2017) go on to demonstrate the arginine DPRs 
disrupt normal U2 snRNP function. Further poly-GR inhibited the formation of the 
spliceosome leading to mis-splicing. Yin et al. (2017) also found the U2 snRNP 
associated proteins were mislocalised to the cytoplasm in C9ORF72 iPSC motor 
neuron whereas it was completely nuclear in controls. On the other hand, U1 snRNP 
proteins were properly nuclear in both patient and control iPSCs motor neurons. In 
additon U2 snRNP dependent exons were found to be preferentially mis-spliced in 
C9 patients. Furthermore mis-splicing resulting from hnRNP H dysfunction, attributed 
to G4C2 RNA toxicity by Conlon et al. (2016) was significantly less frequent that mis-
splicing resulting from U2 snRNP dysfunction in the C9ALS cerebellum and frontal 
cortex. This data strongly suggests DPR induced U2 snRNP dysfunction plays the 
crucial role in the mis-splicing observed in C9 patient brains rather than mis-splicing 
deficits that have been reported to result from the sequestration of RNA binding 
proteins into G4C2 foci.  
1.9.3.4 Poly-GR and poly-PR associated DNA damage and oxidative 
stress 
 
Lopez-Gonzalez et al. (2016) generated multiple iPSC lines differentiated into spinal 
cord motor neurons that produced both RNA foci and detectable levels of DPRs – 
including poly-GR. Analysis of these iPSC motor neurons revealed increased 
expression of γH2AX, a marker of DNA double-strand breaks (DSBs). DNA damage 
activates the p53 pathway, and indeed p53 levels were also increased in C9 patient 
motor neuron iPSCs compared to controls. Poly-GR expression activated the p53 
pathway, increased levels of γH2AX and increased the number of DNA strand 
breaks when transfected into control iPSC motor neurons. Further the toxicity of 
poly-GR in Drosophila was attenuated by reducing p53 levels. Next the authors 
assessed how poly-GR might be causing DNA damage, the production of reactive 
oxygen species (ROS) was significantly increased from 8 weeks onwards in C9 iPSC 
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motor neurons compared to controls. When poly-GR was expressed in HEK293 cells 
and interactome analysis performed – many of the top interactors were mitochondrial 
ribosomal proteins necessary for the translation of 13 subunits of the mitochondrial 
complexes. Mitochondrial membrane potential was found to be elevated in C9 iPSC 
motor neurons and control iPSCs transfected with poly-GR. This data suggests poly-
GR perturbs mitochondrial function by binding to mitochondrial ribosomal proteins. 
DNA damage has been reported in the spinal cord neurons of C9ORF72 ALS 
patients (Farg et al., 2017). Farg et al. (2017) found multiple markers of DNA 
damage such as γH2AX and p-ATM are significantly upregulated in C9ORF72 
patients compared to controls. This research taken as a whole indicates neuronal 
poly-GR disrupts mitochondrial function and induces DNA damage potentially via 
elevated oxidative stress. Further work is needed however to determine what other 
molecular pathways may contribute to DNA damage in C9ALS/FTD. 
1.9.3.5 Poly-GR and poly-PR associated ER Stress and perturbed 
cell signalling pathways 
 
A recent CRISPR-Cas9 screen in human cells and primary neurons has revealed ER 
stress as a potent modifier of arginine DPR toxicity (Haney et al., 2017). ER-resident 
proteins such as TMX2 and CANX were strong modifiers of poly-GR and poly-PR 
toxicity; virtually all of these proteins were members of the endoplasmic reticulum 
membrane protein complex (EMC). Endosomal trafficking genes such as Rab7a 
were also potent poly-PR interactors. The large number of ER associated genetic 
modifiers indicates poly-GR and poly-PR both induce an ER stress response, akin to 
what has been reported for poly-GA toxicity (Zhang et al., 2014; May et al., 2014). To 
confirm this Haney et al. (2017) performed an RNA-seq on primary neurons 
transduced with poly-PR. The most significantly enriched Gene Ontology analysis for 
upregulated genes was the ‘apoptotic signalling pathway in response to endoplasmic 
reticulum stress’. ER stress genes such as ATF4 were upregulated in poly-PR cells; 
further poly-PR toxicity was mitigated by treating cells with an ER stress inhibitor that 
prevents Atf4 induction. A PERK-Atf4 mediated ER stress response has been 
reported in C9ALS/FTD patient brains by Zhang et al. (2014). 
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1.9.3.6 Poly-GR and poly-PR associated disruptions in global protein 
translation 
 
Kanekura et al. (2016) synthesized a C-terminally tagged 20 repeat constructs for 
poly-PR and performed an immunoprecipitation analysis followed by a liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) to identify poly-PR 
interacting proteins. The most abundant interactors were ribosomal proteins, proteins 
involved in splicing and translation initiation and elongation factors indicating poly-PR 
may influence protein translation (Kanekura et al., 2016). Protein translation was 
inhibited following poly-PR and poly-GR expression, but not poly-GA. However, poly-
PR did not alter the phosphorylation levels of eIFs, the phosphorylation status of 
which regulates protein translation. Poly-PR was found to potentially form 
complexes/aggregates with RNA, further RNA induced aggregate formation of both 
poly-PR and poly-GR. Poly-PR/RNA complexes were recognised as misfolded 
proteins in vitro by HSP70; together these findings suggest the arginine DPRs may 
prevents the access of translation factors to mRNA by forming complexes with said 
mRNA; thereby blocking protein synthesis. 
1.9.3.7 Poly-GR and poly-PR disruption of the formation of 
membraneless organelles and their liquid-liquid phase 
separation dynamics 
 
The binding partners of poly-GR and poly-PR were revealed initially by proteomic 
analysis by Lee et al. (2016) and Lin et al. (2016). These studies revealed a strong 
interaction between poly-GR and poly-PR with proteins that contain a low complexity 
sequence domain (LCD). LCDs are amino acid sequences between 75-300 amino 
acids in length with a high evolutionary conservation (Freibaum and Taylor, 2017). 
LCDs are present in one-third of the human proteome, and are predicted to be 
unstructured and consist of a high number of glycine and serine residues 
interspersed with aromatic charged residues (Freibaum and Taylor, 2017). LCDs are 
involved in multivalent, low affinity interactions; hence mediating interactions that can 
be rapidly rearranged; including both protein-protein and protein-nucleic acid 
interactions (Aguzzi and Altmeyer, 2016); these interactions are important for several 
cellular functions – including the formation of  dynamic heterogeneous assembles; 
such as membraneless organelles (Aguzzi and Altmeyer, 2016; Freibaum and 
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Taylor, 2017). Membraneless organelles are multicomponent, viscous liquid-like 
structures that typically contain both RNA and protein molecules and are commonly 
referred to as RNP bodies or granules (Brangwynne et al., 2015). Examples of such 
membraneless organelles include the nucleolus, nuclear pore complex, stress 
granules nuclear speckles and Cajal bodies (Brangwynne et al., 2015; Freibaum and 
Taylor, 2017).  
Membraneless organelle formation occurs through spontaneous liquid-liquid phase 
separations (LLPS); a process in which protein-laden RNAs separate themselves 
from the surrounding aqueous nucleoplasm or cytoplasm (Brangwynne et al., 2015; 
Taylor et al., 2016). The formation of membraneless organelles has been described 
as dynamic liquid demixing process in which cells actively generate phase 
boundaries to confine functional entities for temporary period (Aguzzi and Altmeyer, 
2016). Once a phase transition has occurred it is thought the proteins within the 
liquid compartment find themselves in different solvent environment compared to 
their surroundings, which may promote specific biochemical interactions (Aguzzi and 
Altmeyer, 2016).  Most of the proteins that drive intracellular phase transitions, and 
the formation of membraneless organelles, show strong conformational 
heterogeneity and are referred to together as intrinsically disordered proteins (IDPs) 
(Brangwynne et al., 2015; Aguzzi and Altmeyer, 2016). IDPs do not have well 
defined protein fold like other peptides and are highly flexible; this structural plasticity 
allows IDPs to dynamically adopt different confirmations and undergo a multitude of 
promiscuous multivalent interactions (Aguzzi and Altmeyer., 2016).  
Many IPDs contain LCDs, as noted previously LCDs form multivalent interactions 
and generate energetically favourable higher-order protein assemblies; such factors 
dictate the behaviour of IPDs within complex liquids like the intracellular matrix, 
thereby facilitating phase transitions (Brangwynne et al., 2015; Aguzzi and Altmeyer, 
2016). RNA binding proteins such as FUS, TDP-43 and hnRNPs contain prion-like 
domains (PrLD), a type of LCD that is rich in uncharged polar amino acids and has 
the propensity to self-assemble and aggregate (Taylor et al., 2016; Aguzzi and 
Altmeyer, 2016; Boeynaems et al., 2017). FUS, recombinant TDP-43 and hnRNPs 
have been shown to undergo liquid-liquid phase separations (Boeynaems et al., 
2017) in which they transition from a single mixed aqueous solution into two distinct 
phases; one of which is a concentrated liquid-like droplet (Taylor et al., 2016; 
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Boeynaems et al., 2017). Taylor et al. (2016) note during LLPS RNA binding proteins 
which are prone to fibrillize are placed at a high concentration in close proximity to 
one another increasing the chance of these proteins forming amyloid-like fibrils in the 
cytosol. Indeed Boeynaems et al. (2017) note liquid like droplets mature over time to 
more fibrillary states. ALS causing mutations in proteins such as TDP-43, FUS and 
hnRNPA1 are often found in the PrLD of these proteins (Patel et al., 2015; Murakami 
et al., 2015; Molliex et al., 2015; Lin et al., 2015). Taylor et al. (2016) notes such 
mutations accelerate the transition of liquid like droplets to pathological amyloid-like 
fibrils. Indeed, the formation of pathological aggregates of RNA binding proteins is 
proposed to be a liquid-to-solid phase transition (Molliex et al., 2015; Patel et al., 
2015).  
The molecular signals that trigger phase transitions and how protein assembly into 
membraneless compartments is regulated is not fully known but will be important for 
understanding how perturbed phase transitions transform liquid compartments into 
the fibrous aggregates seen in neurological diseases (Aguzzi and Altmeyer, 2016). 
Poly-GR and poly-PR were shown by Boeynaems et al. (2017) to undergo LLPS in 
vitro, LLPS correlated with arginine content of peptides indicating the arginine 
residues within these DPRs module their LLPS. Further characterisation of poly-PR 
strongly indicated poly-PR droplets behave as a liquid, with poly-PR droplets existing 
in a disordered state. Both poly-GR and poly-PR associate with LCDs; Lin et al. 
(2016) demonstrated poly-PR directly binds to LCDs and the LCD is both necessary 
and sufficient for poly-PR binding and this interaction is polymer-dependent; 
indicating the polymeric structure of the arginine DPRs is the toxic species 
(Freibaum and Taylor, 2017). Mass spectrometry by Boeynaems et al. (2017) 
demonstrated poly-PR interacted with proteins enriched for RNA-binding domains, 
arginine-rich motifs and protein disorder; many of which were components of 
membraneless liquid organelles. 
Important examples of IDPs shown to interact with poly-GR and poly-PR are RNA-
binding proteins associated with or known to cause ALS including FUS, Ataxin-2, 
Matrin-3, hnRNPA2B1 and importantly TDP-43 (Lee et al., 2016; Lin et al., 2016). 
Based on the finding that poly-GR and poly-PR interactors are significantly enriched 
in RNA binding proteins with LCD domains (Lee et al., 2016; Lin et al., 2016) 
involved in the formation of membraneless organelles, Lee et al. (2016) performed a 
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Drosophila RNA interference (RNAi) screen in poly-GR expressing flies. 84.9% of 
the poly-GR/PR interactors found in the proteomics analysis by Lee et al. (2016) 
were genetic modifiers of poly-GR toxicity. Knockdown of these LCD interacting 
proteins revealed 80 suppressors, 35 of which were strong suppressors of poly-GR 
toxicity. 27 enhancers were found, 21 of which were strong enhancers of poly-GR 
toxicity. Genetic modifiers from the poly-GR screen were also found to modify the 
rough eye phenotype of (G4C2)58-expressing flies, shown prior to produce poly-GR 
(Freibaum et al., 2015). Previous studies had shown both poly-GR and poly-PR 
associate with membraneless organelles as the peptides accumulate in the nucleoli 
of cells (Kwon et al., 2014; Wen et al., 2014; Zhang et al., 2014; May et al., 2014; 
Tao et al., 2015). Consistent with these previous studies, Lee et al. (2016) also 
observed this; with poly-PR being exclusively nuclear and poly-GR being both 
nuclear and cytoplasmic. Lee et al. (2016) demonstrated poly-GR and poly-PR are 
recruited to the liquid-like granular component (GC) of the nucleolus; although poly-
GR shows a more stable interaction with the nucleolus potentially due to its 
interaction with dense fibrillar components of the nucleolus. The liquid-like GC 
component of the nucleolus is organised by nucleophosmin (NPM1) (Lee et al., 
2016). NPM1 contains 3 LCDs and undergoes LLPS to form liquid droplets (Mitrea et 
al., 2016; Lee et al., 2016). Poly-GR and poly-PR both directly interacted with NPM1 
and were sufficient to induce LLPS of NPM1. Further poly-GR and poly-PR 
modulated the ability of NMP1 to undergo LLPS with one of its native nucleolar 
binding partners SURF6. Poly-GR and poly-PR in increasing concentrations reduced 
the concentration of SURF6 required to induce LLPS; and when the concentration of 
the arginine DPRs was greater than NPM1, SURF6 could no longer induce LLPS 
indicating they outcompete SURF6 for NPM1 binding. A consequence of this 
nucleolar interaction was a disruption in nucleolar dynamics, nucleolar morphology 
and nucleolar function. The motility of both NPM1 and NCL were significantly 
reduced, the nucleolus of cells expressing either poly-GR or poly-PR was perturbed 
and rRNA synthesis was reduced.  
Lee et al. (2016) then focused on a cytoplasmic membraneless organelle – stress 
granules (SGs). SGs are cytoplasmic assemblies formed of RNA and protein during 
cellular stress (Protter and Parker, 2016). RNA binding proteins are bound by 
increased levels of free mRNA following translational arrest which nucleates SG 
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formation (Jain et al., 2016). SG formation requires LLPS (Lin et al., 2015; Murakami 
et al., 2015). Lee et al. (2016) found both poly-GR and poly-PR interact with 
numerous SG components including G3BP1 and G3BP2 (G3BP) and its binding 
partner Caprin1 – both proteins promote SG assembly. Poly-GR (but not poly-PR) 
co-localised with SG markers, although the expression of either peptide led to 
spontaneous SG assembly in cells. Furthermore, these SGs were poorly dynamic, 
rarely disassembled and their numbers increased over time. Further G3BP when in 
SGs is normally in a rapid dynamic equilibrium with the cytoplasm; however, poly-GR 
and poly-PR impaired the exchange of G3BP between SGs and the cytoplasm.  
These arginine DPR induced SGs were associated with increased risk of cell death.  
The translation of mRNA, stalled upon SG formation, was significantly reduced in 
poly-GR and poly-PR expressing cells demonstrating further SG dysfunction. 
Interestingly TDP-43 was also recruited to poly-GR and poly-PR induced SGs (Lee 
et al., 2016). The interaction between poly-PR and SGs has been further elucidated 
by Boeynaems et al. (2017), finding cytoplasmic poly-PR granules are positive for 
SG markers; further poly-PR induced SG assembly was both dose and length 
dependent. The phosphorylation of eIF2α is required for SG assembly (McInerney et 
al., 2005), using a mutant MEF cell line which has a non-phosphorylatable form of 
eIF2α, Boeynaems et al. (2017) found poly-PR requires the integrated stress granule 
response for SG induction. Additionally, G3BP was also required for poly-PR 
induced SG formation. Further ALS associated proteins with LCDs, ataxin-2 and 
TDP-43, were both enriched in poly-PR induced SGs. Tao et al. (2015) observed 
poly-GR and poly-PR can also prevent SG assembly in response to arsenite induced 
stress.  
Other membraneless organelles are also perturbed by poly-GR and poly-PR. Lee et 
al. (2016) found the assembly of Cajal bodies and the dynamics of nuclear speckles 
was perturbed by these arginine-rich DPRs. Poly-GR and poly-PR also influence the 
biophysical properties of LCD containing RNA binding proteins. Lee et al. (2016) 
found poly-GR and poly-PR were recruited to hnRNP and TIA-1 liquid droplets and 
decreased the critical concentration required for hnRNP and TIA-1 to undergo LLPS. 
Further, the dynamic exchange of hnRNPA1 and TIA-1 between the dense droplet 
phase and the surrounding mono-disperse phase was perturbed by poly-GR and 
poly-PR leading Lee et al. (2016) to suggest these DPRs enhance the multivalent 
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interactions that comprise the liquid phase of RNA binding proteins (figure 
1.19).  Additionally, Boeynaems et al. (2017) found poly-PR, but not poly-GR 
interfered with the spontaneous fusion dynamics of FUS liquid droplets, and FUS 


























Figure 1.19 | Arginine-rich DPR phase separation. The arginine rich DPRs, 
poly-GR and poly-PR, undergo liquid-liquid phase separation in addition to also 
inducing phase separation of numerous proteins harbouring low complexity 
domains, such as intrinsically disordered ALS related proteins involved in RNA 
metabolism and stress granule formation. Poly-GR and poly-PR when expressed 







In summary experimental data demonstrates these DPRs promote phase separation 
of PrLD proteins into liquid droplets. The interactions mediated by LCDs that permits 
LLPS to occur is unknown; although it is thought arginine rich motifs are important 
potentially due to the ability of this residue to participate in charge-charge and Pi-
cation interactions within the multivalent network (Lee et al., 2016; Nott et al., 2015; 
Pak et al., 2015). Indeed Boeynaems et al. (2017) demonstrated the importance of 
electrostatic forces via arginines in LLPS; finding phase transitions correlated with 
the arginine content of peptides hence supporting the function of arginine motifs in 
mediating LLPS. Hence the arginine DPRs likely form strong multivalent interactions 
with proteins harbouring LCDs (Lee et al., 2016); indeed, in the case of NPM1, poly-
GR and poly-PR outcompete the normal binding partner of NPM1, SURF6 for 
binding to NPM1 (Lee et al., 2016). Such strong multivalent interactions make LLPS 
easier to occur essentially causing excessive droplet formation. The dynamics and 
maturation of the liquid droplets formed by PrLD containing proteins is also disrupted 
by the binding of the arginine DPRs. The arginine DPRs appear to make liquid 
droplets more viscous by enhancing these multivalent interactions occurring within 
the liquid phase of PrLD droplets (Lee et al., 2016). This increased viscosity will 
likely enhance the maturation of liquid droplets to a less dynamic and more rigid 
state, as has been shown for the liquid droplets formed by FUS and hnRNPs (Molliex 
et al., 2015; Patel et al., 2015). In support of this Boeynaems et al. (2017) found 
poly-PR accelerates the liquid-to-solid maturation of PrLD droplets. Further the 
strong interaction between poly-GR and poly-PR with the LCD disrupts the dynamic 
exchange of proteins such as FUS and hnRNPA1 between the dense droplet phase 
and the surrounding mono-disperse phase as previously noted (Lee et al., 2016). 
The result of these perturbed and poorly dynamic phase transitions is that the liquid 
compartments of cellular structures that form via phase separations will be disturbed. 
The most obvious consequence is the internal functional balance of the liquid 
components of membraneless organelles will be disrupted (Boeynaems et al., 2017).  
1.9.3.8 Summary of poly-GR and poly-PR toxicity 
 
In summary the arginine DPRs are highly toxic to neurons, particularly in Drosophila 
models (Mizielinska et al., 2014; Yang et al., 2015; Freibaum et al., 2015; 
Boeynaems et al., 2016a). The altered assembly, dynamics, and function of 
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membraneless organelles that result from disturbed phase transitions fully account 
for the widespread cellular abnormalities observed in C9ALS/FTD and can explain 
several of the other mechanisms of poly-GR and poly-PR toxicity. The splicing 
alterations induced by these arginine-rich DPRs observed by Kwon et al. (2014) and 
Yin et al. (2017) is potentially attributable to the alteration of liquid-like properties in 
nuclear speckles by poly-GR and poly-PR (Lee et al., 2016; Freibaum and Taylor, 
2017). Nuclear speckles are enriched in pre-mRNA splicing factors (Spector and 
Lamond, 2011); hence a disruption in their dynamics is likely to affect splicing (Lee et 
al., 2016). Indeed Yin et al. (2017) note U2 snRNP proteins were identified as poly-
GR and poly-PR interactors by Lee et al. (2016) and that many of these U2 snRNP 
proteins contain LCDs. Yin et al. (2017) suggest the interaction between these 
arginine DPRs and LCD containing U2 snRNP proteins may explain why they 
observed a loss of U2 snRNP proteins from nuclear speckles and an accumulation in 
the cytosol. The nucleolar dysfunction observed following arginine DPR expression 
(Kwon et al., 2014; Tao et al., 2015; Mizielinska et al., 2017) is also caused by the 
disruption of the liquid properties of the nucleolus (Lee et al., 2016). LLPS is also 
important for the transport of molecules across the NPC (Schmidt and 
Görlich, 2016). As discussed previously both poly-GR and poly-PR disrupts 
nucleocytoplasmic transport (Jovičić et al., 2015; Boeynaems et al., 2016; Lee et 
al., 2016); further poly-PR was shown by Shi et al. (2017) to bind to and stabilize 
polymeric FG repeats found in the core of the nuclear pore changing the properties 
of the central channel of nucleoporins (NUPs). Hence poly-GR and poly-PR induced 
LLPS deficits may also perturb nucleocytoplasmic transport. Indeed Shi et al. (2017) 
note the sequences found in the FG domains of nucleoporins (repetitions of the 
tripeptide sequence glycine/serine-tyrosine-glycine/serine) are like the LC domains 
found in RNA binding proteins. Low-complexity FG domains have been reported to 
phase separate via multivalent cohesion to form a sieve like selective hydrogel 
barrier (Aguzzi and Altmeyer, 2016). The arginine DPRs appear to act as molecular 
seeds initiating phase transitions by binding to the LCD of intrinsically disordered 
proteins causing liquid demixing; furthermore, due to the strength of the interaction 
between these DPRs and LCDs, the liquid droplets formed become more viscous 







Figure 1.20 | LCD mutations and the arginine DPRs disrupt LCD 
interactions. Multivalent interactions drive phase separations involved in the 
formation of membraneless organelles. Mutations in the low complexity domain 
(LCD) of proteins and the arginine DPRs (poly-GR and poly-PR) derived from the 
G4C2 expansion alter the strength of LCD interactions driving phase separations 
and making the liquid droplets resulting from these phase separations more 





















1.9.4 Poly-GP toxicity 
 
Poly-GP is the second most abundant DPR after poly-GA in the human C9 ALS/FTD 
brain (Schludi et al., 2015). Poly-GP is uncharged and has a compact flexible coil 
structure (Freibaum and Taylor, 2017). Poly-GP is unique amongst the DPRs as it is 
produced from both the sense and anti-sense strand, with the anti-sense poly-GP 
species surprisingly appearing the more abundant species (Zu et al., 2013). Flores et 
al. (2016) demonstrated the poly-GP peptide is resistant to aggregation and does not 
appear to associate with markers of amyloid aggregates consistent with cellular 
models using poly-GP only constructs (Zhang et al., 2014; May et al., 2014; Wen et 
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al., 2014; Tao et al., 2015; Yamakawa et al., 2015). Mass spectrometry analysis has 
revealed poly-GP interacts with few cellular proteins (Lee et al., 2016).  
Evidence for poly-GP toxicity is mixed; with mild (Zu et al., 2013; Yamakawa et al., 
2015) to no toxicity being reported in several studies (Zhang et al., 2014; May et al., 
2014; Wen et al., 2014; Tao et al., 2015). Yamakawa et al, (2015) found poly-GP 
impaired UPS degradation. Using the UPS reporter Ub-G76V-GFP, which is 
normally rapidly degraded by the UPS Yamakawa et al. (2015), observed Ub-G76V-
GFP levels were higher in poly-GP transfected cells. Poly-GP also enhanced cell 
death resulting from exposure to the proteasome inhibitor MG132. Similar results 
were seen for poly-GA and poly-GR. Zu et al. (2013) using a G4C2 construct that 
overexpressed poly-GP (via an insertion of an ATG in the poly-GP frame) found 
increased cell death. In the human brain poly-GP levels associate with 
neuropathological subgroup, poly-GP levels are significantly higher in the frontal 
cortex of ALS/FTD patients compared to FTD frontal cortex poly-GP levels (Gendron 
et al., 2015). Additionally, poly-GP levels are significantly lower in ALS patient 
cerebellum compared to both ALS/FTD and FTD cerebellum. Interestingly Gendron 
et al. (2015) did observe cerebellar poly-GP associates with cognitive impairment in 
ALS and ALS/FTD patients. However, poly-GP levels in frontal cortex, motor cortex 
and the hippocampus did not correlate with cognitive impairment. Furthermore poly-
GP did not associate with age of disease onset or survival after onset (adjusted for 
age of onset and disease subgroup) in any of the previously mentioned brain 
regions. 
1.9.4.1 Poly-GP as a pharmacodynamic biomarker for C9ALS/FTD 
 
Whilst poly-GP toxicity is unlikely to be the primary pathogenic species in 
C9ALS/FTD it does appear to represent a useful biomarker for C9ALS/FTD (Su et 
al., 2014; Gendron et al., 2017; Lehmer et al., 2017). Su et al. (2014) developed a 
poly-GP immunoassay to measure soluble levels of poly-GP in cerebrospinal fluid 
(CSF); poly-GP was only detectable in C9 ALS CSF, but not SALS or control CSF. 
The confirmation of poly-GP as a pharmacodynamic biomarker for C9ALS/FTD has 
come recently from Gendron et al. (2017) and Lehmer et al. (2017). Gendron et al. 
(2017) replicated the previous findings from Su et al. (2017) that poly-GP is 
detectable in C9ALS CSF, however went further in showing that the peptide is 
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detectable in CSF of both symptomatic and asymptomatic C9 ALS and C9ALS/FTD 
expansion carriers. Further characterisation of poly-GP CSF levels in asymptomatic 
expansion carriers by Gendon et al. (2017) revealed CSF poly-GP is stable over 
time. However, poly-GP CSF levels were not a prognostic marker for either C9ALS 
or C9ALS/FTD; CSF levels of poly-GP did not correlate with age at disease onset, 
survival after disease onset, onset site or disease group. No correlation was found 
between poly-GP CSF levels and behavioural impairment. CSF poly-GP was 
associated with cognitive impairment however the significance of this finding was lost 
when the authors adjusted for age at CSF collection, gender, and years of education 
(Gendron et al. 2017). Poly-GP was also detectable in the lymphoblastoid cell lines 
from C9 expansion carriers and in the media of these cells indicating poly-GP is 
actively secreted from cells. Gendron et al. (2017) also found poly-GP was a useful 
marker to test for the effectiveness of ASOs targeting the G4C2 RNA. A 
lymphoblastoid cell line from a C9ALS patient and a line from an asymptomatic C9 
carrier treated with the G4C2 ASO reduced poly-GP levels. This G4C2 ASO reduced 
both intracellular and extracellular poly-GP in C9 iPSC neurons. Furthermore, these 
decreases paralleled reductions in G4C2 RNA; these findings together indicate 
extracellular poly-GP in the CSF can also be used to determine the effectiveness of 
potential treatments. The detection of poly-GP in CSF was confirmed in a second 
study by Lehmer et al. (2017). Hence these studies strongly support a role for poly-
GP as a diagnostic marker for C9ALS/FTD; further poly-GP CSF levels may also 
provide a means to assess the effectiveness of therapies targeting the G4C2 RNA in 
expansion carriers. 
1.9.5 Poly-PA toxicity 
 
Poly-PA is the final DPR translated from the repeat expansion. Poly-PA is translated 
from the anti-sense C4G2 strand.  Poly-PA inclusions are exceptionally rare (Schludi 
et al., 2015; Mackenzie et al., 2015), with only very rare inclusions being observed in 
the cortex or motor neurons of patients (Mackenzie et al., 2015); although poly-PA 
aggregates have been reported in one study to be more prevalent in motor neurons 
than poly-GA inclusions (Cooper-Knock et al., 2015). Poly-PA has a compact flexible 
coil structure and is uncharged, and consistent with its structure the peptide is 
seemingly inert (Freibaum and Taylor, 2016). No study utilizing alternative codons 
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has reported any evidence of poly-PA toxicity or that it forms inclusions (Freibaum 
and Taylor, 2016) with the protein being diffusely cytoplasmic in cellular models 
(Zhang et al., 2014; May et al., 2014; Wen et al., 2014; Yamakawa et al., 2015). 
Despite no evidence for poly-PA toxicity a recent study has suggested poly-PA may 
play a protective role by ameliorating poly-GA toxicity. Lee et al, (2017) found poly-
PA is sequestered by poly-GA and that co-expression of poly-PA with poly-GA 
reduces poly-GA toxicity by reducing its aggregation in vitro and in vivo in chick 
embryos. 
1.9.6 Evidence against DPR toxicity 
 
Despite both in vitro and in vivo model systems convincingly demonstrating the 
potent toxicity of the DPRs, particularly poly-GR and poly-PR (Gitler and Tsuiji, 2016; 
Moens et al., 2017) studies of DPR distribution in the human brain are contradictory 
to this. Gitler and Tsuiji, (2016) note if DPRs are the driving factor behind 
pathogenesis then it would be predicted they would accumulate in the most 
vulnerable regions of the brain affected in C9ALS/FTD; and that DPR abundance 
should correlate with disease severity. This is however not the case; DPR pathology 
does not correlate with neurodegeneration or clinical severity (Davidson et al., 2014; 
Mackenzie et al., 2014; Davidson et al., 2016; Mackenzie et al., 2015; Schludi et al., 
2015).  
Mackenzie et al, (2015) performed a detailed quantitative analysis and clinic-
pathological correlation of DPR proteins in C9ALS/FTD carriers. Other than poly-GA 
where a moderate positive association was found between the amount of poly-GA 
DNs in the upper cortical layers of the frontal cortex and local degeneration; no other 
significant correlation was found between DPR pathology and degeneration in either 
the frontal cortex or LMNs. Indeed, the DPRs are exceptionally rare in spinal cord 
motor neurons (Gomez-Deza et al., 2015; Mackenzie et al., 2015; Davidson et al., 
2016) with the antisense sense DPRs poly-PA and the highly toxic poly-PR being 
exceptionally rare throughout the brain (Schludi et al., 2015; Mackenzie et al., 2015). 
Furthermore Mackenzie et al. (2015) observed no association for disease duration 
for any DPR protein. A moderate negative association between poly-GA pathology in 
the frontal cortex and age of onset was found for overall cohort; however, the 
authors’ note this finding should be treated with caution as the correlation was driven 
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by two C9ALS/FTD cases with an extremely high poly-GA burden. In fact, exclusion 
of these two cases removed the significance of this association. Further no 
correlation was seen for poly-GA or any of the DPRs for age of onset for either pure 
FTD or pure ALS. In addition, no correlation was seen between any of the other 
DPRs and age of onset and no DPR protein pathology correlated with disease 
duration. A healthy case with a short 30 repeat unit expansion was reported by Gami 
et al. (2015); DPR pathology (in addition to RNA foci) was seen - suggesting the 
presence of DPRs is not sufficient for disease; although the abundance of DPR 
pathology was not reported. Furthermore, DPR toxicity does correlate with length of 
the dipeptide in model systems (Mizielinska et al., 2014). 
A problem for the suggestion DPRs drive toxicity in C9ALS/FTD is the lack of DPR 
inclusions in vulnerable neuronal populations; especially the arginine DPRs, in spinal 
cord motor neurons (Gomez-Deza et al., 2015). Wen et al. (2014) reported the 
presence of poly-PR nuclear inclusions that co-localised with the nucleolus and 
extranuclear poly-PR in C9ALS and C9ALS/FTD spinal cords; although bizarrely the 
antibody used also detected poly-PR aggregates (although less frequently) in the 
spinal cords of non C9ALS patients and healthy controls. Cooper-Knock et al. (2015) 
were able to detect cytoplasmic poly-PR inclusions in motor neurons which were 
more numerous than poly-GA or poly-GR inclusions. Others have failed to reproduce 
this finding using the same poly-PR antibodies. Mackenzie et al. (2015) saw 
extremely rare poly-PR inclusions in the spinal cord observing fine or coarse 
granular nuclear labelling with larger regions of immunopositive staining seen in both 
C9 and controls, leading to the conclusion that the staining was non-specific. 
Davidson et al. (2016) reported a nuclear staining pattern in anterior horn cells 
similar to Mackenzie et al. (2015) with the poly-PR antibody used by Cooper-Knock 
et al. (2015), further Davidson et al. (2016) did not detect any poly-PR cytoplasmic or 
nuclear inclusions. Additionally the same staining pattern was observed in controls. 
Schludi et al. (2015) also reported no poly-PR spinal cord aggregates using their 
own antibody; Gomez-Deza et al. (2015) observed poly-PR inclusions in spinal cord 
motor neurons but they were exceptionally rare using the poly-PR antibody 
generated by Gendron et al. (2013); only one poly-PR spinal cord inclusion was seen 
per section was seen in 3 of the 10 C9 cases studied. Differences in antibody 
specificity and cell types stained likely play a role, however Davidson et al. (2016) 
117 
 
note Wen et al. (2014) did not specify the spinal cord cell type in which they 
observed poly-PR nuclear inclusions or the case numbers they investigated.  Further 
Schludi et al. (2015) found intranuclear poly-GR and poly-PR inclusions observed in 
cellular models produced from alternative codon constructs do not correspond to 
what is seen in the human brain. Arginine DPR intranuclear inclusions derived from 
protein only constructs show a pronounced nuclear and nucleolar 
localization whereas those in the human brain are mainly cytoplasmic, and when 
nuclear are paranucleolar; attached next to the nucleolus - but not co-localising with 
it. Furthermore, overexpressed poly-GR and poly-PR (and poly-GP) are not p62 
positive, whereas the majority of inclusions in the human brain are p62 positive 
(Schludi et al., 2015).  
It has been argued that the arginine DPRs are so difficult to detect in post-mortem 
analysis because they are so highly toxic (particularly poly-PR), thereby the affected 
neurons are quickly lost and not present by the time of patient death (Gitler and 
Tsuiji, 2016). Further, the potently toxic poly-PR may not need to accumulate at such 
high levels to cause neuronal death. Gitler and Tsuiji, (2016) note the DPRs may 
exist in multiple conformations or strains like other disease related proteins such as 
tau, α–syn and Aβ, hence current DPR antibodies may not be able to detect these 
DPR species, thereby providing a misleading picture about DPR pathology. 
Differences in DPR expression pattern combined with differential aggregation 
properties and toxicities may influence the prevalence and distribution of DPR 
inclusions seen in the post-mortem brain. Edbauer and Haass, (2016) note in 
Alzheimer’s disease (AD), the accumulation of the amyloid β-peptide (Aβ) pathology 
occurs decades before dementia onset in the neocortex, and then spreads 
centripetally toward the brain stem. Edbauer and Haass, (2016) argue by the time 
AD is diagnosed the Aβ pathology has plateaued and no longer correlates well with 
the progression of AD - as is the case with the DPRs in C9ALS/FTD. Given the poor 
correlation between DPR inclusion bodies and areas of neurodegeneration 
Mackenzie et al. (2015) investigated the soluble forms of DPR proteins and whether 
there is any difference in C9 soluble species between different C9 clinical 
manifestations. However, the authors observed no specific differences in the 
banding patterns of the soluble protein fractions using DPR antibodies between C9 
cases, controls and C9 cases with different clinical presentations. Mackenzie et al. 
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(2015) interpreted this as a lack of evidence for the presence of potentially soluble 
toxic DPR species.  
Of note, not all post-mortem analysis argues against DPR protein toxicity. Proudfoot 
et al. (2014) reported the case of a 26 year old expansion carrier with a severe 
developmental disability who died of unrelated causes and had abundant poly-GA 
pathology but no TDP-43 inclusions. Gendron et al. (2015) found cerebellar poly-GP 
levels were significantly lower in ALS patients compared to FTD or ALS/FTD; further 
the cerebellar levels of poly-GP correlated with cognitive score. A similar finding was 
observed for poly-GA levels, but this did not associate with cognitive score. 
However, both cerebellar poly-GP and poly-GA levels correlated with V3 mRNA 
expression, repeat size, disease onset and survival after onset (Gendron et al 2015). 
Hence cerebellar levels of the DPRs correlate with neuropathological and clinical 
phenotypes. Indeed, one argument that has been used to doubt the contribution of 
the DPRs to C9ALS/FTD pathogenesis is their high burden in regions of the brain 
not typically associated with ALS/FTD, particularly the cerebellum. However there 
have been reports of cerebellar atrophy in C9FTD cases (Bocchetta et al., 2016); 
further longitudinal neuroimaging study of expansion carriers revealed preferential 
volume loss in the thalamus and cerebellum (Mahoney et al., 2012). Cerebellar 
ataxia has also been reported to be associated with expansions in C9ORF72 
(Lindquist et al., 2013) and longer repeats in the cerebellum are associated with 
poorer survival in expansion carriers (van Blitterswijk et al., 2013). Furthermore post-
mortem analyses on patients with the C9ORF72 expansion who have died early of 
the disease show abundant DPR pathology only; further indicating DPR pathology 
precedes that of TDP-43 and may initiate the disease cascade (Proudfoot et al 2014; 
Baborie et al 2015; Vatsavayai et al 2016; Davidson et al 2016).  
Vatsavayai et al., (2016) reported on two C9 cases; the first a C9FTD case showing 
focal degeneration in brain regions lacking TDP-43 pathology but harbouring foci and 
DPRs; hence neurodegeneration can occur in the absence of TDP-43 aggregates; 
which normally correlates with areas of neuronal loss in C9ALS/FTD (Mackenzie et 
al., 2014). There was still a poor correlation between individual DPRs and RNA foci 
with regional patterns of neurodegeneration, suggesting that alone the specific 
pathological features of repeat expansion are not sufficient to cause degeneration; 
however, a combination of the different features in a neuron may be toxic. To 
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address this potential hypothesis Vatsavayai et al. (2016) looked for RNA foci and 
p62 positive inclusions finding neurons do indeed harbour more than one of these 
pathological features to different extents in multiple brain regions. This was 
particularly striking in the medial pulvinar thalamus (mPULV) where 27% of neurons 
contained sense foci, anti-sense foci and a DPR inclusion. Importantly focal 
neurodegeneration was seen in the mPULV. Case 2 provided an exciting opportunity 
to study the presymptomaic and symptomatic stages of C9FTD from the same 
patient. Case two was an atypical C9ALS/FTD case that had undergone a temporal 
lobe resection for epilepsy 5 years prior to the onset of FTD symptoms. Imaging 
revealed presymptomaic volume reductions suggesting early degeneration resulting 
from the repeat expansion. Pathological analysis of the presymptomatic tissue 
showed both foci and DPR pathology whereas TDP-43 pathology was absent. 
However, at autopsy TDP-43 pathology was abundant; interestingly the most 
degenerative neurons were those lacking nuclear TDP-43 staining but did not 
harbour a pathological inclusion. Interestingly Scaber and Talbot, (2016) note this is 
the fourth publication to report minimal TDP-43 pathology in C9FTD (Gijselinck et al., 
2012; Proudfoot et al., 2014; Baborie et al., 2015; Vatsavayai et al., 2016) while no 
such cases have been reported for C9ALS. Further they note the DPRs are 
incredibly rare in the spinal cord; whereas they are much more common in cortical 
regions; hence there may be differences in DPR contribution to different clinical 
manifestations of the repeat expansion. 
1.9.7 Summary of DPR toxicity  
 
In summary the data from protein only DPR models in vivo and in vitro provide 
strong support for the toxicity of arginine DPRs, with poly-GA being identified as toxic 
in some model systems (Moens et al., 2017) (figure 1.21). Mechanisms of poly-GR 
and poly-PR toxicity have been recently elucidated (Lee et al., 2016; Lin et al., 2016; 
Boeynaems et al., 2017). The arginine DPRs interact with the LCD of proteins 
involved in the formation of membraneless organelles leading to a disruption in their 
dynamics; although the precise mechanism by which they are toxic to neurons is not 
yet fully resolved (Moens et al., 2017). At present it has not been demonstrated 
whether poly-GR or poly-PR is sufficient or necessary to cause the pathology 







Figure 1.21 | Cellular impairments associated with DPR toxicity. Both poly-
GR/PR and poly-GA have shown to be toxic in different model systems. Cellular 
functions associated with poly-GR/PR toxicity include nucleolar dysfunction, altered 
splicing, impaired nucleocytoplasmic transport, perturbed RNA granule dynamics 
and altered intracellular transport. Poly-GA has been shown to impair the function 






models overexpressing the arginine DPRs will be important to this. Human post-
mortem data suggests the DPRs precede TDP-43 pathology; however, DPR 
inclusions do not correlate with regional neurodegeneration, whereas TDP-43 
burden does (Mackenzie et al., 2014). The arginine DPRs are however less 
aggregation prone due to their hydrophilic properties, hence sensitive assays to 
measure soluble forms of the arginine DPRs will be important in helping clear up the 





1.11  Loss vs gain of function  
 
Cellular and animal models of the G4C2 repeat expansion have provided major 
insights into the C9ALS/FTD disease mechanisms. Knockout of the C. elegans 
(Therrien et al., 2013) and Zebrafish orthologus of C9orf72 (Ciura et al., 2013) has 
led to motor phenotypes and neurodegeneration. However, a common finding from 
all murine knockout models is the lack of any apparent neurodegeneration or TDP-
43 pathology (O’Rourke et al., 2016; Atanasio et al., 2016; Burberry et al., 2016; 
Sudria-Lopezet al., 2016; Jiang et al., 2016; Sullivan et al., 2016). This discepenacy 
between models suggests the function of the protein is redundant to some extent 
and its loss can be compensated in mice and potentially humans too. These findings 
clearly indicate a loss of protein function is not sufficient to cause the disease. 
However, the function of C9ORF72 in autophagy, immune dysregulation, axon 
growth and stress granule dynamics propose a modulatory role for a loss of protein 
function in disease pathogensis. Indeed, it has recently been demonstrated by Shi et 
al., (2018) that repeat expansion associated reductions in C9ORF72 levels can 
cause neurodegeneration via an accumulation of glutamate receptors and defective 
clearance of the DPRs. This is not entirely surprising considering the function of 
C9ORF72 in autophagy and that the DPRs are mainily processed through autophagy 
(Cristofani et al., 2018), hence a loss of protein function in disease may make 
neurons hypersensitive to DPR toxicity. One potential explanation as to why 
C9ORF72 knockout mice show no overt neurodegenerative phenotype may be lack 
due to the gain of function pathology in these models - if C9ORF72 modulates 
neuronal vulnerability to toxic stimuli rather than its loss causeing toxicity directly. For 
example, DPRs cause a mis-splicing of the EAAT2 transporter in astrocytes (Kwon 
et al., 2014) which may potentially cause excitotoxicty in neuronal populations with 
an accumulation of glutamate receptors due to reduced levels of C9ORF72 (Shi et 
al., 2018). Such findings suggest increasing/restoring C9ORF72 protein amounts 
may help modulate gain of function related toxicity.  
G4C2 repeat expansion models provide clear evidence that the toxic gain of function 
mechanisms are both necessary and sufficient to cause neurodegeneration (Chew et 
al., 2015), although they are limited by their inability to distinguish between RNA and 
DPR toxicity. To circumvent this several studies have developed strategies to study 
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the contribution of repeat RNA and DPRs separately. The consensus from such work 
is that the DPRs, particularly the arginine DPRs, are highly toxic whereas the toxicity 
of the G4C2 RNA in insolation is milder – with its toxicity depending on the subcellular 
localisation and model system in which the repeat RNA is expressed. C9orf72 BAC 
transgenic mice present with RNA foci but no neurodegeneration (O’Rourke et al., 
2015; Peters et al., 2015). In Drosophila Moens et al., (2018) observed no 
neurodegenerative phenotypes in flies expressing either sense of anti-sense repeat 
RNA despite the presence of both cytoplasmic and nuclear foci in neurons. In 
Zebrafish however both sense and anti-sense repeat RNAs induce toxicity (Swinnen 
et al., 2018). The discrepancies between model systems using similar constructs is 
puzzling. One potential explanation for this is that RNA binding proteins essential for 
repeat RNA toxicity are not conserved in Drosophila. However, Moens et al., (2018) 
show Glorund, the Drosophila homologue of hnRNP H is sequestered into RNA foci 
in flies and when knocked down via RNAi causes a degenerative phenotype in flies, 
suggesting the sequestration of RNA binding proteins into RNA foci is not sufficient 
to cause neurodegeneration. Indeed Swinnen et al., (2018) found no direct 
correlation between RNA foci and toxicity in their Zebrafish model, however the 
authors note the RNA was mainly localised to the cytoplasm, both diffisuley as well 
as in foci – suggesting RNA toxicity may result from cytoplasmic, rather than nuclear 
repeat RNA. ISwinnen et al., (2018) report that Pur-alpha overexpression reduces 
RNA foci numbers without being present in foci, suggesting it interacts with soluble 
repeat RNA, which may drive repeat RNA toxicity. Indeed, a possible toxic effect of 
cytoplasmic RNA not incorporated into foci is supported by neuronal patient iPSCs 
(Burguete et al., 2015). Therefore, one potential explanation for lack of any 
phenotype observed following RNA expression in flies could be the marked RNA foci 
in this model when compared to the more diffuse cytoplasmic RNA seen in the 
Zebrafish model.  
Protein only constructs designed to study the individual DPRs in isolation of the 
repeat RNA have given a broad consensus that the arginine DPRs (poly-GR and 
poly-PR) are highly toxic (Moens et al., 2017), indeed it appears they are the 
‘primary’ gain of function mechanism. The disruption of membraneless organelles 
that result from abnormal phase transitions induced by these DPRs can account for 
many of the widespread cellular abnormalities observed in C9ALS/FTD models. Of 
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the other DPRs only poly-GA has shown mild toxicity depending on the model 
system used, with Drosophila being resisent to poly-GA toxicity (Mizielinska et al., 
2014) whereas neurodegeneration, cognitive dysfunction and motor impairment is 
seen following poly-GA expression in mice (Zhang et al., 2016). The development of 
rodent models to study arginine DPR toxicity will be vital to understanding the 
contribution of these DPRs to neurodegeneration and ALS/FTD releated 
phenotypes. An important issue with DPR toxicity is the lack of spatial correlation 
between DPRs and regions that undergo severe cell loss in FTLD and ALS in 
addition to their high abundance in areas of the brain not typically associated with 
disease such as the cerebellum. Although, a more recent thorough and standardised 
analysis of DPRs in clinically-related and clinically-unrelated regions of the brain 
found poly-GR was more abundant in clinically related than clinically unrelated areas 
(Saberi et al., 2018). The lack of association in previous studies may owe to arginine 
methylation, which would lead to several complex post-translational modifications of 
poly-GR. It possible different poly-GR antibodies used in different papers detect 
different species. Decoupling RNA and DPR toxicity remains however a challenge 
without creating artificial constructs or relying on overexpression systems. It it is 
clear both can be toxic (particularly for the arginine DPRs) in a dose-dependent 
manner, however whether they are toxic at physiological levels is still unknown. A 
better understanding of RAN translation and the mechanisms underpinning this non-
conventional form of translation will enable the development of tools which will allow 
DPR expression, translated at physiological levels, to be turned off and on in 
endogenous systems such as iPSCs without disrupting the structure of the repeat 
RNA (figure 1.22). Such a tool would also help establish a pathogenic chain of 
events in C9ALS/FTD which at present is lacking. Another strategy would be to 
develop repeat RNA constructs in which a specific DPR (such as poly-GR) is 
produced in frame with a degradable reporter gene which would allow the expression 
of that DPR to be modulated without disrupting translation of the other DPRs. 
Current DPR only mouse models (Zhang et al., 2016; Zhang et al., 2018) show 
neurodegeneration and behavioural phenotypes but no TDP-43 pathology – where 
as BAC transgenic mice with a combination of both DPR and RNA pathology (Chew 
et al., 2015; Lui et al., 2016) show TDP-43 inclusions and neurodegeneration. Such 
data argues for a combination of both the gain of function mechanisms to be fully 







Figure 1.22 | Further work needed to study DPR toxicity at physiological 
levels. To separate RNA and DPR toxicity without using overexpression models 
and to study DPR toxicity at physiological levels the identification of compounds 
that can specifically block RAN translation will be needed. The development of 
such compounds requires a greater understanding of RAN translation 
mechanisms and proteins that specifically regulate RAN translation. Adapted from 



















1.12   Summary of disease mechanisms  
 
In summary major progress has been made since the 2011 discovery of the repeat 
expansion in C9ORF72 in elucidating the underlying pathogenic mechanisms. There 
is evidence to support both loss and gain of function mechanisms; however current 
research demonstrates a loss of C9ORF72 protein function is not sufficient to cause 
disease. Both the G4C2 RNA and DPR expression (in particular, poly-GR and poly-
PR) have been shown to be neurotoxic and disrupt a number of cellular processes. 
Establishing which of these correlate with neuronal loss will be an important future 
area of work. It is likely both the gain and loss of function mechanisms act 
synergistically to induce disease, indeed both the repeat RNA and arginine DPRs 
have been shown to disrupt nucleocytoplasmic transport and cause nucleolar 
dysfunction. A loss of protein function may also play a modulatory role via its role in 




1.13 TDP-43 dysfunction in C9ALS/FTD 
 
C9ALS/FTD, like 97% of all ALS cases and 45% of FTD cases is a TDP-43 
proteinopathy (Ling et al., 2013). Unlike DPR and RNA foci pathology, TDP-43 
pathology is highly correlated with both brain areas showing the most 
neurodegeneration and clinical symptoms (Mackenzie et al., 2014; DeJesus-
Hernandez et al., 2017). Based on this it has been proposed TDP-43 mislocalisation 
and aggregation is the most likely effector of C9 repeat associated toxicity; however 
no casual relation and mechanistic link has been fully established (Edbauer and 
Haass, 2016). Edbauer and Haass, (2016) note pathogenic TDP-43 mutations cause 
mainly regional TDP-43 pathology highly similar to the TDP-43 pathology seen in 
sporadic ALS/FTD cases; indicating the frontotemporal cortex and motor neurons 
are prone to cytoplasmic TDP-43 accumulation.  
A multiple hit hypothesis has been proposed by Dormann and Haass, (2011) in 
which multiple stressors are required for the accumulation of TDP-43 into insoluble 
inclusions. The first hit is argued to be defective nuclear import which causes a 
cytoplasmic accumulation of TDP-43 (Dormann and Haass, 2011); a second hit is 
required for aggregate formation which is suggested to be a cellular stress that 
causes stress granule formation (Dormann & Haass, 2011). Such a multiple-hit 
model has been demonstrated for FUS; FUS mutations that disrupt the NLS lead to 
a diffuse cytoplasmic distribution of FUS without the formation of FUS aggregates. 
However, when cells are stressed cytoplasmic FUS begins to accumulate in SGs 
(Bosco et al., 2010; Dormann et al., 2010). Edbauer and Haass, (2016) propose that 
the DPR proteins and/or the repeat RNA are the additional stressors that cause 
TDP-43 pathology in C9/ALS FTD. Edbauer and Haass, (2016) have proposed an 
amyloid cascade model for C9ORF72 pathogenesis in which the DPRs and/or repeat 
RNA trigger a toxic cascade prior to the onset of clinical symptoms. The authors note 
this is akin to what occurs in AD where accumulation of the Aβ is the most probable 
initial trigger at the start of the disease cascade, followed by subtle synaptic and 
early cognitive dysfunction, the deposition of tau into tangles leading to the 
impairment of synaptic functional and neuronal loss. Importantly Edbauer and 
Haass, (2016) note in this cascade the Aβ pathology occurs decades before 
dementia onset in the neocortex and then spreads centripetally toward the brain 
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stem; Edbauer and Haass, (2016) argue by the time AD is diagnosed the Aβ 
pathology has plateaued and no longer correlates well with the progression of AD as 
is the case with the DPRs in C9ALS/FTD. Using AD as an example to model 
C9ALS/FTD pathogenesis Edbauer and Haass (2016) propose neurodegeneration is 
caused by the cytoplasmic accumulation of abnormally phosphorylated TDP-43 
similar to abnormally phosphorylated tau in AD. Hence, they argue the lack of any 
association between the DPRs and neurodegeneration is potentially explained by the 
triggering of a slow cascade that occurs before clinical symptoms which later 
sustains itself independently of the trigger like what has been proposed for Aβ 
plaques in AD.  
In support of this post-mortem analyses in patients with the C9ORF72 expansion 
who have died early of the disease show abundant DPR pathology only; further 
indicating DPR pathology precedes that of TDP-43 (Proudfoot et al 2014; Baborie et 
al 2015; Davidson et al 2016). Vatsavayai et al. (2016) could show TDP-43 
pathology occurs only at symptomatic and not pre-symptomatic stages of disease; 
DPRs were however found at both stages. Cellular studies have also linked a loss of 
C9ORF72 protein function to TDP-43 accumulation. For example, Sellier et al. 
(2016) found reduced expression of C9ORF72 via shRNA mediated knockdown in 
mouse embryonic cortical neurons caused a ~30kDA fragment of mouse TDP-43 
(Tdp-43) to accumulate. Phosphorylated cytoplasmic aggregates of Tdp-43 were 
also observed in these neurons. Furthermore, overexpression of C9ORF72 reduced 
the aggregation propensity of the D196G mutant of TDP-43. Other cellular models 
have not replicated this; Maharjan et al. (2016) saw TDP-43 levels and localisation 
were unchanged by either C9-CRISPR knockdown or overexpression of the long 
isoform of C9ORF72. Xiao et al. (2015a) did observe a depletion of C9-S from the 
nuclear membrane in patient spinal cord motor neurons, further this loss from the 
nuclear membrane correlated with a mislocalisation of KPNB1, RAN and TDP-43. 
However, no animal model of C9ORF72 loss of function has shown any sort of 
TDP-43 pathology (Ciura et al., 2013; Koppers et al., 2015; O’Rourke et al., 2016; 
Atanasio et al., 2016; Burberry et al., 2016; Sudria-Lopezet al., 2016; Jiang et al., 
2016; Sullivan et al., 2016). This strongly argues against a loss of function of the 
protein being sufficient to cause TDP-43 accumulation. 
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If the DPRs and/or RNA foci act as such stressors, causing TDP-43 dysfunction 
leading to subsequent neurodegeneration as is proposed Edbauer and Haass., 
(2016), the question is which of these gain of function pathogenic species generated 
from the G4C2 is the main stressor in this cascade. For example, are both the DPRs 
and pathogenic RNA necessary for TDP-43 dysfunction, or is just one of these 
sufficient, and if so, in the case of the DPRs, is one or all of the DPRs required for 
TDP-43 cytosolic accumulation and aggregation. Murine C9 bacterial artificial 
chromosome (BAC) models have been generated that produce RNA foci and RAN 
dipeptides early during the life of these mice, but show no TDP-43 pathology and no 
neurodegeneration or motor phenotypes (O’Rourke et al 2015; Peters et al 2015). 
Neurodegeneration is seen in murine models that present TDP-43 pathology (Chew 
et al 2015; Liu et al 2016a); interestingly in the Liu et al. (2016a) C9 BAC model 
TDP-43 aggregation occurred at end-stage, after the formation of both DPRs and 
RNA foci. In the Chew et al. (2015) viral vector model, of the 250 cortical cells with 
TDP-43 inclusions all contained at least one nuclear sense RNA foci; whilst ~75% of 
cells also contained a poly-GA aggregate. Chew et al. (2015) suggest as all cells 
investigated harboured RNA foci, that the G4C2 RNA and/or the RNA foci may be the 
instigator of TDP-43 pathology. Cooper-Knock et al. (2015) also suggest the anti-
sense C4G2 RNA may drive TDP-43 pathology; finding that anti-sense RNA foci, but 
not sense RNA foci, correlate with TDP-43 mislocalisation in patient motor neurons. 
In a reported RNA-only pure repeat Drosophila generated by Xu et al. (2013) 
increased cytoplasmic Drosophila TDP-43 is observed (Zhang et al., 2015); although 
undetectable levels of DPRs cannot be ruled out in this model; and as noted 
previously are detected under certain conditions. Jiang et al. (2016) in their BAC 
model observed increased phosphorylated TDP-43 at end stage but saw no 
mislocalisation or aggregation; both sense and anti-sense foci were produced in 
these mice in addition to all three sense DPRs. The anti-sense DPRs were not 
detectable in this model and were also not probed for by Liu et al. (2016a).  
A number of studies suggest it is the DPRs that cause TDP-43 pathology. Liu et al. 
(2016a) observed TDP-43 inclusions and behavioural phenotypes only in BAC mice 
that produced DPRs. Khosravi et al., (2017) suggest poly-GA may mediate TDP-43 
mislocalisation. Khosravi et al., (2017) generated a TDP-43 NLS reporter which 
consisted of RFP fused to the NLS of TDP-43. In control conditions the TDP-43 NLS 
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reporter was completely nuclear. However, when co-expressed with poly-GA 
significant levels of the reporter were found in the cytoplasm indicating nuclear 
import mediated by the TDP-43 NLS is perturbed. Manual counting of cells revealed 
~40% of cells containing a poly-GA inclusion showed mislocalisation of the reporter. 
Manual counting also revealed ~20% of poly-GR and poly-PR inclusion bearing cells 
also had mislocalisation of the TDP-43 NLS reporter. Manual analysis revealed poly-
GR led to a significant mislocalisation of the reporter although this significance was 
lost when an automated analysis was performed. It must be noted the authors did 
not comment on the reported frequency of poly-GR inclusions which could bias the 
results; poly-GR inclusions are rarer than poly-GA inclusions (Schludi et al., 2015) 
potentially due to the high toxicity of the peptide, especially in model systems (Gitler 
and Tsuiji, 2016; Moens et al., 2017) and its flexible-coil secondary structure 
(Freibaum and Taylor, 2017). Additionally, the authors did note that expression 
levels of poly-PR were significantly lower than poly-GA.  
Khosravi et al. (2017) also found importin α/β-mediated nuclear import, the import 
pathway involved in TDP-43 shuttling, is perturbed by poly-GA expression in addition 
to also enhancing the localisation of TDP-43 to cytoplasmic granules in transfected 
hippocampal neurons. No change in the amount of TDP-43 in cytoplasmic granules 
was seen for poly-GR; a significant increase was seen for poly-PR from a manual 
analysis but after automated analysis the significance was lost. Interestingly forcing 
poly-GA into the nucleus prevented cytoplasmic TDP-43 mislocalisation. Finally, 
Khosravi et al. (2017) observed overexpression of proteins involved in importin α/β-
mediated shuttling of TDP-43 such as KPNA3, KPNA4 and Nup62, but not Ran or 
RanGAP1, restored nuclear localisation of the TDP-43-NLS reporter following poly-
GA expression. It is important to point out that the authors saw no changes in the 
localisation of endogenous TDP-43 following DPR expression. Lee et al. (2017) 
observed significant TDP-43 cleavage in poly-GA expressing cells in a dose 
responsive manner which increased in parallel to the appearance of higher 
molecular weight poly-GA on western blot. However, Lee at al. (2017) did not report 
any TDP-43 aggregates or mislocalisation in poly-GA expressing cells. However, in 
poly-GA only mouse models developed by Zhang et al. (2016) only very rare 
phosphorylated TDP-43 aggregates were seen despite neurodegeneration, 
behavioural abnormalities and evidence for impaired nuclear import. Schludi et al. 
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(2017) in their poly-GA mouse model did observe phosphorylated TDP-43 but again 
no TDP-43 aggregates or even cytoplasmic accumulation of TDP-43 at 12 months of 
age.  
Other studies suggest the highly toxic arginine DPRs cause TDP-43 mislocalisation. 
A cell culture model expressing 80 G4C2 repeats developed by Mori et al. (2016) 
demonstrated cytoplasmic TDP-43 re-distribution when all three sense DPRs, poly-
GP, poly-GA and poly-GR were present in cells, but not with either just poly-GP or 
poly-GA or the combination of the two (Mori et al 2016). The authors note in the 
replies to one of the reviewers of their paper that they do indeed speculate poly-GR 
accumulation contributes to TDP-43 mislocalisation; however, they were unable to 
quantify this as cells expressing poly-GR only were too rare to find. Furthermore, 
poly‐GA and poly‐GR double‐positive cells, but not cells with only poly-GA, 
frequently had cytosolic TDP‐43 accumulation. Indeed, the lack of poly-GR only cells 
may be due to the high toxicity of the peptide; but when present with poly-GA its 
detrimental effects may potentially be modulated, but they are still sufficient to 
disrupt TDP-43 dysfunction. Such events are consistent with the finding by Yang et 
al. (2015) that poly-GA sequesters poly-GR and modulates its toxicity in Drosophila 
and cells. Indeed Yang et al. (2015) hypothesise poly-GA may be neuroprotective 
during the early stages of disease by trapping the highly toxic poly-GR in inclusions 
allowing it to be efficiently degraded; however, over time elevated levels of non-
aggregated poly-GR will increase to the point where it starts to disrupt cellular 
pathways. A recent analysis of DPRs in clinically-related and clinically-unrelated 
regions of the CNS found poly-GR was more abundant in clinically related compared 
clinically unrelated areas and co-localised with TDP-43 aggregates found in 
dendrites, such findings were not observed for any of the other DPRs (Saberi et al., 
2018). 
Based on their mechanisms of toxicity the arginine DPRs poly-PR and poly-GR 
seem likely candidates to cause TDP-43 dysfunction. As discussed, the arginine 
DPRs disrupt nucleocytoplasmic transport; including proteins involved in the importin 
α/β-mediated pathway involved in the shuttling of TDP-43 between the cytoplasm 
and nucleus (Jovičić et al., 2015; Boeynaems et al., 2016a; Lee et al., 2016; Shi et 
al., 2017). Boeynaems et al. (2016b) argue based on a review of the literature and 
bioinformatics analysis that deficits in nucleocytoplasmic transport play a key initial 
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role in the initiation of disease. Dormann and Haass, (2011) propose in their multiple 
hit hypotheses for TDP-43 aggregation that the first hit is defective nuclear import, 
which leads to cytoplasmic accumulation of TDP-43. The arginine DPRs provide this 
first hit; however, Dormann and Haass, (2011) argue without a second hit the protein 
remains soluble and no aggregates will be observed. Dormann and Haass, (2011) 
propose impaired SG dynamics may be the key second hit. The arginine-rich DPRs 
however provide this important second hit through their disruption of the formation of 
membraneless organelles (Lee et al., 2016; Lin et al., 2016; Boeynaems et al., 
2017). SGs dynamics are particularly interesting in the context of TDP-43 
cytoplasmic accumulation and aggregation. SGs are thought to be an important step 
in the aggregation of RNA binding proteins in ALS and FTD (Dormann and Haass., 
2011). SGs are cytoplasmic membrane less organelles that form in response to 
cellular stress (Aulas and Vande Velde., 2015).  
The transformation of liquid droplets like SGs into pathological aggregates is an 
attractive hypothesis via which arginine-DPR mediated TDP-43 aggregation may 
occur in C9ALS/FTD. Indeed, several groups have proposed that the accumulation 
of TDP-43 into cytoplasmic SGs leads to its aggregation (Ramaswami et al, 2013; Li 
et al., 2013; Aulas and Vande Velde, 2015 Becker et al., 2017). TDP-43 is a known 
component of stress granules; previous work has shown it forms part of stress 
granules by interacting with stress granule proteins including TIA-1 (Liu-Yesucevitz 
et al., 2010; Bentmann et al., 2012). Indeed, there is good evidence to show 
pathological TDP-43 inclusions may originate from SGs. Becker et al. (2017) 
investigated the role of the RNA binding protein ataxin-2 in TDP-43 aggregation. 
Ataxin-2 is suppressor of TDP-43 toxicity in flies and yeast and intermediate-length 
polyglutamine expansions in this gene are a risk factor ALS (Elden et al., 2010). 
Furthermore ataxin-2 regulates the assembly of SGs (Kaehler et al., 2012). Hence 
Becker et al. (2017) found ataxin-2 knockdown significantly decreased the number of 
SGs with endogenous TDP-43. TDP-43Tg/TgAtxn2−/− transgenic mice had markedly 
decreased TDP-43 aggregation supporting the hypothesis that decreasing ataxin-2 
reduces the association of TDP-43 with SGs and its propensity to aggregate.  
Recently Mackenzie et al. (2017) discovered mutations in the PrLD of the RNA 
binding SG protein TIA1 cause ALS/FTD. Importantly TIA1 ALS/FTD was a TDP-43 
proteinopathy. TIA1 mutations lowered the protein concentration required for the 
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protein to undergo LLPS and form liquid droplets at higher protein concentrations; 
hence TIA1 mutant phase separation is enhanced by stronger intermolecular protein-
protein interactions – similar to what is proposed for the increased LLPS caused by 
poly-GR and poly-PR (Lee et al., 2016). TIA mutations led to SGs which had 
impaired disassembly; importantly TDP-43 containing SGs accumulated because of 
TIA mutations. The recruitment of TDP-43 into these SGs led to TDP-43 becoming 
completely immobile and insoluble. Normally the solubility change in TDP-43 was 
reversible 3 hours after 30 minutes of stress; however, when stress persisted for 1 
hour TDP-43 became permanently insoluble. This supports the mounting evidence 
that perturbed SG dynamics are involved in pathological TDP-43 aggregation in 
ALS/FTD.  
The finding that poly-GR and poly-GR perturbs phase transitions disrupting both 
nucleocytoplasmic transport and SG formation provides the molecular basis for TDP-
43 aggregation in C9ALS/FTD. An important step in investigating the development of 
TDP-43 pathology in C9ALS/FTD will be the study of TDP-43 in poly-GR and poly-
PR animal models which is yet to be done. The investigation of TDP-43 localisation 
in animal models expressing these DPRs from alternative codons will be important 





1.14   Aims 
 
A non-coding G4C2 repeat expansion in C9ORF72 has been identified as major 
genetic cause of ALS and FTD and the combined ALS/FTD. An amyloid cascade 
hypothesis for C9 mediated neurodegeneration has been proposed in which 
stressors causes TDP-43 aggregation and cytoplasmic mislocalisation (Edbauer and 
Haass, 2016). It has been proposed that the DPRs and/or RNA foci act as such 
stressors, causing TDP-43 dysfunction leading to subsequent neurodegeneration 
(Edbauer and Haass, 2016). Hence this project aims to establish whether there is a 
link between the DPRs and TDP-43 pathology. The three major aims are as follows: 
 
1. Characterise RAN translation and the DPRs produced in Drosophila 
harbouring uninterrupted G4C2 repeats of different lengths. 
 
2. Generate and validate Drosophila expressing the DPRs from non G4C2 
codons. 
 
3. Investigate the potential pathogenic link between the DPRs and TDP-43 





Chapter 2: Materials and Methods 
2.1 Drosophila husbandry 
2.1.1 Standard Fly Storage and food 
Fly stocks were maintained at 25oC in humid incubator (LMS) set to a 12 hour 
light/dark cycle. Flies were maintained on standard cornmeal food.  
Recipe for standard cornmeal food (per 1L): 
Distilled H2O – 1L 
Dried active yeast (Allinson) – 17.5g 
Soya flour (Neal’s Yard) – 10g 
Sugar (Tate and Lyle) – 32g 
Fine cornmeal (Dunn’s River) – 73.1g 
Malt extract (Oxoid) – 46.2g 
Agar (Sigma) - 6g 
Nipagin (Methyl 4-hydroxybenzoate) (Sigma) diluted in 96% v/v ethanol (Fisher) – 
2.5g in 25ml ethanol 
Propionic acid (Aldrich) – 5ml 
2.1.2 Fly Storage for ageing experiments and ageing food 
 
For aging experiments day 1 male and female flies were collected and allowed to 
mate for ~48 hours on standard cornmeal food. After ~48 hours the males were 
removed, and the females were transferred to and maintained on a 15% sugar/yeast 
medium at 25oC in humid incubator (LMS) set to a 12 hour light/dark cycle. Ageing 
flies were flipped onto new food every 3-4 days. 
Recipe for 15% sugar/yeast medium (per 1L): 
Distilled H2O – 1L 
Dried active yeast (Allinson) – 150g 
Sugar (Tate and Lyle) – 150g 
Agar (Sigma) - 15g 
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Nipagin (Methyl 4-hydroxybenzoate) (Sigma) diluted in 96% v/v ethanol (Fisher) – 3g 
in 30ml ethanol 
Propionic acid (Aldrich) – 3ml 
2.2 GAL4/UAS 
 
All fly lines were obtained from the Bloomington Stock Centre unless stated 
otherwise 
The GAL4/UAS system allows both selective expression and knockdown of target 
genes in a cell and tissue specific manner (figure 2.1). The system consists of two 
parts; the yeast transcription factor GAL4 and the upstream activating sequence 
(UAS). The GAL4 binds to UAS to initiate transcription of a gene of interest 
downstream of the UAS. GAL4 expression is directed by a tissue specific native 
promoter; hence the gene of interest is only transcribed where the GAL4 is present - 
in a defined population of cells. The key feature of this tool is that the GAL4 gene 
and the UAS-target are separated into two different transgenic lines, which when 
crossed brings the GAL4 and UAS together allowing selective overexpression of a 



























2.2.1 GAL4 Lines 
For the present study the Elavc155-GAL4 driver (BL#458) was chosen for selective 
overexpression of a gene of interest in all differentiating neurons. Expression of 
transgenes in ellipsoid body neurons was achieved using UAS-mCD8-GFP;EB1-
GAL4 (generated in Hirth lab from BL#5137 and BL#432). Overexpression in 
photoreceptors was achieved using GMR-GAL4 (BL#1104) and Rhodopsin 1-GAL4 
(RH1-GAL4) (gift from Manolis Fanto - King’s College London). Salivary gland 
expression studies were carried out with FKH-GAL4 (gift from Eric Baehrecke - 
University of Massachusetts). 
2.2.2 UAS Lines 
The G4C2 fly lines used in this study were generated by Alan Stepto and Yoshitsugu 







Figure 2.1 | The GAL4/UAS system. The GAL4/UAS system allows tissue or cell 
specific expression of a gene of interest. The yeast transcription factor GAL4 
recognises the upstream activating sequences (UAS). The gene of interest is 
cloned downstream of the UAS promoter. GAL4 binds to UAS enabling 
transcription of the gene of interest. GAL4 expression is under the control of a 
tissue specific enhancer, hence the gene of interest is only expressed where 
GAL4 is selectively expressed. The GAL4 and UAS-target gene inserts are kept 
separate in two different transgenic lines. Only by crossing these two fly lines will 
the GAL4/UAS system be activated. From St Johnstone, (2002). 
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repeats were cloned into the 3’UTR of disease unrelated gene DsRed2. All G4C2 
constructs were inserted into the genome at a common insertion site via φC31-
mediated site-specific integration into flies harbouring an attP insertion at site ZH-
86FB on the third chromosome (BL#23647). The following lines were generated: 
w1118; +; UAS-DsRed2  
w1118; +; UAS-DsRed2-(G4C2)8A 
w1118; +; UAS-DsRed2-(G4C2)32 
w1118; +; UAS-DsRed2-(G4C2)56 
w1118; +; UAS-DsRed2-(G4C2)64 
w1118; +; UAS-DsRed2-(G4C2)128A 
w1118; +; UAS-DsRed2-(G4C2)128B 
w1118; +; UAS-DsRed2-(G4C2)8B 
w1118; +; UAS-DsRed2-(G4C2)38  
Generation of transgenic flies was performed by the Cambridge transgenic fly facility 
(Cambridge University, UK) for the 8B and 38 G4C2 constructs. Due to facility closing 
after the generation of 8B and 38 transgenic lines, the remaining UAS-G4C2 
constructs were sent to Bestgene, USA for genomic insertion. 
Gene fragments coding for individual DPR sequences were generated by GeneArt 
(ThermoFisher Scientific). Fragments were ligated into the pUASTattB (Bischof et 
al., 2007) also by GeneArt (ThermoFisher Scientific). UAS-DPR Constructs were 
then sent to Bestgene, USA for transgenesis.  All UAS-DPR constructs were inserted 
into the genome at a common insertion site via φC31-mediated site-specific 
integration into flies harbouring an attP insertion at site attp40 on the second 
chromosome (y1 w67c23; P{CaryP}attP40). Genomic PCR confirmation of insertion 
onto the attp40 landing site was confirmed by BestGene, USA. The following lines 
were generated: 
w1118; UAS-GA8; + 
w1118; UAS-GA64; +  
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w1118; UAS-GR8; +  
w1118; UAS-GR64; + 
w1118; UAS-PR8; + 
w1118; UAS-PR64; +  
w1118; UAS-PA8; +  
w1118; UAS-PA64; +  
The UAS-288 RNA-Only line was kindly provided by Adrian Isaacs and Linda 
Partridge (University College London). Construction of genomic TBPH is described 
in a previous publication (Diaper et al., 2013a). Nuclear localisation signal (NLS) 
mutant (gΔNLS) was generated via mutation containing PCR by Yoshitsugu Adachi 
(Hirth lab, KCL). 
2.3 Generation of polyclonal and monoclonal poly-GP 
antibodies 
 
Two anti-GP antibodies were generated during this project. 
An anti-GP rabbit polyclonal antibody was generated by immunisation of rabbits with 
the following peptide sequence – GPGPGPGPGPGPGPGP (GPx8). The resulting 
antiserum was purified against the immunisation peptide. This work was conducted 
by Invitrogen. 
Anti-GP mouse monoclonal was generated by immunisation of mice with the 
following peptide sequence - GPGPGPGPGPGPGPGPGPGP (GPx10). The 
resulting antiserum was purified against the immunisation peptide. This work was 




2.4 Western blotting 
2.4.1 Solutions for western blotting for Drosophila tissue 
Radioimmunoprecipitation assay (RIPA) buffer and RIPA+ buffer for Drosophila 
tissue 
50 mM Tris (Roche) with HCL added (Sigma) to achieve a pH of 7.5 
150 mM NaCl (Fisher) 
1% (v/v) NP-40 (Calibochem) 
5 mM EDTA (Sigma) 
0.5% (w/v) Sodium deoxycholate (Sigma) 
0.1% (w/v) SDS (Sigma-Aldirch) 
Made up to 100ml with ddH2O 
To make RIPA+ one complete mini protease inhibitor tablet (Roche) and one 
phosphatase inhibitor tablet (Roche) was dissolved in 7ml of RIPA buffer. 
Laemmli sample buffer (5x) 
312.5 mM Tris (Roche) with HCL (Sigma) added to achieve a pH of 6.8 
10% (w/v) SDS (Sigma-Aldirch) 
250 mM DTT (Life Technologies) 
50% (v/v) Glycerol (Santa Cruz) 
Resolving gel 
Resolving gel buffer: 
1.5M Tris (Roche) with HCL (Sigma) added to achieve a pH of 6.8 
Made up to desired volume with ddH2O 
Resolving gel: 
30% degassed acrylamide (% v/v varied depending on gel %) 
ddH2O (% v/v varied depending on gel %) 
25% (v/v) resolving gel buffer 
1% (v/v) 10% (w/v) SDS 
Stacking gel 
Resolving gel buffer: 
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0.5M Tris (Roche) with HCL (Sigma) added to achieve a pH of 6.8 
Made up to desired volume with ddH2O 
Stacking gel: 
30% degassed acrylamide (% v/v varied depending on gel %) 
ddH2O (% v/v varied depending on gel %) 
25% (v/v) stacking gel buffer 
1% (v/v) 10% (w/v) SDS 
Running buffer (1x) 
25 mM Tris (Roche) 
192 mM Glycine (Sigma) 
0.1% (w/v) SDS (Sigma-Aldrich) 
Made up to 1L with ddH2O 
Transfer buffer (1x) 
25 mM Tris (Roche) 
192 mM Glycine (Sigma) 
20% (v/v) Methanol (Fisher) 
Made up to 1L with ddH2O 
Phosphate buffered saline (PBS) 
5X PBS tablets (Sigma) dissolved in 1L ddH2O 
Phosphate buffered saline-Tween (PBST) 
5X PBS with 0.1% (v/v) Tween-20 (Sigma) 
2.4.2  Solutions for western blotting from human post mortem 
brain tissue 
Radioimmunoprecipitation assay (RIPA) buffer and RIPA+ buffer for human post 
mortem tissue 
50 mM Tris (Roche) with HCL added (Sigma) to achieve a pH of 7.5 
150 mM NaCl (Fisher) 
1% (v/v) NP-40 (Calibochem) 
5 mM EDTA (Sigma) 
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0.5% (w/v) Sodium deoxycholate (Sigma) 
0.1% (w/v) SDS (Sigma-Aldirch) 
Made up to 100ml with ddH2O 
To make RIPA+ one complete mini protease inhibitor tablet (Roche) was dissolved in 
7ml of RIPA buffer. 
UREA lysis buffer 
7M urea (Sigma) 
2M thiourea (Sigma) 
4% CHAPS (CALBIOCHEM)  
30 mM Tris (Sigma) 
Made up to desired volume with ddH2O 
Laemmli sample buffer (5x), resolving gel, stacking gel, running buffer (1x), transfer 
buffer (1x), PBS and PBST used in the western blotting lysate from brain is identical 
to that used for Drosophila tissue. 
2.4.3  Protein extraction for Drosophila samples 
For Drosophila samples, mated females were snap frozen in liquid nitrogen and then 
vortexed to remove the heads. Heads were homogenised using a sterile pestle in 
RIPA+ buffer at a volume 40ul per 6 fly heads. Following homogenisation samples 
were sonicated and then left on ice for 40 minutes. The homogenate was then spun 
at 14,000rpm at 4oC and the supernatant removed.  
2.4.4  Protein extraction from human brain 
 
2.4.4.1 Extraction of soluble protein from human brain tissue 
 
100mg of frontal cortex tissue was provided by the MRC London Neurodegenerative 
Diseases Brain Bank, case details can be found in appendix 9; table A9.1.  Frontal 
cortex tissue was homogenized using 15ml falcon tubes (Fisher Scientific) in 1ml of 
RIPA+ buffer using the Bio-Gen PRO200 Homogenizer (PRO Scientific Inc). The 
falcon tubes were then spun at 4000g for 10 minutes at 4°C. The pellet consisting of 
unhomogenised tissue and blood was discarded and the supernatant removed. The 
supernatant was transferred to 1.5ml RNase free Microfuge tubes (Ambion) and 
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spun at 14,000rpm for 10 minutes at 4°C. The supernatant was removed, and this 
was taken as the soluble fraction. The remaining pellets was frozen and stored for 
later extraction of insoluble protein.  
2.4.4.2 Extraction of insoluble protein from human brain tissue 
 
For detection of insoluble KPNA4 in human brain, the pellets described in section 
2.4.4.1 were washed four times 10 minutes with RIPA buffer and sonicated. Pellets 
were then resuspended in 20 µl urea buffer and spun at again at 14,000 rpm for 20 
minutes at 4°C. The supernatant was collected and then prepared for western blot. 
2.4.5   Determining protein concentration 
Protein concentration was determined using the Bicinchoninic kit (BCA) assay kit 
(Thermo Scientific Pierce). A set of serial dilutions of bovine serum albumin (BSA) 
(2mg/ml) and RIPA+ buffer was used to produce a standard curve. Lysate was 
diluted 10x in RIPA+ buffer in duplicate. The assay was performed as per the 
manufacturer’s instructions; the absorption spectra were measured using a 
spectrophotometer (Perkin Elmer Victor3). Absorption spectra values were used to 
determine protein concentration of samples in ug/µl. 
2.4.6  SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
2.4.6.1 Casting the SDS-PAGE gel 
 







Gel Buffer (ml) 10% w/v SDS (ml) 
5% 5.7 1.7 2.5 0.1 
10% 4.1 3.3 2.5 0.1 
15% 2.4 5.0 2.5 0.1 
 
The mixture was degassed for 15 minutes after which 50 μl 10% APS (Sigma) and 5 
μl TEMED (Sigma) was added to make the resolving gel. For the stacking gel 50 μl 
10% APS and 10 μl TEMED were added. 
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2.4.6.2 Running the SDS-PAGE gel 
 
Samples were mixed with 5x Laemmli sample buffer to a working concentration of 
1x, boiled for 5 minutes at 100 oC, separated on an SDS-PAGE gel and then 
transferred to the nitrocellulose membrane (Pall). The membrane was then blocked 
either in odyssey blocking buffer (OBB) (Li-Cor) (mixed 1:1 in PBS) or 5% dry milk in 
PBS-T, depending on whether the membrane was being imaged using the Odyssey 
Fc (Li-Cor) or via chemiluminescent substrate (Amersham ECL Prime Western 
Blotting Detection Reagent, GE Healthcare). The Primary antibody solution was then 
left overnight at 4oC. Membranes were then washed 3x 5 minutes in PBS-T and 
incubated with secondary antibody for 1 hour at room temperature with agitation. 
Membranes were further washed 4x 5 minutes in PBS-T before imaging. The signal 
was visualised with either chemiluminescent substrate or by using an Odyssey Fc. 
2.4.6.3 Antibodies used for western blotting from Drosophila tissue 
 
The following primary antibodies and dilutions were used;  
 
The following secondary antibodies and dilutions were used;  
Antibody Dilution Source 
Rabbit polyclonal anti-
DsRed2 
1:1000 Clontech (632496) 
Mouse monoclonal anti-
GP 
1:1000 Abmart (Hirth lab, King’s 
College London) 
Mouse monoclonal anti-
GA clone 5E9 








1:1000 Abcam (ab8227) 
Mouse monoclonal anti-
beta tubulin clone E7 
1:600 Developmental Studies 
Hybridoma Bank 
Antibody Dilution Source 
Polyclonal goat anti-rabbit 






mouse IgG (HandL) 
conjugated Alexa Fluor 
680 




2.4.6.4 Antibodies used for western blotting from human tissue 
 
The following primary antibodies and dilutions were used;  
 
The following secondary antibodies and dilutions were used;  
 
2.5 Dot blotting 
 
2.5.1  Dot blotting protocol for detecting poly-GR 
 
Dot blotting was used for the detection of poly-GR using a protocol previously 
described by Mizielinska et al. (2014). Fly heads were collected and homogenised in 
RIPA+ buffer as reported in section 2.4.3. The homogenate was heated at 95oC for 5 
minutes. At this point an aliquot was taken and added in equal amounts to 2x 
Laemmli sample buffer and then heated again at 95°C for 5 minutes; this sample 
was then used for the tubulin loading control. The remaining sample was treated with 
10µg/ml of proteinase K (Ambion) for 30 minutes at 37°C and then added in equal 
amounts to 2x Laemmli buffer. The sample was then heated at 95°C for 5 minutes 
and used to probe for DPR proteins. 2 μl of lysate was pipetted onto nitrocellulose 
membrane (Pall) and then left to dry at room temperature for 15 minutes.  
Membranes were then blocked in OBB mixed 1:1 with PBS for 1 hour at room 
temperature. Membranes were then left overnight at 4°C with primary antibody 
Antibody Dilution Source 
Goat polyclonal anti-
KPNA4 
1:750 Abcam (ab6039) 
Rabbit polyclonal GAPDH 
14C10 
1:5000 Cell Signaling 
Technology (2118S) 
Antibody Dilution Source 
Polyclonal goat anti-rabbit 
IgG (whole molecule)-
Peroxidase 
1:10000 Sigma (A0545) 
Polyclonal rabbit anti-goat 
IgG (whole molecule)-
Peroxidase 
1:10000 Sigma (A8919) 
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diluted in OBB with 0.1% (v/v) tween-20 (Sigma-Aldrich). Following incubation with 
primary antibody membranes were washed 3x 5 minutes with PBS-T. Secondary 
antibodies were applied for approximately 1 hour at room temperature diluted to the 
required concentration in OBB with 0.1% (v/v) tween-20. 
2.5.2  Antibodies used for dot blotting 
 
The following primary antibodies and dilutions were used;  
 






Antibody Dilution Source 
Rabbit polyclonal anti-GR 1:1000 Kind gift from David Mann 
(University of 
Manchester) 
Rabbit polyclonal anti-GR 1:1000 Kind gift from Leonard 
Petrucelli (Mayo Clinic) 
Rabbit polyclonal anti-GP 1:5000 Eurogentec 
(Hirth/Gallo/Shaw labs, 
King’s College London) 
Mouse monoclonal anti-
GP 
1:1000 Abmart (Hirth lab, King’s 
College London) 
Rabbit polyclonal anti-PR 1:1000 Kind gift from Leonard 
Petrucelli (Mayo Clinic) 
Rabbit polyclonal anti-PA 1:1000 Kind gift from Leonard 
Petrucelli (Mayo Clinic) 
Mouse monoclonal anti-
beta tubulin clone E7 
1:300 Developmental Studies 
Hybridoma Bank 
Antibody Dilution Source 
Polyclonal goat anti-rabbit 






mouse IgG (HandL) 
conjugated Alexa Fluor 
680 




2.6 Immunohistochemistry (IHC) of Drosophila tissue 
 
2.6.1  Solutions for IHC of Drosophila tissue  
 
0.1M Sodium phosphate dibasic (Na2HPO4) 
0.1M Sodium phosphate monobasic (NaH2PO4) 
0.1M Sodium phosphate buffer (PB) 
0.1M Na2HPO4 was added to NaH2PO4 to achieve a pH of 7.4 
0.1M Lysine HCL (PBL) (100ml solution) 
3.6% (w/v) Lysine HCL (Sigma-Aldrich) 
Na2HPO4 was added to achieve a pH of 7.4 
0.1M PBS added until volume was 100ml 
2% and 4% Paraformaldehyde fix (PLP) 
For larval brains, pupal eye discs and adult Drosophila brains: 
75% (v/v) PBL 
25% (v/v) 8% (w/v) paraformaldehyde (Sigma-Aldrich) 
For Drosophila salivary glands: 
50% (v/v) PBL 
50% (v/v) 8% (w/v) paraformaldehyde (Sigma-Aldrich) 
PB-Triton X (PBT) 
0.5% (v/v) Triton X-100 (Sigma) in 0.1M PB. 
PBT-normal goat serum (PBT-NGS) 





2.6.2  Larval brain, pupal eye discs and adult brain dissection 
and staining 
 
Larval brains, pupal eye discs and adult brains were dissected in cold 0.1M PB in a 
time window of a maximum of 30 minutes. Following dissection, the tissue was fixed 
in 2% PLP and left rotating for 1 hour at room temperature. After fixation, the tissue 
was washed 3x 5min in PBT and then blocked in 10% PBT-NGS for 15 minutes. 
Samples were then agitated overnight rotating at 4oC in the appropriate 
concentration of primary antibody diluted in 10% PBT-NGS. Proceeding overnight 
incubation, the primary antibody solution was removed by 3x 5 minute PBT washes 
and the secondary antibody added diluted in 10% PBT-NGS. Tissues were agitated 
for 3 hours in the dark at room temperature with secondary antibody, after which the 
secondary antibody was removed, and the tissue washed 2x 15 minutes in PBT 
followed by a final 2x 15 minutes wash in PB. Samples were then incubated 
overnight at 4oC with Vectasheild containing 4’,6-diamidino-2-phenylindole (DAPI) 
(Vector laboratories, H1200). Following incubation with DAPI the samples were then 
mounted on glass slides (Thermo Scientific) with cover slips placed on top sealed 
with clear nail varnish. 
2.6.3  Salivary gland dissection and staining 
 
Salivary glands were dissected and stained using a protocol adapted from Freibaum 
et al. (2015). Salivary glands were dissected in cold PB for total time of 15 minutes. 
Salivary glands were then fixed with 4% PLP for 15 minutes via rotation and then 
washed 3x 5 minutes in PBT. The samples were then blocked for 1 hour in 10% 
PBT-NGS and then left rotating overnight at 4oC with primary antibody diluted in 10% 
PBT-NGS. After overnight primary antibody staining the salivary glands were 
washed 3x 10 minutes in PBT. Following PBT washes the tissues were left with 
secondary antibody for 1 hour agitating at room temperature. For a final step the 
secondary antibody was removed, and the samples washed 3x 10 minutes in PBS 
and then left at 4oC overnight in Vectasheild w/ DAPI. The salivary glands were then 




2.6.4  Antibodies used for IHC of Drosophila tissue 
 
Antibody Dilution Source 
Rabbit polyclonal anti-GP 1:1000 Eurogentec 
(Hirth/Gallo/Shaw labs, 
King’s College London) 
Mouse monoclonal anti-
GA clone 5E9 
1:500 Merck Millipore 
(MABN889) 
Rat monoclonal anti-GR 
clone 5A2 
1:300 Merck Millipore 
(MABN778) 
Mouse monoclonal anti-
HA clone 6E2 
1:500 Cell Signal (2367S) 
Rabbit polyclonal anti-HA 1:500 Santa Cruz (sc-805) 
Rabbit polyclonal anti-
TBPH 




1:300 Kind gift from C. Staber 




















1:500 Abcam (ab24609) 
Rabbit polyclonal anti-
dNup50 
1:10000 Kind gift from J. 









The following secondary antibodies and dilutions were used;  
 
Antibody Dilution Source 
Goat anti-Rabbit IgG 
(H+L) Highly Cross-
Adsorbed Secondary 
Antibody, Alexa Fluor 488 
1:150 Life Technologies (A-
11034) 
Goat anti-Mouse IgG 
(H+L) Highly Cross-
Adsorbed Secondary 
Antibody, Alexa Fluor 488 




Goat anti-Rabbit IgG 
(H+L) Highly Cross-
Adsorbed Secondary 
Antibody, Alexa Fluor 568 
1:150 Life Technologies (A-
11011) 
Goat anti-Mouse IgG 
(H+L) Highly Cross-
Adsorbed Secondary 
Antibody, Alexa Fluor 568 
1:150 Life Technologies (A-
11031) 
Goat anti-Rabbit IgG 
(H+L) Highly Cross-
Adsorbed Secondary 
Antibody, Alexa Fluor 647 
1:150 Life Technologies (A-
21245) 
Goat anti-Mouse IgG 
(H+L) Highly Cross-
Adsorbed Secondary 
Antibody, Alexa Fluor 647 
1:150 Life Technologies (A-
21236) 
Goat anti-Rat IgG (H+L) 
Highly Cross-Adsorbed 
Secondary Antibody, 
Alexa Fluor 647 
1:150 Life Technologies (A-
21247) 
 
2.7 IHC staining of post-mortem human brain tissue 
 
All staining was performed on 7µm frontal cortex tissue sections was provided by the 
MRC London Neurodegenerative Diseases Brain Bank, case details can be found in 
appendix 9; table A9.1.    
2.7.1  Solutions for IHC staining of post-mortem human brain 
tissue 
 
95% Industrial methylated spirit (IMS) 
99% IMS (Solmedia) diluted in appropriate volume of dH2O 
70% Industrial methylated spirit (IMS) 
99% IMS (Solmedia) diluted in appropriate volume of dH2O 
Citrate Buffer pH 6.0 
Sodium citrate tribasic dihydrate (Sigma) dissolved in dH2O 




Tris buffered saline (TBS) pH 7.4 
Trizma base (Sigma) 
Sodium Chloride (Sigma) 
Phosphate buffered saline (PBS) pH 7.4 
10x PBS tablets (Severn Biotech) dissolved in 1L ddH20 
3,3′-Diaminobenzidine (DAB) solution 
1 DAB tablet (Sigma) dissolved in 20ml TBS 
1% Acid Alchohol 
70% IMS 
200µl HCL (Sigma) 
2.7.2  DAB immunolabeling 
 
Frontal cortex sections were initially warmed on a hotplate. Sections were dewaxed 
by sequential washing in the following solutions. 2 minutes in xylene (Solmedia), 
followed by a 2 minute wash in fresh xylene. Tissue was then washed in in 99% IMS 
alcohol (Solmedia) for 2 minutes, another wash in fresh 99% IMS alcohol and finally 
a few seconds wash in 95% IMS. Hydrogen peroxide (VWR chemicals) was then 
used to quench the hydrogen peroxidases that naturally exist within tissue slices. 
Endogenous peroxidases were blocked by placing tissue sections in 300ml of 
ethanol (Solmedia) with 7ml of 30% aqueous hydrogen peroxide solution (VWR) for 
30 minutes. Sections were then washed in running tap water and then washed in 
dH2O. Citrate buffer treatment was then used to open antigen epitopes. Sections 
were placed in a plastic container filled with citrate buffer (pH 6.0) and the lid 
covered with Clingfilm. Sections were then microwaved at full power (800kW) for 8 
minutes followed by being microwaved again 2x 8 minutes on simmer. Sections were 
cooled in cold running tap water and then washed 2x minutes in TBS, after which a 
hydrophobic wax ring was drawn around the tissue. The tissue was then blocked in 
the appropriate normal goat blocking serum (NGS) (Dako) diluted 1:10 in TBS for 20 
minutes, after which the primary antibody was added at the appropriate 
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concentration diluted in TBS with NGS at 1:100. Sections were left overnight at 4oC. 
Proceeding overnight incubation, the tissue was washed 2x 5 minutes in TBS and 
then left with the appropriate secondary antibody for 45 minutes at room 
temperature. The tissue was then washed 2 x minutes with TBS and then incubated 
with ABC HRP solution (ThermoFischer Scientific) prepared 40 minutes in advance. 
Sections were incubated with the ABC HRP solution for 45 minutes and then washed 
2 x minutes in TBS. Filtered DAB solution activated with hydrogen peroxide was 
added to the tissue until appropriately stained. The excess DAB solution was then 
washed in cold running tap water for 10 minutes after which the sections were 
counter-stained with haematoxylin (Harris Haematoxylin) for 20 seconds – 1 minute. 
Following the haematoxylin counter-stain sections were washed in cold running tap 
water for 5 minutes and then placed in acid alcohol for 2 seconds, washed again in 
running tap water and then dH2O. Sections were then dehydrated by washing 
sequentially in the following solutions for 2 minutes – IMS alcohol (70%) wash, IMS 
alcohol (95%) wash, 1st IMS alcohol (99%) wash, 2nd IMS alcohol (99%) wash, 1st 
Xylene wash, 2nd Xylene wash, 3rd Xylene wash and 4th Xylene wash. Tissue 
sections were then mounted using DPX mounting medium (VWR) and glass 
coverslips. 
2.7.3  Double immunofluorescence staining of post-mortem 
human brain tissue 
 
Frontal cortex sections were initially warmed on a hotplate. Sections were then 
dewaxed by being washed for 2 minutes in xylene, followed by another 2 minute 
wash in fresh xylene. After xylene washes the tissue was the further washed in 99% 
IMS for 2 minutes, proceeded by another wash in fresh 99% IMS and finally a 30 
second wash in 95% IMS. IMS was removed with a 5 minute wash in dH2O. Tissue 
sections then underwent citrate buffer treatment. Sections were placed in a plastic 
container filled with citrate buffer (pH 6.0) and the lid covered with Clingfilm. The 
sections were then microwaved at full power (800kW) for 8 minutes and then 
microwaved 2x 8 minutes on simmer. Tissue sections were then cooled down in cold 
tap water before being transferred to fresh dH2O for 5 minutes. Following citrate 
buffer treatment sections were circled with hydrophobic wax and blocked for 45 
minutes in normal goat serum (Dako) at room temperature 1:10 in PBS. Tissue 
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sections were then left overnight at 4oC with primary antibodies diluted to appropriate 
concentration in 10% PBS-NGS. Following overnight incubation with primary 
antibody the tissue sections were washed 2 x 5 minutes in PBS. Secondary antibody 
was then applied also diluted to the required concentration in 10% PBS-NGS. 
Secondary antibodies were left on for 45 minutes at room temperature in the dark. 
Sections were then washed 3 x minutes in PBS and then underwent sudan black 
treatment. 0.15g of sudan black (Acros Organics) dissolved in 50ml 70% ethanol 
was prepared 45 minutes in advance. The sudan black solution was left to mix and 
was then filtered before being applied to the tissue sections. Sections were left with 
sudan black for 10 minutes before being washed 8 x 2 minutes with PBS. Tissue 
sections were then mounted with glass coverslips and Vectasheild containing DAPI. 
2.7.3.1 Antibodies used for immunostaining of human tissue 
 
The following primary antibodies and dilutions were used;  
 





Antibody Dilution Source 
Rabbit polyclonal anti-
KPNA4 













1:500 Merck Millipore 
(MABN889) 
Rat monoclonal anti-GR 
5A2 
1:50 Merck Millipore 
(MABN778) 
Antibody Dilution Source 
Biotinylated swine anti-
rabbit immunoglobulin  
1:100 Agilent Dako (P0399) 
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The following secondary antibodies and dilutions were used for double 
immunofluorescence; 
 
2.8 Fluorescence in situ hybridisation (FISH) 
 
2.8.1  Solutions for FISH 
 
RNase free PBS Phosphate-saline buffer (PBS) (ThermoScientific) 
RNase free PBS Tween-20 
RNase free PBS 
0.1% (v/v) Tween-20 (Sigma) 
RNase free PBS Triton X-100 
RNase free PBS 
0.5% (v/v) Triton-X-100 
Prehybridisation buffer 
2x Saline sodium citrate (SSC) (Sigma) 
40% Formamide (Fluka) 
Salmon sperm DNA (1mg/ml) (Ambion) 
0.1% Tween-20 
 
(G2C4)4 Oligonucleotide probe (IDT) 
Antibody Dilution Source 
Goat anti-Mouse IgG 
(H+L) Highly Cross-
Adsorbed Secondary 
Antibody, Alexa Fluor 488 
1:150 Life Technologies (A-
11001) 
Goat anti-Rat IgG (H+L) 
Highly Cross-Adsorbed 
Secondary Antibody, 
Alexa Fluor 488 
1:150 Life Technologies (A-
11006) 
Goat anti-Rabbit IgG 
(H+L) Highly Cross-
Adsorbed Secondary 
Antibody, Alexa Fluor 568 












2.8.2 FISH of larval salivary glands 
 
The protocol used adapted from Tran et al (2015). Salivary glands were dissected in 
cold PBS and fixed in 4% PFA for 20 minutes. Samples were washed three times for 
10 minutes in RNase-free PBS containing 0.1% Tween-20 and then permeabilised 
with PBS-0.5% Triton X-100 for 10 minutes followed by a 30-minute incubation in 
prehybridisation buffer at 55°C. Samples were incubated for 2 hours at 55oC in 
prehybridisation buffer containing an Alexa488-labelled (G2C4)4 RNA probe 
(0.2ng/μl). Samples were then washed in pre-warmed wash buffer A for 30 minutes 
at 55oC and twice in wash buffer B for 30 minutes at room temperature. After 
washing with 0.1% Tween-20 once for 10 minutes, samples were blocked and 
probed as described for IHC (section 2.6.3) for mouse anti-phospho-RNA 
polymerase II 4H8 (1:500, Abcam) and secondary antibody used was Alexa 
fluorochrome 568 (Life Technologies). FISH stained salivary glands were mounted 









2.9 Semithin retinal sections 
 
2.9.1 Solutions for semithin retinal sections 
 
Fixative solution 
2% glutaraldehyde (Fluka) in 0.1M PB pH 7.2  
Post-fixative solution  
50% (v/v) osmium (Electron Microscopy Sciences),  
50% (v/v) PB (0.2M)  
Resin 
Resin is composed of four components:  
Epoxy resin (A = 54g), hardener (B = 44.5g), accelerator (C = 2.5g) and plasticiser 
(D = 10g) (Durcapan ACM, Sigma Life Science). 
1% Toluidine-blue in borax  
1g Toluidine blue 
2g Borax (Sigma) 
Made up to 100ml with deionised water 
 
2.9.2 Semithin retinal sections 
 
Flies were anaesthetised with CO2 and then decapitated with a scalpel. Heads were 
then split in two with the right eye being kept for sections. 35 days old males’ eyes 
were incubated in 100μl of the fixative solution and then centrifuged at 14,000rpm for 
30 seconds at 4°C. The same volume of post-fixative solution was added for 30 
minutes on ice; this solution was then replaced with 100% of post-fixation solution for 
5 hours. Progressive dehydration by ethanol (30%, 50%, 70%, 90%, and 100%) was 
proceeded prior to two 10 minute propylene oxide washes at room temperature. 
Eyes were then incubated in mix (1:1) of propylene oxide (Sigma-Aldrich) and epoxy 
resin overnight. Retinas were embedded the following day in 100% epoxy resin 
between 4 and 6 hours at room temperature and thereafter baked at 80°C overnight. 
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The blocks were then trimmed to remove any excess resin around the samples and 
the surfaces smoothened to help visualization under the ultramicrotome. Sections of 
1µm sections were performed using a ultramicrotome (Leica Ultracut UTC). Floating 
sections were placed onto a glass slide and then dried on a hot plate and stained 
with 1% toluidine-blue in borax using a filtered syringe to apply the solution onto the 
samples. The slides were then put again onto the hot plate at 100°C for 10 seconds 
followed by washing with deionised water. After the slides were dried they were 
mounted in DPX (Sigma), covered with coverslips and left to harden. Images were 
taken with light microscopy (AxioImager Z1, Zeiss). Quantification has been 
performed by counting the number of photoreceptors on 100 ommatidia on average 
per picture using ImageJ. 
2.10  Confocal microscopy and image processing 
 
For all immunofluorescent staining of Drosophila tissue and human brain images 
were obtained using a Lecia TCS SP5 confocal microscope with Leica Application 
Suite Advanced Florescence (LAS-AF) software (version 2.0.2). The fluorescent 
channels were scanned sequentially to prevent bleed-through. All tissues were 
scanned at a resolution of 1024x1024 pixels. Images and Z-projections were 
processed using ImageJ (http://imagej.nih.gov/ij/).  
2.11  Behavioural assays 
 
2.11.1  Startle-Induced Negative Geotaxis 
 
The startle-induced negative geotaxis protocol is used to assess the climbing 
performance of flies. Startled-induced negative geotaxis was performed using 
modified 25ml serological pipettes (Costar). The bottom of the pipette was sealed 
with parafilm (Alpha Laboratories) and the top cut off and sealed with cotton wool. A 
maximum of 15 flies (ntotal) were anaesthetised and gently placed into the pipettes 
and then left to recover and acclimatise for approximately 30 minutes in a 25°C 
incubator. For an initial test trial flies were firmly tapped to the bottom and then 
allowed to climb for 45 seconds. This was the repeated a further 3 times; however, 
for these test trials after 45 seconds the total number of flies below the 2ml line 
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(nbottom) and the total number of flies that were above the 25ml line (ntop) was 
counted. Furthermore a 90 second recovery period was given between each trial. 
Based on the ntop and nbottom scores a performance index was calculated for the three 
trials using the following equation: 
PI = 0.5 X (ntotal + ntop - nbottom) / ntotal 
All geotaxis was performed at the same 4 hour interval each day (between 12:00pm 
– 4:00pm). Only mated females were tested. 
2.11.2  Video Assisted Motion tracking 
 
All motion tracking was performed on mated females only. Flies were anesthetized 
and placed in tracking arenas; modified 6 well plates (diameter of 35mm) filled with 
silicone rubber (Sylguard)  leaving approximately 3mm of space for flies to walk but 
not jump or fly. Flies were anaesthetised briefly and then transferred into the wells of 
the tracking arena. Flies were left to recover and acclimatise in a temperature 
controlled incubator (Stuart Scientific) set to 25°C for 45 minutes. All tracking was 
performed at 25°C in this temperature controlled incubator. After acclimatisation fly 
movement was recorded for approximately 30 minutes using a monochrome camera 
(Point Grey, FL3-FW-14S3M-C) mounted above the tracking arenas. Files were 
recorded using the FlyCap2 (http://flycap2.software.informer.com) and Fview 
(http://code.astraw.com/projects/motmot/fview.html) software. All recordings were 
performed during the first hour of the light/dark cycle dark phase. Fly movie format 
(.fmf) videos of fly walking behaviour were loaded onto Ctrax software 
(http://ctrax.sourceforge.net) which allows analysis of the position of the flies during 
the video recordings. This positional data was the exported and analysed in 
MATLAB (Mathworks, version 2014a). Any errors in the tracking of the flies was fixed 
with the FixErrors GUI (Branson et al., 2009, 
http://ctrax.sourceforge.net/fixerrors.html). Fixed trajectories were then analysed in 
MATLAB using custom script written by Dr. Dickon Humphrey and Jonah Dearlove 
(Hirth lab). Such analysis provided mean activity, activity vs inactivity and activity 
over time for individual flies recorded. Activity was defined as movement per frame 
above a velocity of 2mm/second. Percentage of time active, activity per minute and 
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raster plots for each fly were generated in MATLAB from custom code. Statistical 
analysis was performed by exporting data to GraphPad Prism 6. 
2.12   Statistics 
GraphPad Prism 6 was used for the statistical analyses performed within the results 
section. For a comparison of means with less than 2 experimental conditions an 
unpaired t-test was used. A chi-square test was used for the semithin retinal sections 
to determine whether difference between the expected number of photoreceptors 
and the observed number of photoreceptors differed. For a comparison of means 
with numerous experimental conditions (n>2) and one independent variable, a one-
way analysis of variance (ANOVA) was utilised. For a comparison of means with 
numerous experimental conditions (n>2) and two independent variables, a two-way 
ANOVA was utilised. Post-hoc analysis was performed using Fisher’s least 
significant difference (LSD). Multiple comparisons were corrected for using the 
Bonferroni-Holm method, in which non-adjusted p-values are ranked in order, from 
lowest to highest. By adjusting for the number of experimental conditions the alpha 
level is corrected and p-values are tested agaisnt alpha in a stepwise manner. The 




Chapter 3: Characterisation of RAN 
translated dipeptide repeat proteins in a 
Drosophila models of the G4C2 repeat 
expansion 
Three non-mutually exclusive mechanisms of toxicity have been attributed to the 
G4C2 repeat expansion; a loss of C9ORF72 protein function, G4C2 RNA toxicity and 
DPR toxicity. Drosophila have no homologue of C9ORF72, hence fly models of the 
G4C2 expansion have focused on the two pathogenic gain of function mechanisms 
resulting from the expression of repetitive G4C2 RNA. The overwhelming evidence 
from Drosophila models of this hexanucleotide repeat expansion points toward the 
DPRs being the major drivers of pathogenesis in ALS and FTD. This chapter 
characterised the DPRs produced in a novel Drosophila model of flies expressing 














3.1 G4C2 repeat containing constructs used in this study 
 
Multiple transgenic flies containing different lengths of the G4C2 repeat sequence 
were used in this study. In these flies the repeat sequence is located in the 3’ 
untranslated region (3’UTR) of the red fluorescent protein DsRed2 (figure 3.1). 
These constructs were designed based on a similar approach used by Li et al. 
(2008) and Yu et al. (2011) to model CAG and CUG RNA expansions in Drosophila 
for spinocerebellar ataxia type 3 (SCA3) and Myotonic Dystrophy Type 1 (DM1) 
respectively. In both these studies the repetitive RNA was cloned into the 3’UTR of 
DsRed2, a protein with no connection to disease pathogenesis and was shown not 
to confound repeat associated toxicity. Plasmids containing 8 (denoted as 8B), 38 
and 56 G4C2 repeats in the 3’UTR of EGFP were generated by Younbok Lee (Shaw 
Lab) and published in Lee et al. (2013). The EGFP was removed and the repeats 
inserted into the 3’UTR of DsRed2 contained within the pUAST attb vector for site 
specific integration into the Drosophila genome by Yoshitsugu Adachi (Hirth lab). 
The 8 (denoted as 8A), 32, 64 and 128 DsRed2 repeat containing constructs were 
generated in the Hirth lab by Alan Stepto and Yoshitsugu Adachi via sequential 
doubling of 4x G4C2 repeats ligated into the 3’UTR of DsRed2 in the pUAST attb 
vector. Confirmation of insertion into the ZH86FB locus was confirmed by Alan 
Stepto via RT-PCR. Repeat size was confirmed by Alan Stepto and Brad Smith 
(Shaw Lab) via Sanger sequencing and repeat primed PCR respectively. Expression 
of DsRed2 RNA containing G4C2 repeats was confirmed via both southern and 
northern blotting by Alan Stepto. Due to repeat instability, the 128 repeat line was 

























Figure 3.1 | Schematic of the G4C2 constructs used in this study. Schematic 
of generated constructs with different lengths of uninterrupted G4C2 repeats 
cloned into 3’ UTR of the disease-unrelated marker gene DsRed2; variable linker 
sequences between DsRed2 stop codon and start of G4C2 repeats are indicated 





3.2 G4C2 RNA foci cannot be detected in G4C2 repeat 
expressing larval salivary glands  
 
One potential pathogenic mechanism derived from the G4C2 expansion is the 
formation of nuclear G4C2 RNA foci and the subsequent sequestration of RNA 
binding proteins into these foci. As later experiments in this thesis utilise salivary 
gland cells of L3 Drosophila larvae to investigate DPR toxicity; RNA foci were probed 
for in this tissue using the FKH-GAL4 driver. Foci were investigated in salivary 
glands in all repeat containing flies and a positive control - a G4C2 RNA-only fly line 
previously characterised and validated in Mizielinska et al. (2014). This RNA-only 
construct consists of a 288 G4C2 expansion with base pair interruptions containing 
stop codons inserted every 12 G4C2 repeats, leading to a stop codon in all sense and 
antisense reading frames.  This construct still forms stable RNA G-quadruplexes and 
RNA foci but does not produce detectable levels of DPRs (Mizielinska et al, 2014). 
Fluorescence in situ hybridisation (FISH) using an Alexa488-labelled (G2C4)4 RNA 
probe was performed. No signal was observed in negative controls (FKH/+ and 
FKH>DsRed2) or in salivary glands cells with 8 G4C2 repeats (FKH>(G4C2)8B) 
(figure 3.2). The 288-RNA only control showed multiple large and small foci in a 
single salivary gland cell (figure 3.2). FISH in salivary glands expressing 32 or more 
repeats showed a single large foci per cell (figure 3.2). Both Mizielinska et al. (2014) 
and Tran et al. (2015) previously also found a single large foci in salivary gland cells 
expressing G4C2 repeats. Tran et al. (2015) found in flies with intronic 160 G4C2 
repeats flanked by parts of the C9ORF72 human intronic and exonic sequence that 
these single foci co-localised with activated Pol-II; indicating they represent the site 
of transgene transcription rather than a “true” RNA foci. To explore this possibility in 
the repeat flies used in this study FISH coupled with fluorescent 
immunohistochemistry was performed, where the repeat containing salivary glands 
were co-stained with the Alexa488-labelled (G2C4)4 RNA probe and an antibody for 
phosphor RNA polymerase II (p-Pol-II). Co-localisation between the single large foci 
and p-Pol-II as was reported by Tran et al., (2015) was seen in salivary gland cells 
expressing 32 or more repeats. Therefore, the signal detected by (G2C4)4 RNA probe 
in the repeat flies may represent the start site of G4C2 RNA transcription rather than 







Figure 3.2 | True sense RNA foci are not detected in larval salivary glands of pure repeat 
flies. Fluorescence in situ hybridization of a (G2C4)4 RNA probe together with immunostaining for 
phospho RNA polymerase II (p-Pol-II) identifies co-localisation at site of transcription in cells 
expressing 288 G4C2 repeat RNA only, as well as for 32, 56, 64, 38 repeats and 36 G4C2 repeat 





















3.3 No read-through translation of DsRed2 stop codon 
in G4C2  
 
The location of the repeats in the 3’UTR of DsRed2, and the presence of a TAG stop 
codon before the 3’UTR is expected to prevent translational read-through of the 
repeat sequence. Hence to confirm no DsRed2-DPR fusion proteins were translated 
in repeat containing flies, western blots were performed on lysate generated from the 
heads of flies expressing the differing DsRed2 constructs in post-mitotic neurons 
using the ElavC155-GAL4 driver (figure 3.3). Membranes were probed with antibody 
specific for DsRed2 with anti-beta Tubulin as a loading control. DsRed2 as expected 
was not seen in the negative control genotype (ElavC155/+) and runs at its predicted 
molecular weight of 27.6kDa in the DsRed2 positive control (ElavC155>DsRed2). The 
presence of an identical weight band in all DsRed2-G4C2 repeat containing fly lines 
no matter the length of repeat indicates little or no translational read-through is 
occurring (figure 3.3). DsRed2 does not run higher than its molecular weight at 
27.6kDa. Hence any DPRs detected in flies harbouring G4C2 repeats are likely a 
product of RAN translation rather than read-through translation of the repeats.  
DsRed2 protein levels were significantly increased in all repeat containing lines 
compared to the DsRed2 control (appendix 1; figure A1; quantification performed by 
Alan Stepto). The levels of DsRed2 also differed between different repeat lines 
(appendix 1; figure A1). DsRed2 protein levels were significantly higher in the 38 
repeat flies compared to the 8A, 8B, 32, 56 and 64 repeat lines. There was no 
significant difference in DsRed2 protein levels between the 32, 56 and 64 repeat 
lines. The DsRed2 levels were also significantly higher in the 32 and 64 repeat lines 












Figure 3.3 | No higher molecular weight DsRed2 protein is detected in flies 
harbouring G4C2 repeats. Western blot analysis of RIPA soluble protein from 
day 5 head extracts showing the expected ~26 kDa DsRed2 band in all G4C2 
construct expressing flies, but not in negative control (Elavc155/+), indicating no 





















3.4 Poly-GP is translated in a length and construct 
dependent manner 
 
To assess whether the G4C2 mRNA was subject to RAN translation in this model, the 
pan-neuronal driver ElavC155-Gal4 was used, and protein lysate from 5-day old fly 
heads was probed with a novel monoclonal mouse poly-GP antibody (the 
characterisation of these antibody can be found in appendix 3, (figure A3 A and A3 
B). Poly-GP not detected in controls (ElavC155/+ and ElavC155>DsRed2) or in flies 
harbouring ≤8 repeats, however was detected at variable levels in all flies harbouring 
≥32 repeats. This is consistent with the hypothesis that there is a length-dependent 
threshold for RAN translation initiation, and that this threshold may lie between 8 and 
32 G4C2 repeats.  
Interestingly significantly higher levels of poly-GP were observed in the 32 and 64 
G4C2 repeat lines, with much lower levels seen in the 38 and 56 G4C2 repeat lines 
(figure 3.5B). Hence the expression of poly-GP detected in each condition varied 
dramatically in both a length and construct dependent manner. Furthermore, the 
poly-GP bands in the 32 (~37 kDa and ~ 30 kDa), 56 (~50 kDa), 64 (many bands 
detected between ~30-50 kDa) and 38 (~38 kDa) repeat lines were detected at a 
much higher molecular weight than expected assuming translation initiates at the 
first G4C2 repeat and ends at the first stop codon in the 3’ UTR (13.87 kDa; 24.29 
kDa; 27.77 kDa; and 16.47 kDa respectively). Quantification of poly-GP western 














Figure 3.5 | Translation of G4C2 derived poly-GP. (A) Western blotting and 
quantification of poly-GP expression in 5-day old flies expressing G4C2 repeats 
pan-neuronally (ElavC155-Gal4). Poly-GP was detectable in the 32, 56, 64 and 38 
G4C2 repeat lines at differing sizes. No poly-GP signal was detected in the 
negative controls (Elav C155/+ and Elav C155>DsR2) or in flies expressing 8 repeats 
(Elav C155>(G4C2)8A). (B) Quantification of western blots for expression of poly-
GP. A one-way ANOVA demonstrated there to be a significant difference between 
the genotypes for poly-GP expression levels (F=133.5, P<0.0001). Bonferroni-
Holm corrected multiple comparisons can be found in appendix 7, table A7; 
(*denotes significant difference from other genotypes). Mean with SEM is shown 





3.5 Poly-GA is translated in a length and construct 
dependent manner  
 
The two most prevalent DPRs produced from the G4C2 expansion is poly-GA from 
the sense strand (Schludi et al., 2015). Hence whether the repeat flies used in this 
study also produce poly-GA was investigated using the mouse monoclonal anti-GA 
antibody (5E9) generated and validated by Mackenzie et al. (2013).  Western blotting 
of protein lysate from 5 day old Drosophila heads expressing the repeats specifically 
in neurons using the ElavC155 driver revealed RAN translation of poly-GA in a length 
and construct dependent manner as was observed for poly-GP (figure 3.6A). No 
Poly-GA was detectable in the two negative controls (ElavC155/+ and 
ElavC155>DsRed2) or in flies with 8 repeats. Poly-GA was detectable in the 32 (~35 
kDa), 38 (~37 and ~40 kDa), 56 (~40 kDa) and 64 repeat (~37 and ~45 kDa) 
containing lines. The levels of poly-GA expression followed the same pattern as was 
seen for poly-GP. Poly-GA protein levels were significantly higher in the 32 and 64 
repeat flies compared to both 56 and 38 repeat flies (figure 3.5B). As was the case 
for poly-GP, poly-GA ran at a higher molecular weight than predicted for the 32, 56, 
64 and 38 repeat constructs (13.92 kDa; 24.35 kDa; 27.83 kDa and 16.53 kDa 
respectively). As is the case for poly-GP, multiple band sizes of poly-GA are seen, 
specifically in the 64 and 38 repeat lines. Quantification of poly-GA western blots 















Figure 3.6 | Translation of G4C2 derived poly-GA. (A) Western blotting and 
quantification of poly-GA expression in 5-day old flies expressing G4C2 repeats 
pan-neuronally (ElavC155-Gal4). Poly-GA was detectable in the 32, 56, 64 and 38 
G4C2 repeat lines at differing sizes. No poly-GA signal was detected in the 
negative controls (Elav C155/+ and Elav C155>DsR2) or in flies expressing 8 repeats 
(Elav C155>(G4C2)8A). (B) Quantification of western blots for expression of poly-
GA. A one-way ANOVA demonstrated there to be a significant difference between 
the genotypes for poly-GA expression levels (F=80.04, P<0.0001). Bonferroni-
Holm corrected multiple comparisons can be found in appendix 7, table A7; 
(*denotes significant difference from other genotypes). Mean with SEM is shown 







3.6 Subcellular localisation of poly-GP and poly-GA 
differs between G4C2 repeat containing fly lines 
 
In the human brain, poly-GP and poly-GA form neuronal cytoplasmic inclusions, 
neuronal intranuclear inclusions and dystrophic neurites particularly in the frontal 
cortex and cerebellum (Schludi et al., 2015). Immunofluorescent staining of 
Drosophila L3 larval brains was performed to determine the subcellular localisation 
of poly-GP and poly-GA in vivo using the rabbit poly-GP antibody (Hirth/Gallo/Shaw 
labs) and the poly-GA antibody generated by Mackenzie et al. (2013).  No poly-GP 
or poly-GA was detected in control larval ventral nerve cord (VNC) neurons that did 
not express the hexanucleotide sequence (Elav C155>DsRed2) (figure 3.7). DPRs 
were however detected in the larval VNC of the 56 and 64 G4C2 repeat lines. 
Interestingly, the poly-GP and poly-GA observed in VNC neurons of larvae 
expressing 56 and 64 repeats displayed differential sub-cellular localisations (figure 
3.7). For the 56 repeat larval VNC, poly-GP was diffusely nuclear, with regions of 
intense nuclear staining also observed. Poly-GP in the 64 repeat line was 
predominantly diffusely cytoplasmic with less intense diffuse nuclear staining. No 
regions of intense nuclear staining were observed in the 64 repeat VNC neurons. 
Thus, poly-GP displayed a completely different pattern of localisation between the 56 
and 64 repeat conditions. The relatively low levels of poly-GA in the 56 repeat line 
compared to the 64 repeat line, as evidenced by SDS-PAGE, was not detectable by 
immunofluorescent staining. At such low levels a neuron may be able to efficiently 
clear the peptide preventing it accumulating via protein degradation pathways. In 
flies expressing 64 repeats however, poly-GA had a diffuse nuclear staining with 
compact regions of intense staining in nuclei. No cytoplasmic poly-GA was detected 









Figure 3.7 | Subcellular localisation of poly-GP and poly-GA in the L3 larval 
ventral nerve cord. Poly-GP and poly-GA are not detected in the DsRed2 
negative control larval ventral nerve cord (VNC) (Elav C155>DsRed2). Poly-GP has 
a diffuse nuclear localisation in addition to nuclear accumulations in the 56 repeat 
larval VNC (ElavC155>(G4C2)56). Poly-GA was not detectable by 
immunohistochemistry in the 56 repeat VNC. Poly-GA in the 64 repeat larval VNC 
(Elav C155>(G4C2)64) was diffusely nuclear with nuclear accumulations; poly-GP 
had a predominantly cytoplasmic stain with also some weak diffuse nuclear 





3.7 Poly-GR is only detected in 38 G4C2 repeat fly line 
 
The third sense DPR translated from the G4C2 expansion is the arginine rich DPR 
poly-GR. Poly-GR inclusions are observed much less frequently compared to poly-
GP and poly-GA in post mortem material (Schludi et al., 2015., Mackenzie et al., 
2015). However, more recently it has been demonstrated that of the five DPRs, only 
poly-GR is significantly found more often in clinically relevant brain areas than in 
unrelated brain areas of ALS patietns (Saberi et al., 2018), furthermore poly-GR was 
shown to form dendritic-like aggregates within the motor cortex which co-localized 
with pTDP-43 inclusions (Saberi et al., 2018). This data combined with the disease 
models showing toxicity of the arginine DPRs (Mizielinska et al., 2014) makes the 
detection of poly-GR in the flies used in this study important due to its increasing 
association with both disease anatomy and toxicity. Owing to difficulties in detecting 
poly-GR by SDS-PAGE, due to the highly positive charge of the dipeptide, a dot blot 
protocol previously developed by Mizielinska et al., (2014) to detect RAN translated 
poly-GR in flies was performed. Dot blots were performed using two previously 
published poly-GR antibodies (Gendron et al., 2013; Mann et al., 2013) (figure 3.8). 
Lysate from HEK293 cells (provided by Younbok Lee) was used as a positive control 
to confirm the specificity of the poly-GR antibodies. Positive control lysate confirmed 
the poly-GR binding capacity of the antibodies used to probe fly lysate. No poly-GR 
was detectable in the negative controls (ElavC155/+ and ElavC155>DsRed2). No poly-
GR signal above background seen in controls was detected for the 8B, 32, 56, 64 
and 128 repeat lines. Poly-GR signal above background was however seen in the 38 
G4C2 repeat fly line for both poly-GR antibodies tested; suggesting that only the 38 

































Figure 3.8 | Translation of G4C2 derived poly-GR. Two published poly-GR 
antibodies (A) Gendron et al., 2013) and (B) Mann et al., 2013) were used to 
detect the presence of poly-GR in RIPA soluble lysate from flies expressing 38 
G4C2 repeats but not other repeat lines. No poly-GR was detectable in negative 
controls (Elav C155/+ and Elav C155>DsR2). Positive control of lysate from HEK293 
cells expressing poly-GR from a non G4C2 template was used. Samples were 




3.8 Subcellular localisation of poly-GR in 38 repeat flies 
 
A different poly-GR antibody, rat monoclonal 5H9 (Mori et al., 2013) has been 
determined to be the most sensitive antibody for detecting poly-GR inclusion bodies 
in patient tissue compared to other available poly-GR antibodies (Mackenzie et al., 
2015). Rat monoclonal 5H9 was used to probe day 5 adult fly brains for poly-GR 
(figure 3.9). Dissections for poly-GR localisation were performed in collaboration with 
Alan Stepto. No poly-GR signal was detectable in the negative control (Elav 
C155>DsR2) or the 8A, 8B, 32, 56 and 64 fly lines. 5H9 immunohistochemistry 
revealed a diffuse perinuclear staining pattern in the 38 repeat flies. Small 
accumulations of poly-GR were also seen, mainly perinuclear, but also occasionally 



















Figure 3.9 | Poly-GR is only detectable in the 38 repeat fly brain. 
Immunohistochemistry from 5-day old adult brains shows poly-GR is only 
detected in flies expressing 38 G4C2 repeats but is not detected in the negative 
control (Elav C155>DsR2) and flies expressing 8A. 8B, 32, 56 or 64 G4C2 repeats. 
Poly-GR displays a diffuse perinuclear localisation with regions of intense 
























Figure 3.10 | Anti-sense DPRs were not detected in flies expressing G4C2 
repeats. Published poly-PR and poly-PA antibodies (Gendron et al., 2013) were 
used to detect the presence of anti-sense DPRs in RIPA soluble lysate from flies 
expressing 38 G4C2 repeats. No anti-sense DPRs were detectable the using anti-
PR and anti-PA antibodies. Samples were also probed with anti-β-tubulin to 
confirm approximately equal loading of protein. 
3.9   Anti-sense DPRs are not detected in G4C2 fly lines 
 
In addition to translation from the sense G4C2 strand, the anti-sense C4G2 is 
transcribed and translated to produce three anti-sense DPRs – poly-GP, poly-PR 
and poly-PA. Anti-sense RAN translation was probed in the repeat flies via dot 
blotting using previously validated and published poly-PR and poly-PA used to detect 
protein deposits in human post mortem tissue (Gendron et al., 2013). Day 5 lysate 
from fly heads expressing the repeats in neurons were probed for poly-PR and poly-
PA (figure 3.10). No poly-PR or poly-PA signal was detected in controls (ElavC155/+ 
and ElavC155>DsRed2) or the 8A, 8B, 32, 56, 64 and 38 repeat fly lines. Hence there 
was no evidence for anti-sense DPRs. Anti-sense RAN translation either does not 
occur in these flies or levels are below the threshold for detection using these 











3.10  Discussion 
 
3.10.1 No RNA foci were detected in the L3 salivary glands 
of DsRed2-G4C2 flies 
 
Using an Alexa488-labelled (G2C4)4 RNA probe to perform FISH in the salivary gland 
cells of larvae expressing 32 or more repeats showed the presence of a single large 
“foci” per cell. Both Mizielinska et al. (2014) and Tran et al. (2015) previously 
observed a single large “foci” in salivary gland cells expressing G4C2 repeats. Tran et 
al. (2015) found these single large “foci” co-localised with activated Pol-II; indicating 
they represent the transcriptional start site. Indeed, when salivary gland cells 
expressing the repeat constructs used in this study were co-stained with the 
Alexa488-labelled (G2C4)4 RNA probe and an antibody for p-Pol-II, the single foci 
observed co-localised with p-Poll-II. The lack of foci in the G4C2 repeat containing 
lines does not exclude the possibility that the foci are produced from the constructs 
used in this study. Indeed the 38 and 56 repeat constructs have been shown to form 
numerous nuclear RNA foci in SH-SY5Y cells previously by Lee et al. (2013). Tran et 
al. (2015) could detect numerous small and large foci in larval glia and neurons from 
their 160 intronic construct; hence it will be important in future to investigate RNA foci 
in neurons for the DsRed2-repeat flies used in this thesis. Tran et al. (2015) also 
studied G4C2 RNA transcribed as part of a poly(A) mRNA using 36 G4C2 repeat flies 
(36R-poly-(A)) generated in the Mizielinska et al. (2014) study. Not only were the 
levels of RNA in the 36R-poly-(A) flies much greater than in the spliced intronic 160 
G4C2 flies despite the same transgenic insertion site, but most of the RNA in these 
flies was cytoplasmic in larval glia and motor neurons; with the only nuclear signal 
being the single large dot representing the transcriptional start site. The G4C2 
repeats in the DsRed2 flies used in this study are in the 3’UTR so will be part of the 
poly-(A) mRNA transcript like the 36R-poly-(A) flies where most of the RNA is 
cytoplasmic (Mizielinska et al., 2014, Tran et al., 2015). Nuclear RNA foci might 
therefore potentially be difficult to detect in the current model due to the nature of the 
construct as most of the RNA is exported to the cytoplasm where it undergoes RAN 
translation. Any foci seen will likely be cytoplasmic like what is observed for the 36R-
poly-(A) flies.  
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Importantly, in salivary gland cells expressing the 288 G4C2 RNA-only construct, 
although a large bight signal co-localising with p-Pol-II was seen, G4C2 RNA was 
also detected in the nucleus that didn’t co-localise with p-Pol-II - including several 
smaller dots akin to the foci seem in patient iPSC neurons (Almedia et al., 2013). 
Hence this RNA only fly line was deemed an appropriate RNA-only control for later 
studies investigating DPR toxicity from alternative codon constructs in salivary gland 
cells. 
3.10.2 DsRed2 levels are higher in DsRed2-G4C2 repeat 
containing flies 
 
DsRed2 protein levels were found to be elevated in flies harbouring >8 G4C2 repeats 
in the 3’UTR of DsRed2 compared to controls expressing only DsRed2 without 
repeats in the 3’UTR. The 3’UTR of mRNA is important for the localisation and 
stability of the transcript (Matoulkova et al., 2012). The G4C2 repeat RNA forms DNA 
and RNA G-quadruplexes (G4) (Haeusler et al., 2014). RNA G4s in the both the 5’ 
and 3’ UTR of an RNA transcript have been demonstrated to have key functions in 
RNA metabolism including mRNA splicing, polyadenylation, mRNA localisation and 
importantly mRNA translation (Song et al., 2016). For example, using luciferase 
reporter assays the presence of 5’ UTR G4 structures have been shown to correlate 
with translation repression of numerous human mRNAs (Song et al., 2016). 
Furthermore, Crenshaw et al. (2015) found a G4 in the 3′-UTR of APP mRNA inhibits 
the expression of the APP protein. Beaudoin and Perreault, (2013) found G4s in the 
3’ UTR can enhance translation by increasing the efficiency of alternative 
polyadenylation sites. Most evidence suggests 5’ and 3’ UTR G4s inhibit cap-
dependent canonical translation via influencing eIF4A-sensitivity (Song et al., 2016). 
Intriguingly the opposite appears to be true for non-canonical cap-independent forms 
of translation, G4 structures in the 5’UTR enhance IRES mediated mRNA translation 
rather than supress it through unknown mechanisms (Song et al., 2016). Hence the 
enhanced DsRed2 levels seen in the presence of G4C2 repeats in the DsRed2 
3’UTR could be due an interaction between RNA G4 structures formed by the 
repeats and proteins important non-canonical translation; if G4C2 RAN translation 




3.10.3 Length dependent RAN translation 
 
DPRs RAN translated from the G4C2 mRNA is one of the major unique pathological 
hallmarks of the C9ALSFTD brain. In this study DPRs were detectable in flies 
harbouring 32, 56 64 and 38 G4C2 repeats. No DPRs were detectable in flies 
harbouring shorter than 32 repeats. The threshold for RAN translation of the G4C2 
expansion is yet to be determined however clues can be gathered from models of 
repeat toxicity and patients harbouring the repeat expansion.  
Gami et al. (2015) found all 5 DPRs in the cerebellum, frontal and temporal cortices 
of a 30 unit G4C2 repeat expansion carrier. However, no DPRs are detected in post-
mortem brain tissue from <20 G4C2 repeat unit cases. For example, Beer et al., 
(2014) identified a patient with clinically typical ALS with a 16 unit G4C2 repeat 
expansion with no DPR pathology. Hence patient post-mortem studies suggest the 
critical length for RAN translation lies somewhere between 20 – 30 repeats. Cellular 
models also suggest a critical repeat number is required for the initiation of RAN 
translation. Zu et al. (2013) detected poly-GP, poly-GA and poly-GR from a 30 G4C2 
repeat construct transfected in HEK293T cells. RAN translation was again length 
dependent – no DPRs were observed in a 4 G4C2 repeat unit construct but DPR 
levels increased as the repeat length increased from 30 to 60 and 120 repeats. Mori 
et al. (2013a) also found a length-dependent increase in translation of the poly-GP 
and poly-GA peptides from G4C2 repeat constructs in vivo. Increasing amounts of 
poly-GA was detectable beginning at 38 repeats – no DPRs were detectable at 11 
and 28 repeats. Drosophila models of the G4C2 expansion have also provided 
insights into the repeat length required for RAN translation to occur. DPRs have 
been observed at 28, 30, 36, and 58 repeat units but not at 3 and 8 repeats 
(Mizielinska et al., 2014, Freibaum et al., 2015, Zhang et al., 2015). Freibaum et al. 
(2015) observed minimal translation at 28 repeats with a large increase in detectable 
DPRs at 58 repeats. Zhang et al. (2015) expressing a 30 repeat unit construct found 
poly-GR was only detectable with 2x copies of the construct and required a heat-
shock GAL4 with an accompanying heat-shock for expression. Poly-GR was not 
seen with a single copy of the 30 repeat construct, furthermore poly-GP was not 
observable under any conditions. However, Zhang et al. (2015) found both poly-GR 
and poly-GP were measurable in flies with a single copy of a 36 repeat construct 
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generated by Mizielinska et al. (2014); furthermore poly-GR did not require a heat-
shock to be detected. Poly-GA aggregates are seen throughout the brain of BAC 
mice with 36 repeats; however, it appears expression levels of G4C2 RNA need to be 
sufficiently high enough as no DPRs were seen in mice with 37 repeats in the same 
study (Liu et al., 2016c). Similarly, the different fly models have differences in the 
transgenic insertion sight and genomic context of the repeats - both of which strongly 
influences transgene expression levels, hence it is difficult to directly compare 
between the different fly models.  
Nevertheless, when fly (Mizielinska et al., 2014, Freibaum et al., 2015, Zhang et al., 
2015) in vitro (Zu et al., 2013, Mori et al., 2013a) post-mortem human work (Beer et 
al., 2014, Gami et al., 2015) and BAC models (Liu et al., 2016c) are all viewed in 
parallel - in addition to the results presented in this study - a noticeable trend 
becomes apparent. It seems RAN translation of the G4C2 expansion initiates at a 
repeat unit number in the high 20’s but is however likely weak and inefficient based 
on what has been observed (Mori et al., 2013a; Freibaum et al., 2015). However, at 
repeat lengths >30 repeats, there is large increase RAN translation efficiency and 
hence DPR production. In the current study a significant difference in poly-GP and 
poly-GA levels was seen for the 32 and 64 repeat lines, with the 64 repeat flies 
producing higher amounts of both DPRs. In all the studies discussed previously DPR 
expression increases as the G4C2 repeat number increases. For example, in the Liu 
et al. (2016a) BAC transgenic model mice with 500 repeats showed more severe 
DPR accumulation compared to those with 36 repeats. This finding that the initiation 
of RAN translation is strongly influenced by the length of the repeats is similar to 
findings on RAN translation in other neurological diseases caused by repeat 
expansions (Zu et al., 2011; Kearse et al., 2016). In summary studies of the 
hexanucleotide repeat expansion suggest the critical length for RAN translation of 
from the G4C2 expansion is in the range of 20 – 30 repeat units and that greater 
repeat length favours RAN translation and DPR accumulation. 
It is also worth noting that both poly-GP and poly-GA ran at a higher molecular 
weight that would be predicted based on the repeat size from which they are 
translated from. Such a phenomenon is seen in other studies investigating poly-GP 
from pure and alternative codon repeat constructs (Zu et al 2013; Yamakawa et al., 
2015; Mizielinska et al., 2014). Yamakawa et al. (2015) found poly-GA, poly-PA, 
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poly-PR and poly-GP all seem to run higher than expected indicating a decreased 
electromobility of highly repetitive peptides potentially due to abnormal SDS-binding 
properties, the way the DPRs fold, or a post-translational modification (Yamakawa et 
al., 2015). It is also possible the unique C-terminal sequences of poly-GP and poly-
GA due to translation from the 3’UTR of DsRed2 may also influence how the 
proteins run on the gel. Multiple poly-GP bands were seen in the 32 and 64 repeat 
lines at different molecular weights; multiple poly-GA bands were seen in the 38 and 
64 repeat flies. There are many reasons why this might occur - for example the 
proteins could be potentially cleaved, RAN translation could be initiating at different 
points along the repeat sequence or terminating at different points producing 
different sized poly-GP and poly-GA peptides. Indeed Tabet et al., (2018) and Green 
et al., (2017) both report codons 5’ of the repeats other than the CUG in the (+1) 
frame also influences RAN translation albeit to a lesser extent than the (+1) CUG. If 
RAN translation is initating at different sites within the repeats then the higher than 
expcted molecular weight bands may be due to large C-terminal read-throughs of the 
DsRed2 3’UTR, hence it will be important to determine extact start site of RAN 
translation in the repeat constructs used in this study through either ribosomal 
profiling or site directed mutagenisis. Another explanation for multiple bands seen on 
SDS-PAGE for poly-GP and poly-GA is that the peptides may self-associate to form 
dimers or even higher order oligomers and not just exist in a monomeric state. 
Multiple band sizes for poly-GP by western blotting were reported by Yamakawa et 
al., (2015) and Cristofani et al., (2017) using a 100 peptide repeat alternative codon 
poly-GP only construct.  
3.10.4 Construct dependent RAN translation  
 
Both the expression and identity of the DPRs detected in the different G4C2 fly lines 
used in this study varied dramatically in a length and construct dependent manner 
(Table 1). The 32 and 64 repeat lines produce high levels of poly-GP and poly-GA 
whilst the 56 repeat line also produces only poly-GP and poly-GA but at much lower 
levels. The 38 repeat line produces all three sense DPRs, poly-GP, poly-GA and 
poly-GR. All constructs were inserted at the same location in the genome in the 
3’UTR of the DsRed2 transgene; hence differences in DPR expression profile cannot 












The G4C2 repeats in the flies used in this study are contained within the DsRed2 
poly(A) mRNA transcript, hence are likely exposed to ribosomal scanning during 
DsRed2 translation. No translational read-through of DsRed2 is seen (figure 3.3); 
however, it is known that the ribosomal complex can keep scanning after translation 
of the upstream open reading frame and reinitiate again further downstream 
(Jungreis et al., 2011; Rogers et al., 2017). Hence, DPR translation is initiating either 
in the sequence 5’ of the repeats and/or within the repeat sequence itself. The 
repeats are uninterrupted in these flies and identical within each construct apart from 
length, however there is variability in sequence 5’ of the repeat region. Indeed, when 
generating these constructs, some variation in the linker sequence between the 
DsRed2 stop codon and the start of the G4C2 repeat sequence was introduced by 
chance. The 5’ linker flanking the start of the repeats, after the DsRed2 STOP 
codon, differs in between the 38, 56, 32 and 64 repeat constructs (figure 3.11).  
Recent work has begun shed light upon potential mechanisms underlying RAN 
translation. Kearse et al. (2016) demonstrated RAN translation of CGG repeats in 
fragile X-associated tremor/ataxia syndrome requires traditional cap-dependent 40S 
ribosomal scanning, however the start site for translation differs from traditional AUG 
initiated translation. RAN translation, depending on the reading frame, could initiate 
within the repeat sequence itself or upstream of the repeats on AUG like codons. 
The addition of STOP codons upstream of the CGG repeat strongly inhibited RAN 
translation of the FMR-polyGly protein. Further, using mass spectrometry Sellier et 
Table 1 | The different linkers 5’ of the repeats in relation to DPRs detected 
and DPR expression levels. Constructs with the same linker sequence (32, 64 
repeat constructs) produce the same combination and levels of DPRs. 
 
 
*Expression level based on quantitative western blotting of DsRed2 protein levels; 





al. (2017) found translation of the FMR-polyGly protein initiated at an ACG close 
cognate start codon 32 nucleotides upstream of the CGG expansion. Investigations 
into mechanisms of RAN translation of G4C2 repeat expansion have revealed 
similiary that the translation of the DPRs is dependent on the sequence 5’ of the 
repeats. G4C2 RAN translation initiates in the poly-GA frame (+1) on a near-cognate 
CUG codon 5’ of the repeats in the context of a strong kozak sequence (Green et al., 
2017; Tabet et al., 2018). Translation in poly-GP (+2) and poly-GR (+3) frames 
occurs through ribosomal frameshifting (Tabet et al., 2018).  
In the DsRed2-G4C2 model characterized in this study DPR levels and production 
correlated with the sequence 5’ of the G4C2 repeats. For constructs with the same 
linker sequence and linker length the same pattern of DPR expression is seen; e.g. 
for the 32x and 64x repeat lines high levels of poly-GP and poly-GA are produced. 
The 56x repeat line on the other hand, despite a similar repeat length number to the 
64 line, produces significantly lower levels of poly-GP and poly-GA - the linker 
sequence however is not only different but also longer in length (34bp compared to 
24bp). Hence it is plausible to speculate that the different upstream sequences 5’ of 
the repeats in the different DsRed2-repeat flies’ impacts RAN translation. However, 
analysis of the codons within these linker sequences reveals DPR levels and identity 
does not correlate with the presence of near-cognate start codons or STOP codons 
(figure 3.11).  A CUG is present in the (+1) frame 5’ of the repeats in all DsRed2 
constructs however, the presence of this CUG does not explain the DPR expression 
profile observed in these flies. For example. In the 32 and 64 repeat flies the CUG 
codon is present in the (+1) poly-GR reading frame, yet poly-GR is not detected in 
these lines. Rather poly-GA (+2) and poly-GP (+3) are produced much more 
abundantly. The 38 repeat flies, the only line in which poly-GR is detected harbour 
two AUG like (AUC and AGG) codons in the (+2) poly-GR frame, however a UAG 
STOP codon is present in the poly-GA (+3) frame just before the repeats yet this 


















The different DPR profiles in the flies used in this study are an interesting 
observation; the current study however is limited in its ability to draw conclusions 
about mechanisms of RAN translation other than speculation. To study whether the 
5’ linker sequence is behind the different DPR profiles observed; further work should 
be conducted where the linkers are swapped between different constructs and DPR 
expression profile then probed for. For example, if the 56x G4C2 construct has the 
same 5’ sequence upstream of the repeats as the 32 and 64 lines would it now 
produce high levels of poly-GP and poly-GA? Similarly, if the 32, 56 or 64 repeat 
constructs have the same 5’ linker as the 38, would they start to produce poly-GR?  
3.10.5 No anti-sense DPRs are detectable in DsRed2-G4C2 
repeat lines 
 
The anti-sense DPRs poly-PR and poly-PA were not detected in any of the flies used 
in this study using previously published antibodies. So far anti-sense foci, but not 
anti-sense DPRs, have been reported in any of the published G4C2 mouse models 
(Chew et al., 2015; Peters et al., 2015; O’Rourke et al., 2015; Liu et al., 2016c; Jiang 
et al., 2016). Anti-sense DPRs have also not been reported in other fly models of the 




Figure 3.11 | AUG-like and STOP codons in the 5’ linker sequences of the 
G4C2 DsRed2 flies that produce DPRs. Schematic of constructs with different 
lengths of uninterrupted G4C2 repeats cloned into 3’ UTR of disease-unrelated 
marker gene DsRed2 (in red); variable linker sequences between DsRed2 stop 
codon and start of G4C2 repeats are indicated, as are AUG-like codons and DPR 
produced. Expression levels (+, low; ++, moderate; +++ high) of RNA-translated 




Tran et al., 2015). How anti-sense transcription of the C4G2 sequence occurs is 
unknown. Anti-sense transcripts are known to arise from independent promoters, 
bidirectional promoters and cryptic promoters (Pelechano and Steinmetz, 2013). 
Hence it is likely some form anti-sense promotor is present within the C9ORF72 
gene. If this is the case then no anti-sense DPRs or even anti-sense RNA would be 
seen from model systems that study the repeat expansion in isolation of the full 
C9ORF72 genomic landscape such as viral vector mouse models (Chew et al., 
2015) or Drosophila models (Mizielinska et al., 2014; Freibaum et al., 2015; Zhang et 
al., 2015; Tran et al., 2015).  
There are several explanations as to why no anti-sense DPRs were observed. It 
could be that their expression levels are too low to be detectable via dot blotting; 
indeed poly-PR and poly-PA are extremely rare in the human brain (Mackenzie et 
al., 2015); indicating anti-sense RAN translation is less efficient than sense RAN 
translation. It is also possible anti-sense DPRs are not produced at all as anti-sense 
transcription requires some form of promotor (Pelechano and Steinmetz, 2013), 
hence anti-sense RNA would not be produced from the UAS/GAL4 system used to 
express the repeats in Drosophila. Furthermore, the presence of bidirectional 
promoters appears to be species-dependent, with the genome of Drosophila 
containing much lower levels of bidirectional promoters compared to yeast and 
humans (Pelechano and Steinmetz, 2013). To produce anti-sense RNA the 
deliberate insertion of an anti-sense UAS for the GAL4 transcription factor to bind to 
would be needed. Further one could also utilise a C4G2 construct under the control of 
a UAS promotor. Transgenic BAC models with the whole 29.6kb C9ORF72 gene, 
with upstream and downstream sequences, potentially provide the means to study 
both sense and anti-sense DPRs in the same model system as the whole C9ORF72 
genomic landscape is present. Anti-sense foci have been detected in C9ORF72 BAC 
mice containing 140.5kb upstream and exons 1-6 of C9ORF72 (Peters et al., 2015) 
and C9ORF72 BAC mice containing 140kb upstream and exons 1-5 of C9ORF72 
(Jiang et al., 2016) further suggesting some form of anti-sense promotor lies within 
this region. Although, no anti-sense RNA was detected in the intronic Tran et al. 
(2015) Drosophila model consisting of exon 1, some of intron 1 (with the 
G4C2 expansion) and exon 3 of human C9ORF72. Human C9ORF72 iPSCs also 
give the same benefits as BAC transgenic mice as the whole C9ORF72 gene with 
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the repeats can be studied, however, anti-sense foci or DPRs have not been fully 
investigated in current C9ORF72 iPSC lines (Donnelly et al., 2013; Sareen et al., 
2013; Lopez-Gonzalez et al., 2016; Dafinca et al., 2016); although trace amounts of 
poly-PR were reported by Dafinca et al. (2016) in their C9 iPSC motor neurons.  
3.10.6 Poly-GP and poly-GA localisation differed in different 
DsRed2-G4C2 repeat lines 
 
The localisation of poly-GP varied substantially between the 56 and 64 repeat lines. 
In the 56 repeat line poly-GP was mainly diffusely nuclear with intense nuclear poly-
GP accumulations consistent with the paranucleolar inclusions seen in C9ALS/FTD 
frontal cortex (Schludi et al 2015). For the 64 repeat flies poly-GP was predominantly 
diffusely cytoplasmic with a weak nuclear stain but with no intense nuclear 
accumulations.  
The cytoplasmic inclusions of poly-GP seen in patient post-mortem brain were not 
observed in any of the flies used in this study. Numerous cellular models used to 
assess poly-GP toxicity using both G4C2 and alternative codon constructs have 
found the peptide to be predominantly diffusely localised in both the cytoplasm and 
nucleus without the formation of inclusions (Zu et al., 2013; May et al., 2014; Zhang 
et al., 2014; Yamakawa et al., 2015; Schludi et al., 2015; Tao et al., 2016; Callister et 
al., 2016). Nuclear and cytoplasmic inclusions of poly-GP have been reported in one 
Drosophila model expressing 58 G4C2 repeats (Freibaum et al., 2015) and in aged 
G4C2 repeat murine models (Chew et al., 2015, Peters et al., 2016, O’Rourke et al., 
2016, Liu et al., 2016c, Jiang et al., 2016). However numerous cellular models used 
to assess poly-GP toxicity using both G4C2 and alternative codon constructs have 
found the peptide to predominantly diffusely localised in both the cytoplasm and 
nucleus without the formation of inclusions (Zu et al., 2013; May et al., 2014; Zhang 
et al., 2014; Yamakawa et al., 2015; Schludi et al., 2015; Tao et al., 2016; Callister et 
al., 2016). This is consistent with the biophysical properties of the peptide that it is 
uncharged with a compact flexible coil structure (Freibaum and Taylor., 2017). Poly-
GP is much for soluble than the most aggregation prone and common DPR poly-GA, 
indeed a greater percentage of total poly-GP is soluble compared to insoluble in 
brain tissue whilst the opposite is the case for poly-GA (Gendron et al., 2015). This 
solubility of poly-GP has led to investigations in the potential of the peptide as 
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biomarker for C9ALS/FTD in CSF (Gendron et al., 2017; Lehmer et al., 2017). Hence 
poly-GP does not appear to be highly prone to forming insoluble proteinaceous 
inclusions on its own. Poly-GP inclusions may occur due to its interaction with other 
DPRs. For example, Yamakawa et al. (2015) found poly-GR and poly-PR sequesters 
both poly-GP and poly-GA into aggregates. Lee et al., (2017) found poly-GA 
sequesters poly-GP. Poly-GR has been shown to accumulate in cytosolic poly-GA 
inclusions in Drosophila and human iPSC neurons (Yang et al., 2015). Poly-GP 
aggregates could be age-dependent and attributable to a build-up over time of the 
peptide in the patient brain. A recent study demonstrated that whilst under basal 
conditions poly-GP mainly accumulates as an SDS-soluble species levels insoluble 
poly-GP increase 5 fold when autophagosome formation is inhibited (Cristofani et 
al., 2017). The authors also found poly-GP was the only DPR to accumulate in the 
insoluble fraction following proteasome inhibition. The C9ORF72 protein itself has 
been shown to play a role in the initiation of autophagy (Webster et al., 2016a; 
Yang et al., 2016) and its loss impairs autophagic functions (Sellier et al., 2016). 
Further poly-GA toxicity has been linked to proteasome dysfunction (May et al., 
2014; Zhang et al., 2014; Zhang et al., 2016). The interaction between both factors 
may be important for the aggregation of poly-GP. 
Many model systems studying poly-GA toxicity in isolation have shown the peptide to 
be highly aggregation prone – predominantly forming cytoplasmic inclusions (Zu et 
al., 2013; May et al., 2014; Zhang et al., 2014; Yamakawa et al., 2015; Schludi et al., 
2015; Tao et al., 2016; Callister et al., 2016). Poly-GA was undetectable in the 56 
repeat line but interestingly was predominantly nuclear in the 64 repeat line; forming 
nuclear inclusions.  As was the case for poly-GP in the 56 repeat flies, these nuclear 
poly-GA inclusions seen in the 64 repeat line strongly resembles the paranucleolar 
poly-GA inclusions seen in C9ALS/FTD frontal cortex (Schludi et al., 2015). Nuclear 
inclusions of poly-GA have been observed in a poly-GA protein only mouse model 
where it sequestered proteins involved in nuclear cytoplasmic transport and nuclear 
UPS-related proteins (Zhang et al., 2016). The nuclear localisation of poly-GP and 
poly-GA may be attributable to the small size of the dipeptides; in mice poly-GP 
produced 66 repeats is primarily nuclear (Chew et al., 2015) whereas poly-GP forms 
mainly cytoplasmic aggregates in mice with repeat expansions in the hundreds 
(O’Rourke et al., 2015; Peters et al., 2015; Jiang et al 2016). Jiang et al. (2016) 
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suggest shorter DPR proteins are more soluble hence more freely diffuse through 
the nuclear pore forming the nuclear aggregates seen by Chew et al. (2015).  
The difference in poly-GP localisation between the 56 and 64 flies could be 
attributable to the vastly different expression levels of poly-GP between these two 
lines. A second explanation may be due to the different non-GP peptide C-terminals 
the poly-GP proteins are predicted to have in the 56 and 64 repeat lines assuming 
translation halts at the first stop codon 3’ of the repeats (figure 3.12). These C-
terminals may alter the biophysical properties of the peptide. Interestingly all six RAN 
proteins are predicted to have unique C-terminal sequences in the human brain (Zu 
et al., 2013). Immunostaining with specific antibodies has shown DPRs with unique 
C-terminal flanking regions aggregate in patient brains (Zu et al., 2013). How these 
C-terminals influence DPR biophysical properties or toxicity is unknown but 
broadens the study of DPR toxicity further than just the repetitive peptide motifs 
themselves (Cleary and Ranum, 2017). Although it should be noted that the C-
terminal sequence for the 56 and 64 repeat flies do not differ greatly, for example, 
the predicted C-terminal for poly-GP in the 56 repeat flies is identical to the C-
terminal for the 64 repeat flies except for an extra Proline. To confirm/exclude 
whether the different subcellular localisation of poly-GP and poly-GA between the 
repeat flies is due to the extra peptide sequence translated from the 3’UTR of 
DsRed2, alternative codon constructs could be generated for poly-GA and poly-GP 
which harbour these extra C-terminal amino acids. The expression of such 
constructs could then be compared to poly-GA and poly-GP constructs without this 































Figure 3.12 | Construct specific differences in the putative C-terminal 
sequences of DPRs. The C-terminal protein sequences between the repeats and 
the first downstream stop codon are predicted to differ in length and amino acid 
composition for the different constructs in each reading frame. This figure was 







In summary this chapter has demonstrated RAN translation occurs in a novel 
Drosophila model of the repeat expansion in which the repeats have been cloned 
into the 3’UTR of the disease unrelated transgene DsRed2. Only RAN translation of 
the sense DPRs were observed; no anti-sense DPRs were detected. No DPRs were 
seen in flies with 8 repeats however were seen from 32 repeats and above. DPR 
identity and expression differed between the different G4C2 fly lines. The 32 and 64 
repeat fly lines produced poly-GP and poly-GA. The 56 repeat fly line also produced 
only poly-GP and poly-GA but at a lower level compared to 32 and 64 flies. Poly-GR 
is detectable only in the 38 repeat fly line. Hence RAN translation occurs in this 
model, however in both a length and construct dependent manner; potentially due to 
construct specific differences in the linker sequence 5’ of the repeats or construct 







Chapter 4: Neuronal toxicity of G4C2 
repeats is dependent upon both DPR 
identity and expression levels 
The preceding chapter described DPR expression and localisation in flies harbouring 
different lengths of G4C2 RNA cloned in the 3’ UTR of DsRed2. RAN translation 
occurs in this model, however in both a length and construct dependent manner. The 
64 repeat line produces high levels of poly-GP and poly-GA compared to the 56 
repeat line - despite similar G4C2 repeat length sizes. RAN translation of poly-GP 
and poly-GA is also observed in the 38 repeat flies, however uniquely also produces 
the third sense DPR, poly-GR. These reported differences in DPR levels and 
expression profile between different G4C2 expressing fly lines facilitated assessment 
of the toxicity of different combinations and levels of DPRs derived from RAN 















4.1 Neuronal expression of 38 repeats produces a 
severe early-onset deficit in climbing performance 
whereas late-onset decreases in climbing performance 
are seen in flies expressing high levels of poly-GP and 
poly-GA 
 
C9ALS/FTD patients are characterised by a progressive decline in motor functions 
resulting from the loss of lower and upper motor neurons (Swinnen and Robberecht, 
2014). Whether the expression of G4C2 RNA and RAN translated DPRs had any 
impact on Drosophila motor performance was investigated. Assessment of motor 
behaviour resulting from neuronal expression of G4C2 repeats was performed by 
measuring the innate climbing response of flies through startled induced negative 
geotaxis (SING). The natural response of a fly when startled in a closed environment 
is to climb up to the top of its enclosure. Defects in climbing performance are 
indicative of underlying neuronal dysfunction (Coulom and Birman, 2004). Climbing 
performance was investigated at days 5 and days 20 post eclosion using the pan-
neuronal driver ElavC155 (figure 4.1). At 5 days of age, flies expressing 38 G4C2 
repeats recorded a significant and severe deficit in climbing ability, relative to all 
other genotypes tested (figure 4.1A and C). The climbing performance of the 38 
repeat flies and its 8 repeat control at day 5 (ElavC155>(G4C2)8B) were assessed in 
the same geotaxis assay as the two controls (Elav C155/+ and Elav C155>DsR2) and 
the other repeat lines; however, the data is separated for clarity in figure 4A and C. 
By day 20, the 38 repeat flies were unable to climb, whereas all other genotypes 
performed as they had at day 5 (figure 4.1B and D). As with the day 5 geotaxis data 
the climbing performance of all repeat flies and controls was assessed in the same 
geotaxis assay for day 20, however, the data set is again separated in the figure for 
clarity. In summary the 38 repeat line which produces all three sense DPRs, poly-
GP, poly-GA and poly-GR have a severe early onset behavioural phenotype. This 
phenotype was not caused by the enhanced G4C2 RNA levels or increased 
transgene expression of DsRed2 in the 38 repeat line. This was confirmed by 
generating flies harbouring two copies of the 64 repeat construct which have 
significantly higher levels of DsRed2 protein compared to both flies with a single 
copy of the 64 construct and the 38 repeat flies (appendix 2, figure A2 A; performed 
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by Alan Stepto). Day 5 climbing performance was not significantly different between 
the 2x 64 flies and the 1x 64 flies; however, both were significantly impaired 
compared to the 38 repeat line (appendix 2, figure A2 B; performed by Alan Stepto). 
No difference in climbing performance was seen between the 32, 56 and 64 lines 
producing only poly-GP and poly-GA at days 5 and 20 between each other and 
controls. 
To establish whether expression of poly-GA and poly-GP contribute to behavioural 
impairment with age in flies, the 32, 56 and 64 repeat flies and the respective 
controls were aged to 40 days and subjected to SING. The 38 repeat flies did not 
survive up to day 40 hence could not be assessed at this later time point. In SING 
the performance of flies expressing 56 G4C2 repeats with low levels poly-GA and 
poly-GP could not be distinguished from control flies expressing either 0 (Elav/+ and 
ElavC155>DsR2) or 8 G4C2 (ElavC155>(G4C2)8A) repeats up to day 40 (figure 4.1E). 
Hence neither the 56 G4C2 repeat RNA nor the poly-GP and poly-GA expression in 
this line induced any measurable deficit in climbing performance. The 32 and 64 
repeat lines however developed a mild, yet significant impairment in climbing 
performance compared to the 56 line and controls at day 40 (figure 4.1E). DsRed2 
transgene expression levels did not differ in these between the 32, 56 and 64 lines 
(appendix 1: figure A1), indicating the mild motor impairment seen is attributable to 
the high poly-GP and/or poly-GA protein levels produced.  Geotaxis was performed 




































Figure 4.1 | A severe decline in climbing performance is seen in flies 
expressing 38 repeats expressing detectable levels of poly-GR; whereas 
late-onset decreases in climbing performance are seen in flies expressing 
high levels of poly-GP and poly-GA. (A-D) A two-way ANOVA was used to 
compare the mean differences in climbing performance (the performance index - 
PI) between the different genotypes at days 5 and 20. The PI of flies was 
significantly affected by both genotype (F=183.5, p<0.0001) and age (F=21.61, 
p<0.0001), further there was a significant interaction between genotype and age 
(F=9.710, p<0.0001). Post-hoc analysis was performed using Bonferroni-Holm 
corrected multiple comparisons which can be found in appendix 10, table A10. 
Post-hoc analysis revealed the 38 repeat flies had a significantly worse PI 
compared to all genotypes at day 5 (p<0.0001) and day 20 (p<0.0001). There 
were no significant differences for any other genotypes at these two time points. 
The performance of the 38 repeat flies and its respective controls at days 5 and 
20 geotaxis was assessed in the same assay as the other genotypes but is 
separated in the figure for clarity. Each data point represents the PI of ~15 flies. 
Mean with SEM is shown for each genotype (n=3-4). (E) A significant difference in 
the PI of genotypes tested at day 40 was observed using a one-way ANOVA 
(F=8.479, p<0.0001). Post-hoc analysis was performed using Bonferroni-Holm 
corrected multiple comparisons which can be found in appendix 10, table A10. 
Post-hoc analysis revealed the 32 and 64 repeat flies had a significantly worse PI 
at day 40 compared to other genotypes. Note that flies expressing 32 and 64 
repeats, but not 56 G4C2 repeats, show motor impairment by day 40 compared to 
controls. Each data point represents the PI of ~15 flies.  Mean with SEM is shown 





4.2 Open-field motor activity is severely impaired in the 
38 repeat flies 
 
As SING is a stimulus-dependent assay, flies were subjected to a stimulus-
independent open-field motor assay to establish whether behavioural impairment 
persisted in this condition. Open-field motor tracking for the 38 repeat flies and the 
respective controls (Elav/+ and Elav(G4C2)8B) were performed by Alan Stepto. Day 
20 aged flies expressing 38 G4C2 repeats performed significantly worse than age 
matched controls expressing 0 or 8B repeats (figure 4.2A and B).  The 38 repeat 



















Figure 4.2 | Reduced open field activity is seen in flies expressing 38 
repeats. (A) Open field behavioural activity at day 20; flies harbouring 38 repeats 
were less active than controls across the 30 minutes of tracking. (B) The 
percentage of the time each fly spent active was plotted. A one-way ANOVA 
revealed a significant effect of genotype on % activity of flies (F=30.54, 
p<0.0001). Post-hoc analysis was performed using Bonferroni-Holm corrected 
multiple comparisons which can be found in appendix 10, table A10. Post-hoc 
analysis revealed the 38 repeat flies had a significantly less % of time active 
compared to the controls (Elav/+ and Elav>(G4C2)8B, p<0.0001) which did not 
significantly differ from one another. The data points represent the mean % 






4.3 Open-field motor activity is impaired in flies 
expressing high levels of poly-GP and poly-GA at day 40 
 
Stimulus-independent open-field motor performance was also conducted on day 40 
flies expressing 8, 32 64 and 64 repeats in neurons. Analysis of the movement of 
these flies showed that the 32 and 64 G4C2 repeat lines, both of which produce high 
levels of poly-GP and poly-GA, have significantly decreased time spent active as 
compared to the DsRed2 (Elav C155>DsR2) and 8 repeat (ElavC155>(G4C2)8A) 
controls and the 56 repeat line – which produces low levels of poly-GP and poly-GA 
compared with the 32 and 64 flies (figure 4.3A and B). Rasta plots for each genotype 
in which each individual bar represents the movement of a single fly over 30 minutes 
(with black space indicating when the fly is active and white space representing 
inactivity) were generated (figure 4.3C). These plots show that at the individual fly 
level the 32 and 64 flies spend much more time inactive than the 56 line and the 8 
repeat and DsRed2 controls. Taken together with the SING data, when the high 
poly-GP and poly-GA 32 and 64 repeat lines are compared with the low poly-GP and 
poly-GA 56 repeat line - these results indicate that poly-GP and/or poly-GA when 
expressed at high enough levels cause an impairment in motor performance and by 
proxy neuronal dysfunction. Furthermore, as no motor impairment in the 56 repeat 
line is seen despite similar transgene expression levels (as measured by DsRed2 
protein levels) between the 32, 56 and 64 lines - this suggest the expression of G4C2 
RNA does not cause this toxicity consistent with other fly models studying G4C2 RNA 































Figure 4.3 | Reduced open field activity is seen in aged flies expressing high 
levels of poly-GP and poly-GA.  (A) Open field behavioural activity at day 20; 
flies harbouring 32 and 64 repeats were less active than controls across the 30 
minutes of tracking. (B) The percentage of the time each fly spent active was 
plotted. A one-way ANOVA revealed a significant effect of genotype on % activity 
of flies (F=10.77, p<0.0001). Post-hoc analysis was performed using Bonferroni-
Holm corrected multiple comparisons which can be found in appendix 10, table 
A10. Post-hoc analysis revealed flies expressing 32 and 64 repeats were 
significantly less active than control and flies expressing 8 or 56 repeats. Data 
points are mean % activity for individual flies with overall mean and SEM (n=18-
30). (C) Raster plots demonstrating activity of individual flies over a 30 minute 
period. White bars represent periods of inactivity whereas black bars represent 
bouts of activity. Flies with 32 or 64 G4C2 repeats that express high levels of poly-
GP and poly-GA were less active compared to controls and flies with 56 G4C2 




4.4 Age dependent neurodegeneration is enhanced in 
flies expressing 38 G4C2 repeats 
 
The most severe behavioural phenotypes correlate with the presence of poly-GR, 
whereas poly-GA and poly-GP correlate with mild later onset deficits in motor 
performance. This data indicates poly-GR is a highly potent driver of toxicity in 
Drosophila neurons whereas poly-GP and poly-GA are relatively well tolerated until 
later ages. To explore whether the severe motor impairment seen in the poly-GR 
expressing 38 repeat line was caused by underlying neuronal abnormalities age-
dependent neurodegenerative cell loss was investigated. The compound Drosophila 
external eye and underlying photoreceptor morphology is classical way to assess 
neurodegenerative phenotypes in flies (Hirth, 2010). The DsRed2 control, 8, 64 and 
38 repeat constructs were expressed in the largest class of photoreceptor cells in the 
Drosophila compound eye using Rh1-GAL4, the promotor for the major rhodopsin in 
the fly eye (Colley, 2012). The adult Drosophila compound eye consists of around 
800 ommatidia arranged hexagonally (Kumar, 2012). Each hexagonal ommatidium 
contains 8 photoreceptors (R1-R8), the R1-R6 photoreceptors sit on the outside of 
the hexagonal ommatidium where as R7 and R8 are in the centre - the R7 
photoreceptor sits atop R8, hence in any given focal point of view only R1-R7 
photoreceptors can be viewed (Kumar., 2012). The R1-R7 photoreceptors in an 
ommatidium can be easily seen under a bright field microscope and the number of 
photoreceptors in an individual ommatidia counted and scored (e.g. % of 
ommatidium with 7, 6, 5 etc. photoreceptors). In Drosophila photoreceptors are 
neurons which send axonal projections to structures within the fly brain (Mollereau et 
al., 2001) hence the the compound eye is commonly used to easily investigate 
neurodegenerative phenotypes (Hirth, 2010)  
Semithin retinal sections and quantification were performed in collaboration with Adel 
Boudi (Fanto Lab, KCL). As Drosophila photoreceptors are neurons, neuronal loss 
was measured by the number of remaining photoreceptor neurons in each 
ommatidium at 35 days of age. No observable differences in R1-R7 photoreceptor 
were seen between the controls and the G4C2 repeat containing lines after 14 days 
(data not shown). At 35 days of age some degeneration was seen in DsRed2 control 
and the 8B and 64 repeat lines (figure 4.5A). The representative distribution of 
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neurodegeneration in the fly retina was plotted as histogram for each genotype with 
number of photoreceptors per ommatidium (1-7) plotted on the X axis and % of total 
ommatidia with a specific number of photoreceptors on the Y axis (figure 4.5B). For 
the DsRed2, 8B and 64 fly lines the majority of ommatidium had between 4-6 
photoreceptors (figure 4.5B). However, for the 38 repeat line most of the 
ommatidium contained between 1-3 photoreceptors. Hence enhanced age-
dependent neurodegeneration of photoreceptors was seen only in the 38 repeat line 
when compared to the controls (Rh1>DsRed2 and Rh1>(G4C2)8B) and 64 G4C2 
repeat fly line. 100 ommatidium were counted per individual compound eye (N of 5-6 
eyes for each genotype). To calculate the total % degeneration seen in the 38 repeat 
line compared to the DsRed2, 8B and 64 lines the same 100 ommatidium were 
counted and the number of photoreceptors showing degeneration was scored. This 
was used to calculate the % of photoreceptors showing degeneration. This revealed 
35.2%, 31.1% and 31.4% of photoreceptors were degenerated in DsRed2, 8B and 
64 lines respectively. For the 38 repeat line 64.6% photoreceptors were degenerated 
again demonstrating enhanced age dependent cell loss because of 38 repeat 
expression (figure 4.5 C). In summary this data reveals expression of the 38 repeat 
construct causes a significant loss of neurons compared to controls at the same time 































Figure 4.5 | Advanced neuron loss is seen in flies expressing 38 G4C2 
repeats.  (A) Semi-thin retinal sections of 35 days old flies over-expressing 
DsRed2 (n=5), (G4C2)8B (n=6), (G4C2)38 (n=6) or (G4C2)64 (n=5), under the 
control of Rhodopsin1 promotor (Rh1>). Higher magnification of the retina 
structure is displayed on the top right inset. Scale bar, 20µm. (B) Histogram 
showing the distribution of photoreceptors in the ommatidia (displaying 1 to 7 
photoreceptors per ommatidium) the distribution is shifted toward less 
photoreceptors per ommatidium for the 38 repeat line compared to the controls 
and the 64 repeat line (p<0.0001). A chi-square test on contingency table was 
performed, reported in appendix 10, table A10 (C) Histogram indicating 
percentage photoreceptor loss. A one-way ANOVA was performed which 
demonstrated a significant effect of genotype on photoreceptor loss (F=23.50, 
p<0.0001). Post-hoc analysis was performed using Bonferroni-Holm corrected 
multiple comparisons which can be found in appendix 10, table A10. Post-hoc 
analysis revealed the 38 repeat expressing flies show enhanced age related 
neurodegeneration compared to controls and the 64 repeat line; ***p<0.0001 with 
mean and SEM shown (n=5-6). 
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4.5 Discussion   
4.5.1  Poly-GR expression correlates severe early onset motor 
impairment and neurodegeneration whereas poly-GP and poly-
GA correlate with late onset motor impairment 
 
This study has investigated a Drosophila model of C9ALS/FTD in which different 
lengths of uninterrupted G4C2 repeats were expressed in the 3’UTR of the disease-
unrelated DsRed2 transgene. Sense DPRs were detected in flies expressing ≥32 
repeats; the levels and combinations of which correlated with the linker sequence 5’ 
of the repeats. High levels of poly-GP and poly-GA were observed in the 32 and 64 
repeat lines, which have the same 5’ linker sequence, however much lower levels 
were seen in 38 and 56 repeat lines, both of which have their own unique 5’ linker 
sequence. Hence for G4C2 repeats of a different length, the same linker produced 
similar DPR expression profiles, in agreement with findings that the sequence 5'-
prime of repeats impacts RAN translation (Green et al., 2016). Of note, poly-GR was 
only detected in flies expressing 38 repeats.  
The differential expression profiles thus facilitated assessment of the toxicity of 
different combinations and levels of RAN translated DPRs. This revealed high levels 
of poly-GA and poly-GP accumulation correlated with late onset age-related 
phenotypes, whereas poly-GR accumulation – only detected in the 38 repeat line –  
correlated with a rapid onset and progression of disease as measured by deficits in 
motor performance and neurodegeneration. This phenotype was not caused by the 
enhanced G4C2 RNA levels or the increased expression of DsRed2 seen in the 38 
repeat line. This was confirmed by generating flies harbouring two copies of the 64 
repeat construct which have significantly higher levels of DsRed2 protein compared 
to both flies with a single copy of the 64 repeat construct and the 38 repeat line. Day 
5 climbing performance was not significantly different between the 2x 64 flies and the 
1 x 64 flies, however were both significantly impaired compared to the 38 repeat line 
(appendix 2; figure A2). Taken together, these data indicate poly-GR and/or a 
combination of poly-GP/GP/GR (and not DsRed2 expression or G4C2 RNA levels) 
causes the early-day 5 behavioural phenotype seen in the 38 G4C2 repeat line.  
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Poly-GP and poly-GA at high levels has no impact on the motor performance of flies 
at day 5 and 20; only when flies are aged to day 40 is a mild reduction in climbing 
performance and motor activity seen. This motor impatient is unlikely to be 
attributable to the effects of the G4C2 RNA as no motor deficits are seen at day 40 in 
the low poly-GP and poly-GA expressing 56 repeat flies; which not only have a 
similar repeat length to the 64 but also have the same transcript levels based on 
DsRed2 expression (appendix 2; figure A1). Therefore, this data suggests this late-
onset phenotype is caused by poly-GP and/or poly-GA.  The different behavioural 
phenotypes seen and their relation to the DPR expression profile and levels is 










Which of the DPR species is responsible for the severe early onset phenotype seen 
in the 38 repeat line? The individual DPRs can be studied in isolation of the 
potentially pathogenic G4C2 RNA and other DPRs. This is done by making 
recombinant DPR proteins and using the degeneracy in the genetic code. From 
these models there is a consistent finding that the arginine DPRs – poly-GR and 
poly-PR – are high neurotoxic (Freibaum and Taylor, 2017). Poly-GR and poly-PR 
are particularly detrimental when expressed in flies – with all studies using 
Drosophila to model their toxicity showing they cause severe neurodegeneration and 
a marked reduction in their survival and lifespan (Mizielinska et al., 2014; Wen et al., 
2014; Freibaum et al., 2015; Yang et al., 2015; Boeynaems et al., 2016; Lee et al., 
2016). RNA only models have shown the G4C2 RNA is not toxic to flies (Mizielinska 
 
Table 2 | The DPR expression profile in relation to the motor phenotypes 
observed. Constructs with the same linker sequence produce the same 
combination and levels of DPRs Severe early onset phenotypes correlate with 
poly-GR expression; high levels of poly-GP and poly-GA expression correlate with 
late onset motor phenotypes. 
 
 
*Expression level based on quantitative western blotting of DsRed2 protein levels; 




et al., 2014; Tran et al., 2015). The arginine rich DPRs have recently been shown to 
bind to proteins with low complexity domains (LCDs) – many of these proteins form 
parts of membraneless organelles such stress granules, nuclear speckles and 
nucleoli - impairing their assembly, dynamics, and function (Lee et al., 2016, Lin et al 
2016., Boeynaems et al., 2017). Other pathogenic mechanisms associated with poly-
GR and poly-PR toxicity include disrupted nucleocytoplasmic transport (Jovičić et al., 
2015; Boeynaems et al., 2016a), disrupted mitochondrial function (Lopez-Gonzalez 
et al., 2016), nucleolar stress (Tao et al., 2015) and a blocking of global protein 
translation (Kanekura et al., 2016).  
It is also possible a combination of poly-GP/GA/GR cause toxicity in the 38 repeat 
flies. Mori et al. (2016) found TDP-43 mislocalisation was enhanced in cells 
expressing both poly-GA and poly-GR. Further in the human brain there is a poor 
correlation between individual DPRs and RNA foci with regional neurodegeneration. 
Vatsavayai et al. (2016) suggest a combination of the different features in a neuron 
may be toxic; in support of this the authors found in two C9FTD cases that 27% of 
medial pulvinar thalamus (mPULV) neurons contained a combination of C9 
pathologies and was one of the most degenerated regions in both cases. However, it 
has also been shown poly-GA and poly-GR when co-expressed is neuroprotective in 
flies; as poly-GA sequesters poly-GR into its inclusions thereby mitigating its toxicity 
(Yang et al., 2015). Further the present study has shown poly-GP and poly-GA co-
expression at higher levels together produces a late-onset phenotype. Hence based 
on the above it is most probable that the severe early behavioural phenotype and 
neurodegeneration seen in the 38 repeat line is caused by the poly-GR peptide. 
A late-onset day 40 phenotype is seen in the 32 and 64 repeat flies expressing high 
levels of poly-GP and poly-GA. This phenotype is likely caused by the high levels of 
poly-GP and poly-GA seen in these two lines, as the 56 repeat line which produces 
much lower levels of poly-GP and poly-GA but shows no phenotype at day 40. This 
is despite the 56 line having a repeat length like the 64 and similar transcript levels 
based on DsRed2 expression. This therefore indicates the G4C2 RNA is not behind 
this late onset phenotype. Hence, this data suggests poly-GP and poly-GA cause a 
late disease onset, and the expression levels of these DPRs appears to be an 
important factor in the timing of this. Further the expression pattern and levels of 
poly-GP in the 32 and 64 repeat flies is unchanged at days 5, 20 and 40 (appendix 4; 
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figure A4 A and A4 B). The finding that levels of poly-GP is still the same at different 
ages suggests poly-GR is produced at the later day 40 timepoint at which the motor 
impairment is observed. This model is unable to distinguish whether the combination 
of both DPRs or just one of poly-GP and poly-GA is the toxic species behind the late 
onset phenotype. Zu et al. (2013) using a G4C2 construct to overexpress poly-GP 
(via an insertion of an ATG in the poly-GP frame) did find increased cell death. 
However, in protein only models studying poly-GP toxicity (May et al., 2014., Wen et 
al., 2014., Freibaum et al., 2015., Tao et al., 2015, Yamakawa et al., 2015., Lee et 
al., 2016; Lee et al., 2017) only one of these studies have identified a very mild toxic 
role for poly-GP through impairments of the ubiquitin-proteasome system 
(Yamakawa et al., 2015). Poly-GP alternative codon Drosophila have been 
generated (Freibaum et al., 2015, Lee et al., 2016) and although the peptide did not 
cause any obvious external eye degeneration, these flies were not aged. Poly-GP 
could exert some toxicity after accumulating overtime. Indeed, no studies have 
investigated whether exposure to poly-GP alone causes any age-related deficits in 
motor performance or reduced life-span. In addition, cerebellar poly-GP has been 
associated with cognitive deficits in expansion carriers (Gendron et al., 2015).  In the 
56 repeat flies poly-GP was nuclear, forming paranucleolar accumulations as has 
been previously reported by in human C9 frontal cortex (Schludi et a., 2015). In the 
higher expressing 64 repeat flies poly-GP showed a predominantly diffuse cytosolic 
localisation. Diffuse cytosolic poly-GP may have a role in toxicity; whereas nuclear 
poly-GP appears to not confer toxicity. The precise subcellular localisation of the 
DPRs may alter their toxicity, for example it has been shown rerouting poly-GA 
aggregates from the cytoplasm to the nucleus prevents cytosolic TDP-43 
accumulation (although the toxicity was not assessed) and the nuclear localisation of 
poly-GR and poly-PR is necessary for their toxicity (Rudich et al., 2017).  
Like poly-GP, when poly-GA is expressed in isolation in flies no early-onset 
neurodegeneration is seen (Freibaum et al., 2015; Lee et al., 2016). Poly-GA on the 
other hand has been shown to be at least mildly toxic in several different model 
systems, although much less toxic than the arginine DPRs when directly compared 
in the same model system (Freibaum and Taylor., 2017). Protein only poly-GA 
murine models have shown the peptide causes age related impairments in cognition 
and motor performance in addition to inflammation and neurodegeneration (Zhang et 
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al., 2016; Schludi et al., 2017). Whilst no poly-GA external eye degeneration is 
observed, such flies do show a reduced lifespan compared with controls when aged 
(Mizielinska et al., 2014). Although other fly studies have reported poly-GA is 
neuroprotective (Yang et al., 2015). Poly-GA in the 64 repeat flies formed 
paranucleolar accumulations reminiscent of the nuclear inclusions reported in C9 
human frontal cortices (Schludi et al., 2015); further paranucleolar poly-GA 
aggregated with heterochromatin and H3K9me2 (a marker of transcriptional 
repression) in the human frontal cortex, suggesting a link between poly-GA, gene 
transcription and transcriptional silencing (Schludi et al., 2015).   
4.5.2  Conclusion 
 
In summary the different DPR profile and levels of expression observed in the G4C2 
flies used in this study provided an opportunity to compare the behavioural toxicity 
caused by different combinations and levels of DPRs RAN translated from the G4C2 
expansion. Severe early onset deficits in climbing performance and motor activity 
were only seen in the 38 repeat line - the only line in which poly-GR could be 
detected. Late onset behavioural phenotypes were seen in aged 32 and 64 repeat 
flies expressing high levels of poly-GP and poly-GA compared to controls and 
importantly the 56 repeat line which produced significantly lower levels of both poly-
GP and poly-GA. The 56 repeat flies had similar transgene levels to the 32 and 64 
repeat flies suggesting G4C2 RNA is not contributing to the age related phenotype 
seen in these flies. A better understanding of the localisation and behaviour of poly-
GP and poly-GA in aged flies may potentially provide insight into the age-related 
motor impairment seen in the 32 and 64 repeat flies.  Hence severe early 
behavioural phenotypes correlated with the presence of poly-GR whereas poly-GP 
and/or poly-GA cause late-onset behavioural impairment dependent on their 




Chapter 5: Generation of alternative codon 
DPR only constructs and characterisation 
of the toxicity and localisation of 
alternative codon ATG derived poly-GR 
and poly-GA 
The expression of poly-GR correlates with an early-onset severe motor impairment 
and neurodegeneration in flies; whereas high levels of poly-GP and poly-GA 
correlate with an age-dependent decline in motor performance. To study DPR 
toxicity further alternative codon constructs, designed to produce a DPR (e.g. poly-
GR) from non-G4C2 codons and not from RAN translation were generated. Such 
constructs allow individual DPRs to be investigated independently of each other and 
allow DPR toxicity to be studied in isolation of G4C2 RNA toxicity.   Alternative codon 
constructs producing different lengths of pure DPR (8 and 64) were designed for 
poly-GA, poly-GR, poly-PR and poly-PA. A poly-GP alternative codon construct was 
unable to be synthesised due to the high GC content of the codons required despite 
avoiding using the G4C2 sequence. The previous chapters focused on RAN 
translation and toxicity of the sense DPRs as the anti-sense DPRs were either 
undetectable or not produced in the DsRed2-G4C2 repeat flies studied in this work. 
Hence characterisation and study of the DPRs focused on the poly-GA and poly-GR 










5.1 Alternative codon constructs used to produce DPRs 
from non G4C2 RNA 
 
Alternative codon constructs producing different lengths of pure DPR protein were 
designed for all DPRs except poly-GP due to failures in generating and cloning a 
sequence with such a high GC content (despite the use of non G4C2 codons) (figure 
5.1). The constructs included an insect-specific Kozak sequence (xACAAA) 
(Schleich et al., 2014) for efficient translation as well as 5’ HA and 3’ Myc tags for 
detection in vivo. Care was taken to avoid the presence of any G4C2 repeats in the 
design of the constructs or any repetitive stretches of the same codons. These 
constructs have a traditional ATG codon hence the individual DPRs are translated 
from normal canonical mechanisms rather than RAN translation. Both short length 8 
DPR repeat and longer length 64 DPR repeats constructs were generated (figure 
5.1). These protein only constructs were sent to BestGene, USA for transgenisis. All 
constructs were inserted into the genome at a common insertion site via φC31-
mediated site-specific integration into flies harbouring an attP insertion at site attp40 
on the second chromosome (y1 w67c23; P{CaryP}attP40). Genomic PCR confirmation 
of insertion onto the attp40 landing site was confirmed by BestGene, USA. As the 
previous chapters investigating DPR toxicity in the DsRed2-G4C2 repeat flies focused 
on the sense DPRs rather than the anti-sense- the reminder of this chapter focuses 
on the characterisation of the poly-GA and poly-GR alternative codon constructs. Full 



































Figure 5.1 | Schematic of the alternative codon, non G4C2-derived DPR 
constructs used in this study. Schematic depiction of non-G4C2 alternative 
codon constructs designed to produce different lengths of pure DPR (8 DPR 
repeats and 64 DPR repeats) for poly-GA, poly-GR, poly-PR and poly-PA, flanked 
by 5’ Myc tag and 3’ HA tag. 
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5.2 Poly-GR cause severe neurodegeneration when 
expressed in the Drosophila eye 
 
The arginine-rich DPRs poly-GR and poly-PR have been demonstrated to be highly 
toxic in several studies; particularly in Drosophila models (Mizielinska et al., 2014; 
Wen et al., 2014; Yang et al., 2015; Freibaum et al., 2015; Boeynaems et al., 2015; 
Lee et al., 2016). To assess the toxicity of the poly-GR64 alternative codon DPR-
only constructs designed in this study, the poly-GR8, poly-GR64 and poly-GA64 
constructs were expressed in the fly eye using the GMR-GAL4 driver (figure 5.2). As 
reported previously in the literature, the poly-GR64 constructs show a severe 
degenerative phenotype in eye (figure 5.2). No change in external eye morphology is 
seen in flies expressing poly-GR8 or poly-GA64 (figure 5.2), These data replicates 
what has been shown in several Drosophila studies of DPR toxicity, that poly-GR 
toxicity is length dependent and poly-GA does not cause external degeneration when 
expressed in the fly eye (Mizielinska et al., 2014; Wen et al., 2014; Yang et al., 2015; 











Figure 5.2 |  The poly-GR64 construct when expressed in the Drosophila 
compound eye causes severe degeneration. The poly-GR8, poly-GA64 and 
poly-GR64 constructs were expressed in the compound eye of the fly using the 
GMR-GAL4 driver. Poly-GR8 and poly-GA64 expression did not alter the external 
morphology of the fly eye. Poly-GR64 on the other hand caused a severe 
degeneration of the eye. 
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5.3 Poly-GA and poly-GR show different subcellular 
localisations  
 
In vitro models of epitope and GFP tagged DPRs produced from protein only 
constructs have shown different and distinct subcellular localisation and aggregation 
properties of the 5 DPRs (May et al., 2014; Zhang et al., 2014; Wen et al., 2014 
Yamakawa et al., 2015; Tao et al., 2015). To confirm the successful expression of 
the individual DPRs from the poly-GA64 and poly-GR64 constructs the UAS-DPR 
transgenes were expressed in the larval eye disc using the GMR-GAL4 driver (figure 
5.3). L3 larval eye discs were dissected and stained with HA antibody. Poly-GA64 
(GMR>GA64) localisation in the photoreceptor neurons of the L3 larval eye disc is 
predominantly diffusely nuclear and cytoplasmic, staining is seen both in the nucleus 
of the ommatidium and the surrounding cytosol, although small compact spherical 
inclusions are also observed. Poly-GR64 (GMR>GR64) in the L3 larval eye disic is 
exclusively cytoplasmic in photoreceptor neurons, some perinuclear staining is also 
seen with the poly-GR surrounding the nuclei of individual photoreceptors of a single 
ommaditium. Although these DPRs form inclusions in the patient brain (Schludi et 
al., 2015, Mackenzie 2015) only poly-GA formed aggregates at this early time point 
consistent with previous studies and its compact aggregate structure (May et al., 

























Figure 5.3 | The DPRs show diffuse subcellular localisations with only poly-
GA forming inclusions in L3 larval eye discs. Confocal images of L3 larval eye 
discs immunolabelled for anti-HA which reveals DPR accumulation. Poly-GA is 
diffusely nuclear and cytoplasmic although forms compact inclusions at this early 
time point (white arrow); Poly-GR at this stage is predominantly diffusely 






5.4 Poly-GR localisation changes from cytoplasmic to 
nuclear over time 
 
No cytoplasmic or nuclear aggregates of poly-GR were seen in the L3 larval eye 
disc. Previous studies have shown the arginine containing DPRs poly-GR and poly-
PR localise to the nucleus and form nuclear inclusions in human post mortem tissue 
in both in vivo and in vitro models of DPR toxicity (May et al., 2014; Wen et al., 2014; 
Boeynaems et al., 2016). Protein translation occurs in the cytoplasm hence poly-GR 
and poly-PR must actively translocate into the nucleus. To study the dynamics of the 
nuclear aggregation of poly-GR in Drosophila, neuronal tissue was probed at two 
different time points. Poly-GR64 localisation was studied in Drosophila 
photoreceptors using the GMR-GAL4 driver. Eye discs were dissected at two stages 
– the L3 larval stage and ~48 hours later at the pupal stage (figure 5.4A).  Poly-GR 
initially shows a diffuse cytoplasmic distribution in L3 larval eye discs, however 
rapidly within 48 hours, at the pupal stage, poly-GR64 localisation dramatically 
changes, where the protein is found predominantly in the nucleus and also 
perinuclear (figure 5.4A). Furthermore, nuclear poly-GR64 formed distinct nuclear 
inclusions (figure 5.4A) Hence the poly-GR64 peptide rapidly translocated from the 
cytoplasm into the nucleus where it aggregates.  
To circumvent the pupal lethality of the poly-GR64 construct using the pan neuronal 
driver ElavC155 driver (data not shown) the EB1-GAL4 driver was utilised to study 
poly-GR localisation in adult brain. EB1-GAL4 specifically targets the Drosophila 
upper motor neurons and becomes active in the latter pupal stages of development 
and stays activated during the lifespan of the fly in the ellipsoid body ring upper 
motor neurons (Diaper et al., 2013a) (figure 5.4B). Previous work overexpressing the 
Drosophila homologue of TDP-43, TBPH, has shown the loss of this small population 
of neurons does not alter the lifespan of flies unlike pan neuronal expression of 
TBPH, therefore this driver is ideal to study poly-GR at a cellular resolution (Diaper 
et al., 2013a). The EB1-GAL4 driver is co-expressed with a membrane-bound form 
of GFP (UAS-mCD8::GFP) which allows axons and synaptic terminals to be seen. 
EB1-GAL4 driven poly-GR64 and control brains were dissected and stained with 
anti-HA. EB1 neurons were identified by membrane bound GFP auto-fluorescence. 
Adult brains were dissected at two time points – day 2 and day 18 (figure 5.4C). Day 
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18 was chosen as the end time-point as flies expressing poly-GR64 in EB1 neurons 
displayed no obvious motor impairment at this age, hence it was decided to dissect 
the flies rather than age them further. No HA signal was detected in EB1 neurons in 
the control (EB1>mCD8::GFP) flies (figure 5.4C). For EB1 driven poly-GR64 as was 
the case for the L3 eye discs, poly-GR at day 2 is diffuse and cytoplasmic however in 
aged day 18 fly brains the protein is perinuclear and localised to the nucleus where 
inclusions are observed (figure 5.4C). EB1-GAL4 dissections were performed by 















































Figure 5.4 | Poly-GR accumulation changes over time; from diffusely 
cytoplasmic to the formation of predominantly nuclear aggregates. (A) 
Confocal images of L3 and pupal eye discs of GMR>GR64 flies immunolabeled 
for HA and DAPI, indicating poly-GR distribution. Localisation of HA/poly-GR 
initially reveals diffuse cytoplasmic distribution and within 48 hours (L3 to pupal 
transition) also shows nuclear inclusions. (B) Confocal image of EB1>mCD8::GFP 
adult Drosophila brain immunolabeled with anti-Brp (magenta) and anti-GFP 
(green) highlighting Gal4/UAS activity targeted to ellipsoid body circuitry (from 
Zoe Ludlow PhD thesis; KCL, Hirth lab). (C) Confocal images of ellipsoid body 
neurons at day 2 and day 18 expressing UAS-mCD8::GFP either alone or in 
conjunction with UAS-GR64. Immunolabeling for HA reveals diffuse cytoplasmic 
and perinuclear distribution of poly-GR by day 2 and by day 18 also identifies 







5.5 Poly-GR nuclear inclusions do not co-localise with 
the nucleolar marker fibrillarin 
 
The preceding section has shown poly-GR rapidly forms nuclear inclusions in vivo. 
Previous research with both poly-GR and poly-PR alternative codon constructs in 
cellular models has demonstrated these nuclear aggregates frequently co-localise 
with the nucleolus (Schludi et al., 2015; Tao et al., 2016; Callister et al., 2016). To 
determine whether the nuclear inclusions of poly-GR64 co-localised with the 
nucleolus Drosophila L3 salivary glands and brains expressing poly-GR64 were co-
stained with the nucleolar marker fibrillarin, a component of a nucleolar small nuclear 
ribonucleoprotein (figure 5.5A). Alternative codon poly-GR64 was expressed in the 
salivary gland cells of larvae using the FKH-GAL4 driver. Salivary gland cells stained 
with HA did not detect any signal for the short repeat poly-GR8 construct 
(FKH>GR8). Poly-GA64 formed both cytoplasmic and nuclear aggregates; poly-
GA64 nuclear inclusions did not co-localise with fibrillarin (figure 5.5A). Poly-GR64 
formed nuclear aggregates, however these did not co-localise with the nucleolus 
(figure 5.5A). No co-localization was seen between nuclear poly-GR64 inclusions 
and nucleolar fibrillarin in salivary gland cells (figure 5,5A).  
To confirm the findings in the salivary gland cells the poly-GR64 transgene was 
expressed in neurons using the pan neuronal ElavC155 driver (figure 5.5B). L3 larval 
brains were dissected and stained with anti-HA and anti-fibrillarin. Poly-GR64 
nuclear inclusions in the ventral nerve cord also did not co-localise with fibrillarin - 
although were adjacent to the nucleolus (figure 5.5B). Interestingly these findings 
mirror what is seem in patient tissue where 78% of nuclear poly-GR intranuclear 
inclusions are attached to the nucleoli - but never co-localising with the nucleolus 
(Schludi et al., 2015). Furthermore, double immunostaining of p62 and nucleolin 
revealed no colocalization (Schludi et al., 2015). Similar reports of a ‘nucleolar 
studding’ pattern for DPRs around but not directly within the nucleolus was also 
reported by Vatsavayai et al. (2016). It remains unclear how these inclusions interact 
with the nucleolar structure and whether this interaction leads to nucleolar 
dysfunction. Hence the intranuclear inclusions seen in the poly-GR64 resembles 














Figure 5.5 | Poly-GR forms nuclear inclusions that aggregate adjacent to the 
nucleolus. (A & B) Confocal images of L3 larval eye discs and larval ventral 
nerve cord immunolabeled for anti-HA and the nucleolar marker fibrillarin. 
Staining shows poly-GR nuclear inclusions that are adjacent to, but do not co-
localise with the nucleolus. Scale bars, 10µm (A), 5µm (B). . 
 



















5.6 Poly-GA but not poly-GR aggregates are p62 
positive  
 
The DPR inclusions in the patient brain are negative for TDP-43 but positive for p62 
and ubiquitin (Mackenzie et al., 2014). p62 (or Sequestome-1) targets specific 
cargoes for autophagy (Rusten and Stenmark, 2010). Only overexpressed poly-GA 
from alternative codon constructs co-localises with p62 - none of the other DPRs, 
including nuclear poly-GR and poly-PR, formed p62 positive inclusions (May et al., 
2014; Zhang et al., 2014; Schludi et al., 2015; Callister et al., 2016). Drosophila have 
one homologue of p62, Ref(2)P (Nezis et al,, 2008). Ref(2)P localises to age-related 
proteinaceous aggregates and aggregations induced by proteasome and autophagy 
inhibition and is necessary for the formation of aggregates in the fly brain (Nezis et 
al,, 2008).  
Alternative codon poly-GR8, poly-GA64 and poly-GR64 was expressed in the 
salivary gland cells of larvae using the FKH-GAL4 driver. The 288-G4C2 RNA only 
construct which does not produce DPRs was also included as DPR negative control. 
Salivary gland cells stained with an antibody specific for Ref(2)P revealed the protein 
to be predominantly cytoplasmic with a very weak nuclear stain in controls (FKH/+, 
FKH>GR8) (figure 5.6). In salivary gland cells expressing the 288-G4C2 RNA only 
construct (FKH>288 RO) Ref(2)P resembled the diffuse cytosolic staining seen in 
controls (figure 5.6). However, for poly-GA64 expressing salivary glands virtually all 
of the diffuse cytoplasmic Ref(2)P was gone – the protein was sequestered into poly-
GA64 inclusions (figure 5.6). Interestingly for poly-GA64 inclusions with halo-like 
structures, Ref(2)P was observed in the centre of these accumulations – similar 
observations have been seen in both cellular models and the post-mortem brain for 
poly-GA and p62 (Schludi et al., 2015). Nuclear poly-GR64 inclusions on the other 
hand were not Ref(2)P positive, with the protein keeping its predominantly 
cytoplasmic localisation and weak nuclear stain (figure 5.6). This is unlike what is 
seen in patient tissue where poly-GR p62-negative inclusions only occur extremely 
rarely in the cytoplasm and nucleus; the vast majority of cytosolic and nuclear poly-
GR inclusions are p62 positive (Schludi et al., 2015). Hence, these findings indicate 
that like current cellular protein only DPR models, in vivo poly-GR models do not fully 






















Figure 5.6 | Poly-GA, but not poly-GR inclusions are Ref(2)P positive. 
Salivary gland cells expressing poly-GA64, poly-GR64 and controls were stained 
with Ref(2)P, the Drosophila homologue of p62. Ref(2)P displayed a 
predominantly diffuse cytoplasmic localisation in controls (FKH/+ and FKH>GR8) 
and the G4C2 RNA only line (FKH>288 RO). However this diffuse cytosolic 
Ref(2)P labelling is not present following poly-GA64 expression (FKH>GA64), 
with the protein being sequestered into poly-GA inclusions as in the human brain. 




5.7.1  Poly-GR when expressed in the Drosophila eye causes 
severe neurodegeneration  
 
Poly-GR expression the fly eye caused severe external compound eye degeneration. 
This data recapitulates the findings from previous fly models studying DPR toxicity 
demonstrating the arginine DPRs are the main drivers of toxicity in C9ALS/FTD 
(Mizielinska et al., 2014; Wen et al., 2014; Yang et al., 2015; Freibaum et al., 2015 
Boeynaems et al., 2015; Lee et al., 2016). Further this also strongly suggests poly-
GR is most likely responsible for the enhanced motor phenotype and retinal 
degeneration seen in the 38 G4C2 repeat line characterised in this study.  
5.7.2  Poly-GR localisation changes from cytoplasmic to 
nuclear over time but inclusions do not co-localise with the 
nucleolus  
 
Poly-GR64 stained for at early time points (the L3 larval eye disc and day 2 adult 
EB1 neurons) show a diffuse cytoplasmic labelling; however, as flies are aged the 
protein translocated into the nucleus where it formed inclusions. This transition into 
the nucleus is likely down to the highly negative charge of the peptide (Freibaum and 
Taylor., 2017) compared to the positively charged histones that package and order 
DNA into nucleosomes. A nuclear accumulation of the arginine DPRs has been 
observed cellular models of DPR toxicity (Zhang et al., 2014; May et al., 2014; Wen 
et al., 2014; Tao et al., 2015; Yamakawa et al., 2015; Callister et al., 2016; Khosravi 
et al., 2017; Lee et al., 2017). Poly-GR could be actively transported into the nucleus 
by mimicking a nuclear localisation signal (NLS). A non-classical group of NLSs that 
are arginine–glycine-rich, known as RG-NLSs, have been identified in yeast proteins 
including yeast hnRNP A1 (Cautain et al., 2014). Poly-GR has already been shown 
to interact with the LCD domain of hnRNAP A1 altering its biophysical properties 
(Lee et al., 2016).  These RG-NLSs have similar characteristics to the non-classical 
PY-NLS that consists of an N-terminal hydrophobic motif, a central arginine and the 
C-terminal PY sequence. Proteins with the PY-NLS motif are imported into the 
nucleus via the transportin-1 receptor (Cautain et al., 2015). Transportin-1 is a strong 
enhancer and suppressor of poly-PR neurodegeneration in a Drosophila and yeast 
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screen (Jovičić et al., 2015; Boeynaems et al., 2016a). Boeynaems et al. (2017) 
performed computational docking simulations predicting that poly-PR interacts with 
transportin-1 suggesting the peptide could potentially compete with transportin-1 for 
NLS containing protein cargoes. In support of this the RNA-binding protein Elav, a 
known binding partner of transportin-1, accumulated in the cytoplasm of flies 
expressing poly-PR.  Hence like poly-PR, poly-GR, based on its glycine and arginine 
residues, might also bind to transportin-1 and be transported into the nucleus where 
it accumulates and forms inclusions. It is interesting to note however that FUS is a 
known transportin-1 cargo; yet FUS pathology is not seen in C9ALS/FTD. 
Furthermore, both poly-GR and poly-PR interact with numerous nuclear proteins by 
binding to their LCDs; including RNA binding proteins, nucleolar proteins, nuclear 
speckle proteins, cajal body proteins (Lee et al., 2016). Additionally, poly-PR has 
been shown to bind to the FG-repeats within the central channel of the NPC (Shi et 
al., 2017).  
Nuclear poly-GR64 inclusions were found to be adjacent to the nucleolus in 
Drosophila L3 larval salivary glands and neurons; although did not directly co-
localise with the nucleolus as has been reported in cellular models (Zhang et al., 
2014; May et al., 2014; Wen et al., 2014; Tao et al., 2015; Schludi et al., 2015; 
Callister et al., 2016). Several studies have reported nucleolar poly-GR cause’s 
nucleolar enlargement and impaired ribosome biogenesis by binding to the LCD of 
nucleolar proteins perturbing phase transitions in the liquid compartment of this 
membraneless organelle (Kwon et al., 2014; Tao et al, 2015; Callister et al., 2016; 
Lee et al., 2016). In the human brain however, poly-GR inclusions do not localise to 
the nucleolus like in cellular models; rather they are para-nucleolar (Schludi et al., 
2015). Schludi et al. (2015) observed no co-localisation between poly-GR and the 
nucleolar marker fibrillarin in frontal cortex neurons; leading the authors to question 
the role of nucleolar stress in pathogenesis as unlike cellular models in post-mortem 
tissue and the structure and size of the nucleolus is unaffected (Schludi et al., 2015). 
A more recent study by Mizielinska et al. (2017) investigating nucleolar dysfunction 
in C9FTD frontal cortex revealed nucleolar volume in neurons is reduced in patient 
brains compared to controls. Intriguingly although nucleolar volume was on average 
lower in the C9FTD frontal cortex – nucleolar volume was increased in neurons with 
cytoplasmic poly-GR inclusions. Increased nucleolar volume was also seen in vivo in 
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a Drosophila poly-GR protein only model, in this model (as in the poly-GR64 flies 
used in this study and what was reported by Schludi et al. (2015) previously in 
patient brains) poly-GR inclusions did not co-localise with fibrillarin but were adjacent 
to it. Mizielinska et al. (2017) demonstrate poly-GR does not need to directly 
aggregate with nucleolar proteins to cause nucleolar dysfunction; showing 
cytoplasmic poly-GR causes nucleolar dysfunction in patient brains and in vivo. To 
explain this Mizielinska et al. (2017) propose that in these neurons with a high 
enough poly-GR load that cytoplasmic or nuclear inclusions are present - that 
soluble poly-GR, undetectable by immunofluorescence is interacting with nucleolar 
proteins and disrupting nucleolar functions. Hence despite the fact poly-GR in patient 
brains and the poly-GR64 flies used in this study does not co-localise with nucleolus, 
the peptide still can cause nucleolar dysfunction.  
5.7.3  Poly-GA expression has no obvious effect on external 
eye morphology but forms cytoplasmic and nuclear inclusions 
that are p62 positive  
 
No changes in external eye morphology were observed for poly-GA. This is 
consistent with previous Drosophila models in which poly-GA repeats have no toxic 
effect when expressed in the eyes of young flies (Mizielinska et al., 2014; Wen et al., 
2014; Yang et al., 2015; Freibaum et al., 2016). However it has been shown 
previously that poly-GA causes a reduction in lifespan from day 50 onwards when 
expressed pan-neuronally in Drosophila (Mizielinska et al., 2014). Furthermore poly-
GA/poly-GP correlated with a late-onset motor impairment in the 32 and 64 G4C2 
repeat lines used in this study. This suggests either poly-GA induced neuronal 
toxicity slowly accumulates over time before any overt behavioural toxicity is seen or 
the ageing nervous system is more vulnerable to poly-GA inclusions. Hence insight 
into poly-GA toxicity and evidence for poly-GA induced neurodegeneration in flies 
will come from a characterisation of neuronal poly-GA localisation and behaviour in 
flies expressing poly-GA at ages in which phenotypes are seen.  
Poly-GA formed both cytoplasmic and nuclear inclusions which were Ref(2)P 
positive - Ref(2)P is the Drosophila  homologue of p62. In the human brain DPR 
inclusions are p62 positive, hence the poly-GA inclusions produced from the poly-
GA64 constructs resemble what is seen in the human post mortem brain (Schludi et 
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al., 2015). Nezis et al. (2008) demonstrated previously that Ref(2)P localises to age-
induced protein aggregates in the fly brain and aggregates induced by deficits in 
autophagy or the proteasome. This suggests poly-GA could cause defective 
autophagy or proteasome dysfunction and such processes may contribute to the 
reduced lifespan observed in poly-GA flies by Mizielinska et al. (2014) and the late 
onset motor impairment in the 32 and 64 G4C2 repeat flies studied in this thesis. 
5.7.4  Conclusion 
 
In summary this chapter has characterised alternative codon ATG driven poly-GA 
and poly-GR expression in a Drosophila model generated during this project. Poly-
GA forms cytoplasmic and nuclear Ref(2)P positive inclusions; despite this poly-GA 
did not cause external degeneration of the Drosophila eye replicating what has been 
shown in several Drosophila studies of DPR toxicity (Mizielinska et al., 2014; Wen et 
al., 2014; Yang et al., 2015; Freibaum et al., 2015). Poly-GR on the other hand 
formed nuclear inclusions adjacent to the nucleolus and was highly toxic; indicating 
poly-GR is the toxic species causing the severe early motor impairment in the 38 




Chapter 6: TBPH localisation in flies 
expressing either poly-GA, poly-GR or 
G4C2 RNA only 
In addition to DPR and RNA pathology, patients harbouring the G4C2 expansion are 
also characterised by mislocalisation and neuronal cytoplasmic inclusions of the 
RNA binding protein TDP-43 (Al-Sarraj et al., 2011). TDP-43 pathology, unlike DPR 
pathology, shows strong correlations with both clinical features and 
neurodegeneration (Mackenzie et al., 2014; Gomez-Deza et al., 2015,;Mackenzie et 
al., 2015). However, how TDP-43 becomes pathogenic in expansion carriers is 
currently unknown. Murine models show RNA foci and RAN dipeptides develop 
early, but are not sufficient to drive neurodegeneration in the absence of TDP-43 
pathology (O’Rourke et al., 2015; Peters et al., 2015), however neurodegeneration is 
seen murine models that present TDP-43 pathology (Chew et al., 2015; Liu et al., 
2016c). Interestingly in one of these models TDP-43 aggregation occurred at end-
stage, after the formation of both DPRs and RNA foci (Liu et al., 2016c). Furthermore 
post-mortem analysis on patients with the C9ORF72 expansion who have died early 
of the disease show abundant DPR pathology only; further indicating DPR pathology 
precedes that of TDP-43 (Proudfoot et al., 2014; Baborie et al., 2015; Vatsavayai et 
al., 2016). An amyloid cascade hypothesis for C9 mediated neurodegeneration has 
been proposed in which specific stressors causes TDP-43 aggregation and 
cytoplasmic mislocalisation (Edbauer and Haass, 2016). The above data suggests 
DPRs and/or RNA foci act as such stressors, causing TDP-43 dysfunction leading to 









6.1 Cytoplasmic TBPH accumulation is a consequence 
of poly-GR expression 
 
The Drosophila homologue of TDP-43 is known as TAR DNA-binding protein-43 
homolog (TBPH). TBPH shares all the major protein domains found in human TDP-
43 (Diaper et al., 2013a) and has been shown to have conserved functions in 
relation to RNA processing (Romano et al., 2014). Both neuronal overexpression 
and knockdown of TBPH is toxic to flies, causing motor impairment and age-related 
neurodegeneration (Diaper et al., 2013a). TBPH localisation was investigated in the 
salivary gland cells of controls; DPR only fly lines and the RNA only 288 G4C2 repeat 
fly line generated by Mizielinska et al. (2014). 
The FKH-GAL4 driver was used to express either poly-GR64 or poly-GA64 in 
salivary gland cells. This driver was chosen as the salivary gland cells have a large 
nuclei and cytoplasm that can easily be distinguished. In control salivary gland cells 
(FKH/+ and FKH>GR8) TBPH labelling was predominantly nuclear, a weak 
cytoplasmic TBPH signal was also seen as has been previously reported in 
Drosophila neurons (Diaper et al., 2013a). TBPH localisation was indistinguishable 
from the controls for G4C2-288 repeat RNA only expressing salivary gland cells, 
remaining predominantly nuclear. TBPH was also mainly nuclear in salivary gland 
cells expressing poly-GA, however cytosolic TBPH co-localised with poly-GA64 
inclusions in the cytoplasm of salivary gland cells. Poly-GR64 expression in salivary 
gland cells caused a dramatic increase in cytoplasmic TBPH – without a noticeable 
nuclear loss. A cytoplasmic accumulation of TBPH without noticeable nuclear loss 
was also seen in when poly-GR64 was expressed in photoreceptor neurons but not 





















Figure 6.1 | DPR but not G4C2 RNA expression disrupts the localisation of 
Drosophila TDP-43. Salivary glands immunolabeled with TBPH, the Drosophila 
homologue of TDP-43. In controls (FKH/+ and FKH>GR8) TBPH localisation is 
mainly nuclear. Compared to controls, poly-GA64 (FKH>GA64) expression 
causes cytoplasmic TBPH aggregates that co-localise with poly-GA inclusions 
(arrowheads). Poly-GR64 (FKH>GR64) expression leads to diffuse cytoplasmic 
mislocalisation of TBPH (asterisks) in all cases examined. Note, poly-GR64 
expression also causes enlarged nuclei compared to controls. The expression of 
G4C2 RNA has no impact of TPBH localisation (FKH>288 RO). A minimum of 5 
salivary glands were scanned per genotype; in each salivary gland 30 cells were 
investigated. Scale bars, 20µm. 
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6.2 Cytoplasmic TBPH enhances G4C2 toxicity 
 
As nuclear depletion and cytoplasmic accumulation of TDP-43 is a characteristic 
feature of patients harbouring repeat expansions in C9ORF72, it was hypothesised 
that the cytoplasmic accumulation of TBPH may contribute to the early-onset 
phenotype in the 38 G4C2 repeat fly line that produces poly-GR. To investigate the 
impact cytoplasmic TBPH has on toxicity, a TBPH construct with a mutated NLS 
(TBPHΔNLS) under control of the endogenous TBPH promoter was used (figure 
6.2A) that causes cytoplasmic accumulation of TBPH in the cells flies harbouring the 
construct (appendix 7; figure A7). To determine whether elevating the levels of 
cytoplasmic TBPH within these flies would enhance the behavioural phenotype 
observed in the repeat flies, the TBPHΔNLS construct was combined with 38 and 64 
repeat flies and respective controls (figure 6.2B).  The TBPHΔNLS construct had no 
significant impact on climbing performance at day 5 when co-expressed with 64 
G4C2 repeats that produces only poly-GP and poly-GA or when expressed in a 
control fly line (Elav>ΔNLS/+) (figure 6.2B) day 5. However, in the 38 G4C2 repeat 
line, (that in addition to poly-GP and poly-GA also produces poly-GR); TBPHΔNLS 
significantly enhanced the climbing deficit seen at day 5 as measured by SING 
compared to the 38 repeats on their own (figure 6.2B). Hence co-expressing 






   
 
 
Figure 6.2 | Cytoplasmic TBPH enhances G4C2-related motor impairment. 
(A) Schematic of genomic TBPH region indicating exon (black boxes) intron 
structure, and protein coding start (ATG) and stop codon (TAA); pink asterisk 
indicates bipartite nuclear localisation signal (NLS) for wild type (WT) TBPH and 
mutant (ΔNLS) constructs subcloned into pUC 3GLA vector and inserted by site-
specific integration at ZH86Fb on the third chromosome. (B) Day 5 motor 
performances of control flies and flies co-expressing ΔNLS-TBPH with 64 or 38 
G4C2 repeats. A significant difference in the PI of genotypes tested at day 5 was 
observed using a one-way ANOVA (F=218.6, p<0.0001). Post-hoc analysis was 
performed using Bonferroni-Holm corrected multiple comparisons which can be 
found in appendix 10, table A10. Post-hoc analysis revealed co-expression of 
ΔNLS-TBPH had no impact on the day 5 motor performances of control flies or 
flies expressing 64 G4C2 at day 5. However, enhanced cytoplasmic TBPH 
causes a significant impairment of motor performance in flies expressing 38 G4C2 
repeats compared to 38 repeat flies not expressing ΔNLS-TBPH (p<0.0001). 




6.3 Increasing cytoplasmic TBPH levels enhances 
translation of DPRs 
 
TDP-43 has several functions in the cytoplasm (Ederle and Doorman, 2017) 
including regulatory roles in mRNA stability, mRNA trafficking and mRNA 
translation (Ederle and Doorman, 2017). These functions could be impacted by 
TDP-43 cytosolic accumulation. Of interest are the roles of TDP-43 in mRNA 
stability and mRNA translation. The expression of cytoplasmic TDP-43 has been 
shown previously to alter protein translation (Russo et al., 2017). Furthermore 
human TDP-43 has been shown to regulate the translation of peptides from a repeat 
expansion in a Drosophila SCA31 model (Ishiguro et al., 2017). Therefore it was 
speculated that enhanced cytoplasmic TBPH may have impact on DPR production in 
flies co-expressing both TBPHΔNLS and G4C2 repeats. Flies containing G4C2 
repeats that also co-expressed the TBPHΔNLS were probed with poly-GP and poly-
GA antibodies (figure 6.3). No DPRs were detected in any of the control fly lines 
(Elav/+ and Elav>ΔNLS/+) (figure 6.3A and C). However, when both the 38 and 64 
repeat constructs were combined with TBPHΔNLS, the G4C2-TBPHΔNLS flies 
demonstrated higher DPR expression levels compared to repeat containing flies not 
expressing TBPHΔNLS for both poly-GP (figure 6.3A and B) and poly-GA (figure 
6.3C and D). The effect was only not significant for poly-GP in flies expressing 38 
repeats, however levels also appeared increased and significance may be reached 
with more replicates. Due to inabilities in accurately quantifying poly-GR levels with 
the current dot blot detection methodology this DPR was not probed for, although as 
demonstrated in chapter 3.8 of this thesis poly-GR was only detectable in the 38 
repeat line at the timepoints probed for in this experiment. These western blots were 






















Figure 6.3 | Cytoplasmic TBPH enhances DPR levels. (A,B) Flies expressing 
64 G4C2 repeats that also co-expressed the TBPHΔNLS construct demonstrated 
higher poly-GP levels compared to repeat containing flies not expressing 
TBPHΔNLS (t=11.02, ***;p<0.001). However, this effect was not significant in flies 
expressing 38 repeats. Mean and SEM are represented (n=3). (C,D) Flies 
expressing 64 and 38 G4C2 repeats also co-expressing the TBPHΔNLS construct 
demonstrated higher poly-GA levels compared to repeat containing flies not 
expressing TBPHΔNLS. (t=4.637, **; p<0.01), (t=12.15, ***;p<0.001). Mean and 




6.4.1 DPR expression, but not G4C2 RNA, disrupts Drosophila 
TDP-43  
 
The C9ALS/FTD post-mortem brain is characterized by the presence of RAN 
translated DPR inclusions and also cytoplasmic inclusions of the RNA binding 
protein TDP-43. Establishing a link between these two pathological hallmarks of the 
disease is a key question in the field that remains unanswered (Edbauer and Haass, 
2016). The localisation of Drosophila TDP-43, TBPH, in control salivary gland cells 
(FKH/+ and FKH>GR8) was predominantly nuclear with weak cytoplasmic TBPH 
also observed. TBPH staining was indistinguishable from controls in the G4C2-288 
repeat RNA only line. Poly-GA64 expression did not alter this nuclear localisation of 
TBPH; however the protein formed deposits in the cytoplasm of salivary gland cells 
which co-localised which poly-GA64 inclusions. Poly-GR64 on the hand also did not 
cause a nuclear reduction in salivary gland cells; however its expression led to a 
striking increase in cytoplasmic TBPH. 
Murine models have shown that expression of the G4C2 expansion is sufficient to 
cause TDP-43 pathology (Chew et al 2015, Liu et al 2016a). Chew et al. (2015) 
using a viral vector to express repeats in the mouse brain found phosphorylated 
endogenous mouse TDP-43 inclusions in the cortex and hippocampus of 
(G4C2)66 mice but not (G4C2)2 controls. Liu et al. (2016a) found C9ORF72 BAC mice 
also harbour TDP-43 inclusions in degenerating neurons. Taken together these 
studies indicate the gain-of-function mechanisms derived from the expansion are 
sufficient to cause TDP-43 dysfunction. Human post-mortem work has revealed 
TDP-43 pathology appears after the formation of RNA foci and DPRs (Proudfoot et 
al., 2014; Baborie et al., 2015; Vatsavayai et al., 2016). Furthermore TDP-43 
pathology is only present in end-stage BAC mice (Liu et al., 2016c). Thus the 
question is which of the toxic gain-of-function species produced from the G4C2 repeat 
expansion causes TDP-43 dysfunction (Edbauer and Hass, 2016). Some studies 
have suggested the G4C2 RNA may underlie TDP-43 mislocalisation. For example in 
the Chew et al. (2015) viral vector model cells with TDP-43 inclusions all contained 
at least one nuclear sense RNA foci. Cooper-Knock et al. (2015) found anti-sense 
RNA foci, but not sense RNA foci, correlate with TDP-43 mislocalisation in patient 
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motor neurons. In a G4C2 Drosophila model generated by Xu et al. (2013), reported 
to be RNA only, increased cytoplasmic Drosophila TDP-43 is observed (Zhang et al., 
2015). However in the present study the expression of a 288 repeat RNA only G4C2 
construct which forms foci in salivary gland cells does not cause any mislocalisation 
of Drosophila TDP-43. This suggests the G4C2 RNA is not the primary cause of TDP-
43 dysfunction in C9ALS/FTD. This supports data from the DsRed2 repeat flies 
characterised earlier in which behavioural toxicity did not correlate with G4C2 RNA 
expression levels. 
The salivary gland studies suggest rather that it is the DPRs that cause TDP-43 
dysfunction. Poly-GR expression caused a large accumulation of Drosophila TDP-43 
in the cytoplasm of salivary gland cells. Yamakawa et al. (2015) reported a co-
localisation between TDP-43 and poly-GR/poly-PR inclusion bodies in the cytoplasm 
of HEK293T cells. Similar findings were reported by Lee et al. (2016) who observed 
a co-localisation between TDP-43, poly-GR/poly-PR and SG markers in the cytosol 
in HeLa cells. Mori et al. (2016) demonstrated cytoplasmic TDP-43 re-distribution 
when all three of the sense DPRs (poly-GP, poly-GA and poly-GR) were detected in 
a cell, but not with poly-GP or poly-GA alone or a combination of these DPRs (Mori 
et al 2016). The authors note in the replies to one of the reviewers of the manuscript 
that poly-GR accumulation likely contributes to TDP-43 mislocalisation; however they 
could not report on this as cells expressing poly-GR only were too rare quantify. 
Furthermore, poly‐GA and poly‐GR double‐positive cells, but not cells with only poly-
GA, frequently had cytosolic TDP‐43 accumulation. Interestingly it was also 
observed that poly-GA inclusions often co-localised with TBPH in the cytoplasm of 
salivary gland cells expressing poly-GA64. Previous research has demonstrated a 
link between TDP-43 aggregation and poly-GA inclusions. For example in the human 
brain poly-GA inclusions have been shown to co-localise with TDP-43 aggregates; 
with poly-GA being in the centre of such inclusions suggesting it precedes TDP-43 
aggregation (Mackenzie et al., 2013). Chew et al. (2015) found in their mouse model 
that ~75% of cells with TDP-43 inclusions also contained a poly-GA aggregate. Rare 
phosphorylated TDP-43 aggregates have also been reported in a poly-GA only 
mouse model. Khosravi et al. (2017) found cytosolic poly-GA inclusions disrupt the 
nuclear import of a reporter containing the NLS of TDP-43, inducing the partial 
mislocalisation of TDP-43 into cytoplasmic granules. Furthermore forcing poly-GA to 
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the nucleus rescued this. Hence the data from the present study further supports the 
link between poly-GA pathology and TDP-43 aggregation.  
Hence these findings taken together strongly suggest that DPR accumulation, and 
not G4C2 RNA, causes TDP-43 dysfunction in C9ALS/FTD. Poly-GR expression 
caused a striking cytoplasmic accumulation of Drosophila TDP-43, whilst poly-GA 
expression led to the formation of cytoplasmic deposits of Drosophila TDP-43 which 
partially co-localised with poly-GA aggregates.  
6.4.2  Cytoplasmic TBPH enhances G4C2 toxicity  
 
In the 38 G4C2 repeat line that produces all 3 sense DPRs, expression of 
TBPHΔNLS significantly enhanced the climbing deficit seen at day 5 as measured by 
SING compared to the 38 repeats expressed on their own. Hence cytoplasmic TDP-
43 is an enhancer of the G4C2 toxicity in flies. Intestinally a cytoplasmic accumulation 
of Drosophila TDP-43 is seen following poly-GR expression which also shows early 
toxicity as evidenced by severe degeneration in the compound eye. Further, 
Drosophila TDP-43 inclusions that co-localise in the cytoplasm with poly-GA are 
seen as a result of poly-GA expression in salivary gland cells – but poly-GA does not 
cause any external degeneration when expressed in the Drosophila eye. This 
suggests a cytoplasmic redistribution of TBPH without the need for aggregate 
formation facilitates toxicity. Previous work has demonstrated that cytoplasmic TDP-
43 is toxic and is itself sufficient to cause neurodegeneration. Barmada et al. (2010) 
found mutant TDP-43 toxicity correlated with a cytoplasmic accumulation of TDP-43 
but not the formation of aggregates. Neither nuclear TDP-43 levels nor aggregates 
were predictors of neuronal cell death; cellular survival was strongly predicted by the 
amount of TDP-43 in the cytoplasm. Russo et al. (2017) found mutant TDP-43 with a 
non-functional nuclear localisation sequence (NLS) was toxic despite little aggregate 
formation. In vivo models have been developed to study the role of cytoplasmic TDP-
43 in disease onset and progression. These models utilise either variants of TDP-43 
that lead to cytosolic accumulation or mutant forms of the protein where the NLS has 
been mutated specifically so it is non-functional leading to the protein accumulating 
in the cytoplasm. Ritson et al. (2010) expressed forms of TDP-43 with either 
mutations in the NLS or nuclear export signal (NES) in the Drosophila eye in addition 
to wild-type human TDP-43 overexpression. Wild-type TDP-43 expression in the fly 
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eye produced a mild degenerative phenotype whilst the NES mutant TDP-43 
produced no external eye phenotype. NLS-mutant TDP-43 expression however in 
produced a strong degenerative phenotype.   
Evidence from mouse models also suggests TDP-43 aggregates are not required for 
toxicity and that elevated cytoplasmic levels of TDP-43 are sufficient in induce 
toxicity. Mice expressing human TDP-43 with a defective NLS (hTDP-43-ΔNLS) 
demonstrated progressive neurodegeneration in the neocortex, hippocampus and 
corticospinal tract. These mice also had a clasping motor phenotype - a measure of 
spastic motor impairment. Importantly, whilst cytoplasmic TDP-43 caused a loss of 
upper motor neurons leading to motor spasticity, only extremely rare cytoplasmic 
ubiquitinated pTDP-43 aggregates were observed; indicating cytoplasmic 
aggregation of TDP-43 is not required for its cytotoxicity and subsequent 
neurodegeneration (Igaz et al., 2011). hTDP-43-ΔNLS expression did however 
cause a reduction in endogenous mouse TDP-43 (mTDP-43) and neuronal cell loss 
correlated with the reduction of nuclear mTDP-43 staining. Arnold et al. (2013) found 
the toxicity of ALS-causing TDP-43 variants (TDP-43Q331K and TDP-43M337V) 
occurred without any nuclear loss of the human TDP-43 transgene or the formation 
of insoluble TDP-43 aggregates; however, TDP-43 was also not localised to the 
cytoplasm in these mice and neurodegeneration again correlated with the loss of 
endogenous mTDP-43 as in the Igaz et al. (2011) study.  
Igaz et al. (2011) used a CaMK2α promoter which did not direct hTDP-43-ΔNLS 
expression to the spinal cord; hence the hTDP-43-ΔNLS mouse model did not 
develop an ALS-like phenotype. To overcome this the same group used a Dox-
suppressible neurofilament heavy chain promoter for brain and spinal cord 
expression of hTDP-43-ΔNLS to further study the role of cytoplasmic TDP-43 in 
neurotoxicity (Walker et al., 2015). These mice developed progressive atrophy in 
cortical regions, neuromuscular junction and spinal cord in addition to severe 
muscular atrophy. The hTDP-43-ΔNLS mice also presented with several early onset 
ALS-like motor impairments and early death. Further studies with these mice 
revealed the expression of hTDP-43-ΔNLS also led to cognitive deficits hence 
mimicking FTD symptoms as well (Alfieri et al., 2014). Pathological phospho-TDP-43 
(pTDP-43) accumulations were observed in 28% of neurons at end-stage but only 2 
% spinal cord motor neurons had TDP-43 inclusions, despite this 50% of motor 
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neurons were lost in hTDP-43-ΔNLS mice by end stage further indicating 
cytoplasmic TDP-43 aggregates do not drive toxicity (Walker et al., 2015). 
Suppression of hTDP-43-ΔNLS also led to a phenotypic recovery which, although 
was accompanied by the removal of inclusions, cannot fully be attributed to this - as 
pTDP-43 inclusions were extremely rare in motor neurons as mentioned previously. 
Whilst the rescue of motor phenotypes by suppression of the hTDP-43-ΔNLS 
transgene supports cytoplasmic TDP-43 toxicity, these mice also had nuclear 
reduction of endogenous mTDP-43 which returned following removal of cytoplasmic 
human TDP-43 (Walker et al., 2015). Therefore, while this study and the Igaz et al. 
(2011) study point towards cytoplasmic TDP-43 aggregates not being major drivers 
of toxicity, both models are unable to distinguish whether the clearance of 
cytoplasmic TDP-43 and its suppression was responsible for the phenotypes and 
dramatic rescue seen or whether these were caused by the loss of nuclear TDP-43 
and its subsequent return to the nucleus in the rescue experiment when hTDP-43-
ΔNLS is suppressed.  
Interestingly, even though mTDP-43 was cleared from the nucleus, Igaz et al. (2011) 
found a high proportion of the hTDP-43-ΔNLS protein was nuclear, suggesting a loss 
a nuclear TDP-43 per say is not entirely responsible for toxicity as the TDP-43-ΔNLS 
protein is also localised to the cytoplasm. This implies cytoplasmic TDP-43 has a 
direct neurotoxic effect itself (Igaz et al., 2011). Further characterisation of the 
CaMK2α hTDP-43-ΔNLS mice by Amile-Wolf et al. (2015) found that although 
endogenous mTDP-43 is lost; total nuclear TDP-43 protein levels are maintained in 
these mice. RNA seq analysis of the hTDP-43-ΔNLS mice revealed transcriptomic 
changes that were directly attributable to a gain of cytoplasmic TDP-43 function as 
comparisons with RNA-seq data from mice injected with a TDP-43 ASO revealed 
only little similarity. Furthermore, splicing changes were observed in the ASO mice 
but not the ΔNLS-hTDP-43 mice; indicating nuclear TDP-43 function is retained in 
these mice (Amile-Wolf et al., 2015). Hence the unchanged levels of nuclear TDP-43 
combined with the large increase in cytoplasmic TDP-43 protein levels and minimal 
number of cytoplasmic TDP-43 aggregates strongly suggests a toxic gain of 
cytoplasmic TDP-43 function is responsible for toxicity and the changes in gene 
expression observed in the hTDP-43-ΔNLS mice.  
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Taken together the above results strongly suggest that TDP-43 is mislocalised to the 
cytoplasm is toxic and causes neurodegeneration. How might cytoplasmic TDP-43 
cause toxicity? Microarray data from CaMK2α hTDP-43-ΔNLS mice revealed an 
increase in the levels of chromatin assembly and histone genes, suggesting a role 
for cytoplasmic TDP-43 in both transcription and histone transcript stability (Igaz et 
al., 2011). The RNA seq on these mice by Amile-Wolf et al. (2015) revealed 
cytoplasmic TDP-43 caused an upregulation of genes linked to transcription, 
assembly of chromatin, the nucleolus and protein metabolism. Cytoplasmic TDP-43 
was also associated with a downregulation of genes with roles in synaptic activity 
and the posttranslational modification of proteins. Cytoplasmic TDP-43 caused a 
misregulation in the processing of histone 3’UTR genes. Deficits in both chromatin 
assembly and the nucleolus were seen in both the hTDP-43-ΔNLS mice and FTD-
TDP post mortem tissue. The authors suggest a gain of cytoplasmic TDP-43 causes 
a dysregulation of nuclear dynamics. The cytosolic functions of TDP-43 in mRNA 
stability, mRNA trafficking and mRNA translation (Ederle and Dormann, 2017) 
could also all be impacted by TDP-43 cytosolic accumulation (Barmada et al., 
2010). 
In summary, clear evidence shows cytoplasmic TDP-43 mislocalisation is toxic 
independent of aggregate formation. The data presented shows interaction between 
the G4C2 expansion and a cytosolic mislocalisation of TDP-43; specifically, that it is 
an enhancer of G4C2 induced motor impairment. In poly-GR64 expressing salivary 
gland cells a strong cytoplasmic accumulation of TDP-43 is seen; it is tempting to 
speculate some of the poly-GR toxicity is mediated by this mislocalisation of TDP-43. 
One would predict if this cytoplasmic accumulation of TDP-43 does contribute to 
GR64 toxicity then reducing the cytoplasmic accumulation of TDP-43 would provide 
a rescue. Lee et al. (2016) found an RNAi to TBPH completely rescued the survival 
of poly-GR only flies to 100%, although this will also cause a nuclear reduction of the 
protein, it does suggest a toxic gain of TDP-43 function, rather than a loss per say, 





6.4.3  Cytoplasmic TBPH enhances DPR levels 
 
As discussed in the last section TDP-43 has several functions in the cytoplasm 
(Ederle and Doorman, 2017). Of interest are the roles of TDP-43 in mRNA stability 
and mRNA translation. If these functions are perturbed either the stability of the 
G4C2 mRNA could be affected or RAN translation of the G4C2 mRNA could be 
directly impacted – both possibilities could alter DPR levels. In the current study 
increasing cytoplasmic TBPH not only enhanced G4C2 mediated motor impairment, 
but also DPR levels. When the TBPHΔNLS construct was combined with the both 
the 38 and 64 repeat constructs, and poly-GP and poly-GA levels examined, the 
amounts of both DPRs were significantly increased in flies co-expressing the 
TBPHΔNLS compared to repeat flies without.  
Several studies have now shown TDP-43 regulates the translation of certain 
mRNAs. Recombinant TDP-43 has been shown to behave as a translational 
repressor in vitro (Wang et al., 2008). TDP-43 also supresses the translation of 
Rac1, GluA1, and Map1b mRNAs via its interaction with the FMRP-CYFIP 
translational inhibition complex (Majumder et al., 2012; Majumder et al., 2016). In 
flies TDP-43 has been shown to regulate translation of Futsch mRNA at the 
neuromuscular junction (Coyne et al., 2014). Translational changes have also been 
reported in the motor neurons of a TDP-43 mouse model - with the RNA binding 
proteins DDX58 and MTHFSD being identified as misregulated (MacNair et al., 
2016). Two separate TDP-43 proteomic studies discovered a large component of the 
TDP-43 interactome are proteins that regulate translation, including translation 
initiation factors and ribosomal proteins (Freibaum et al., 2010; Kim et al., 2010). In 
neurons cytoplasmic TDP-43 has been shown to form mobile RNA granules that 
contain mRNA binding proteins suggesting TDP-43 is involved in the transport and 
translation of these proteins (Alami et al., 2014). TDP-43 is also a component of 
stress granules which regulate translation during stress (Aulas and Vande Velde, 
2015).  Recently Russo et al. (2017) using a ΔNLS TDP-43 construct demonstrated 
cytoplasmic TDP-43 acts as global inhibitor of protein synthesis; the authors found 
TDP-43 RNA granules consist of polyribosomes which associate with the 
translational machinery. Overexpression of ΔNLS-TDP-43 led to increases in total 
amounts of the translation repressor 4E-BP1 and a decrease in the phosphorylation 
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of eIF4E; the consequence of which was repressed global protein translation. The 
interaction between cytoplasmic TDP-43 and the translational machinery was via the 
ribosomal protein RACK1. If cytoplasmic TDP-43 is a translational repressor, it is 
surprising that its co-expression with the G4C2 repeat constructs enhances DPR 
production in flies rather than inhibits it. Cytoplasmic TDP-43 suppression of 
translation has only been studied for canonical cap dependent ATG context (Russo 
et al., 2017); RAN translation of the G4C2 repeats involves non-canonical translation 
initiation mechanisms; whether cytoplasmic TDP-43 might affect canonical and non-
canonical translation differently remains to be seen.   
Another way in which enhancing the cytosolic levels of TDP-43 could impact the 
levels of DPRs is through changes in its interaction with the G4C2 RNA. Recently 
TDP-43 has been shown to play a vital role in regulating repeat associated 
translation in spinocerebellar ataxia type 31 (SCA31). SCA31 is neurological and 
neuromuscular disease caused by microsatellite pentanucleotide repeat expansions 
in an intron shared by the genes BEAN1 and TK2 (Sato et al., 2009). Ishiguro et al., 
(2017) focused on the TGGAA repeat expansion in SCA31 which is translated into 
poly-pentapeptide repeat (PPR) proteins. Both TDP-43 and FUS were found to bind 
to the UGGAA RNA repeats; further overexpression of human wt-TDP-43 
suppressed the UGGAA rough eye phenotype in flies. TDP-43 interacted with 
UGGAA RNA via its RNA recognition motif and caused the UGGAA RNA foci 
produced to be smaller, although not degraded; suggesting TDP-43 acts as a 
chaperone for the folding of UGGAA RNA. However, remarkably, wt-TDP-43 co-
expression reduced levels of the poly-WNGME PPR protein translated from the 
UGGAA expansion; further, this suppression was independent of the RNA 
recognition motif (RRM) of wt-TDP-43. Similar effects on RNA foci formation and 
PPR expression were seen for FUS and hnRNPA2B1.  
The authors suggest that TDP-43 and other RNA binding proteins may act as 
chaperones for repeat RNA and propose three mechanisms as to how TDP-43 might 
reduce repeat associated translation. Firstly, by binding to the UGGAA expansion 
TDP-43 blocks the scanning ribosome, hence translation initiation. Secondly the 
RNA chaperone activity of TDP-43 changes the structural conformation of the 
UGGAA RNA required for translation of the repeats. Thirdly and finally the binding of 
TDP-43 to the UGGAA repeats in the nucleus prevents cytoplasmic transport and as 
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a consequence translation; in support of this MBNL1 expression represses repeat 
associated translation via a nuclear retention of repeat CUG/CAG RNA (Kino et al., 
2015). Recent work by Zu et al. (2017) on RAN translation of the 
CCTG⋅CAGG expansion in DM2 supports the latter of these hypotheses; it was 
found that the translation of RAN proteins was modulated by the sequestration and 
nuclear retention of the repeat RNA by MBNL1. The TBPHΔNLS fly line used in this 
study not only causes a cytoplasmic accumulation of TBPH but also comes with a 
concomitant nuclear reduction of endogenous TBPH (Hirth lab unpublished data; 
appendix 7; figure A7). If this reduction of nuclear TBPH is sufficient to affect the 
normal nuclear function of the protein; then based on what was proposed by Ishiguro 
et al. (2017) for the interaction between TDP-43 and UGGAA mRNA; an increase in 
repeat associated proteins might be expected. For example TBPH would no longer 
be preventing the transport of G4C2 repeat RNA into the cytoplasm or no longer 
binding to the RNA in the nucleus in such a way that induces structural changes in 
the G4C2 repeat RNA unfavourable for translation. The data in this chapter presents 
evidence that endogenous fly TBPH can have the opposite effect on repeat 
associated translation reported by Ishiguro et al. (2017) and previous reports that 
cytoplasmic TDP-43 is a translation repressor (Russo et al., 2017). One explanation 
for this is that the interaction between TDP-43 and repeat RNA differs between 
different repeat sequences. TDP-43 preferentially binds to UG repeats hence its 
interaction with the UGGAA expansion in SCA31 is not unexpected (Polymenidou et 
al., 2011), further TDP-43 is found in the SCA31 RNA foci in human cerebellar 
purkinje neurons (Ishiguro et al., 2017). This suggests TDP-43 interacts differently 
with different repeat mRNAs. TDP-43 could for example induce a conformation 
change specific to the G4C2 sequence that promotes translation rather than 
decreases like for the UGGAA expansion. However, no direct binding has been 
shown between TDP-43 and G4C2 RNA in patient tissue and TDP-43 is not found to 
be sequestered into G4C2 RNA foci like other RNA binding proteins. 
Intriguingly a partial knockdown of TBPH in the Ishiguro et al. (2017) UGGAA 
Drosophila model increased foci formation; but had no effect on repeat translated 
PPR protein levels. Furthermore when the RRM of TDP-43 was depleted PPR 
translation was still supressed. This observation suggests it is plausible that the 
increase in DPR expression seen as a consequence of TBPHΔNLS expression 
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could be attributable to some gain of toxic function resulting from enhanced cytosolic 
TDP-43, rather than a loss of nuclear function. The question is there any evidence 
for an interaction between cytosolic TDP-43 and the G4C2 RNA that could potentially 
promote translation from the G4C2 sequence? Ishiguro et al. (2016) found TDP-43 
binds to G-quadruplex structures (G4), and is involved in the transport of G4 mRNAs 
to neurites where they are translated via the local protein translation complexes. This 
study suggests there is an important interaction between G-quadruplex mRNAs and 
cytosolic TDP-43 function in relation to intracellular trafficking of and local translation 
of G4 mRNAs. Could the enhanced DPR levels be due to increased translation at 
neurites that results from increasing cytosolic TBPH levels? DPRs are localised to 
axons (Hirth lab unpublished data; appendix 8; figure A8); further Burguete et al., 
(2015) found G4C2 RNA is localised in neurites where it induces branching defects 
and disrupts transport granule function. Hence it is not completely unfeasible to 
suggest DPRs could be translated locally in neurites.  
It is also possible the increase in DPRs seen as a result TBPHΔNLS expression is 
unrelated to the role of TDP-43 in regulating protein translation or a potential 
interaction with the G4C2 RNA. For example enhancing the levels of cytoplasmic 
TDP-43 may impact protein degradation or autophagy which could cause the DPRs 
to accumulate. Further DPR production has been shown to be increased under heat 
shock conditions in flies (Tran et al., 2015; Freibaum et al., 2015), hence increased 
cellular stress via an artificial increase in cytoplasmic TBPH could also cause an 
increase in DPR production. Irrespective of the causes, these results suggest a 
potential feedback loop in which the DPRs, specifically poly-GR, cause enhanced 
levels of cytoplasmic TDP-43, which itself further enhances the DPR levels leading 
to a cascade of events that ultimately culminates in neurodegeneration. Although 
levels of poly-GR were not probed for when the repeat lines were combined with the 
TBPHΔNLS construct, due to difficulties in accurately quantifying and detecting this 
peptide, it is tempting to speculate that the enhanced phenotype seen for the 38 




6.4.4  Conclusion 
The present study shows poly-GR on its own caused a cytoplasmic accumulation of 
Drosophila TDP-43, whereas poly-GA expression led to formation of inclusions of 
Drosophila TDP-43 in the cytoplasm. No changes in TDP-43 localisation or 
morphology were observed from the expression of a G4C2 RNA only construct. An 
amyloid cascade hypothesis for C9ALS/FTLD has been proposed where specific 
stressors cause TDP-43 to aggregate and become mislocalised to the cytoplasm 
(Edbauer and Haas, 2016). These results indicate the DPRs, and not the G4C2 RNA, 
is the key stressor in this cascade, accumulating early during disease progression 
and subsequently causing TDP-43 to be mislocalised to the cytoplasm. Furthermore 
cytoplasmic TDP-43 also enhances DPR production which excitingly suggests some 
kind of feedback mechanism where DPR mediated cytoplasmic TDP-43 
accumulation enhances DPR production; potentially further exacerbating TDP-43 





Chapter 7: Investigation of the localisation 
of nucleocytoplasmic transport proteins in 
flies expressing either poly-GR or poly-GA  
Several studies have reported that both G4C2 RNA and DPRs impact 
nucleocytoplasmic transport (NCT), which may account for cellular toxicity observed 
in these C9 models (Zhang et al., 2015, Freibaum et al., 2015, Jovičić et al., 2015, 
Boeynaems et al., 2016a). Therefore I investigated whether the accumulation and 
aggregation of poly-GA and poly-GR affects NCT by looking at the localisation of 
important components of the NCT machinery which have also been identified as 
modifiers of G4C2 toxicity in previous studies (Zhang et al., 2015; Freibaum et al., 
2015; Jovičić et al., 2015; Boeynaems et al., 2016a). Proteins involved in the 
shuttling of cargoes between the nucleus and cytoplasm and vice versa can roughly 
be divided into 3 categories (Cautain et al., 2015). Firstly, there are the nucleoporins 
(Nups) which build the nuclearpore complex (NPC); there are around 30 different 
vertebrate Nups in total that can be divided into 3 subgroups – the transmembrane 
Nups that anchor the NPC to the nuclear envelope, the FG-Nups which contain 
phenylalanine-repeats which selectively regulate nuclear transport, and finally the 
structural Nups that act as scaffold connecting the transmembrane Nups and the 
FG-Nups (Cautain et al., 2015). The second group of proteins are the nuclear 
transport receptors (NTRs). The NTRs constantly move between the cytoplasm and 
nucleus binding to their cytoplasmic or nuclear cargoes NLS and NES domains. The 
NTRs that bind to a proteins NLS domain and mediate their translocation into the 
nucleus are known as importins. NTRs that bind to proteins in the nucleus mediating 
their export from the nucleus into the cytosol are known as exportins (Cautain et al., 
2015). The majority of NTRs are members of the karyopherin-β (KPNB) protein 
family (Cautain et al., 2015). Each member recognizes its own unique set of cargo 
proteins or RNAs (Cautain et al., 2015). KPNB proteins bind either directly or 
indirectly via adaptors to their protein and RNA cargoes. The adaptor proteins are 
specialized cargoes carrying an N-terminal NLS known as the importin β-binding 
domain (Pumroy and Cingolani, 2015). In the classic NLS pathway adaptor proteins 
bind to the NLS of the transport cargoes in the presence of KPNB1. The major class 
of adaptor proteins is the karyopherin-α (KPNA) protein family; there are 7 different 
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KPNAs divided into three subfamilies (Pumroy and Cingolani, 2015). The different 
subfamilies show selectivity for specific protein cargoes. Once formed the 
heterotrimeric KPNB/A/NLS-cargo complex shuttles through the NPC (Pumroy and 
Cingolani, 2015). The final component of the nuclear transport process is the Ran 
system. The shuttling of proteins into and out of the nucleus requires metabolic 
energy and this is provided by the small Ras-like GTPase Ran via GTP hydrolysis 
(Cautain et al., 2015).  
TDP-43 is transported into the nucleus via the classic nuclear import pathway just 
described (Dormann and Haass, 2011).  Defective nuclear import has been 
proposed to be the first step in the development of TDP-43 proteinopathy (Dormann 
and Haass, 2011), hence the morphology of proteins involved in the classic nuclear 










Figure 7.1 | Nuclear transport of TDP-43 via the classic nuclear import 
pathway. TDP-43 shuttles between the nucleus and cytoplasm via the classic 
nuclear import pathway. (1) The KPNAs (such as KPNA2 and KPNA4) bind to the 
nuclear localisation sequence (NLS) of TDP-43. (2) This KPNA-TDP-43 complex 
is then bound by KPNB1 in the cytoplasm forming the heterotrimeric 
KPNB/A/NLS-cargo complex shuttles through the NPC. (3) RCC1 is the nuclear 
exchange factor for RAN; converting RanGDP to RanGTP.  RanGTP binding to 
KPNB1 causes the importin complex to dissociate thereby releasing TDP-43. (4) 
KPNB1 recycles back into the cytoplasm bound to RanGTP. (5) The KPNAs are 
recycled back into the cytoplasm together with CSE1L (also known as CAS) and 
RanGTP. (6) RanGAP together with RanBP1 increases the hydrolysis of RAN 
catalysing the conversion of RanGTP to RanGDP resulting in the dissociation of 
from KPNAs releasing them from the KPNA/CSE1L/RanGTP. Adapted from 




7.1 Poly-GR or poly-GA expression does not cause a 
gross mislocalisation of proteins involved in the Ran 
system  
 
Nucleocytoplasmic transport across the nuclear pore complex requires metabolic 
energy. The energy docking and undocking of transport cargoes is provided by the 
actions of small Ras-like GTPase RAN which exists in two nucleotide bound states; 
RanGTP and RanGDP. Energy for nuclear import comes from the GTP hydrolysis of 
RanGTP to RanGDP. RanGAP1 increases the hydrolysis of RAN inducing its 
GTPase activity; catalysing the conversion of RanGTP to RanGDP (Cautain et al., 
2015). In its GDP bound state RAN dissociates from KPNAs releasing them from 
the KPNA/CAS/RanGTP complex allowing them to bind to their cytosolic cargoes 
(Stewart, 2007). Consistent with its function, RanGAP1 is localised on the 
cytoplasmic side of the nuclear pore (Fox and Tibbetts, 2015). Drosophila have one 
homologue of RanGAP1 known as RanGAP. The FKH-GAL4 driver was used to 
express either poly-GR64 or poly-GA64 in salivary gland cells. This driver was 
chosen as the salivary gland cells have large nuclei and cytoplasm that can easily be 
distinguished. Salivary gland cells were stained with an anti-RanGAP antibody 
(Kusano et al., 2003) and anti-HA (figure 7.2A). In controls (FKH/+ and FKH>GR8) 
RanGAP shows a smooth perinuclear localisation around the whole nuclear 
envelope as has been previously reported (Kusano et al., 2003) (figure 7.1A). This 
smooth perinuclear staining was also observed in 288-G4C2 RNA only (FKH>288 
RO), GA64 (FKH>GA64) and GR64 (FKH>GR64) expressing salivary gland cells 
respectively (figure 7.2A). Hence no inclusions, cytoplasmic and nuclear puncta or 
sequestration of RanGAP into DPR aggregates was observed as has been reported 
in patient post-mortem tissue, viral vector (G4C2)66 mice and a poly-GA only mouse 
model (Zhang et al., 2015; Zhang et al., 2016). 
RCC1 (also known as RanGEF) is the nuclear exchange factor for RAN; converting 
RanGDP back to RanGTP. In the nucleus, RanGTP binds to KPNB, leading to 
conformational change in KPNB - causing the importin complex to dissociate thereby 
releasing the cargo (Stewart, 2007).  Hence RCC1 has the opposite function to 
RanGAP1. RCC1 is bound to chromatin therefore is exclusively nuclear (Carazo-
Salas et al., 1999). The Drosophila homologue of RCC1 is known as Bj1/dRCC1 
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(Frasch, 1991); dRCC1 is required for the nuclear import of NLS cargoes (Shi and 
Skeath, 2004). dRCC1 is diffusely nuclear in controls (FKH/+ and FKH>GR8) (figure 
7.2B) with extremely weak cytoplasmic staining. This nuclear staining was preserved 
in the poly-GA64 (FKH>GA64), poly-GR64 (FKH>GR64) and 288-G4C2 RNA only 
salivary glands (FKH>288 RO) (figure 7.1B) Some dRCC1 was present in poly-GA64 
inclusions consistent with previous reports in murine models demonstrating poly-GA 
sequesters proteins involved in nucleocytoplasmic transport into inclusions (Zhang et 
al., 2016). dRCC1 staining was indistinguishable from controls in poly-GR64 
expressing salivary gland cells – no decrease in dRCC1 nuclear staining was 
observed as has been previously reported in C9orf72-ALS patient–derived neurons 






















Figure 7.2 | Poly-GR and poly-GA accumulation does not alter the 
morphology of proteins involved in the Ran system. (A) Salivary glands were 
immunolabeled with RanGAP. No changes were seen in localisation of RanGAP 
in poly-GA64 (FKH>GA64), poly-GR64 (FKH>GR64) and RNA only (FKH>288 
RO) expressing salivary glands compared to the controls (FKH/+ and FKH.GR8). 
RanGAP was perinuclear in all genotypes. (B) Salivary glands were 
immunolabeled with dRCC1. No changes were seen in localisation of these 
proteins in poly-GA64 (FKH>GA64), poly-GR64 (FKH>GR64) and RNA only 
(FKH>288 RO) expressing salivary glands compared to the controls (FKH/+ and 
FKH>GR8). dRCC1 was nuclear in all genotypes; however co-localised with poly-
GA inclusions in the cytoplasm. A minimum of 8 salivary glands were scanned per 




7.2 Poly-GR or poly-GA expression does not cause a 
gross mislocalisation of FG-repeat containing 
nucleoporins  
 
The nucleoporins (Nups) build the NPC which regulates the flow of macromolecules 
from the cytoplasm to the nucleus and vice versa. Nups can be grouped into 3 
categories based on structure and function; the transmembrane Nups, the structural 
Nups and the FG-Nups. The FG-repeat Nups were focused on as it has been 
recently shown that the anti-sense arginine DPR, poly-PR, binds to the central 
channel of the nuclear pore via an interaction with the polymeric form of the FG-
repeat domain (Shi et al., 2017). Additionally, the FG-repeat Nup62 has recently 
been shown to be affected in both Huntington’s disease mouse models and post 
mortem tissue (Grima et al., 2017). The following FG-repeat Nups were investigated 
MAB414 which labels several FG-Nups including Nup62, Nup153, Nup214, and 
Nup358 (figure 7.3A) and also Drosophila Nup50 (figure 7.2B). The FKH-GAL4 
driver was used to express either poly-GR64 or poly-GA64 in salivary gland cells. 
MAB414 surrounded the nuclear envelope uniformly in the controls (FKH+ and 
FKH>GR8) (figure 7.3B). No gross morphological differences were observed 
between controls and the 288-G4C2 RNA only (FKH>288 RO) and poly-GA64 
(FKH>GA64) salivary gland cells (figure 7.3B). Poly-GR64 (FKH>GR64) expressing 
salivary gland cells also showed a smooth distribution of MAB414 around the nuclear 
envelope (figure 7.3A). Nup50 in controls was exclusively nuclear with an intense 
staining around the nuclear envelope (FKH>+ and FKH>GR8). This distribution was 
unaltered in 288-G4C2 RNA only (FKH>288 RO) salivary gland cells and also poly-
GA64 (FKH>GA64) salivary gland cells despite cytoplasmic and nuclear aggregation 
of the latter (figure 7.3B). Nup50 staining in poly-GR64 (FKH>GR64) salivary glands 
was also indistinguishable from controls despite nuclear poly-GR64 aggregation 
(figure 7.3B).  In summary no obvious differences were seen in Nup morphology 






















Figure 7.3 | Poly-GR and poly-GA accumulation does not alter the 
morphology of the nuclear pore complex. (A) Salivary glands were 
immunolabeled with MAB414 which labels FG-NUPs. No changes were seen in 
localisation of MAB414 in poly-GA64 (FKH>GA64), poly-GR64 (FKH>GR64) and 
RNA only (FKH>288 RO) expressing salivary glands compared to the controls 
(FKH/+ and FKH.GR8). MAB414 was perinuclear in all genotypes. (B) Salivary 
glands were immunolabeled with Nup50. No changes were seen in localisation of 
these proteins in poly-GA64 (FKH>GA64), poly-GR64 (FKH>GR64) and RNA 
only (FKH>288 RO) expressing salivary glands compared to the controls (FKH/+ 
and FKH>GR8). Nup50 was nuclear in all genotypes with perinuclear enrichment. 




7.3 Drosophila karyopherin-α proteins are depleted 
from the nucleus and accumulate in the cytoplasm as a 
result of poly-GR expression 
 
Proteins larger than 40 kDa in size are transported through the NPC via the NTRs 
(Cautain et al., 2015). The major NTRs are the KPNBs which bind either directly or 
indirectly to their protein cargoes (Cautain et al., 2015). TDP-43 is shuttled into the 
nucleus via the classic nuclear import pathway which involves the indirect binding of 
KPNB1 to TDP-43 via the KPNAs (Mihevc et al., 2017). Once in the nucleus this 
KPNB/KPNA/TDP-43 complex dissociates via binding of RAN-GTP to KPNB1; the 
RAN-GTP bound KPNB1 is then recycled back into the cytoplasm. KPNA 
cytoplasmic recycling is mediated via their binding with the nuclear export factor CAS 
also bound to RAN-GTP (Mihevc et al., 2017). KPNB1 and CAS are crucial to TDP-
43 import; if they are knocked down KPNA recycling is diminished leading to the 
formation of cytosolic TDP-43 inclusions (Nishimura et al., 2010). The KPNA family 
of NTRs can be subdivided into three categories named α1, α2 and α3 (Pumroy and 
Cingolani, 2015).  All 5 tested human KPNAs bind TDP-43; however KPNA3 and 
KPNA4, the 2 members of the α2 KPNA subfamily (Pumroy and Cingolani, 2015) are 
the strongest interactors with TDP-43 (Nishimura et al., 2010). Drosophila have 
homologues for the majority of human KPNA and KPNB NTRs (Chen et al., 2015). 
KPNA2 was identified as one of the strongest poly-GR and poly-PR interactors in a 
proteomics screen (Lee et al., 2016). Based on previous work suggesting KPNA 
dysfunction is key to TDP-43 aggregation (Nishimura et al., 2010), the localisation of 
the Drosophila homologue of KPNA4, Importin-α3 and the Drosophila homologue of 
KPNA2, Pendulin/Importin-α2 (a member of the α1 KPNA subfamily) was 
investigated (figure 7.4A and B). Unfortunately antibodies for the Drosophila 
homologues of KPNB1 (Ketel) (Lippai et al., 2000) and CAS (Dcas) (Tekotte et al., 
2002) were either no longer avaliable or did not work, hence could not be studied in 
this thesis.  
The FKH-GAL4 driver was again used to express either poly-GR64 or poly-GA64 in 
salivary gland cells. Importin-α3 in controls (FKH/+ and FKK>GR8) is present in both 
the cytoplasm and nucleus although predominantly nuclear with enrichment around 
the nuclear envelope (figure 7.4A). This staining pattern is maintained in poly-GA64 
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(FKH>GA64) and 288-G4C2 RNA only salivary glands (FKH>288 RO). However, 
poly-GR64 (FKH>GR64) expression led to a nuclear depletion and cytosolic 
accumulation of Importin-α3 (figure 7.4A). Pendulin in controls was present in both 
the nucleus and cytoplasm with an enrichment in the nucleus (FKH/+ and 
FKK>GR8); again, this staining pattern was maintained in poly-GA64 (FKH>GA64) 
and 288-G4C2 RNA only (FKH>288 RO) (figure 7.4B). Poly-GR64 (FKH>GR64) 
expression on the other hand led to a dramatic nuclear depletion of Pendulin and 
cytosolic accumulation (figure 7.4B). Interestingly both proteins were present in 
some cytoplasmic poly-GA64 inclusions; furthermore, cytosolic levels of Pendulin 
appeared reduced in poly-GA64 flies which may be due to its sequestration into poly-























Figure 7.4 | Poly-GR causes a nuclear depletion of Drosophila KPNA2 and 
KPNA4. (A) Salivary glands were immunolabeled with Importin-α3 (KPNA4). No 
changes were seen in localisation of Importin-α3 in poly-GA64 (FKH>GA64) and 
RNA only (FKH>288 RO) expressing salivary glands compared to the controls 
(FKH/+ and FKH>GR8). Importin-α3 was predominantly nuclear with enrichment 
around the nuclear envelope in these genotypes, although importin-α3 was 
sequestered into some poly-GA64 inclusions. However poly-GR64 (FKH>GR64) 
expression led to a nuclear depletion of importin-α3. (B) No changes were seen in 
localisation of Pendulin in RNA only (FKH>288 RO) expressing salivary glands 
compared to the controls (FKH/+ and FKH>GR8). Poly-GA64 (FKH>GA64) 
expression however led to the sequestration of Pendulin into cytoplasmic poly-
GA64 inclusions. Poly-GR64 (FKH>GR64) expression led to a nuclear depletion 
and cytosolic accumulation of Pendulin. A minimum of 8 salivary glands were 






7.4.1  A nuclear depletion Drosophila KPNA2 and KPNA4, 
previously implicated in ALS/FTD, is observed as a 
consequence of poly-GR expression  
 
Recent yeast, fly and mouse models have shown both nuclear import and export are 
disrupted by the presence of both the DPRs and G4C2 RNA (Zhang et al., 2015, 
Freibaum et al., 2015, Jovičić et al., 2015, Boeynaems et al., 2016a, Zhang et al., 
2016). Important proteins involved in nucleocytoplasmic transport are clearly 
disrupted by the presence of G4C2 RNA and DPRs. In the present study poly-GR 
expression led to a nuclear depletion and cytoplasmic accumulation of the 
Drosophila homologues of KPNA2 and KPNA4. Poly-GA caused an aggregation of 
Drosophila KPNA2 and KPNA4 in the cytoplasm; these inclusions co-localised with 
poly-GA. No abnormalities in the NPC (as evidenced by staining for FG-repeat nups 
using MAB414 and Nup50 antibodies) or proteins involved in the Ran pathway (as 
evidenced by staining for the Drosophila homologues of RanGAP1 and RCC1) were 
observed as has been previously reported (Zhang et al., 2015; Freibaum et al., 
2015). Some dRCC1 was however present in poly-GA64 inclusions.  
The RAN specific GTPase activating protein RanGAP1 had been shown to have 
increased nuclear localisation and form aggregates in C9ORF72 repeat expansion 
post-mortem motor cortex in contrast to its normally smooth perinuclear staining in 
neurologically healthy controls (Zhang et al., 2015). Increased nuclear localisation of 
the nucleoporin Nup205 was also observed in motor cortex cells by Zhang et al. 
(2015). Strong disruptions of the nuclear pore complex were also reported by 
Freibaum et al. (2015), the authors observed Nup107 in salivary gland cells had a 
distinct nuclear boundary but in cells expressing G4C2-58, the Nup107 staining was 
wrinkled and formed inclusions in close proximity to the nuclear envelope. Human 
iPSCs show increased cytoplasmic and reduced nuclear staining of RCC1, a Ran 
guanine nucleotide exchange factor (Jovičić et al., 2015). In a recent murine poly-GA 
only mouse model both RanGAP1 and Pom121, an inner membrane nuclear protein, 
were sequestered into poly-GA inclusions and were also mislocalised in mice 
expressing 66 G4C2 repeats from a viral vector (Zhang et al., 2016). RanGAP1, 
Nup88 and Nup62 all co-aggregate with the mutant Huntington protein in two 
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separate mouse models of Huntington disease (HD) (Grima et al., 2017). 
Furthermore RanGAP1 was found be aggregated in post-mortem HD striatum whilst 
Nup62 was mislocalised to either the cytoplasm or the nucleus in HD striatum (Grima 
et al., 2017). Additionally the HD-RAN proteins were also shown to impair nuclear 
import (Grima et al., 2017).   Hence strong evidence implicates deficits in the NPC 
and Ran system as potentially causative of the nucleocytoplasmic transport defects.  
However, in the DPR only poly-GR64 model used in this study, despite a 
cytoplasmic TBPH redistribution no gross mis-localisation or disruption of the NPC 
proteins, RanGAP or dRCC1 was observed. For poly-GA no sequestration of 
RanGAP or NPC proteins into poly-GA aggregates was seen like reported by Zhang 
et al. (2016); although dRCC1 was sequestered into cytosolic poly-GA inclusions. 
Both RanGAP and the NPC appear morphologically undisturbed, at least at the time 
points studied whilst dRCC1 nuclear localisation was also preserved despite 
previous reports demonstrating the protein was depleted from the nucleus in C9 
iPSCs by Jovičić et al. (2015). Not all studies have observed changes in the NPC or 
RanGAP; indeed a recent BAC mouse model that produced all 3 sense DPRs and 
demonstrated neuronal loss in the hippocampus in addition to cognitive deficits 
showed no mislocalised, discontinuous or punctate aggregates of RanGAP1 or 
Lamin B at 22 months of age (Jiang et al., 2016). Jovičić et al. (2015) saw no 
changes in RanGAP1 morphology in human C9ALS iPSCs. Although partial 
RanGAP1 mislocalisation was observed for poly-GA by Zhang et al. (2016), another 
poly-GA only mouse model reported no changes in RanGAP1. Similarly, Khosravi et 
al. (2017) found no evidence for altered Ran localisation or RanGAP1 co-
aggregation with poly-GA inclusions in their cellular model; nor could the expression 
of either protein rescue the cytosolic accumulation of a TDP-43 reporter.  
On the other hand, a striking nuclear reduction of the Drosophila homologues of 
KPNA2 (Pendulin) and KPNA4 (Importin-α3) was observed following poly-GR 
expression. Does this nuclear depletion and accumulation of KPNAs in the cytosol 
cause the cytoplasmic TDP-43 accumulation also observed as a consequence of 
poly-GR expression? Nishimura et al. (2010) found knockdown of individual KPNAs 
did not result in cytosolic TDP-43 accumulation; although the authors suggest that 
this may be because TDP-43 is imported into the nucleus by more than one KPNA. 
Indeed Nishimura et al. (2010) found 5 human KPNAs bind TDP-43 (KPNA1, 
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KPNA2, KNPA3, KPNA4, KPNA6 – although KPNA2 and KPNA4 were the strongest 
TDP-43 interactors). However knockdown of KPNB1 and CAS caused TDP-43 to 
accumulate in the cytoplasm and aggregate. Importantly knockdown of KPNB1 and 
CAS disrupted KPNA localisation; with CAS knockdown causing KPNA2 to 
accumulate in the nucleus and KPNB1 knockdown leading to a cytosolic 
accumulation and nuclear depletion of KPNA2 – like observed in this study for the 
Drosophila KPNA2 homologue Pendulin. This led Nishimura et al. (2010) to propose 
inhibition of nuclear import of KPNAs leads to cytosolic TDP-43 accumulation, as 
they directly bind TDP-43, but an initial disruption in KPNB proteins is key to KPNA 
dysfunction. Unfortunately Drosophila CAS and Drosophila KPNAB1 could not be 
tested. Poly-GR caused Drosophila TDP-43 to accumulate in the cytoplasm without 
an observable loss of nuclear Drosophila TDP-43. A nuclear depletion of TDP-43 
may take time to develop and hence may not be observable in the early larval time 
point studied. Interestingly, analogous to what was reported for the effect of poly-GR 
on Drosophila TDP-43 localisation in this study, Nishimura et al. (2010) found 
KPNB1 knockdown caused a nuclear depletion and cytoplasmic accumulation of 
KPNA2, and, as just noted, this was accompanied by a concomitant cytoplasmic 
accumulation of TDP-43 in cells – however, despite this cytosolic increase in TDP-
43, no loss of nuclear TDP-43 was seen in KPNB1 siRNA treated cells.  
How might poly-GR disrupt KPNA localisation? Poly-GR is known to cause oxidative 
stress (Lopez-Gonzalez et al., 2016) and previous work has demonstrated the 
KPNAs are also mislocalised in cells exposed to oxidative stress (Kodiha et 
al., 2008). Poly-GR also causes poorly dynamic SGs that do not disassemble in the 
cytoplasm, the KPNAs have been shown to be SG components. KPNA2 is found 
abundantly in SGs following arsenite treatment (Fujimura et al., 2010). Mahboubi et 
al. (2013) expanded this further finding all three of the KPNA subfamilies (α1, α2 and 
α3) are components of SGs under stress conditions. This recruitment appeared 
specific to SGs as the KPNAs were not found in P-bodies. Mahboubi et al. (2013) 
and Chang and Tarn. (2009) found KPNB family members, which bind the KPNAs in 
the cytoplasm are recruited to SGs however this was not the case for CAS which 
binds the KPNAs in the nucleus (Mahboubi et al., 2013). The KPNAs and KPNB 
were present in more than 90% of SGs in total. The presence of KPNA and KPNB 
proteins in SGs has led to the suggestion that they are also involved in SG assembly 
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(Mahboubi et al., 2013). Mahboubi et al. (2013) suggest KPNA and KPNB proteins 
may be involved in transporting RNAs and proteins to the growing SG. Hence it will 
be important to look if KPNA and KPNB proteins are present in the poorly dynamic 
SGs induced by poly-GR (Lee et al., 2016). Deficits in the NPC resulting from poly-
GR expression may also be involved in the cytoplasmic accumulation of the KPNAs 
observed. Just because no morphological deficits were observed this does not mean 
the function of the NPC is not impaired; indeed poly-PR, binds to the FG-repeats in 
the central channel of the pore making the NPC less permeable. Poly-GR may act 
through similar mechanisms meaning the KPNAs are unable to diffuse through the 
NPC. Indeed, as just noted indirect support that a combination of NPC and KPNA 
dysfunction could be important for TDP-43 mislocalisation comes from Khosravi et 
al. (2017) who found overexpression of NPC proteins, KPNA3 and KPNA4 but not 
Ran or RanGAP1 rescues cytosolic TDP-43 accumulation. Poly-GR also strongly 
interacts with KPNA2/Pendulin hence some aspect of this direct interaction may also 
disrupt the localisation of this nuclear import adaptor protein (Lee et al., 2016).  
Both KPNA2 and KPNA4 Drosophila homologues were sequestered into poly-GA 
inclusions in the cytoplasm consistent with previous reports in murine models 
demonstrating poly-GA sequesters proteins involved in nucleocytoplasmic transport 
into inclusions (Zhang et al., 2016). A link between TDP-43 dysfunction, poly-GA and 
the KPNAs has recently been shown by Khosravi et al. (2017). The authors 
observed poly-GA expression causes a TDP-43-NLS reporter to be recruited 
cytoplasmic granules in transfected hippocampal neurons.  Khosravi et al. (2017) 
found KPNA/B-mediated nuclear import, the import pathway involved in TDP-43 
shuttling, is perturbed by poly-GA expression. Poly-GA inhibited the nuclear import of 
the KPNA4 cargo p65. In addition poly-GA specifically inhibited KPNA/B-mediated 
nuclear import as poly-GA had no impact on TNPO mediated nuclear import which 
involves the binding of TNPO to PY-NLS motifs. The localisation of a reporter 
containing the PY-NLS of hnRNPA1 was not affected by poly-GA expression. Finally 
Khosravi et al. (2017) observed overexpression of proteins involved in importin α/β-
mediated shuttling of TDP-43 such as KPNA3, KPNA4 and NUP62, but not Ran or 
RanGAP1, restored nuclear localisation of the TDP-43-NLS. How might poly-GA 
cause cytoplasmic aggregation of KPNAs? Poly-GA amyloidogenic fibrils form a 
parallel β-sheet structure; Woerner et al. (2016) demonstrated in a landmark paper 
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that cytoplasmic β proteins sequester nucleocytoplasmic transport proteins – 
including KPNA2 and KPNA4 – into cytoplasmic inclusions. This was specific to 
cytoplasmic β proteins aggregates, as nuclear β proteins aggregates did not impact 
the localisation of nucleocytoplasmic transport proteins. In support of this Khosravi et 
al. (2017) found rerouting poly-GA aggregates into the nucleus prevented 
cytoplasmic mislocalisation of TDP-43. Hence the secondary structure of poly-GA 
may underlie the sequestration of KPNA2 and KPNA4 into poly-GA inclusions. TDP-
43 directly binds to KPNA2 and KPNA4 (Nishimura et al., 2010) hence the presence 
Drosophila TDP-43 in poly-GA inclusions could be due to its direct binding to these 
nuclear adaptors in the cytoplasm.  
Finally no changes in the localisation of nucleocytoplasmic transport proteins was 
observed following the expression of a G4C2 RNA only construct which does not 
produce DPRs. This argues the disrupted nucleocytoplasmic transport observed in 
G4C2 fly models is attributable to the actions of the DPRs, rather than the G4C2 RNA 
(Zhang et al., 2015; Freibaum et al., 2015). 
7.4.2  Conclusion 
 
In summary an investigation of the different components involved in 
nucleocytoplasmic transport, including proteins involved in the Ran pathway 
(RanGAP1 and RCC1) and the nuclear pore complex (FG-repeat containing Nups)  
revealed the Drosophila homologues of nuclear import adaptor proteins, KPNA2 
(Pendulin) and KPNA4 (Importin-α3), involved in the nuclear import of TDP-43, are 
depleted from the nucleus and accumulate in the cytoplasm following poly-GR 
expression, suggesting a loss of KPNA function. Interestingly although Drosophila 
KPNA2 and KPNA4 are both sequestered by poly-GA into aggregates they are not 
depleted from the nucleus like what is observed following poly-GR expression 
suggesting a failure in nuclear import of the KPNAs is important to the phenotype 
observed in the poly-GR salivary gland cells. An inhibition of the nuclear import of 
KPNAs has been proposed previously to lead to cytosolic TDP-43 accumulation 
(Nishimura et al., 2010). Hence a loss of KPNA function may be responsible for the 
cytoplasmic TBPH accumulation observed following poly-GR expression.  
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Chapter 8: Human KPNA4 is affected in 
both sporadic FTD-TDP and C9FTD/ALS 
post-mortem tissue and is sequestered 
into pathological TDP-43 inclusions 
TDP-43 is transported into the nucleus via this classic nuclear import pathway 
(Nishimura et al., 2010). The localisation Importin-α3, the Drosophila homologue of 
KPNA4 and Pendulin, the Drosophila homologue of KPNA2, are disrupted via poly-
GR expression. KPNA4 and KPNA2 directly bind TDP-43 and are involved in its 
nuclear transport (Nishimura et al., 2010). KPNA2 nuclear staining was previously 
shown by Nishimura et al. (2010) to be reduced in FTD-TDP frontal cortex compared 
to controls; furthermore, cytoplasmic KPNA2 staining was also absent in FTD-TDP 
neurons. KPNA2 levels were also downregulated in FTD-TDP frontal cortex tissue. 
KPNA2 cytoplasmic staining was increased in ALS spinal cords compared to 
controls. To investigate whether KPNA4 expression and localisation is also disrupted 
in TDP-43 proteinopathies, the abundance and distribution of KPNA4 and KPNA2 
was investigated in the frontal cortex of C9FTD and sporadic TDP-43 positive FTD 
(FTD-TDP) patients. Details on the cases used for the human post-mortem study 










8.1 Soluble protein levels of KPNA4 are downregulated 
in SFTD-TDP and C9FTD frontal cortex and present in 
the detergent-insoluble UREA fraction 
 
To determine whether nuclear import may be perturbed in sporadic FTD-TDP and 
C9FTD, western blotting was performed on frontal cortex lysate from controls, 
sporadic FTD-TDP and C9-FTD cases (figure 8.1A & B). Membranes were probed 
for the Drosophila homologue of Importin-α3 – KPNA4. The protein levels of the 
RIPA soluble fraction of KPNA4 were lower in both sporadic FTD-TDP and C9FTD 
frontal cortex samples compared to neurologically healthy controls (figure 8.1A). 
Although there was a clear trend showing soluble levels of KPNA4 were lower in the 
disease brain - this was not statistically significant likely due to the low number of 
samples probed (n=4-5) (figure 8.1B). Two of the disease samples (lanes 8 and 11, 
figure 8.1B) show no KPNA4 signal. A vital element of postmortem research is tissue 
quality, which unlike animal tissue – can not be controlled accurately at death (Stan 
et al., 2006). Numerous pre- and postmortem factors influence tissue quality which in 
turn influences the accuracy of results (Stan et al., 2006). To determine whether the 
lack of KPNA4 in these samples is an accurate representation of KPNA4 levels or a 
confound due to poor tissue quality, the standard of these two cases should be 
assessed using measures such as tissue pH, markers of RNA quality (such as RNA 
Integrity Number) and several measures of protein quality.   
Despite this the decrease in the soluble levels of KPNA4 suggests the protein could 
be accumulating in the insoluble fraction, indicating aggregate formation. 
Aggregation prone disease related proteins such as tau and amyloid-β are insoluble 
in strong-detergent buffers but can be solubilised by urea buffer and analysed on 
SDS-PAGE (David et al., 2010). To explore the possibility that KPNA4 might have 
altered solubility in disease tissue, RIPA extracted insoluble pellets from 
homogenised frontal cortex samples were treated with urea buffer to isolate the 
detergent insoluble proteins from the pellet. No KPNA4 signal was seen from the 
urea soluble fraction from control cases. However, for sporadic FTD-TDP and C9-
TDP, KPNA4 was present in the urea fraction, with a high molecular weight band 
seen in the stacking gel; especially in C9FTD cases (figure 8.1A). This suggests the 








Figure 8.1 | Western blot analysis of extracts from post-mortem frontal cortex 
of patients with sporadic FTD-TDP, C9FTD and control brain samples. (A & B) 
Accumulated KPNA4 is found in the insoluble fraction of sporadic FTD-TDP and 
C9FTD samples (black arrow), but not in controls. (B) Quantitative western blotting 
soluble KPNA4 indicates down-regulation in both conditions however this was not 





8.2 Immunolabeling reveals mislocalisation and 
aggregation of KPNA4 in sporadic FTD-TDP and C9FTD 
frontal cortex 
 
The presence of KPNA4 in the urea fraction suggests the protein may be forming 
inclusions in the sporadic FTD-TDP and C9FTD brain. To investigate localisation of 
KPNA4 in disease frontal cortex sections from control, sporadic FTD-TDP and C9-
FTD cases were probed with a KPNA4 specific antibody. KNPA4 immunolabeling in 
controls showed a uniform distribution in neurons with both nuclear and cytoplasmic 
distribution (figure 8.2 a, b, c, d). In sporadic FTD-TDP cases, there are two different 
staining patterns; either increased nuclear staining accompanied by a lesser intensity 
of cytoplasmic labelling (figure 8.2 e, f) or nuclear clearing with preserved or mildly 
increased cytoplasmic positivity (figure 8.2 e, g). In C9FTD cases there was 
increased KPNA4 immunoreactivity compared to controls and sporadic FTD-TDP 
(figure 8.2A i). In addition KPNA4 staining in C9FTD revealed cells with absent 
nuclear staining and harbouring immunoreactive cytoplasmic inclusions (figure 8.2 
k). Further positivity in neuronal cell processes consistent with axons and dystrophic 
neurites was also observed in C9FTD frontal cortex. (figure 8.2l). Interestingly, in 
both sporadic FTD-TDP and C9FTD brains nuclear depletion was often 
accompanied by nucleolar immunoreactivity (figure 8.2 f, j). Semi-quantitative 
analysis of KPNA4 DAB immunolabeling was performed by neuropathologist Dr. 
Tibor Hortobagyi (KCL). KPNA4 localisation was further probed via 
immunofluorescence. KPNA4 was distributed between the cytoplasm and nucleus in 
controld (figure 8.3 a, b, c; figure 8.4) as has been previously reported in human 
spinal cord (Latiman et al., 2017) and cell lines (Woerner et al., 2016). In the 
sporadic FTD-TDP (figure 8.3 d, e, f; figure 8.4) and C9FTD (figure 8.3 g, h, I; figure 
8.4) cases KPNA4 was completely depleted in a number of some neurons. Hence 
these data suggest KPNA4 is mislocalised in FTD TDP-43 proteinopathies. A semi-
quantitive analysis of the frequency with which this KPNA4 mislocalisation was 



















Figure 8.2 | KPNA4 localisation is disrupted in the post-mortem frontal 
cortex of patients with sporadic FTD-TDP, C9FTD but not control brain 
samples. (a-d) DAB immunolabeling in controls showed a uniform KPNA4 
distribution in neurons with both nuclear and cytoplasmic localisation. (e-h) In 
sporadic FTD-TDP cases, cells lacking nuclear KPNA4 immunolabeling show 
nucleolar immunoreactivity (e, f). Cells with increased nuclear staining show 
decreased cytoplasmic labelling (e, g, black arrowhead), whereas cells with 
nuclear depletion show preserved or mildly increased cytoplasmic 
immunolabeling (e, h, black arrows). (i-l) In C9ALS/FTD cases, KPNA4 DAB 
immunolabeling in the nucleolus is also observed compared to sporadic FTD-TDP 
and control cases (j). Numerous cells with absent nuclear KPNA4 immunostaining 
display immunoreactive cytoplasmic inclusions (k, white arrowhead) and also (l) 
immunolabeled neuronal cell processes indicative of dystrophic neurites (white 









Figure 8.3 | Nuclear depletion and cytoplasmic accumulation of KPNA4 in 
sporadic FTD-TDP and C9FTD human frontal cortex. (a-c) KPNA4 
immunolabeling in neurons of control cases reveals uniform distribution in both 
nucleus and cytoplasm. (d-f) In sporadic FTD-TDP cases, immunolabeling 
reveals nuclear depletion and cytoplasmic accumulation of KPNA4. (g-i) In 
C9FTD cases, immunolabeling reveals further pronounced nuclear depletion and 









Figure 8.4 | Nuclear depletion of KPNA4 in sporadic FTD-TDP and C9FTD 
human frontal cortex. KPNA4 immunolabeling in neurons of control cases 
reveals a uniform distribution in both nucleus and cytoplasm. In sporadic FTD-
TDP cases, a nuclear depletion and cytoplasmic accumulation of KPNA4 was 
observed. In C9ALS/FTD cases, a further pronounced nuclear depletion and 
cytoplasmic accumulation of KPNA4 was seen. Scale bar, 10μm. 
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8.3 KPNA4 overlaps with phospho-TDP-43 inclusions in 
patient brains  
 
Insoluble aggregates of the RNA binding protein TDP-43 is the pathological hallmark 
of C9ALS/FTD (Mackenzie et al., 2014). Using an antibody specific for 
phosphorylated TDP-43 (pTDP-43) sporadic FTD-TDP, C9FTD and control frontal 
cortex tissue was co-stained for both pTDP-43 and KPNA4. KNPA4 immunolabeling 
in controls showed a uniform distribution in neurons with both nuclear and 
cytoplasmic distribution with a weak nuclear TDP-43 labelling (figure 8.5). pTDP-43 
inclusions were detectable in both sporadic FTD-TDP and C9-FTD frontal cortex 
sections but not in controls (figure 8.5). In sporadic FTD-TDP cases and C9-FTD 
neurons were seen in which KPNA4 was depleted from the nucleus and 
accumulates in the cytoplasm where it co-localised with pTDP-43 inclusions (figure 
8.5). In the FTD-TDP and C9FTD cases investigated in this study the KPNA4 
inclusions were more prominent in the C9FTD and always positive for pTDP-43. 
However numerous cells also showed a nuclear depletion of KPNA4 but no p-TDP-
43 inclusion (figure 8.6). Further cases are needed to quantify the severity of KPNA4 












Figure 8.5 | KPNA4 is present in phospho-TDP43 inclusions in sporadic 
FTD-TDP, and C9FTD frontal cortex. KPNA4 immunolabelling in frontal cortex 
control cases reveals uniform neuronal distribution in both nucleus and cytoplasm 
(top row); immunolabeled phospho-TDP-43 inclusions are detectable in both 
sporadic FTD-TDP (middle row) and C9FTD (lower row). Note that in both 
sporadic FTD-TDP and C9FTD, but not in controls, immunolabelling reveals 
nuclear depletion and cytoplasmic accumulation of KPNA4 that overlaps with 









Figure 8.6 | KPNA4 is present in phospho-TDP43 inclusions in sporadic 
FTD-TDP, and C9FTD frontal cortex. KPNA4 immunolabelling in frontal cortex 
control cases reveals uniform neuronal distribution in both nucleus and cytoplasm 
(top row); immunolabeled phospho-TDP-43 inclusions are detectable in both 
sporadic FTD-TDP (middle row) and C9FTD (lower row). Note that in both 
sporadic FTD-TDP and C9FTD, but not in controls, immunolabeling reveals 
nuclear depletion and cytoplasmic accumulation of KPNA4 that overlaps with 
accumulated phospho-TDP-43 (pTDP-43; arrowheads). Scale bars, 22µm. 
266 
 
8.4 KPNA4 is not sequestered into DPR inclusions in 
C9FTD frontal cortex  
 
Neuronal cytoplasmic and intranuclear inclusions of RAN translated DPRs are the 
major and distinctive pathological hallmark of the C9ALS/FTD brain (Mori et al., 
2013a; Ash et al., 2013). C9FTD, FTD-TDP and control frontal cortex tissue was co-
stained for KPNA4 and each of the three sense DPRs, poly-GP, poly-GA and poly-
GR. Poly-GA was stained for using the mouse monoclonal antibody 5E9 antibody 
validated in Mackenzie et al. (2013) and later confirmed as the best of the currently 
available poly-GA antibodies for immunohistochemistry (Mackenzie et al., 2015). 
Star-shaped neuronal cytoplasmic inclusions of poly-GA were seen in C9FTD frontal 
cortex as has been previously reported (Ash et al., 2013; Mori et al., 2013; Schludi et 
al., 2015). Cytosolic KPNA4 partially overlapped with poly-GA inclusions (figure 8.7). 
For poly-GP the previously characterised mouse monoclonal antibody generated in 
this study was used to probe for the peptide. Staining revealed star like cytoplasmic 
poly-GP inclusions in the frontal cortex that again partially overlapped with KPNA4 
cytoplasmic staining. Poly-GR was stained for using the rat monoclonal 5H9 
antibody (Mori et al., 2013), the most sensitive antibody for detecting poly-GR 
inclusion bodies in patient tissue (Mackenzie et al., 2015). Poly-GR inclusions were 
relatively rare and difficult to find however when found appeared to also overlap 
slightly with cytoplasmic KPNA4. However, KPNA4 did not appear to be sequestered 
into DPR inclusions. Further, as was the case for phospho-TDP-43 staining, cells 
also displayed KPNA4 nuclear depletion without the presence of a DPR aggregate 
(figure 8.8). Additional case studies are needed to quantify if nuclear depletion of 

















Figure 8.7 | KPNA4 cytoplasmic staining partially overlaps with DPR 
inclusions. In C9ALS/FTD frontal cortex sections, poly-GA, poly-GP and poly-GR 










Figure 8.8 | KPNA4 nuclear depletion is seen in cells without DPR 
inclusions. In C9FTD frontal cortex sections KPNA4 nuclear depletion is seen 
with (arrows) and without (arrow heads) poly-GA, poly-GP and poly-GR 





8.5.1  KPNA4 mislocalisation is seen in both C9FTD and FTD-
TDP frontal cortex 
 
Within the human genome there are seven different KPNA isoforms. The KPNA 
family of nuclear transport receptors are subdivided into three families named α1, α2 
and α3 (Pumroy and Cingolani, 2015). All KPNA isoforms have conserved protein 
structure consisting of an N-terminal auto inhibitory, importin-β-binding (IBB) domain 
and a helical C-terminal Arm (Armadillo)-core that binds to protein cargoes with an 
NLS (Pumroy and Cingolani, 2015). Although the KPNA isoforms have almost 
identical amino acid sequences and 3D structures – they show a high degree of 
selectivity for distinct NLS containing protein cargoes (Pumroy and Cingolani, 2015).  
The α1 family consists of karyopherin α2 (KPNA2) and the recently discovered 
karyopherin α7 (KPNA7) (Kelley et al., 2010). KPNA2 is the major NLS binding 
karyopherin whilst little is known about KPNA7 (Pumroy and Cingolani, 2015). 
Despite being members of the α1 family, KPNA2 and KPNA7 show distinct 
subcellular localisations. The steady state cellular localisation of KPNA2 is 
predominantly cytoplasmic and KPNA7 exclusively nuclear, suggesting divergent 
functions in the α2 family (Kelley et al., 2010). KPNA2 shows high specificity for 
several important protein cargos linked to C9ALS/FTD including ADAR3 (Maas and 
Gommans, 2009), a member of the ADAR RNA editing family of enzymes. ADAR3 
has been shown to colocalise with sense RNA foci in C9 IPSC motor neurons and 
post-mortem motor cortex (Donnelley et al., 2013). Furthermore the protein 
accumulates in the nucleus of patient tissue and knockdown of ADAR3 decreases 
RNA foci numbers in iPSC neurons (Donnelley et al., 2013).  
The α2 family consists of karyopherin α3 (KPNA3) and karyopherin α4 (KPNA4) 
(Pumroy and Cingolani, 2015). KPNA3 and KPNA4 have exceptionally high 
homology in both identity and sequence, with 86% identity and 92% sequence 
conservation (Pumroy and Cingolani, 2015). KPNA3 and KPNA4 have been shown 
to be the NTR for several important NLS containing proteins including NF-κB 




The α3 family consists of karyopherin α1 (KPNA1), karyopherin α5 (KPNA5) and 
karyopherin α6 (KPNA6) (Pumroy and Cingolani, 2015). The family are highly 
homologous and hence are likely to have similar functions (Pumroy and Cingolani, 
2015). The most studied interaction between a protein cargo transported into the 
nucleus and members of the α3 family is transport of the phosphorylated STAT1 
homodimer or the STAT1/STAT2 heterodimer into the nucleus by KPNA1 (Pumroy 
and Cingolani, 2015). 
The KPNAs are involved in the classic nuclear import pathway of which half of all 
human proteins are transported by (Mihevc et al., 2017). In this pathway, the KPNAs 
bind to the classic NLS on their protein cargoes. KPNB1 then binds to the KPNA-
cargo dimer and the whole complex translocates across the nuclear pore into the 
nucleus (Mihevc et al., 2017). Once in the nucleus this tripartite complex dissociates 
by RAN-GTP binding to KPNB1; the KPNB1-RAN-GTP complex is recycled back to 
the cytoplasm and the KPNAs transfer back into the cytoplasm in a complex of 
KPNA, RAN-GTP and CAS (cellular apoptosis susceptibility) (Mihevc et al., 2017). 
TDP-43 nuclear import occurs through the KPNA/KPNB1 import pathway (Nishimura 
et al., 2010; Mihevc et al., 2017). KPNA mediated TDP-43 nuclear transport uses the 
N-terminal bipartite nuclear localisation signal of TDP-43 (Ayala et al., 2008; 
Winton et al., 2008). Nishimura et al. (2010) using a GST-pulldown found all 
members of the KPNAs bind to TDP-43 directly hence likely mediate its import into 
the cytoplasm. However, the GST-pulldown showed TDP-43 has preferential binding 
to members of the α2 family – KPNA3 and KPNA4. Additionally, KPNA binding to 
TDP-43 was abolished using mutant TDP-43ΔNLS. Although RNAi interference to all 
karyopherin α isoforms did not induce a cytoplasmic accumulation of TDP-43 
suggesting redundancy in KPNA isoform transport of TDP-43. Interestingly 
Nishimura et al. (2010) saw RNAi knockdown of two members of the karyopherin β 
family - karyopherin-β1 (KPNB1) and CAS did lead to the cytoplasmic accumulation 
and formation of TDP-43 aggregates although GST pulldown revealed KPNB1 
binding to TDP-43 is much weaker than TDP-43 binding to KPNAs 3 and 4. 
Nishimura et al. (2010) found in FTD-TDP post-mortem cortical lysate that CAS and 
KPNA2 were significantly downregulated. Immunohistochemical analysis revealed 
nuclear KPNA2 and both CAS nuclear and cytoplasmic immunoreactivity were 
reduced in patient cortical neurons. In sporadic ALS spinal cord lysate KPNA2 and 
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KPNA6 protein levels were significantly increased with KPNA2 cytoplasmic staining 
increased in ALS spinal cords compared to controls. Hence the classic nuclear 
import pathway is affected in both diseases characterised by TDP-43 cytoplasmic 
accumulation and aggregation. Intriguingly CAS was strongly affected in FTD-TDP 
but not sporadic ALS suggesting differences between the two diseases. Interestingly 
KPNB1 knockdown caused a nuclear loss of KPNAs – whilst CAS knockdown 
caused KPNA cytoplasmic accumulation; furthermore, as noted previously KPNB1 
and CAS knockdown cause cytoplasmic TDP-43 accumulation. Nishimura et al. 
(2010) propose that this loss of KPNAs from the cytoplasm or an inhibition of nuclear 
import could lead to increased cytosolic TDP-43.  
In the current study both a nuclear loss and nuclear accumulation of KPNA4 is seen 
in sporadic FTD-TDP and C9-FTD. This finding taken together with the Nishimura et 
al, (2010) results indicates a disruption of the KPNA/KPNB1 import pathway may 
underlie disrupted transport of TDP-43 and its subsequent cytoplasmic 
accumulation. Indeed, other important members of the KPNA/KPNB1 import 
pathway have demonstrated to be affected in disease associated tissue. For 
example, nuclear contour irregularity and a strong reduction in nuclear KPNB1 was 
seen in ALS spinal cords (Kinoshita et al., 2009).  Xiao et al. (2015a) demonstrated 
that KPNB1, and Ran-GTPase pathology correlates with cytoplasmic TDP-43 
accumulation and aggregation. Interestingly a loss of the C9ORF72 short isoform 
from the nuclear membrane also correlated with KPNB1, RAN and TDP-43 
mislocalistion. This supports the Nishimura et al. (2010) cell work showing KPNB1 
disruption causes enhanced cytosolic TDP-43 localisation and work in a progranulin 
knockout mouse model which demonstrated RAN-GTPase nuclear trafficking 
correlated with a reduction in TDP-43 from the nucleus (Ward et al., 2014). Not all 
DAPI labelled cells show KPNA4 immunolabeling. There are 7 KPNA human 
isoforms, although they have different cargoes, there is likely redundancy in their 
function. Indeed all 7 have been shown to bind TDP-43 to different extents 
(Nishimura et al., 2010). Hence the levels of individual KPNA isoforms could depend 
on the precise needs of a cell at a certain time. For example, both transcript and 
protein levels of the KPNAs dynamically change during oocyte development in the 
mouse (Mihalas et al., 2015). Whether the transcript and protein levels of KPNAs are 
also dynamic in adult cells, such as neurons, is unknown, however it is plausible to 
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speculate this could occur as different cargoes are transported by different KPNAs. 
There could also be cell-type specific expression differences of KPNA isoforms 
between neurons, different neuronal subtypes and glia. For example, the different 
KPNA isoforms are differentially expressed in oligodendrocytes progenitor cells 
(Latiman et al., 2017). Co-staining of KPNA4 with markers for neurons, astrocytes 
and oligodendrocytes should be performed to investigate this possibility. 
The data from the present study supports pathological disturbances in members of 
the classical nuclear import pathway leads to accumulation of TDP-43 in the 
cytoplasm. A loss of KPNAs from the cytoplasm, or the inhibition of their import into 
the nucleus, may lead to cytoplasmic accumulation of TDP-43 as has been proposed 
by Nishimura et al, (2010). Further work is needed to see whether the KPNA4 
pathology seen in current body of work correlates with cytoplasmic TDP-43 
accumulation however its sequestration into TDP-43 cytoplasmic inclusions suggests 
this may be the case.   
The majority of disease causing proteins in ALS and FTD are RNA binding 
proteins, in disease these proteins are depleted from the nucleus and form 
inclusions in the cytoplasm. How this nuclear depletion and subsequent 
cytoplasmic accumulation initiates is unknown particularly in sporadic forms of both 
diseases (Boeynaems et al., 2016b). Boeynaems et al. (2016b) through both a 
review of the literature and bioinformatics analysis found RNA binding proteins and 
nucleocytoplasmic transport have major roles in ALS and FTD pathogenesis. The 
authors propose defective nuclear transport bridges nuclear loss and cytoplasmic 
accumulation, having a key initiating role in disease. In support of this studies have 
shown without doubt nucleocytoplasmic transport is a implicated by both G4C2 RNA 
and DPR toxicity (Zhang et al., 2015, Freibaum et al., 2015, Jovičić et al., 2015, 
Boeynaems et al., 2016). The observation that KPNA4 is perturbed sporadic FTD-
TDP cases further supports this notion that disturbances in nucleocytoplasmic 
transport are a key disease mechanism in ALS and FTD. 
There are direct mechanistic links between pathological gain of function features of 
the C9ORF72 repeat expansion and impaired nucleocytoplasmic transport. Shi et al., 
2017) found poly-PR shifts nuclear pore protein FG repeats toward a polymerised 
state proposing this causes impairments in nuclear cytoplasmic shuttling. Defective 
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nuclear pore functioning could lead to a disruption in KPNA shuttling and subsequent 
TDP-43 mislocalisation and aggregation as proposed by Nishimura et al. (2010). 
KPNA4 nuclear depletion was observed in cells however which did not contain a 
DPR inclusion; however it could be the soluble forms of these DPRs that are the 
toxic species responsible which would not be detected using current antibodies 
(Gitler and Tsuiji, 2016). KPNA4 mislocalisation and aggregation however was also 
seen in C9ORF72 negative, sporadic FTD-TDP post mortem tissue. The DPRs are 
obviously not present in C9ORF72 negative sporadic cases; hence the question is 
how KPNA4 is affected in C9ORF72 negative forms of FTD. A recent study by 
Woerner et al. (2016) suggests defective proteostasis could impair nuclear import. 
This study found both cytoplasmic β protein aggregates and human disease proteins 
such as TDP-43 caused mislocalisation of aggregation of nuclear pore proteins and 
nuclear import receptors which led to impaired protein import and mRNA export. For 
example Woerner et al. (2016) investigated the transport of NF-κB. NF-κB is a 
transcription factor transported into the nucleus by KPNA3 and KPNA4. In cells 
expressing cytoplasmic β protein aggregates and TDP-43, NF-Κb nuclear import was 
impaired – the protein remained cytoplasmic. Although the authors did not co-stain 
TDP-43 and KPNA4 in their cellular model, cytoplasmic β protein aggregates were 
shown to sequester KPNA4 into inclusions. The Woerner et al. (2016) paper shows a 
clear dysfunction and co-aggregation of KPNA4 because of cytoplasmic protein 
aggregates; similar results were seen for KPNA2. If as this paper suggests nuclear 
transport deficits are caused by cytoplasmic protein aggregation; defective nuclear 
transport would be predicted to be seen in many neurodegenerative diseases 
characterised by cytoplasmic proteinaceous inclusions – and not just specific to the 
C9ORF72 expansion. Woerner et al. (2016) saw nuclear pore and KPNA dysfunction 
following expression Htt96Q and ParkinΔC. RanGAP1, Nup88 and Nup62 aggregate 
with mutant huntington in two in HD mouse models (Grima et al., 2017). RanGAP1 
aggregated and Nup62 was mislocalised to either the cytoplasm or the nucleus in 
HD striatum (Grima et al., 2017). Hence defective proteostasis leading to the 
aggregation of TDP-43 will disrupt nuclear import and export by sequestering 
nucleocytoplasmic transport proteins that interact with TDP-43 – including direct 
bindings partners like KPNA4. This sequence of events would suggest defective 
nucleocytoplasmic transport occurs after and rather is caused by cytoplasmic TDP-
43 accumulation. The nuclear depletion of KPNA4 was seen in the sporadic FTD-
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TDP frontal cortex was not however always accompanied by a TDP-43 aggregate. 
Hence aggregation of TDP-43 may not be the sole cause of the KPNA4 
mislocalisation observed. TDP-43 regulates the splicing and transcription of 
nucleocytoplasmic transport proteins (Dormann and Haass, 2011). Hence a loss of 
TDP-43 function via cytoplasmic accumulation (without aggregation) and/or nuclear 
depletion may also perturb nucleocytoplasmic transport. How nucleocytoplasmic 
transport and TDP-43 may be disturbed in non-C9ORF72 ALS/FTD is discussed in 
greater depth in the final discussion of this thesis. 
KPNA4 has many interesting properties and functions that makes its dysfunction 
interesting and worth studying further. KPNA4, KPNB1, RanBP1 via a mechanism 
that involves intra-axonal protein synthesis work together to signal nerve injury to 
induce regeneration of an injured axon in the PNS (Twiss et al., 2016). KPNA4 is 
required for oligodendrocyte differentiation (Latiman et al., 2017). Of particular 
interest is the specific role of KPNA4 in the shuttling of NF-Κb from the nucleus to 
the cytoplasm. NF-Κb is a protein complex that regulates a proinflammatory 
signalling, the pathway is activated by proinflammatory cytokines such as IL-1 and 
TNFα (Lawrence, 2009). Upon activation the NF-κB complex translocates into the 
nucleus where it acts as a transcription factor inducing the expression 
proinflammatory genes such as cytokines, chemokines, and adhesion molecules 
(Lawrence., 2009). The NF-kB family of transcription factors are p65, p50, p52, c-
REL, and RELB, these proteins all form homodimers and heterodimers with each 
other during NF-Kb inflammatory signalling (Roussos et al., 2013). In neurons, the 
most common NF-Kb heterodimer is the p65 and p50 complex (Gutierrez and 
Davies, 2011). A classic hallmark of familial and sporadic ALS patients is 
neuroinflammation including astrogliosis and microglial activation (Frakes et al., 
2014). Loss of function mutations in optineurin have been found in ALS patients 
(Maruyama et al., 2010); optoneurin knockdown has been shown to cause 
neurodegeneration by NF-κB activation (Akizuki et al., 2013). Another ALS causing 
gene TBK1 is also linked to inflammation (Oakes et al., 2017).  
NF-Κb p65 mRNA and protein levels are high in sporadic ALS spinal cords 
compared to controls and TDP-43 co-localises with p65 in both patient glia and 
neurons and TDP-43 transgenic mice (Swarup et al., 2011). TDP-43 also acted as 
co-activator of p65 as glial cells expressing higher levels of TDP-43 had an 
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increased inflammatory response. Inhibition of NF-Κb activity reduced 
neurodegeneration and motor phenotypes in TDP-43 transgenic mice (Swarup et al., 
2011). Hence TDP-43 toxicity may in part be mediated by a disturbance of the NF-
Κb signalling pathway. Both immunoprecipitation and immunofluorescence 
demonstrated an interaction between TDP-43 and p65 in temporal lobe neuronal 
nuclei in patients with mild cognitive impairment (Ohta et al., 2014). It has recently 
been shown that TDP-43 prevents TNF-α induced NF-κB nuclear translocation 
inhibiting its activity (Zhu et al., 2015). This TDP-43 mediated inhibition occurred 
through TDP-43 competing for binding with KPNA4 as when TDP-43 was 
overexpressed p65 association with KPNA4 was significantly decreased in TNF-α 
treated cells compared to non-treated control cells (Zhu et al., 2015). As noted 
previously GST-pull down by Nishimura et al. (2010) showed KPNA4 to be the 
strongest binder of TDP-43. Zhu et al. (2015) propose two hypotheses as to how, 
TDP-43 may compete with p65 for KPNA4 binding preventing its nuclear localisation 
thereby inhibiting its activity. Firstly TDP-43 could compete with p65 for KPNA4 
binding in the cytoplasm which reduces p65 nuclear transport; or secondly TDP-43 
binds to KPNA4 in the nucleus reducing its cytoplasmic levels resulting in defective 
p65 nuclear translocation. Additionally, NF-κB gene and protein levels and its 
nuclear activation are significantly reduced in the superior temporal gyrus of 
schizophrenia patients – this was associated with a decrease in the levels of KPNA4 
and an SNP within the KPNA4 locus (Roussos et al., 2013). This SNP in KPNA4 was 
associated with increased schizophrenia susceptibility (Roussos et al., 2013); 
interestingly repeat expansions in C9ORF72 are causes of, albeit rare, 
schizophrenia spectrum disorders (Galimberti et al., 2014). 
8.5.2  Conclusion 
 
The data from the present study further adds to the increasing body of evidence 
showing nucleocytoplasmic transport is disrupted in C9ORF72 expansion associated 
disease. Preliminary evidence from a small number of cases has shown KPNA4 was 
depleted from the nucleus in sporadic FTD-TDP frontal cortex neurons. Further work 
is needed to establish whether KPNA4 nuclear depletion correlates with a 
cytoplasmic accumulation of wild-type TDP-43, TDP-43 inclusions or DPR pathology 
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in larger number of cases. It will also be important to investigate KPNA4 localisation 





Chapter 9: General discussion 
This study has investigated G4C2 derived DPR protein toxicity in a pure G4C2 repeat 
fly model and a DPR protein only fly model. Both models converge to show the 
sense DPR poly-GR is highly neurotoxic; poly-GA and poly-GP were associated with 
milder toxicity in pure repeat flies whilst the G4C2 RNA did not appear to confer 
toxicity. C9ALS/FTD, like 97 % of ALS and 45 % of FTD cases is a TDP-43 
proteinopathy, characterised by the nuclear depletion and formation of cytoplasmic 
aggregates of the RNA binding protein TDP-43 (Ling et al., 2013). TDP-43 pathology 
correlates with neurodegeneration and clinical symptoms in C9ALS/FTD (Mackenzie 
et al., 2014) hence TDP-43 dysfunction is thought to be the most likely effector of 
neuronal loss in C9ALS/FTD (Edbauer and Haass, 2016). A key question in 
C9ALS/FTD is the link between the hexanucleotide repeat expansion and TDP-43 
pathology. Edbauer and Haass, (2016) have proposed an amyloid cascade like 
hypothesis for C9ALS/FTD pathogenesis in which specific stressors cause the 
deposition of TDP-43 into the cytoplasm and its subsequent aggregation. The data 
from the present study demonstrate that the DPRs are key to this disease cascade. 
When an alternative codon poly-GR construct is expressed in flies a striking 
cytoplasmic accumulation of the Drosophila homologue of TDP-43 – TBPH – is 
seen. In addition Poly-GA expression led to the formation of cytoplasmic inclusions 
of TBPH whereas no changes in TBPH localisation were observed following 
expression of the G4C2 RNA only. These results strongly suggest the DPRs are 
involved in the development of TDP-43 pathology seen in C9ALS/FTD. These 
alterations were accompanied by changes in the localisation of importins α2 and α3, 
the Drosophila homologues of karyopherins KPNA2 and KPNA4, respectively. 
However, nucleocytoplasmic transport components such as RanGAP and nuclear 
pore complex proteins previously implicated in C9ALS/FTD were morphologically 
unperturbed. No changes in the localisation of nucleocytoplasmic transport proteins 
were seen following the expression of the G4C2 RNA only. Further, the cytoplasmic 
mislocalisation of TBPH enhanced DPR levels and cytotoxicity. Similar phenotypes 
were observed for patient frontal cortex in sporadic FTD-TDP and C9FTD; with 
KPNA4 being depleted from the nucleus and overlapping with TDP-43 inclusions. 
278 
 
Taken together, these findings establish DPR accumulation as a cause of TDP-43 
proteinopathy. 
9.1 DPR levels and identity correlate with toxicity in a 
G4C2 repeat Drosophila model 
 
RAN translation and motor impairment was investigated in multiple transgenic flies 
containing different lengths of the G4C2 repeat sequence located in the 3’ 
untranslated region of the red fluorescent protein DsRed2. These constructs were 
designed based upon a similar approach used by Li et al. (2008) and Yu et al. (2011) 
to model CAG and CUG RNA expansions in Drosophila for spinocerebellar ataxia 
type 3 (SCA3) and Myotonic Dystrophy Type 1 (DM1). DsRed2 was chosen as it has 
no connection with disease pathogenesis and did not confound repeat associated 
toxicity in these two studies. The DPR expression profile was investigated in flies 
harbouring repeat lengths of 8, 32, 38, 56 and 64. No DPRs were detectable in flies 
with <32 repeats indicating a length dependent threshold for RAN translation. The 
levels and identity of the DPRs produced differed in a construct dependent manner 
which correlated with the linker after the DsRed2 STOP codon 5’ of the start of the 
repeats as flies harbouring constructs with the same 5’ linker sequence produced the 
same DPR expression profile. This differences in DPR expression profile across the 
different constructs facilitated the investigation of the toxicity mediated by different 
levels and combinations of DPRs. 
The 32 and 64 repeat flies both produced high levels of poly-GP and poly-GA 
compared to the other repeat lines. Both the 32 and 64 repeat flies had a late onset 
motor phenotype characterised by a reduction in climbing performance and activity 
at day 40 compared to all other genotypes tested at this time point. Of interest is the 
comparison of these two lines with the 56 repeat flies. The 56 repeat flies produced 
much lower levels of poly-GP and poly-GA and displayed no signs of motor 
impairment at day 40 in the assays used in this study. Importantly transgene 
expression levels (as measured by DsRed2 protein levels) were similar between the 
56 repeat flies and the 32 and 64 repeat flies suggesting the phenotypes seen in the 
32 and 64 repeat lines is not attributable to G4C2 RNA toxicity. This supports work in 
other fly models that have demonstrated expression of the G4C2 RNA on its own 
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(without DPRs) is not toxic. Rather this data suggests the behavioural impairment 
seen in the 32 and 64 repeat lines is caused by the high levels of poly-GP and/or 
poly-GA. Hence poly-GP and/or poly-GA is toxic at high enough levels in aged 
neurons. This study was unable to distinguish whether this age related late onset 
phenotype was caused by poly-GP or poly-GA (or a combination of the two). 
However, evidence for poly-GP toxicity in other model systems is mild at best 
(Freibaum & Taylor, 2017) whereas there is a general consensus that poly-GA is 
toxic when expressed at high enough levels (Moens et al., 2017, Freibaum & Taylor, 
2017) though UPS dysfunction and ER stress (May et al., 2014; Zhang et al., 2014; 
Zhang et al., 2016). Further poly-GP expression was higher than poly-GA in the 56 
line indicating the very low levels of poly-GA may be why no day 40 phenotype was 
seen in these flies; conversely this suggests high levels of poly-GA expression may 
be the biggest contributor to the day 40 motor impairment observed in the 32 and 64 
repeat lines. Indeed Mizielinska et al. (2014) found poly-GA causes a reduction in life 
span from day 50 onwards in flies. Hence investigations into how poly-GA 
contributes to age-related toxicity in flies is an interesting future avenue of research. 
A severe early onset motor impairment was observed in the 38 repeat flies that 
produced all three sense DPRs – poly-GP, poly-GA, poly-GR. This motor phenotype 
was again attributable to DPR toxicity rather than G4C2 RNA toxicity as even though 
transcript levels were higher in the 38 repeat line (as evidenced by DsRed2 
expression levels), the generation of a fly line with 2x copies of the 64 construct was 
used to confirm this did not contribute to the early phenotype. Flies harbouring two 
copies of the 64 repeat construct had significantly higher levels of DsRed2 protein 
compared to both flies with a single copy of the 64 construct and the 38 repeat line. 
There was no significant difference in day 5 climbing performance between the 2x 64 
flies and the 1 x 64 flies, however both were significantly impaired compared to the 
38 repeat line (appendix 2; figure A2). Hence DPR toxicity (and not DsRed2 
expression or G4C2 RNA levels) causes the early-day 5 behavioural phenotype seen 
in the 38 G4C2 repeat line. The 38 repeat line is unique as it was the only fly line in 
which poly-GR was detected; hence the presence of poly-GR correlates with severe 
early onset toxicity. This is in line with other studies in Drosophila that poly-GR highly 
neurotoxic (Mizielinska et al., 2014; Yang et al., 2015; Freibaum et al., 2016).  
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In summary this study demonstrates the DPRs and not the G4C2 RNA correlates with 
toxicity in a Drosophila model of the G4C2 repeat expansion in C9ORF72, consistent 
with what has been observed in other Drosophila models (Mizielinska et al., 2014; 
Tran et al., 2015). However, the extent of DPR toxicity was dependent upon DPR 
identity and expression levels. Both poly-GP and poly-GA appear well tolerated, 
however when the expression levels are high enough in combination with age they 
appear sufficient to trigger late onset disease related phenotypes. Poly-GR 
expression on the other hand correlated with a severe early onset motor impairment. 
Flies expressing high levels of poly-GA and poly-GP (not poly-GR) had no 
behavioural impairment at days 5 and 20 whereas by day 20 flies producing 
detectable levels of poly-GR were unable to climb. This demonstrates poly-GR is 
highly toxic compared to poly-GA and poly-GP in line with the general consensus in 
the field that the arginine DPRs specifically have an important pathogenic role in 
C9ALS/FTD (Gitler and Tsuiji, 2016; Freibaum and Taylor, 2017). The lack of spatial 
correlation between the DPRs and regions of the brain showing the most severe 
neurodegeneration is still a contentious issue (Gitler and Tsuiji, 2016). However 
post-mortem analysis only visualises neurons that have survived; if the arginine 
DPRs are as toxic as they appear to be in model systems these neurons may 
already be lost. Further soluble DPR species, which cannot be visualised with 
current antibodies, rather than aggregates, may mediate toxicity. For example, 
aggregates of amyloid-beta do not correlate with neurodegeneration in Alzheimer’s 
disease; rather it is thought the soluble oligomeric form of the protein is what confers 
toxicity (Edbauer and Haass, 2016). 
9.2 DPR, but not G4C2 RNA expression cause 
Drosophila KPNA2, KPNA4 and TDP-43 mislocalisation 
 
C9ALS/FTD is TDP-43 proteinopathy characterised by the nuclear depletion of TDP-
43 and its accumulation into aggregates in the cytosol (Mackenzie et al., 2015). 
TDP-43 pathology correlates with neurodegeneration in C9ALS/FTD (Mackenzie et 
al., 2015) hence it is thought TDP-43 is the most likely effector of neuronal death in 
C9ALS/FTD (Edbauer and Haas, 2011). The question is how does TDP-43 become 
depleted from the nucleus in expansion carriers. Murine models show TDP-43 
aggregation occurs after the formation of both DPRs and RNA foci (Liu et al 2016a). 
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Furthermore, post-mortem analyses on C9ORF72 expansion carriers who died early 
of the disease show abundant DPR pathology only suggesting DPR pathology 
precedes that of TDP-43 (Proudfoot et al., 2015; Baborie et al., 2015; Vatsavayai et 
al., 2016). Based on such findings an amyloid cascade hypothesis for C9 mediated 
neurodegeneration has been proposed in which stressors causes TDP-43 
aggregation and cytoplasmic mislocalisation (Edbauer and Haass, 2016). The DPRs 
and/or RNA foci are argued to be such stressors (Edbauer and Haass, 2016). Hence 
this project investigated whether the G4C2 RNA and the sense DPRs, poly-GR and 
poly-GA, are on their own capable of causing TDP-43 mislocalisation.  
 
The expression of the G4C2 RNA from a construct with forms RNA foci but does not 
produce DPRs (Mizielinska et al., 2014) in Drosophila salivary gland cells caused no 
changes in the normally nuclear localisation of Drosophila TDP-43 (TBPH). This 
finding suggests the G4C2 RNA is not sufficient for TDP-43 mislocalisation in 
C9ALS/FTD. Indeed, this supports findings from other Drosophila models of the 
repeat expansion showing G4C2 RNA expression without the downstream of 
production of DRPs is non-toxic (Mizielinska et al., 2014; Tran et al., 2015). Poly-GR 
expression however on its own caused a cytoplasmic accumulation of TBPH, 
whereas poly-GA caused the formation of inclusions of TBPH in the cytoplasm that 
co-localised with poly-GA. These results indicate the DPRs, and not the G4C2 RNA, 
are the key stressor in this cascade, accumulating early during the disease 
progression and subsequently causing TDP-43 to be mislocalised to the cytoplasm. 
Furthermore, it was found cytoplasmic TBPH expression enhances G4C2 related 
motor phenotypes indicating DPR-mediated mislocalisation of TDP-43 contributes to 
toxicity in C9ALS/FTD. Interestingly forcing Drosophila TDP-43 into the cytoplasm 
was shown to enhance DPR production in G4C2 repeat expressing flies, suggesting 
this enhanced phenotype could be attributable to increased DPR levels. Not only 
does this further support the findings from the pure repeat model investigated in this 
study that correlated phenotypes with DPR toxicity rather than G4C2 RNA, but also 
indicates some kind of feedback mechanism where DPR mediated cytoplasmic TDP-
43 accumulation enhances DPR production; potentially further exacerbating TDP-43 




Dormann and Haass, (2011) propose a multi-hit hypothesis for TDP-43 
proteinopathy in which defective nuclear import is the first stage in the initiation of 
TDP-43 pathology. Numerous screens in flies and yeast have shown poly-GR and 
poly-PR directly bind proteins involved in nuclear import and export; further 
modulating nuclear transport can supress and enhance G4C2 RNA and arginine DPR 
toxicity (Zhang et al., 2015; Freibaum et al., 2015; Jovičić et al., 2015; Boeynaems et 
al., 2016; Lee et al., 2016). Furthermore, the localisation and function of 
nucleocytoplasmic transport proteins have been shown to be disrupted in in vivo 
models of DPR and G4C2 RNA toxicity and in the C9ALS/FTD human brain (Zhang 
et al., 2015; Jovičić et al., 2015; Zhang et al., 2016). TDP-43 is shuttled into the 
nucleus via the classical KPNA/KPNB nuclear import pathway. In this pathway, the 
KPNAs bind to the classic NLS on their protein cargoes. KPNB1 binds the KPNA-
cargo dimer, the complex then translocates across the nuclear pore into the nucleus 
(Mihevc et al., 2017). Once in the nucleus this tripartite complex dissociates by RAN-
GTP binding to KPNB1; the KPNB1-RAN-GTP complex is recycled back to the 
cytosol and the KPNAs transfer back into the cytoplasm in a complex of KPNA, 
RAN-GTP and CAS (Mihevc et al., 2017). To explore potential mechanisms as to 
how the localisation of Drosophila TBPH might be disrupted by poly-GR and poly-GA 
expression the morphology of proteins involved in shuttling TDP-43 into the nucleus 
from the cytoplasm was investigated. No abnormities in the NPC (as evidenced by 
staining for FG-repeat nups using MAB414 and Nup50 antibodies) or proteins 
involved in the Ran pathway (as evidenced by staining for the Drosophila 
homologues of RanGAP1 and RCC1) were observed. Although the Drosophila 
homologue of RCC1 was present in some poly-GA inclusions; however no nuclear 
depletion of RCC1 was reported as previously seen in C9ALS iPSCs (Jovičić et al., 
2015). Furthermore, expression of the G4C2 RNA also did not disrupt the morphology 
of any of the nucleocytoplasmic transport proteins investigated arguing against the 
repeat RNA being the primary toxic species in C9ALS/FTD. This is in line with the 
work on the DsRed2-G4C2 repeat fly model characterised in this thesis in which 
toxicity correlated with DPR identity and expression levels. 
 
However, a striking nuclear reduction of the Drosophila homologues of KPNA2 
(Pendulin) and KPNA4 (Importin-α3) was observed following poly-GR expression. 
Poly-GR could cause a nuclear depletion of KPNA proteins through several 
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mechanisms. Firstly, it has been shown poly-GR causes oxidative stress (Lopez-
Gonzalez et al., 2016), the KPNAs are known to be are mislocalised in cells exposed 
to oxidative stress (Kodiha et al., 2008). Poly-GR could induce deficits in the nuclear 
pore complex (NPC) leading to KPNAs mislocalisation. No morphological deficits 
were seen in the NPC following poly-GR expression in salivary gland cells however 
this does not necessarily mean the function of the NPC is not impaired. Aggregates 
of nuclear pore proteins such as those observed in patient tissue (Zhang et al., 2015) 
may take time to occur and are only detectable at end-stage. The larval salivary 
glands have large nuclei which allow a detailed analysis of the morphology of the 
nuclear pore; however, they represent a very early time point in the Drosophila life-
cycle. NPC morphology could be studied in the neurons of aged poly-GR flies using 
the GAL80ts or GeneSwitch systems to temporally control protein expression. The 
arginine DPRs perturb liquid-liquid phase separations (LLPS) important for the 
function of the NPC (Frey and Görlich, 2007; Hülsmann et al., 2012; Lee et al., 2016; 
Schmidt and Görlich, 2016). The formation of the nuclear pore involves a high local 
concentration of FG-repeat domain containing proteins which imposes pore 
structure; the FG-repeat domain is a type of LCD facilitating phase transitions in the 
pore (Frey and Görlich, 2007; Hülsmann et al., 2012; Schmidt and Görlich, 2016). 
Phase separations of the FG-repeat domains into dense polymer networks gives the 
NPC selectivity as the resulting FG hydrogels act as barriers to normal 
macromolecules but are permeable to nuclear transport receptors which are able to 
bind to the FG repeats in addition to their transport cargoes (Schmidt and Görlich, 
2016)  Shi et al. (2017) found poly-PR binds to FG-repeats stabilising their fibrillar 
form; this is predicted to reduce the dynamics of the central channel thereby 
disrupting the transport of molecules across the pore (Kim and Taylor, 2017). Poly-
GR may also block the nuclear pore like poly-PR meaning the KPNAs are unable to 
diffuse through the NPC, therefore becoming depleted from the nucleus and 
accumulating in the cytoplasm. One experiment to test whether NPC dysfunction 
may contribute would be to overexpress NPC proteins to see if this rescues the 
KPNA nuclear depletion seen following poly-GR64 expression.  
 
Poly-GR also disrupts stress granule (SG) dynamics through perturbed LLPS. In 
fact, nucleocytoplasmic transport proteins have been shown to be components of 
SGs. Chang and Tarn, (2009) found both transportin-1 and KPNB1 associate with 
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SGs following arsenite treatment, furthermore transportin-1 was involved in the 
movement of macromolecules between SGs and P-bodies. Both KPNA2 and RAN 
are also found abundantly in SGs following arsenite treatment (Fujimura et al., 
2010). Mahboubi et al. (2013) expanded this further finding all three of the KPNA 
subfamilies (α1, α2 and α3) are components of SGs under stress conditions. The 
three KPNA subfamilies were recruited to SGs by several different stressors 
including oxidant diethyl maleate, arsenite and heat shock treatment. This 
recruitment appeared specific to SGs as the KPNAs were not found in P-bodies. 
Mahboubi et al. (2013) also replicated the results of Chang and Tarn. (2009) 
showing KPNB1, which binds the KPNAs in the cytoplasm, is recruited to SGs 
however this was not the case for CAS which binds the KPNAs in the nucleus. The 
KPNAs and KPNB1 were present in more than 90% of stress granules in total. The 
presence of these nuclear transport receptors in SGs has led to the suggestion that 
they are also involved in the assembly of SGs (Mahboubi et al., 2013). The 
mechanism by which nuclear import factors are recruited to stress granules is not yet 
known. Nuclear transport proteins may be involved in the assembly of SGs by 
delivering SG components to the growing granule (Mahboudi et al., 2013); indeed, 
KPNA2 knockdown causes a reduction in the size of SGs (Fujimura et al., 2010). 
The interaction between nucleocytoplasmic transport proteins and SGs may be 
mediated by their mRNA interactions. Mahboubi et al. (2013) found KPNA2 
associates with poly(A) mRNA, however it is also easy to speculate that they may be 
recruited to SGs by their protein cargoes, such as TDP-43, a known SG component. 
It will therefore be important to look at SGs in poly-GR expressing salivary glands to 
see if KPNA and KPNB proteins are present in the poorly dynamic SGs induced by 
poly-GR (Lee et al., 2016). Modulating the levels of SG proteins could alleviate 
KPNA mislocalisation. Altering stress granule dynamics to promote their disassembly 
may rescue poly-GR induced cytoplasmic accumulation of TBPH. Indeed Lee et al. 
(2016) found knockdown of several SG proteins; including the Drosophila homologue 
of ataxin-2, completely rescues poly-GR and poly-PR survival. It would be interesting 
to see if this knockout of ataxin-2 could rescue TBPH accumulation in the cytoplasm 
in poly-GR64 flies. It is also important to stain for SG markers to see if they co-




Poly-GR64 expression in salivary gland cells and the L3 larval eye disc caused 
Drosophila TDP-43 to accumulate in the cytosol. Could the KPNA dysfunction 
observed in poly-GR expressing salivary gland cells possibly mediate this? Both 
KPNA2 and KPNA4 bind to TDP-43 in the cytoplasm and are involved in its shuttling 
into the nucleus (Nishimura et al., 2010). Nishimura et al. (2010) found a knockdown 
of the individual KPNAs (including KPNA2 and KPNA4) does not result in cytosolic 
TDP-43 accumulation; although the authors suggest that this may be because TDP-
43 is bound and transported into the nucleus by all the KPNAs. However, when 
KPNB proteins were knocked down in cells TDP-43 was found to accumulate in the 
cytoplasm. Importantly knockdown of the KPNB proteins KPNB1 and CAS disrupted 
KPNA localisation. Nishimura et al. (2010) found CAS was markedly downregulated 
in FTD-TDP frontal cortex and consistent with the western blot data, CAS 
immunoreactivity was reduced in the cytoplasm and nucleus in FTD-TDP frontal 
cortex compared to controls. This led Nishimura et al. (2010) to propose inhibition of 
nuclear import of KPNAs leads to cytosolic TDP-43 accumulation (due to their direct 
interaction with the NLS of TDP-43) - however a disruption of the KPNB proteins is 
key to this. Hence poly-GR could disrupt the KPNB proteins, the consequence of 
which is a mislocalisation of the KPNAs and this KPNA dysfunction could then lead 
to the subsequent cytoplasmic accumulation of TDP-43. Drosophila CAS and 
Drosophila KPNB1 in poly-GR expressing flies could not be tested as the antibodies 
either did not work or were no longer available. Looking at how TBPH localisation 
changes in salivary gland cells expressing poly-GR following knockdown or 
overexpression of KPNA and KPNB proteins will help to determine if a dysfunction in 
the nuclear import receptors does indeed contribute to the cytosolic accumulation of 
TBPH. Poly-GR caused Drosophila TDP-43 to accumulate in the cytoplasm without 
an observable nuclear loss. A nuclear depletion of TDP-43 may take time to develop 
and hence may not be observable in the early larval time point studied. Indeed 
Nishimura et al. (2010) found KPNB1 knockdown caused a nuclear depletion and 
cytoplasmic accumulation of KPNA2, which was accompanied by a concomitant 
cytoplasmic accumulation of TDP-43 in cells – however, no loss of nuclear TDP-43 
was seen in these KPNB1 siRNA treated cells. In another Drosophila model that 
looked at TBPH localisation in salivary gland cells expressing G4C2 repeats, the 
protein was found to accumulate in the cytoplasm but was not depleted from the 
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nucleus (Zhang et al., 2015). Hence nuclear loss may become apparent over time 
and be a secondary event after cytoplasmic accumulation.  
 
The finding that the Drosophila KPNAs are depleted from the nucleus at this early 
larval stage (before TDP-43 is depleted from the nucleus) suggests that KPNA/B 
dysfunction may be an early initiating event in C9ALS/FTD pathogenesis. In a review 
of the literature combined with bioinformatics analysis by Boeynaems et al., (2016b) 
suggested that disturbances in nucleocytoplasmic transport play a vital initiating role 
in the development of ALS/FTD. KPNA/B dysfunction is not the only explanation for 
the cytoplasmic accumulation of Drosophila TDP-43 observed following poly-GR 
expression. As noted the arginine DPRs disrupt in the function of the NPC itself 
making it more viscous, potentially disrupting import and export through the nuclear 
pore (Shi et al., 2017). Hence the cytoplasmic accumulation of TBPH could result 
from an inability of the protein to move through the NPC. The KPNA and KPNB 
proteins may be particularly sensitive to defecits in the NPC due to their constant 
shuttling through the nuclear pore. Khosravi et al. (2017) found the expression of 
KPNA3, NUP54 and NUP62, but not RAN or RanGAP, fully restored nuclear 
localization of the NLS-TDP reporter to control levels further suggesting disturbance 
in the dynamics of NPC and nuclear import receptors is important to TDP-43 
mislocalisation. Interestingly Nishimura et al. (2010) found knockdown of KPNB1 and 
CAS cause a more severe cytoplasmic accumulation of TDP-43 than a knockdown 
of Nups suggesting KPNA/B dysfunction is particularly important to TDP-43 
mislocalisation. Poorly dynamic SGs induced as a consequence of poly-GR 
expression (Lee et al., 2016) could also contribute to TDP-43 and KPNA 
mislocalisation. As discussed in this thesis both TDP-43 and the KPNA/B proteins 
are SG components (Liu-Yesucevitz et al., 2010; Bentmann et al., 2012; McGurk et 
al., 2014; Mahboubi et al., 2013). TDP-43 and nuclear import receptors may become 
trapped in these poorly dynamic SGs in the cytoplasm. Some cellular models have 
observed poly-GR and poly-PR cause TDP-43 to co-localise with SG markers (Tao 
et al., 2015; Lee et al., 2016). It will be interesting to look whether KPNA/B proteins 
are present in the poorly dynamic SGs induced by poly-GR and if they colocalise 




Finally, it was also demonstrated that Drosophila TDP-43 and Drosophila KPNA2, 
KPNA4 and RCC1 were sequestered into poly-GA inclusions in the cytoplasm. Poly-
GA inclusions were p62 positive; suggestive of defective autophagy or proteosome 
dysfunction. Poly-GA has previously been associated with nucleocytoplasmic 
transport dysfunction; Zhang et al. (2016) found nucleocytoplasmic transport proteins 
are sequestered into poly-GA inclusions in poly-GA expressing mice. Khosravi et al. 
(2017) found poly-GA cytoplasmic aggregates cause a TDP-NLS reporter to be 
mislocalised to the cytoplasm; however, the overexpression of KPNA3 and KPNA4, 
the receptors for the classical NLS of TDP-43, rescued this. Poly-GA has also been 
previously shown to disrupt UPS function (Zhang et al., 2014; Zhang et al., 2016); 
poly-GA induced defects in protein degradation may cause this KPNA2 and KPNA4 
inclusion formation in the cytoplasm. Poly-GA may sequester KPNAs leading to an 
exclusion of TDP-43 from the nucleus; making it more vulnerable to be sequestered 
by cytoplasmic poly-GA.  Further poly-GA UPS dysfunction may directly promote the 
aggregation of TDP-43.  
 
Interestingly both poly-GA and poly-GR disrupt the localisation of nuclear import 
proteins yet only poly-GR shows severe toxicity. In poly-GA expressing salivary 
glands nuclear import proteins are sequestered into inclusions in the cytoplasm but 
are not depleted from nucleus – whereas in poly-GR expressing salivary glands 
there is a nuclear depletion of said nuclear import proteins. This suggests a loss of 
nuclear function and/or an inability of these proteins to shuttle between the nucleus 
and cytoplasm could be the potential cause of the severe toxicity seen following 
poly-GR expression. For poly-GA, although Drosophila KPNA2 and KPNA4 are 
present in poly-GA aggregates, non-sequestered functional KPNA2 and KPNA may 
still be able to shuttle through the nuclear pore. Indeed, both KPNAs are still present 
in the nucleus in poly-GA expressing salivary glands indicating there is still enough 
of the non-sequestered protein to circumvent the detrimental effects of KPNA 
sequestration into poly-GA cytoplasmic inclusions. It is possible over time toxicity 
might develop as the number of aggregates increase and more of these import 
proteins become trapped in poly-GA aggregates.  
 
The question therefore is why poly-GR causes a depletion of Drosophila KPNA2 and 
KPNA4 from the nucleus and not poly-GA. One explanation could be a direct 
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interaction between soluble poly-GR and these karyopherins in cytoplasm which 
prevents then from completely shuttling into the nucleus. KPNA2 was present in a 
poly-GR/poly-PR protemoics screen performed by Lee et al., (2016), furthermore 
pulldown demonstrated there is a a direct interaction between these DPRs and 
KPNA2. Poly-GR may have a stronger interaction with these nuclear import proteins 
in the cytoplasm than poly-GA. Nuclear import proteins are SG components 
(Fujimura et al., 2010; Markmiller et al., 2018) and poly-GR causes SGs to form 
which are unable to disassemble (Lee et al., 2016). Future work should therefore 
investigate if KPNA2 and KPNA4 are present in cytoplasmic SGs in poly-GR 
expressing Drosophila tissue. Another potential explanation for this karyopherin 
nuclear depletion could be poly-GR induced disrupions of nuclear pore function. No 
morphological abnormalities of the NPC were observed in this study following poly-
GR expression, however this does not mean the function of the pore itself is not 
disturbed. Like membraneless organelles, such as SGs, nuclear pore proteins are 
known to phase transition from soluble aqueous to hydrogel-like states (Schmidt and 
Gorlich, 2016). The FG-Nups that undergo these phase seperations into a hydrogel 
are responsible for the selectivity of the NPC by providing a permeability barrier. The 
arginine DPRs drisrupt phase separations of proteins with intrinsically disordered 
regions and the FG domains of these FG-Nups share features of these intrinsically 
disordered regions such as low hydrophobicity and high net charge (Schmidt and 
Gorlich, 2016). Hence poly-GR may alter biophysical properties of the hydrogels 
disrupting KPNA2 and KPNA4 import into the nucleus. Indeed poly-PR, binds to the 
FG-repeats in the central channel of the pore making the NPC less permeable (Shi 
et al., 2017).   
 
Furthermore, the different mechanisms by which poly-GR and poly-GA could disrupt 
nucleocytoplasmic transport (perturbed SG dynamics and NPC deficits for poly-GR 
and UPS dysfunction for poly-GA) may explain why a cytoplasmic accumulation of 
TBPH is seen from poly-GR expression whereas poly-GA causes TBPH inclusions in 
the cytosol.  Interestingly when poly-GA and TDP-43 inclusions co-aggregate in the 
human brain; poly-GA is found at the centre of these inclusions suggesting it seeds 
TDP-43 accumulation (Mori et al., 2013a; Mackenzie et al., 2013). Lee et al. (2017) 
found poly-GA is also found in the centre of poly-GP/poly-GA co-aggregates, further 
indicating poly-GA sequesters other proteins into aggregates. One caveat is that 
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poly-GA aggregates and TDP-43 pathology do not correlate in the human post-
mortem brain (Mackenzie et al., 2015); however, poly-GA has been shown to be 
transmissible (Chang et al., 2016; Westergard et al. 2016) which may explain the 
lack of spatial correlation between poly-GA inclusions and TDP-43 pathology 
(Edbauer and Haass, 2016). A proposed model for poly-GR mediated cytoplasmic 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































9.3 KPNA4 is mislocalised in both C9FTD and sporadic 
FTD-TDP frontal cortex 
The present study found KPNA4 localisation (the human homologue of Drosophila 
importin-α3) was disrupted in sporadic FTD-TDP and C9FTD human frontal cortex 
tissue. KPNA4 appeared downregulated in disease compared to controls in frontal 
cortex tissue, although the N number was too low for statistical significance. 
Furthermore, KPNA4 was present in the urea insoluble fraction for sporadic FTD-
TDP and C9FTD suggesting it may be forming insoluble inclusions. Finally, KPNA4 
localisation was perturbed in both sporadic FTD-TDP and C9FTD frontal cortex 
compared to controls. In controls the protein was distributed across the cytoplasm 
and nucleus with an enrichment in the cytoplasm. KPNA4 in sporadic FTD-TDP and 
C9FTD frontal cortex neurons was either depleted from the nucleus or accumulated 
within the nucleus. Nishimura et al. (2010) found CAS was downregulated in 
sporadic FTD-TDP frontal cortices; CAS binds to the KPNAs in the nucleus recycling 
them into the cytoplasm, hence the nuclear accumulation of KPNA4 may be caused 
by an inhibition of CAS mediated KPNA4 nuclear export. The nuclear depletion could 
result from KPNB1 dysfunction which binds KPNA4 in the cytosol. The disruptions in 
the function the NPC and SG dynamics caused by the arginine DPRs may provide 
an explanation for the KPNA4 mislocalisation and TDP-43 aggregation seen in 
C9ALS/FTD frontal cortex as discussed. Although additional post-mortem work is 
needed to investigate whether arginine DPR pathology correlates with the KPNA4 
mislocalisation observed. However, how might KPNA4 and TDP-43 become 
mislocalised in sporadic FTD-TDP where there is no poly-GR to disrupt the NPC or 
SG dynamics?  
There has been an increasing recognition over a number years at nucleocytoplasmic 
transport defects have a role in ALS and FTD cases, including cases not caused by 
the C9ORF72 repeat expansion (Kim and Taylor, 2017). For example, half of the 
mutations in FUS associated with ALS and FTD are located in the C-terminal non-
classical proline-tyrosine nuclear localisation signal (PY-NLS) (Dormann and Haass, 
2011; Kim and Taylor, 2017). Further the extent to which these mutations disrupt the 
nuclear localisation of FUS correlates with both reduced onset and enhanced 
progression of disease (Bosco et al., 2010; Chiò et al., 2009; DeJesus-Hernandez et 
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al., 2010; Dormann et al., 2010). A missense mutation in the NLS of hnRNPA1 is a 
cause of familial ALS, this mutation leads to a nuclear depletion and cytosolic 
accumulation of hnRNPA1 (Liu et al., 2016b). Mutations in GLE1, a component of 
the NPC, have been identified in two motor neuron diseases closely related to ALS - 
lethal congenital contracture syndrome 1 and lethal arthrogryposis with anterior horn 
cell disease (Nousiainen et al., 2008). Further a rare GLE1 loss of function mutation 
has also been recently identified in French and French-Canadian ALS patients 
(Kaneb et al., 2015). As just noted the protein levels and localisation of members of 
the classic importin α/ β pathway such as KNPA2 and CAS are altered in ALS and 
FTD tissue (Nishimura et al., 2010). Trn1 inclusions have also been identified in 
FTD-FUS cases and adult onset ALS without FUS mutations (Neumann et al., 2012; 
Takeuchi et al., 2013).  
Evidence suggests cerebral ageing has a detrimental impact on the NPC (Kim and 
Taylor, 2017) (figure 9.2). Nucleocytoplasmic transport is thought to be one the 
cellular processes affected most by age-related decline, specifically the integrity of 
the NPC (Kim and Taylor, 2017). NPC proteins in neurons are extremely long lived 
and remain in the NPC for the whole lifespan of an organism (Savas et al., 2012; 
Toyarna et al., 2013). Kim and Taylor, (2017) propose this is because in dividing 
cells the NPC disassembles during mitosis, reassembling with newly synthesized 
proteins; however, as neurons are post mitotic the complete disassembly and 
reassembly is not practical, rather NPC proteins are more likely to be slowly replaced 
as a neuron ages for newly translated NPC proteins. This however makes the NPC 
specifically vulnerable to damage from harmful stressors (Kim and Taylor et al, 
2017).  
For example, D’Angelo et al. (2009) found age-dependent deterioration of NPCs, via 
oxidative mediated damage; which led to an increase in the permeability of the 
nuclear pore causing changes in the subcellular concentrations of cytoplasmic 
proteins. Interestingly age-dependent changes in the protein concentrations of 
nuclear transport receptors KPNA2 and CAS have also been reported in fibroblasts 
(Pujol et al., 2002). Mertens et al. (2015) generated induced neurons from human 
donors from a broad range of ages, finding aged induced neurons had specific 
transcriptional profiles including decreases in RanBP17 levels. Furthermore, induced 







Figure 9.2 | Cellular Aging, disease, and nucleocytoplasmic transport. 
Disrupted nucleocytoplasmic transport has been reported as both a 
consequence of age and in neurodegenerative diseases such as ALS. An age-
dependent reduction in levels of proteins involved the transport of molecules 
across the nuclear pore complex, such as the karyopherins and RanBP17 
leads to perturbed nucleocytoplasmic transport resulting in the aggregation of 
proteins in the cytosol which further impairs nuclear import and export via the 
sequestration of nucleocytoplasmic transport factors. From Kim and Taylor, 
(2017) 
 
RanBP17 levels in induced neurons from young donors impaired nucleocytoplasmic 
transport leading to similar transcriptional changes seen in induced neurons from 
aged donors, further solidifying the importance of nucleocytoplasmic transport in 
human ageing. Therefore, one hypothesis for sporadic forms of disease is that 
specific genetic, environmental and molecular stressors make aged neuronal 
populations which are highly susceptible to stress unable mount an adequate stress 
response. One of the first cellular processes to be disrupted is nucleocytoplasmic 
transport due to age-related impairments in the NPC, leading to a disruption in the 
localisation of proteins that shuttle between the nucleus and cytoplasm, including 














A recent landmark paper by Woerner et al. (2016) demonstrating the pathological 
aggregation of β-sheet proteins in cytoplasm impairs nuclear import and export may 
explain the disruption of KPNA4 in sporadic FTD-TDP. Woerner et al (2016) targeted 
artificial β-sheet proteins to either the nucleus or cytoplasm using NES or NLS 
sequences respectively. Cytoplasmic β protein aggregates, but not nuclear β protein 
294 
 
aggregates were highly toxic to cells. Woerner et al. (2016) investigated why there 
were such differences in toxicity between β proteins located in different subcellular 
compartments by looking at their structural properties. Using NIAD-4, a fluorescent 
sensor that binds to amyloid structures; it was found that nuclear β protein 
aggregates only weakly bind the amyloid sensor NIAD-4 compared to their 
cytoplasmic counterparts suggesting significant structural differences between 
cytoplasmic and nuclear aggregates.  
To uncover mechanistically why cytoplasmic, but not nuclear, β proteins were so 
toxic Woerner et al. (2016) probed the localisation behaviour of the β proteins by 
staining for NPC proteins. Using antibodies specific for FG-repeat Nups (e.g. Nup, 
62, Nup152, Nup90) these FG-repeat Nups were found to be recruited to 
cytoplasmic – but not nuclear β protein aggregates. Furthermore, cytoplasmic β 
protein aggregates caused irregularities in the shape of the nuclear envelope and 
nucleus itself. None of this was observed for nuclear β protein aggregates.  Strikingly 
Woerner et al. (2016) also observed human disease proteins forming predominantly 
cytoplasmic aggregates, Htt96Q, TDP-43 and Parkin – also perturbed the NPC, with 
aggregates of FG-repeat Nups seen in the cytoplasm – although they did not 
frequently co-localise with human transgenic proteins with the artificial cytoplasmic β 
protein aggregates. This data therefore suggests cytoplasmic β protein aggregates 
disrupt nuclear cytoplasmic transport.  
To explore this further Woerner et al. (2016) fused an EGFP to both an NLS and 
NES, meaning EGFP is continuously shuttled between the nucleus and cytoplasm. 
The fluorescence of this shuttle GFP (S-GFP) was quantified in the nucleus and 
cytoplasm respectively to investigate defective nuclear cytoplasmic transport as a 
result of β protein aggregates. At equilibrium S-GFP is predominantly cytoplasmic 
indicating nuclear export is faster than nuclear import. Nuclear β protein aggregates 
had no effect on the distribution of S-GFP; however cytoplasmic β protein 
aggregates caused a significant increase in nuclear S-GFP suggesting defective 
nuclear export. This was also observed for cytoplasmic HTT96Q and cytoplasmic 
ParkinΔC aggregates co-expressing with S-GFP. When the exportin inhibitor 
leptomycin B (LMB) was applied to cells S-GFP translocated to the nucleus within 15 
minutes indicating quick nuclear import. This nuclear import was inhibited by 
cytoplasmic β protein aggregates and Htt96Q, but not by nuclear β protein 
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aggregates. Hence cytoplasmic β protein aggregates disrupt both nuclear import and 
export.  
To explore these defects further Woerner et al. (2016) investigated the transport of 
NF-κB. NF-κB is a protein complex that functions as a transcription factor 
transported into the nucleus by nuclear import receptors – specifically members of 
the KPNA α2 family – KPNA3 and KPNA4. In control cells and cells with nuclear β 
protein aggregates NF-κB was transported into the nucleus. However, in cells 
expressing cytoplasmic β protein aggregates and Htt96Q, TDP-43, and ParkinΔC the 
nuclear import of NF-κB was defective – the protein remained cytoplasmic, it did not 
translocate into the nucleus and was sometimes recruited into cytoplasmic β protein 
aggregates. This deficit seemed specific to the nuclear import of NF-κB as the 
upstream NF-κB signalling pathway was not affected. To investigate defective 
nuclear import Woerner et al. (2016) looked at the main import carrier for NF-κB – 
KPNA4. In control cells KPNA4 was distributed in both the cytoplasm and nucleus 
with a stronger cytoplasmic stain. Cytoplasmic β protein aggregates sequestered 
KPNA4 into inclusions; Htt96Q or ParkinΔC aggregates also caused KPNA4 
aggregate formation but these aggregates did not co-localise with human transgene 
protein aggregates. Similar results were seen for KPNA2. Both KPNAs were 
unaffected by nuclear β protein aggregates. The authors however did not look at 
TDP-43 and the KPNAs in their cellular model.  
The Woerner et al. (2016) paper shows a clear dysfunction and co-aggregation of 
KPNAs as a consequence of cytoplasmic protein aggregates. The data from the 
present study shows in human post-mortem tissue that KPNA4 is potentially 
sequestered into TDP-43 aggregates. Woerner et al. (2016) found expression of 
aggregate prone mutant TDP-43 causes a cytoplasmic accumulation of nuclear 
THOC2 – a protein involved in mRNA export. The authors propose transport factors 
may specifically be affected by cytoplasmic aggregates as they often contain 
disordered and low complexity domains causing aberrant interactions with the 
interactive surfaces of cytosolic aggregates.  
The Woerner et al. (2016) study therefore demonstrates that cytoplasmic aggregates 
of β sheet forming human disease proteins impair nucleocytoplasmic transport.  This 
study has a number of important implications with regards to the development of 
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TDP-43 proteinopathy and its relationship with defective nucleocytoplasmic transport 
in sporadic forms of ALS and FTD. One interpretation is that some sort of feed-back 
loop exists in which defective nucleocytoplasmic transport, caused by age-related 
deficits in the NPC, leads to TDP-43 accumulation in the cytoplasm. The subsequent 
aggregation of TDP-43 further disrupts nucleocytoplasmic transport creating a 
vicious cycle. Hence KPNA4 mislocalisation in sporadic FTD-TDP cases could be a 
result of TDP-43 mediated deficits in nucleocytoplasmic transport. A nuclear 
depletion of KPNA4 is in sporadic FTD-TDP frontal cortex was not however always 
accompanied by a TDP-43 aggregate. Hence aggregates of TDP-43 cannot per-say 
be the sole cause of the KPNA4 mislocalisation observed. TDP-43 not only binds 
nucleocytoplasmic transport proteins such as KPNA4, but it may also regulate the 
splicing and transcription of nucleocytoplasmic transport proteins leading to 
downstream defective nuclear import (Dormann and Haass, 2011). Hence a loss of 
TDP-43 function via cytoplasmic accumulation (without aggregation) and/or nuclear 
depletion could also disrupt nucleocytoplasmic transport. This raises the question as 
to whether initial modest TDP-43 mislocalisation can impair nuclear transport on its 
own and form a positive feedback loop, causing more TDP-43 to accumulate and 
aggregate in the cytoplasm.  
Several studies have demonstrated that TDP-43 levels directly impact nuclear 
transport; indicating some kind of feed-back regulation mechanism (Mihevc et al., 
2017). Proteomic analysis has revealed TDP-43 knockdown affects the levels of 
several proteins involved nuclear import and export including Nup153, Nup205, 
Nup160, RAE1, RANBP1, CRM1, IPO5, IPO7, calreticulin and POM121C 
(Štalekar et al., 2015). A loss of TDP-43 has been shown to cause a reduction in 
RAN levels and non-functional RAN mutants lead to a decrease in the amount of 
nuclear TDP-43 (Ward et al., 2014). TDP-43 regulates RAN expression via binding 
to the 3’UTR of its mRNA, hence a loss of nuclear TDP-43 could lead to a 
downregulation of RAN which would further cause TDP-43 nuclear loss and its 
subsequent cytoplasmic accumulation (Mihevc et al., 2017). Hence it will be 
interesting to investigate the localisation and function of nucleocytoplasmic transport 
in model systems in which TDP-43 is mislocalised without the formation of 
aggregates. It would also be intriguing to stain for WT TDP-43 in the human FTD 
frontal cortex to see if the KPNA4 mislocalisation correlated with a cytoplasmic 
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accumulation/nuclear depletion of TDP-43. Another interesting point to note is that 
poly-GA forms a parallel β-sheet structure with similar structural properties to the 
amyloid-beta protein in Alzheimer’s disease (Chang et al., 2016; Freibaum and 
Taylor, 2017). Khosravi et al. (2017) found cytoplasmic, but nuclear poly-GA 
aggregates cause a mislocalisation of TDP-43. Hence the poly-GA induced 
aggregation of Drosophila KPNA2, KPNA4 and RCC1 could be mediated by similar 
mechanisms to what is reported for other cytoplasmic β proteins by Woerner et al. 
(2016). 
The Woerner et al. (2016) study also suggests the accumulation and aggregation of 
TDP-43 in the cytoplasm could precede defective nucleocytoplasmic transport. 
Therefore, what could be the initial trigger of TDP-43 aggregation? Dormann and 
Haass, (2011) proposed nucleocytoplasmic transport could be a secondary 
phenomenon resulting from another primary insult. Another cellular process known 
also to be affected by ageing is the proteostasis machinery (Kim and Taylor, 2017). 
An age-related decline in proteostasis involves defects in the stabilization of correctly 
folded proteins and also protein clearance systems (Saeza and Vilchez, 2014). For 
example, the induction of chaperones, involved in cellular processes that maintain 
proper protein folding in response to stress, such as the heat shock response and 
unfolded protein response, is impaired in ageing (Calderwood et al., 2009).  Further 
when chaperones are overexpressed in vivo life span is increased (Morley and 
Morimoto, 2004; Morrow et al., 2004). In mice mutant strains with long life-spans 
show high levels of heat shock chaperones while mice lacking members of the heat 
shock protein family show increased ageing (Min et al., 2008; Swindell et al., 2009; 
Saeza and Vilchez, 2014). Further both defects in the ubiquitin proteasome system 
(UPS) and autophagy are associated with age (Morimoto and Cuervo, 2014; Saeza 
and Vilchez, 2014). Ageing has been shown to cause several impairments in 
proteasome function including a reduction in the expression of proteasome subunits 
and the disassembly of proteasomes (Vernace et al., 2007; Saeza and Vilchez, 
2014). In yeast age-related UPS dysfunction causes protein aggregation (Andersson 
et al., 2013). Reduced proteasome function as a consequence of ageing has been 
observed in the human cerebral cortex, hippocampus and spinal cord suggesting the 
activity of the proteasome declines with age (Saeza and Vilchez, 2014). Markers of 
autophagy are also reduced in the aged human brain (Saeza and Vilchez, 2014) and 
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using rapamycin to induce autophagy delays ageing in vivo and promotes lifespan 
(Harrison et al., 2009; Bjedov et al., 2010; Wilkinson et al., 2012). 
Impaired proteasome function is associated with sporadic ALS (Kabashi et al., 
2012); autophagy is also upregulated and activated sporadic ALS spinal cord motor 
neurons (Sasaki, 2011). There are links to defective proteostasis in familial forms 
ALS/FTD associated with TDP-43 proteinopathy such as mutations in GRN, VCP, 
SQSTM1, UBQLN2, OPTN, and TBK1. All of these genes are involved in autophagy 
and lysosomal pathways (Hardy and Rogaeva, 2014). It is possible that age related 
deficits proteostasis may be a bigger contributor to the development of TDP-43 
aggregates in sporadic cases than disrupted SG dynamics which may be moe 
important in C9ALS/FTD. Indeed McGurk et al. (2014) investigated the SG marker 
PABP-1 in human spinal cord motor neurons finding the colocalization of PABP-1 
and TDP-43 was twice as frequent in ALS patients with the C9ORF72 expansion 
compared to ALS with no mutation.  
9.4 Outlook  
 
A major question in ALS/FTD is how RNA binding proteins, in particular TDP-43, 
become depleted from the nucleus and sequestered into the cytoplasm (Dormann 
and Haass, 2011). A multi-hit hypothesis for TDP-43 proteinopahy has been 
proposed by Dormann and Haass, (2011) in which the development of TDP-43 
inclusions involves defective nuclear import as an initiating factor followed by SG 
mediated aggregation. For C9ORF72 cases the mechanisms underpinning the 
pathway toward TDP-43 proteinopathy are becoming clearer. The arginine DPRs 
provide both of these proposed hits; their binding to the LCD of proteins and 
subsequent disruption of phase transitions disrupts both the NPC (which will disrupt 
nuclear import) and SG dynamics, leading to SGs which do not disassemble, argued 
to be the basis of TDP-43 inclusion formation (Becker et al., 2017). Poly-GA may 
also have a role through defective proteostasis and the sequestration of 
nucleocytoplasmic transport proteins into its inclusions. The C9ORF72 protein could 
also contribute due its roles in autophagy (Webster et al., 2016a; Sellier et al., 2016) 
- the mechanism by which the DPRs are cleared by (Cristofani et al., 2017), and also 
nucleocytoplasmic transport (Xiao et al., 2015a) and SG formation (Maharjan et al., 
2017). The G4C2 RNA has also been shown to bind to and sequester proteins 
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involved in nucleocytoplasmic transport (Zhang et al., 2015). Further the repeat RNA 
has recently been shown to also undergo phase transitions (Jain and Vale, 2017) 
and it will be interesting to see what role this has in toxicity.  
There are some caveats to DPR mediated disruptions in the nucleocytoplasmic 
transport-SG axis as the cause of TDP-43 pathology in C9ALS/FTD. How can rare 
C9ALS/FTD cases which have DPR pathology, but no TDP-43 pathology be 
explained? Also, if poly-GR and poly-PR perturb phase transitions of RNA binding 
proteins why is the pathology always so specific to TDP-43. Why is FUS or 
hnRNPA1 pathology not seen in the C9ALS/FTD brain? Both proteins undergo 
phase transitions and are SG components like TDP-43 (Patel et al., 2015; Mollieux 
et al., 2015). A further understanding of the structural and functional differences 
between RNA binding such as FUS and TDP-43 may help answer this question. 
Also, what is behind the development of TDP-43 pathology in sporadic cases? 
Recent studies suggest TDP-43 pathology itself perturbs nucleocytoplasmic 
transport (Woerner et al., 2016) suggesting cellular processes other than disrupted 
nuclear import could cause TDP-43 aggregation; which age-related impairments in 
proteostasis being one potential mechanism. A better understanding of 
environmental and genetic risk factors that make some more susceptible to 
developing TDP-43 pathology and how these factors disrupt this nuclear import in 












Chapter 10: Conclusion 
This thesis reports a Drosophila model of C9ALS/FTD characterised by motor 
impairment that varied in age of onset and severity. The characteristics of these 
motor deficits were dependent on the levels and identity of dipeptide repeat proteins 
(DPRs) produced, and not the G4C2 RNA, with severe, early onset phenotypes 
correlating with poly-GR. Expression of poly-GR leads to a cytoplasmic accumulation 
of Drosophila TDP-43, indicating poly-GR is the key stressor in the disease cascade, 
accumulating early during the disease progression and subsequently causing TDP-
43 to be mislocalised to the cytoplasm providing a direct link between two major 
pathological hallmarks of C9 ALS/FTD. Further poly-GA also recruited Drosophila 
TDP-43 into inclusions. Moreover, not only does cytoplasmic TDP-43 enhance G4C2 
toxicity and is sufficient itself for toxicity but show DPR levels are also enhanced by 
the targeted increase in cytoplasmic TDP-43. Furthermore, both poly-GR and poly-
GA disrupt the localisation of the nuclear import protein Importin-α3 and Pendulin in 
flies suggesting defective nuclear import. The human homologue Importin-α3, 
KPNA4 was also mislocalised in sporadic FTD-TDP and C9FTD frontal cortex. Thus, 
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Figure A1| The presence of G4C2 repeats in the 3’UTR of DsRed2 
correlates with increased DsRed2 expression levels. Western blot 
analysis of RIPA soluble protein from day 5 head extracts from flies 
expressing DsRed2. A one-way ANOVA was used to compare DsRed2 
expression levels. Levels of DsRed2 were significantly affected by genotype 
(F=49.88, p<0.0001). Bonferroni-Holm corrected multiple comparisons can 
be found in appendix 7, table A7. This revealed flies expressing DsRed2-38 
repeats had significantly higher levels of DsRed2 compared to all over 
genotypes. There were no significant differences in DsRed2 expression 
levels between the 32 vs 56, 32 vs 64 and 56 vs 64 repeat lines. Intensity of 
DsRed2 signal was adjusted with respect to the signal intensity from the 
corresponding tubulin loading control. Mean with SEM is shown for each 




Appendix 2: Toxicity in the 38 repeat line is not 






















Figure A2 | Increased G4C2 transcript and DsRed2 protein levels do not 
explain neurotoxicity in the 38 G4C2 repeat line (A) Western blot analysis of 
RIPA soluble protein from day 5 head extracts from flies expressing DsRed2-38 
repeats (Elav>DsRed2(G4C2)38), one copy of the DsRed2-64 repeats 
(Elav>DsRed2(G4C2)64) and two copies of the DsRed2-64 repeats 
(Elav>DsRed2(G4C2)64x2). A one-way ANOVA revealed DsRed2 expression level 
was significantly affected by genotype (F=168.7, p<0.0001). Bonferroni-Holm corrected 
multiple comparisons can be found in appendix 7, table A7. This revealed flies 
expressing two copies of DsRed2-64 produced significantly higher levels of 
DsRed2 than flies harbouring one copy of the DsRed2-64 repeat construct and 
also flies expressing DsRed2-38 repeats. Mean with SEM is shown for each 
genotype (n=3). (B) A one-way ANOVA was used to compare the mean 
differences in climbing performance (the performance index - PI) between flies 
expressing DsRed2-38 repeats, one copy of the DsRed2-64 repeats and two 
copies of the DsRed2-64 repeats at day 5. The PI of flies was significantly 
affected by both genotype (F=43.28, p<0.0001). Bonferroni-Holm corrected 
multiple comparisons can be found in appendix 7, table A7. This revealed flies 
expressing DsRed2-38 repeats had a significantly impaired climbing performance 
compared to flies with one copy of DsRed2-64 repeats and two copies of 
DsRed2-64 repeats. Each data point represents the PI of ~15 flies.  Mean with 
SEM is shown for each genotype (n=3). (C) Two copies of the DsRed2-64 
construct increases the number of poly-GP bands detected compared to flies with 
one copy of the DsRed2-64 construct. These experiments and this figure were 




Appendix 3: Validation of a novel monoclonal poly-GP 
antibody 
 
To investigate RAN translation in the hexanucleotide repeat expansion Drosophila 
model used in this study, a monoclonal antibody for the DPR poly-GP was 
generated. This monoclonal poly-GP antibody was generated by the immunisation of 
mice with the following peptide sequence - GPGPGPGPGPGPGPGPGPGP (GPx10) 
by Abmart, China. Poly-GP is highly expressed in the C9ALS/FTD CNS with poly-GP 
inclusions being the second most abundant DPR aggregate found in the post-
mortem brain after poly-GA (Schludi et al., 2015) and has strong potential to be a 
pharmacodynamic marker for C9ALS/FTD due to its solubility (Gendron et al., 2015; 
Gendron et al., 2017; Lehmer et al., 2017). Hence the generation of a highly specific 
monoclonal antibody for poly-GP is not only an important tool for investigating RAN 
translation in vivo and DPR pathology in post-mortem tissue, but also has important 
clinical implications.  
To confirm the specificity of the novel monoclonal poly-GP antibody produced by 
Abmart, lysate from HEK293 cells expressing either - poly-GP, poly-GA, poly-GR, 
poly-PA or poly-PR from alternative non G4C2 codons (provided by Younbok Lee) 
was probed with the monoclonal poly-GP antibody. Dot blotting showed a specific 
high intensity signal for the poly-GP HEK293 cell lysate only (figure 3.4A3 A). No 
signal was seen for the poly-GA, poly-GR, poly-PA or poly-PR lysate. Following 
confirmation that the antibody was specific for the poly-GP peptide and does not 
cross-react with any of the other DPRs, immunofluorescent staining of human 
cerebellum post-mortem tissue was carried out to determine if the antibody could 
detect inclusions characteristic of the C9ALS/FTD brain (figure 3.4A3 B). Staining 
with the monoclonal poly-GP antibody detected the presence of neuronal 
cytoplasmic inclusions of poly-GP in the C9ALS/FTD cerebellum, particularly in the 
granule layer as has been previously reported (Schludi et al., 2015). No poly-GP 
inclusions were found in Alzheimer’s disease (AD) cerebellum. Hence this novel 
monoclonal poly-GP antibody can detect poly-GP with high affinity and specificity 
and was therefore suitable for investigating RAN translation in the brain of flies 






Figure A3 | Validation of novel monoclonal poly-GP antibody. (A) Monoclonal 
poly-GP antibody specifically detects lysate from HEK293 cells expressing GP, 
but not poly-GA, poly-GR, poly-PA or poly-PR. (B) Staining of Alzheimer’s 
disease (AD) and C9ALS/FTD cerebellum revealed the presence of poly-GP 
inclusions in the granule layer of the cerebellum but not in AD cerebellum. Scale 



















Figure A4 | Poly-GP levels do not change over time. (A) Western blot analysis of RIPA soluble 
protein from day 5, 20 and 40 head extracts from flies expressing DsRed2 (Elav>DsR2), 38 G4C2 
repeats (Elav>DsRed2(G4C2)38), 64 G4C2 repeats (Elav>DsRed2(G4C2)64). (B) Quantification of 
western blots for expression of poly-GP. A one-way ANOVA demonstrated there to be no significant 
difference at the different time points for poly-GP expression levels in the 32 (F=0.006913, 





Appendix 4: The expression pattern and levels of of 














































CGTCCACGTCCAAGAGAGCAAAAGCTTATTTCTGAAGAGGACTTG   
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Appendix 6: TBPH localisation in pupal eye discs 




Figure A6 | Cytosolic localisation of TBPH is increased in the pupal eye disc 
of poly-GR expressing flies. Pupal eye discs were immunolabeled with TBPH. 
No changes were seen in localisation of TBPH in controls (GMR/+ and 
GMR>GR8). TBPH was seen in accumulate in the cytoplasm of poly-GR64 
expressing (GMR>GR64) pupal eye discs. Scale bars, 10µm.   
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Appendix 7: ΔNLS-TBPH expression causes a 
cytoplasmic accumulation and concomitant nuclear 




Figure A7 | ΔNLS-TBPH (gΔNLS) expression causes a cytoplasmic 
accumulation of TBPH and a concomitant nuclear reduction. (a-h) Confocal 
images of third instar larval eye discs immunolabeled with anti-TBPH. Flies 
homozygous gΔNLS and those heterozygous for a deletion of TBPH that also 
express one copy of a genomic (gΔNLS) construct gΔNLS reveal (a, b, c, d, 
arrow) diffuse cytoplasmic and nuclear TBPH localisation; in heterozygous TBPH 
mutants with two copies of ΔNLS-TBPH, nuclear clearance of TBPH is much 
more pronounced (e, f, arrowhead) and is also seen (g, h) in homozygous TBPH 
null mutants expressing one copy of ΔNLS-TBPH (i). Scale bars, 10µm.  
Experiments performed by Dr. Dani Diaper. 
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Appendix 8: Poly-GP detectable in axons at the larval 









Figure A8 | Poly-GP is detectable in motor neuron axons of the larval 
neuromuscular junction. Larval neuromuscular junctions were dissected and 
stained for poly-GP and HRP Cy5 which detects motor neurons. No poly-GP 
signal was seen in the motor neuron axons of control genotypes (Elav/+, Elav>0 
and Elav>8). Poly-GP was however detectable in the axons of motor neurons of 
flies expressing 38 repeats (Elav>38) and 64 repeats (Elav>64). Scale bars, 
10µm. These experiments and this figure were generated by Wing Hei Au and 




Appendix 9: Post mortem cases used in this study 
 
Table A9.1 | Details of the post-mortem cases used in this study 
*Green used for western blotting only *Blue used for IHC only *Red used for IHC and 

















MRC ID Diagnosis Age Sex PMD 
A145/02 BBN_15765 Control 55 M 24 
A135/95 BBN_16621 Control 65 M 24 
A154/94 BBN_16733 Control 55 F 24 
A278/96 BBN_16525 Control 77 F 29 
A205/94 BBN_16707 Control 71 F 30 
A281/00 BBN_15274 FTD C9-VE 61 F 5 
A163/07 BBN_15288 FTD C9-VE 80 M 6 
A103/08 BBN_15294 FTD C9-VE 85 F 24 
A370/97 BBN_16467 FTD C9-VE 57 M 2 
A265/00 BBN_15273 FTD C9-VE 50 F 35 
A315/07 BBN_15291 FTD C9+VE 56 M 19 
A163/09 BBN_15300 FTD C9+VE 79 M 35 
A088/00 BBN_15270 FTD C9+VE 57 F 16 
A112/99 BBN_16438 FTD C9+VE 58 F 12 
A117/91 BBN_16969 FTD C9+VE 57 F 12 
A144/12 BBN_4253 ALS/FTD C9+VE 59 F 21 
A205/07 BBN_9863 AD Braak VI M 73 24 
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 * Tissue analysis performed by neuropathologist Dr. Tibor Hortobagyi includes: % of neuronal staining, % of nuclear staining, % of 
cytoplasmic staining, lack of nuclear staining (marked, mild, moderate), dystrophic neurites (+/- and description), inclusions (+/-) 
and background staining (0–none, 1-mild, 2-moderate, 3-intense). 
Case 
Number 



















60 20 40 Mild - - 1  
A103/08 FTD C9-
VE 
50 20 30 Mild - - 0  
A315/07 FTD 
C9+VE 
70 20 50 Marked +Thin and 
elongated 
- 1  
A163/09 FTD 
C9+VE 










Appendix 10: Pairwise comparisons 
 
Table A10 | Bonferroni-Holm adjusted pairwise comparisons 
 





Elav>DsRed2-8A vs Elav>DsRed2-38 <0.0001 0.003333333 
  Elav>DsRed2-32 vs Elav>DsRed2-38 <0.0001 0.003571429 
  Elav>DsRed2-56 vs Elav>DsRed2-38 <0.0001 0.003846154 
  Elav>DsRed2-64 vs Elav>DsRed2-38 <0.0001 0.004166667 
  Elav>DsRed2-8B vs Elav>DsRed2-38 <0.0001 0.004545455 
  Elav>DsRed2-32 vs Elav>DsRed2-8B 0.0004 0.005 
  Elav>DsRed2-8A vs Elav>DsRed2-32 0.0012 0.005555556 
  Elav>DsRed2-64 vs Elav>DsRed2-8B 0.0042 0.00625 
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  Elav>DsRed2-8A vs Elav>DsRed2-64 0.0109 0.007142857 
  Elav>DsRed2-32 vs Elav>DsRed2-56 0.0313 0.008333333 
  Elav>DsRed2-56 vs Elav>DsRed-8B 0.654 0.01 
  Elav>DsRed2-8A vs Elav>DsRed2-56 0.1452 0.0125 
  Elav>DsRed2-56 vs Elav>DsRed2-64 0.2052 0.016666667 
  Elav>DsRed2-32 vs Elav>DsRed2-64 0.3208 0.025 
  Elav>DsRed-8A vs Elav>DsRed-8B 0.6658 0.05 
3.5B One-way 
ANOVA  
Elav>DsRed2-56 vs Elav>DsRed2-64 <0.0001 0.0083333 
  Elav>DsRed2-64 vs Elav>DsRed2-38 <0.0001 0.01 
  Elav>DsRed2-32 vs Elav>DsRed2-56 <0.0001 0.0125 
  Elav>DsRed2-32 vs Elav>DsRed2-64 0.0001 0.0166667 
  Elav>DsRed2-32 vs Elav>DsRed2-38 0.0037 0.025 





Elav>DsRed2-64 vs Elav>DsRed2-38 <0.0001 0.0083333 
  Elav>DsRed2-32 vs Elav>DsRed2-64 <0.0001 0.01 
  Elav>DsRed2-32 vs Elav>DsRed2-38 <0.0001 0.0125 
  Elav>DsRed2-56 vs Elav>DsRed2-64 0.0001 0.0166667 
  Elav>DsRed2-56 vs Elav>DsRed2-38 0.0052 0.025 
  Elav>DsRed2-32 vs Elav>DsRed2-56 0.0062 0.05 
4.3A & C Two-way 
ANOVA 
Elav/+ vs Elav>DsRed2>38 <0.0001 0.001785714 
 
  Elav>DsRed2 vs Elav>DsRed2-38 <0.0001 0.001851852 
 
  Elav>DsRed2-8A vs Elav>DsRed2-38 <0.0001 0.001923077 
 
  Elav>DsRed2-8B vs Elav>DsRed2-38 <0.0001 0.002 
 




  Elav>DsRed2-56 vs Elav>DsRed2-38 <0.0001 0.002173913 
 
  Elav>DsRed2-64 vs Elav>DsRed2-38 <0.0001 0.002272727 
 
  Elav/+ vs Elav>DsRed2>8A 0.0883 0.002380952 
 
  Elav>DsRed2-8A vs Elav>DsRed2-8B 0.1495 0.0025 
 
  Elav/+ vs Elav>DsRed2>32 0.2382 0.002631579 
 
  Elav/+ vs Elav>DsRed2>56 0.2764 0.002777778 
 
  Elav>DsRed2 vs Elav>DsRed2-8A 0.3192 0.002941176 
 
  Elav>DsRed2-8B vs Elav>DsRed2-32 0.3626 0.003125 
 
  Elav>DsRed2-8A vs Elav>DsRed2-64 0.3648 0.003333333 
 




  Elav>DsRed2-8B vs Elav>DsRed2-56 0.413 0.003846154 
 
  Elav/+ vs Elav>DsRed2 0.4664 0.004166667 
 
  Elav>DsRed2-8A vs Elav>DsRed2-56 0.5254 0.004545455 
 
  Elav>DsRed2-8B vs Elav>DsRed2-64 0.5844 0.005 
 
  Elav>DsRed2-8A vs Elav>DsRed2-32 0.5874 0.005555556 
 
  Elav>DsRed2 vs Elav>DsRed2-32 0.6472 0.00625 
 
  Elav>DsRed2 vs Elav>DsRed2-8B 0.6484 0.007142857 
 
  Elav>DsRed2-32 vs Elav>DsRed2-64 0.7139 0.008333333 
 




  Elav/+ vs Elav>DsRed2-8B 0.7842 0.0125 
 
  Elav>DsRed2-56 vs Elav>DsRed2-64 0.7842 0.016666667 
 
  Elav>DsRed2-32 vs Elav>DsRed2-56 0.9259 0.025 
  Elav>DsRed2 vs Elav>DsRed2-64 0.9273 0.05 
4.1B & D Two-way 
ANOVA 
Elav/+ vs Elav>DsRed2>38 <0.0001 0.001785714 
 
  Elav>DsRed2 vs Elav>DsRed2-38 <0.0001 0.001851852 
 
  Elav>DsRed2-8A vs Elav>DsRed2-38 <0.0001 0.001923077 
 
  Elav>DsRed2-8B vs Elav>DsRed2-38 <0.0001 0.002 
 
  Elav>DsRed2-32 vs Elav>DsRed2-38 <0.0001 0.002083333 
 




  Elav>DsRed2-64 vs Elav>DsRed2-38 <0.0001 0.002272727 
 
  Elav/+ vs Elav>DsRed2>56 0.016 0.002380952 
 
  Elav>DsRed2-8A vs Elav>DsRed2-56 0.0416 0.0025 
 
  Elav/+ vs Elav>DsRed2>64 0.0541 0.002631579 
 
  Elav>DsRed2 vs Elav>DsRed2-56 0.0626 0.002777778 
 
  Elav/+ vs Elav>DsRed2-8B 0.0627 0.002941176 
 
  Elav>DsRed2-32 vs Elav>DsRed2-56 0.1017 0.003125 
 
  Elav>DsRed2-8A vs Elav>DsRed2-64 0.15 0.003333333 
 
  Elav>DsRed2-8A vs Elav>DsRed2-8B 0.1683 0.003571429 
 




  Elav>DsRed2 vs Elav>DsRed2-8B 0.2212 0.004166667 
 
  Elav/+ vs Elav>DsRed2>32 0.3082 0.004545455 
 
  Elav>DsRed2-32 vs Elav>DsRed2-64 0.3203 0.005 
 
  Elav>DsRed2-8B vs Elav>DsRed2-32 0.3318 0.005555556 
 
  Elav/+ vs Elav>DsRed2>8A 0.426 0.00625 
 
  Elav>DsRed2-56 vs Elav>DsRed2-64 0.4275 0.007142857 
 
  Elav/+ vs Elav>DsRed2 0.4447 0.008333333 
 
  Elav>DsRed2-8B vs Elav>DsRed2-56 0.4654 0.01 
 




  Elav>DsRed2 vs Elav>DsRed2-32 0.7844 0.016666667 
 
  Elav>DsRed2 vs Elav>DsRed2-8A 0.9648 0.025 
  Elav>DsRed2-8B vs Elav>DsRed2-64 0.9734 0.05 
A2 A One-way 
ANOVA 
Elav>DsRed2-64 vs Elav>DsRed2-64x2 <0.0001 0.0166667 
  Elav>DsRed2-38 vs Elav>DsRed2-64 <0.0001 0.025 
  Elav>DsRed2-38 vs Elav>DsRed2-64x2 0.0037 0.05 
   A2 B   One-way   
ANOVA 
      Elav>DsRed2-64 vs Elav>DsRed2-38        <0.0001      0.0166667 
         Elav>DsRed2-64x2 vs Elav>DsRed2-38        0.0002     0.025 
         Elav>DsRed2-64 vs Elav>DsRed2-64x2        0.1756      0.05 
4.1E One-way 
ANOVA  
Elav/+ vs Elav>DsRed2>64 <0.0001 0.003333333 
  Elav>DsRed2 vs Elav>DsRed2-32 <0.0001 0.003571429 
  Elav>DsRed2 vs Elav>DsRed2-64 <0.0001 0.003846154 
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  Elav>DsRed2-56 vs Elav>DsRed2-64 0.0003 0.004166667 
  Elav/+ vs Elav>DsRed2>32 0.0005 0.004545455 
  Elav>DsRed2-56 vs Elav>DsRed2-32 0.0014 0.005 
  Elav>DsRed2-8A vs Elav>DsRed2-64 0.0023 0.005555556 
  Elav>DsRed2-8A vs Elav>DsRed2-32 0.0068 0.00625 
  Elav>DsRed2 vs Elav>DsRed2-8A 0.0469 0.007142857 
  Elav>DsRed2 vs Elav>DsRed2-56 0.1742 0.008333333 
  Elav/+ vs Elav>DsRed2-8A 0.29 0.01 
  Elav/+ vs Elav>DsRed2 0.3612 0.0125 
  Elav>DsRed2-8A vs Elav>DsRed2-56 0.5177 0.016666667 
  Elav/+ vs Elav>DsRed2-56 0.67 0.025 
  Elav>DsRed2-32 vs Elav>DsRed2-64 0.8354 0.05 
4.2B One-way 
ANOVA  
Elav/+ vs Elav>DsRed2-38 <0.0001 0.0166667 
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  Elav>DsRed2-8B vs Elav>DsRed2-38 <0.0001 0.025 
  Elav/+ vs Elav>DsRed2-8B 0.5006 0.05 
4.3B One-way 
ANOVA  
Elav>DsRed2 vs Elav>DsRed2-32 <0.0001 0.005 
  Elav>DsRed2 vs Elav>DsRed2-64 <0.0001 0.003571429 
  Elav>DsRed2-8A vs Elav>DsRed2-32 0.0001 0.00625 
  Elav>DsRed2-8A vs Elav>DsRed2-64 0.0006 0.007142857 
  Elav>DsRed2-32 vs Elav>DsRed2-56 0.0015 0.008333333 
  Elav>DsRed2-56 vs Elav>DsRed2-64 0.0062 0.01 
  Elav>DsRed2 vs Elav>DsRed2-56 0.0515 0.0125 
  Elav>DsRed2-8A vs Elav>DsRed2-56 0.3509 0.016666667 
  Elav>DsRed2-32 vs Elav>DsRed2-64 0.4006 0.025 
  Elav>DsRed2 vs Elav>DsRed2-8A 0.4093 0.05 
4.4B Chi-square  Elav>DsRed2 vs Elav>DsRed2-8B 0.7701 n/a 
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  Elav>DsRed2 vs Elav>DsRed2-64 0.8816 n/a 
  Elav>DsRed2 vs Elav>DsRed2-38 <0.0001 n/a 
  Elav>DsRed2-8B vs Elav>DsRed2-64 0.9924 n/a 
  Elav>DsRed2-8B vs Elav>DsRed2-38 <0.0001 n/a 
  Elav>DsRed2-64 vs Elav>DsRed2-38 <0.0001 n/a 
4.4C One-way 
ANOVA 
Elav>DsRed2-8B vs Elav>DsRed2-38 <0.0001 0.008333333 
  Elav>DsRed2-64 vs Elav>DsRed2-38 <0.0001 0.01 
  Elav>DsRed2 vs Elav>DsRed2-38 <0.0001 0.0125 
  Elav>DsRed2 vs Elav>DsRed2-8B 0.4188 0.016666667 
  Elav>DsRed2 vs Elav>DsRed2-64 0.4650 0.025 
  Elav>DsRed2-8B vs Elav>DsRed2-64 0.9623 0.05 
6.2B One-way 
ANOVA 
Elav>NLS/+ vs Elav>NLS/DsRed2-38 <0.0001 0.003333333 
  Elav>DsRed2-64 vs Elav>NLS/DsRed2-38 <0.0001 0.003571429 
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  Elav>/+ vs Elav>NLS/DsRed2-38 <0.0001 0.003846154 
  Elav>NLS/DsRed2 vs Elav>NLS/DsRed2-38 <0.0001 0.004166667 
  Elav>NLS/+ vs Elav>NLS/DsRed2-38 <0.0001 0.004545455 
  Elav>DsRed2-64 vs Elav>DsRed2-38 <0.0001 0.005 
  Elav/+ vs Elav>DsRed2-38 <0.0001 0.005555556 
  Elav>NLS/DsRed2-64 vs Elav>DsRed2-38 <0.0001 0.00625 
  Elav>DsRed2-38 vs Elav>NLS/DsRed2-38 <0.0001 0.007142857 
  Elav>NLS/+ vs Elav>NLS-DsRed2-64 0.0946 0.008333333 
  Elav>DsRed-64 vs Elav>NLS/DsRed2-64 0.1161 0.01 
  Elav/+ vs Elav>NLS/DsRed-64 0.3181 0.0125 
  Elav/+ vs Elav>NLS/+ 0.4702 0.016666667 
  Elav/+ vs Elav>DsRed-64 0.5404 0.025 
  Elav>NLS/+ vs Elav>DsRed2 0.9108 0.05 
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6.3B Unpaired t-test Elav>DsRed-64 vs Elav>NLS/DsRed2-64 0.0004 n/a 
  Elav>DsRed2-38 vs Elav>NLS/DsRed2-38 0.0555 n/a 
6.3D Unpaired t-test Elav>DsRed-64 vs Elav>NLS/DsRed2-64 0.0003 n/a 
  Elav>DsRed2-38 vs Elav>NLS/DsRed2-38 0.0098 n/a 
 
 
